words,sentence_id,labels
BRCA1,0,O
is,0,O
secreted,0,O
and,0,O
exhibits,0,O
properties,0,O
of,0,O
a,0,O
granin,0,O
.,0,O
Germline,1,O
mutations,1,O
in,1,O
BRCA1,1,O
are,1,O
responsible,1,O
for,1,O
most,1,O
cases,1,O
of,1,O
inherited,1,B-CompositeMention
breast,1,I-CompositeMention
and,1,I-CompositeMention
ovarian,1,I-CompositeMention
cancer,1,I-CompositeMention
.,1,O
However,2,O
",",2,O
the,2,O
function,2,O
of,2,O
the,2,O
BRCA1,2,O
protein,2,O
has,2,O
remained,2,O
elusive,2,O
.,2,O
We,3,O
now,3,O
show,3,O
that,3,O
BRCA1,3,O
encodes,3,O
a,3,O
190-kD,3,O
protein,3,O
with,3,O
sequence,3,O
homology,3,O
and,3,O
biochemical,3,O
analogy,3,O
to,3,O
the,3,O
granin,3,O
protein,3,O
family,3,O
.,3,O
Interestingly,4,O
",",4,O
BRCA2,4,O
also,4,O
includes,4,O
a,4,O
motif,4,O
similar,4,O
to,4,O
the,4,O
granin,4,O
consensus,4,O
at,4,O
the,4,O
C,4,O
terminus,4,O
of,4,O
the,4,O
protein,4,O
.,4,O
Both,5,O
BRCA1,5,O
and,5,O
the,5,O
granins,5,O
localize,5,O
to,5,O
secretory,5,O
vesicles,5,O
",",5,O
are,5,O
secreted,5,O
by,5,O
a,5,O
regulated,5,O
pathway,5,O
",",5,O
are,5,O
post-translationally,5,O
glycosylated,5,O
and,5,O
are,5,O
responsive,5,O
to,5,O
hormones,5,O
.,5,O
As,6,O
a,6,O
regulated,6,O
secretory,6,O
protein,6,O
",",6,O
BRCA1,6,O
appears,6,O
to,6,O
function,6,O
by,6,O
a,6,O
mechanism,6,O
not,6,O
previously,6,O
described,6,O
for,6,O
tumour,6,B-Modifier
suppressor,6,O
gene,6,O
products,6,O
..,6,O
Ovarian,7,B-Modifier
cancer,7,I-Modifier
risk,7,O
in,7,O
BRCA1,7,O
carriers,7,O
is,7,O
modified,7,O
by,7,O
the,7,O
HRAS1,7,O
variable,7,O
number,7,O
of,7,O
tandem,7,O
repeat,7,O
(,7,O
VNTR,7,O
),7,O
locus,7,O
.,7,O
Women,8,O
who,8,O
carry,8,O
a,8,O
mutation,8,O
in,8,O
the,8,O
BRCA1,8,O
gene,8,O
(,8,O
on,8,O
chromosome,8,O
17q21,8,O
),8,O
",",8,O
have,8,O
an,8,O
80,8,O
%,8,O
risk,8,O
of,8,O
breast,8,B-SpecificDisease
cancer,8,I-SpecificDisease
and,8,O
a,8,O
40,8,O
%,8,O
risk,8,O
of,8,O
ovarian,8,B-SpecificDisease
cancer,8,I-SpecificDisease
by,8,O
the,8,O
age,8,O
of,8,O
70,8,O
(,8,O
ref,8,O
.,8,O
1,9,O
),9,O
.,9,O
The,10,O
variable,10,O
penetrance,10,O
of,10,O
BRCA1,10,O
suggests,10,O
that,10,O
other,10,O
genetic,10,O
and,10,O
non-genetic,10,O
factors,10,O
play,10,O
a,10,O
role,10,O
in,10,O
tumourigenesis,10,O
in,10,O
these,10,O
individuals,10,O
.,10,O
The,11,O
HRAS1,11,O
variable,11,O
number,11,O
of,11,O
tandem,11,O
repeats,11,O
(,11,O
VNTR,11,O
),11,O
polymorphism,11,O
",",11,O
located,11,O
1,11,O
kilobase,11,O
(,11,O
kb,11,O
),11,O
downstream,11,O
of,11,O
the,11,O
HRAS1,11,O
proto-oncogene,11,O
(,11,O
chromosome,11,O
11p15,11,O
.,11,O
5,12,O
),12,O
is,12,O
one,12,O
possible,12,O
genetic,12,O
modifier,12,O
of,12,O
cancer,12,B-Modifier
penetrance,12,O
.,12,O
Individuals,13,O
who,13,O
have,13,O
rare,13,O
alleles,13,O
of,13,O
the,13,O
VNTR,13,O
have,13,O
an,13,O
increased,13,O
risk,13,O
of,13,O
certain,13,O
types,13,O
of,13,O
cancers,13,B-DiseaseClass
",",13,O
including,13,O
breast,13,B-SpecificDisease
cancer,13,I-SpecificDisease
(,13,O
2-4,13,O
),13,O
.,13,O
To,14,O
investigate,14,O
whether,14,O
the,14,O
presence,14,O
of,14,O
rare,14,O
HRAS1,14,O
alleles,14,O
increases,14,O
susceptibility,14,O
to,14,O
hereditary,14,B-CompositeMention
breast,14,I-CompositeMention
and,14,I-CompositeMention
ovarian,14,I-CompositeMention
cancer,14,I-CompositeMention
",",14,O
we,14,O
have,14,O
typed,14,O
a,14,O
panel,14,O
of,14,O
307,14,O
female,14,O
BRCA1,14,O
carriers,14,O
at,14,O
this,14,O
locus,14,O
using,14,O
a,14,O
PCR-based,14,O
technique,14,O
.,14,O
The,15,O
risk,15,O
for,15,O
ovarian,15,B-SpecificDisease
cancer,15,I-SpecificDisease
was,15,O
2,15,O
.,15,O
11,16,O
times,16,O
greater,16,O
for,16,O
BRCA1,16,O
carriers,16,O
harbouring,16,O
one,16,O
or,16,O
two,16,O
rare,16,O
HRAS1,16,O
alleles,16,O
",",16,O
compared,16,O
to,16,O
carriers,16,O
with,16,O
only,16,O
common,16,O
alleles,16,O
(,16,O
P,16,O
=,16,O
0,16,O
.,16,O
015,17,O
),17,O
.,17,O
The,18,O
magnitude,18,O
of,18,O
the,18,O
relative,18,O
risk,18,O
associated,18,O
with,18,O
a,18,O
rare,18,O
HRAS1,18,O
allele,18,O
was,18,O
not,18,O
altered,18,O
by,18,O
adjusting,18,O
for,18,O
the,18,O
other,18,O
known,18,O
risk,18,O
factors,18,O
for,18,O
hereditary,18,B-SpecificDisease
ovarian,18,I-SpecificDisease
cancer,18,I-SpecificDisease
(,18,O
5,18,O
),18,O
.,18,O
Susceptibility,19,O
to,19,O
breast,19,B-SpecificDisease
cancer,19,I-SpecificDisease
did,19,O
not,19,O
appear,19,O
to,19,O
be,19,O
affected,19,O
by,19,O
the,19,O
presence,19,O
of,19,O
rare,19,O
HRAS1,19,O
alleles,19,O
.,19,O
This,20,O
study,20,O
is,20,O
the,20,O
first,20,O
to,20,O
show,20,O
the,20,O
effect,20,O
of,20,O
a,20,O
modifying,20,O
gene,20,O
on,20,O
the,20,O
penetrance,20,O
of,20,O
an,20,O
inherited,20,B-DiseaseClass
cancer,20,I-DiseaseClass
syndrome,20,I-DiseaseClass
A,21,O
novel,21,O
homeodomain-encoding,21,O
gene,21,O
is,21,O
associated,21,O
with,21,O
a,21,O
large,21,O
CpG,21,O
island,21,O
interrupted,21,O
by,21,O
the,21,O
myotonic,21,B-Modifier
dystrophy,21,I-Modifier
unstable,21,O
(,21,O
CTG,21,O
),21,O
n,21,O
repeat,21,O
.,21,O
Myotonic,22,B-SpecificDisease
dystrophy,22,I-SpecificDisease
(,22,O
DM,22,B-SpecificDisease
),22,O
is,22,O
associated,22,O
with,22,O
a,22,O
(,22,O
CTG,22,O
),22,O
n,22,O
trinucleotide,22,O
repeat,22,O
expansion,22,O
in,22,O
the,22,O
3-untranslated,22,O
region,22,O
of,22,O
a,22,O
protein,22,O
kinase-encoding,22,O
gene,22,O
",",22,O
DMPK,22,O
",",22,O
which,22,O
maps,22,O
to,22,O
chromosome,22,O
19q13,22,O
.,22,O
3,23,O
.,23,O
Characterisation,24,O
of,24,O
the,24,O
expression,24,O
of,24,O
this,24,O
gene,24,O
in,24,O
patient,24,O
tissues,24,O
has,24,O
thus,24,O
far,24,O
generated,24,O
conflicting,24,O
data,24,O
on,24,O
alterations,24,O
in,24,O
the,24,O
steady,24,O
state,24,O
levels,24,O
of,24,O
DMPK,24,O
mRNA,24,O
",",24,O
and,24,O
on,24,O
the,24,O
final,24,O
DMPK,24,O
protein,24,O
levels,24,O
in,24,O
the,24,O
presence,24,O
of,24,O
the,24,O
expansion,24,O
.,24,O
The,25,O
DM,25,B-Modifier
region,25,O
of,25,O
chromosome,25,O
19,25,O
is,25,O
gene,25,O
rich,25,O
",",25,O
and,25,O
it,25,O
is,25,O
possible,25,O
that,25,O
the,25,O
repeat,25,O
expansion,25,O
may,25,O
lead,25,O
to,25,O
dysfunction,25,O
of,25,O
a,25,O
number,25,O
of,25,O
transcription,25,O
units,25,O
in,25,O
the,25,O
vicinity,25,O
",",25,O
perhaps,25,O
as,25,O
a,25,O
consequence,25,O
of,25,O
chromatin,25,O
disruption,25,O
.,25,O
We,26,O
have,26,O
searched,26,O
for,26,O
genes,26,O
associated,26,O
with,26,O
a,26,O
CpG,26,O
island,26,O
at,26,O
the,26,O
3,26,O
end,26,O
of,26,O
DMPK,26,O
.,26,O
Sequencing,27,O
of,27,O
this,27,O
region,27,O
shows,27,O
that,27,O
the,27,O
island,27,O
extends,27,O
over,27,O
3,27,O
.,27,O
5,28,O
kb,28,O
and,28,O
is,28,O
interrupted,28,O
by,28,O
the,28,O
(,28,O
CTG,28,O
),28,O
n,28,O
repeat,28,O
.,28,O
Comparison,29,O
of,29,O
genomic,29,O
sequences,29,O
downstream,29,O
(,29,O
centromeric,29,O
),29,O
of,29,O
the,29,O
repeat,29,O
in,29,O
human,29,O
and,29,O
mouse,29,O
identified,29,O
regions,29,O
of,29,O
significant,29,O
homology,29,O
.,29,O
These,30,O
correspond,30,O
to,30,O
exons,30,O
of,30,O
a,30,O
gene,30,O
predicted,30,O
to,30,O
encode,30,O
a,30,O
homeodomain,30,O
protein,30,O
.,30,O
RT-PCR,31,O
analysis,31,O
shows,31,O
that,31,O
this,31,O
gene,31,O
",",31,O
which,31,O
we,31,O
have,31,O
called,31,O
DM,31,B-Modifier
locus-associated,31,O
homeodomain,31,O
protein,31,O
(,31,O
DMAHP,31,O
),31,O
",",31,O
is,31,O
expressed,31,O
in,31,O
a,31,O
number,31,O
of,31,O
human,31,O
tissues,31,O
",",31,O
including,31,O
skeletal,31,O
muscle,31,O
",",31,O
heart,31,O
and,31,O
brain,31,O
.,31,O
Germline,32,O
mutations,32,O
in,32,O
the,32,O
RB1,32,O
gene,32,O
in,32,O
patients,32,O
with,32,O
hereditary,32,B-SpecificDisease
retinoblastoma,32,I-SpecificDisease
.,32,O
We,33,O
have,33,O
analyzed,33,O
the,33,O
27,33,O
exons,33,O
and,33,O
the,33,O
promoter,33,O
region,33,O
of,33,O
the,33,O
RB1,33,O
gene,33,O
in,33,O
familial,33,B-CompositeMention
or,33,I-CompositeMention
sporadic,33,I-CompositeMention
bilateral,33,I-CompositeMention
retinoblastoma,33,I-CompositeMention
by,33,O
using,33,O
single-strand,33,O
conformation,33,O
polymorphism,33,O
analysis,33,O
.,33,O
For,34,O
improvement,34,O
over,34,O
previous,34,O
studies,34,O
",",34,O
a,34,O
new,34,O
set,34,O
of,34,O
primers,34,O
has,34,O
been,34,O
designed,34,O
",",34,O
which,34,O
allow,34,O
for,34,O
amplification,34,O
of,34,O
the,34,O
coding,34,O
and,34,O
splicing,34,O
sequences,34,O
only,34,O
.,34,O
The,35,O
positioning,35,O
of,35,O
the,35,O
polymerase,35,O
chain,35,O
reaction,35,O
(,35,O
PCR,35,O
),35,O
primers,35,O
was,35,O
such,35,O
that,35,O
the,35,O
resulting,35,O
PCR,35,O
products,35,O
were,35,O
of,35,O
different,35,O
sizes,35,O
",",35,O
which,35,O
enabled,35,O
us,35,O
to,35,O
analyze,35,O
two,35,O
different,35,O
exons,35,O
simultaneously,35,O
and,35,O
still,35,O
distinguish,35,O
between,35,O
the,35,O
banding,35,O
profiles,35,O
for,35,O
both,35,O
(,35,O
biplex,35,O
analysis,35,O
),35,O
.,35,O
By,36,O
using,36,O
this,36,O
approach,36,O
",",36,O
we,36,O
were,36,O
able,36,O
to,36,O
identify,36,O
mutation,36,O
in,36,O
22,36,O
new,36,O
patients,36,O
",",36,O
but,36,O
the,36,O
overall,36,O
efficiency,36,O
of,36,O
the,36,O
procedure,36,O
when,36,O
we,36,O
used,36,O
a,36,O
single-pass,36,O
regimen,36,O
was,36,O
only,36,O
48,36,O
%,36,O
.,36,O
The,37,O
mutations,37,O
were,37,O
small,37,O
insertions,37,O
and,37,O
deletions,37,O
and,37,O
point,37,O
mutations,37,O
in,37,O
roughly,37,O
equal,37,O
proportions,37,O
..,37,O
Type,38,B-SpecificDisease
II,38,I-SpecificDisease
human,38,I-SpecificDisease
complement,38,I-SpecificDisease
C2,38,I-SpecificDisease
deficiency,38,I-SpecificDisease
.,38,O
Allele-specific,39,O
amino,39,O
acid,39,O
substitutions,39,O
(,39,O
Ser189,39,O
--,39,O
>,39,O
Phe,39,O
;,39,O
Gly444,39,O
--,39,O
>,39,O
Arg,39,O
),39,O
cause,39,O
impaired,39,O
C2,39,O
secretion,39,O
.,39,O
Type,40,B-SpecificDisease
II,40,I-SpecificDisease
complement,40,I-SpecificDisease
protein,40,I-SpecificDisease
C2,40,I-SpecificDisease
deficiency,40,I-SpecificDisease
is,40,O
characterized,40,O
by,40,O
a,40,O
selective,40,O
block,40,O
in,40,O
C2,40,O
secretion,40,O
.,40,O
The,41,O
Type,41,O
II,41,O
C2,41,O
null,41,O
allele,41,O
(,41,O
C2Q0,41,O
),41,O
is,41,O
linked,41,O
to,41,O
two,41,O
major,41,O
histocompatibility,41,O
haplotypes,41,O
(,41,O
MHC,41,O
),41,O
that,41,O
differ,41,O
from,41,O
the,41,O
MHC,41,O
of,41,O
the,41,O
more,41,O
common,41,O
Type,41,B-SpecificDisease
I,41,I-SpecificDisease
C2,41,I-SpecificDisease
deficiency,41,I-SpecificDisease
.,41,O
To,42,O
determine,42,O
the,42,O
molecular,42,O
basis,42,O
of,42,O
Type,42,B-SpecificDisease
II,42,I-SpecificDisease
deficiency,42,I-SpecificDisease
the,42,O
two,42,O
Type,42,O
II,42,O
C2Q0,42,O
genes,42,O
were,42,O
isolated,42,O
and,42,O
transfected,42,O
separately,42,O
into,42,O
L-cells,42,O
.,42,O
Subsequent,43,O
molecular,43,O
biology,43,O
",",43,O
biosynthetic,43,O
",",43,O
and,43,O
immunofluorescence,43,O
studies,43,O
demonstrated,43,O
that,43,O
C2,43,O
secretion,43,O
is,43,O
impaired,43,O
in,43,O
Type,43,B-SpecificDisease
II,43,I-SpecificDisease
C2,43,I-SpecificDisease
deficiency,43,I-SpecificDisease
because,43,O
of,43,O
different,43,O
missense,43,O
mutations,43,O
at,43,O
highly,43,O
conserved,43,O
residues,43,O
in,43,O
each,43,O
of,43,O
the,43,O
C2Q0,43,O
alleles,43,O
.,43,O
One,44,O
is,44,O
in,44,O
exon,44,O
5,44,O
(,44,O
nucleotide,44,O
C566,44,O
--,44,O
>,44,O
T,44,O
;,44,O
Ser189,44,O
--,44,O
>,44,O
Phe,44,O
),44,O
of,44,O
the,44,O
C2Q0,44,O
gene,44,O
linked,44,O
to,44,O
the,44,O
MHC,44,O
haplotype,44,O
A11,44,O
",",44,O
B35,44,O
",",44,O
DRw1,44,O
",",44,O
BFS,44,O
",",44,O
C4A0B1,44,O
.,44,O
The,45,O
other,45,O
is,45,O
in,45,O
exon,45,O
11,45,O
(,45,O
G1930,45,O
--,45,O
>,45,O
A,45,O
;,45,O
Gly444,45,O
--,45,O
>,45,O
Arg,45,O
),45,O
of,45,O
the,45,O
C2Q0,45,O
gene,45,O
linked,45,O
to,45,O
the,45,O
MHC,45,O
haplotype,45,O
A2,45,O
",",45,O
B5,45,O
",",45,O
DRw4,45,O
",",45,O
BFS,45,O
",",45,O
C4A3B1,45,O
.,45,O
Each,46,O
mutant,46,O
C2,46,O
gene,46,O
product,46,O
is,46,O
retained,46,O
early,46,O
in,46,O
the,46,O
secretory,46,O
pathway,46,O
.,46,O
These,47,O
mutants,47,O
provide,47,O
models,47,O
for,47,O
elucidating,47,O
the,47,O
C2,47,O
secretory,47,O
pathway,47,O
..,47,O
Defective,48,O
dimerization,48,O
of,48,O
von,48,B-Modifier
Willebrand,48,I-Modifier
factor,48,O
subunits,48,O
due,48,O
to,48,O
a,48,O
Cys-,48,O
>,48,O
Arg,48,O
mutation,48,O
in,48,O
type,48,B-SpecificDisease
IID,48,I-SpecificDisease
von,48,I-SpecificDisease
Willebrand,48,I-SpecificDisease
disease,48,I-SpecificDisease
.,48,O
The,49,O
same,49,O
heterozygous,49,O
T,49,O
-,49,O
>,49,O
C,49,O
transition,49,O
at,49,O
nt,49,O
8567,49,O
of,49,O
the,49,O
von,49,B-Modifier
Willebrand,49,I-Modifier
factor,49,O
(,49,O
vWF,49,O
),49,O
transcript,49,O
was,49,O
found,49,O
in,49,O
two,49,O
unrelated,49,O
patients,49,O
with,49,O
type,49,B-SpecificDisease
IID,49,I-SpecificDisease
von,49,I-SpecificDisease
Willebrand,49,I-SpecificDisease
disease,49,I-SpecificDisease
",",49,O
with,49,O
no,49,O
other,49,O
apparent,49,O
abnormality,49,O
.,49,O
In,50,O
one,50,O
family,50,O
",",50,O
both,50,O
alleles,50,O
were,50,O
normal,50,O
in,50,O
the,50,O
parents,50,O
and,50,O
one,50,O
sister,50,O
;,50,O
thus,50,O
",",50,O
the,50,O
mutation,50,O
originated,50,O
de,50,O
novo,50,O
in,50,O
the,50,O
proposita,50,O
.,50,O
The,51,O
second,51,O
patient,51,O
also,51,O
had,51,O
asymptomatic,51,O
parents,51,O
who,51,O
",",51,O
however,51,O
",",51,O
were,51,O
not,51,O
available,51,O
for,51,O
study,51,O
.,51,O
The,52,O
structural,52,O
consequences,52,O
of,52,O
the,52,O
identified,52,O
mutation,52,O
",",52,O
resulting,52,O
in,52,O
the,52,O
CyS2010,52,O
-,52,O
>,52,O
Arg,52,O
substitution,52,O
",",52,O
were,52,O
evaluated,52,O
by,52,O
expression,52,O
of,52,O
the,52,O
vWF,52,O
carboxyl-terminal,52,O
domain,52,O
containing,52,O
residues,52,O
1366-2050,52,O
.,52,O
Insect,53,O
cells,53,O
infected,53,O
with,53,O
recombinant,53,O
baculovirus,53,O
expressing,53,O
normal,53,O
vWF,53,O
sequence,53,O
secreted,53,O
a,53,O
disulfide,53,O
linked,53,O
dimeric,53,O
molecule,53,O
with,53,O
an,53,O
apparent,53,O
molecular,53,O
mass,53,O
of,53,O
150,53,O
kDa,53,O
before,53,O
reduction,53,O
",",53,O
yielding,53,O
a,53,O
single,53,O
band,53,O
of,53,O
80,53,O
kDa,53,O
after,53,O
disulfide,53,O
bond,53,O
reduction,53,O
.,53,O
In,54,O
contrast,54,O
",",54,O
cells,54,O
expressing,54,O
the,54,O
mutant,54,O
fragment,54,O
secreted,54,O
a,54,O
monomeric,54,O
molecule,54,O
of,54,O
apparent,54,O
molecular,54,O
mass,54,O
of,54,O
80,54,O
kDa,54,O
",",54,O
which,54,O
remained,54,O
unchanged,54,O
after,54,O
reduction,54,O
.,54,O
We,55,O
conclude,55,O
that,55,O
CyS2010,55,O
is,55,O
essential,55,O
for,55,O
normal,55,O
dimerization,55,O
of,55,O
vWF,55,O
subunits,55,O
through,55,O
disulfide,55,O
bonding,55,O
of,55,O
carboxyl-terminal,55,O
domains,55,O
and,55,O
that,55,O
a,55,O
heterozygous,55,O
mutation,55,O
in,55,O
the,55,O
corresponding,55,O
codon,55,O
is,55,O
responsible,55,O
for,55,O
defective,55,O
multimer,55,O
formation,55,O
in,55,O
type,55,B-SpecificDisease
IID,55,I-SpecificDisease
von,55,I-SpecificDisease
Willebrand,55,I-SpecificDisease
disease,55,I-SpecificDisease
..,55,O
Wiskott-Aldrich,56,B-Modifier
syndrome,56,I-Modifier
protein,56,O
",",56,O
a,56,O
novel,56,O
effector,56,O
for,56,O
the,56,O
GTPase,56,O
CDC42Hs,56,O
",",56,O
is,56,O
implicated,56,O
in,56,O
actin,56,O
polymerization,56,O
.,56,O
The,57,O
Rho,57,O
family,57,O
of,57,O
GTPases,57,O
control,57,O
diverse,57,O
biological,57,O
processes,57,O
",",57,O
including,57,O
cell,57,O
morphology,57,O
and,57,O
mitogenesis,57,O
.,57,O
We,58,O
have,58,O
identified,58,O
WASP,58,O
",",58,O
the,58,O
protein,58,O
that,58,O
is,58,O
defective,58,O
in,58,O
Wiskott-Aldrich,58,B-SpecificDisease
syndrome,58,I-SpecificDisease
(,58,O
WAS,58,B-SpecificDisease
),58,O
",",58,O
as,58,O
a,58,O
novel,58,O
effector,58,O
for,58,O
CDC42Hs,58,O
",",58,O
but,58,O
not,58,O
for,58,O
the,58,O
other,58,O
Rho,58,O
family,58,O
members,58,O
",",58,O
Rac,58,O
and,58,O
Rho,58,O
.,58,O
This,59,O
interaction,59,O
is,59,O
dependent,59,O
on,59,O
the,59,O
presence,59,O
of,59,O
the,59,O
G,59,O
protein-binding,59,O
domain,59,O
.,59,O
Cellular,60,O
expression,60,O
of,60,O
epitope-tagged,60,O
WASP,60,O
produces,60,O
clusters,60,O
of,60,O
WASP,60,O
that,60,O
are,60,O
highly,60,O
enriched,60,O
in,60,O
polymerized,60,O
actin,60,O
.,60,O
This,61,O
clustering,61,O
is,61,O
not,61,O
observed,61,O
with,61,O
a,61,O
C-terminally,61,O
deleted,61,O
WASP,61,O
and,61,O
is,61,O
inhibited,61,O
by,61,O
coexpression,61,O
with,61,O
dominant,61,O
negative,61,O
CDC42Hs-N17,61,O
",",61,O
but,61,O
not,61,O
with,61,O
dominant,61,O
negative,61,O
forms,61,O
of,61,O
Rac,61,O
or,61,O
Rho,61,O
.,61,O
Thus,62,O
",",62,O
WASP,62,O
provides,62,O
a,62,O
novel,62,O
link,62,O
between,62,O
CDC42Hs,62,O
and,62,O
the,62,O
actin,62,O
cytoskeleton,62,O
",",62,O
which,62,O
suggests,62,O
a,62,O
molecular,62,O
mechanism,62,O
for,62,O
many,62,O
of,62,O
the,62,O
cellular,62,O
abnormalities,62,O
in,62,O
WAS,62,B-SpecificDisease
.,62,O
The,63,O
WASP,63,O
sequence,63,O
contains,63,O
two,63,O
novel,63,O
domains,63,O
that,63,O
are,63,O
homologous,63,O
to,63,O
other,63,O
proteins,63,O
involved,63,O
in,63,O
action,63,O
organization,63,O
..,63,O
X-linked,64,B-SpecificDisease
adrenoleukodystrophy,64,I-SpecificDisease
is,64,O
a,64,O
frequent,64,O
cause,64,O
of,64,O
idiopathic,64,O
Addison,64,B-SpecificDisease
's,64,I-SpecificDisease
disease,64,I-SpecificDisease
in,64,O
young,64,O
adult,64,O
male,64,O
patients,64,O
.,64,O
X-Linked,65,B-SpecificDisease
adrenoleukodystrophy,65,I-SpecificDisease
(,65,O
ALD,65,B-SpecificDisease
),65,O
is,65,O
a,65,O
genetic,65,B-DiseaseClass
disease,65,I-DiseaseClass
associated,65,O
with,65,O
demyelination,65,B-DiseaseClass
of,65,I-DiseaseClass
the,65,I-DiseaseClass
central,65,I-DiseaseClass
nervous,65,I-DiseaseClass
system,65,I-DiseaseClass
",",65,O
adrenal,65,B-DiseaseClass
insufficiency,65,I-DiseaseClass
",",65,O
and,65,O
accumulation,65,O
of,65,O
very,65,O
long,65,O
chain,65,O
fatty,65,O
acids,65,O
in,65,O
tissue,65,O
and,65,O
body,65,O
fluids,65,O
.,65,O
ALD,66,B-SpecificDisease
is,66,O
due,66,O
to,66,O
mutation,66,O
of,66,O
a,66,O
gene,66,O
located,66,O
in,66,O
Xq28,66,O
that,66,O
encodes,66,O
a,66,O
peroxisomal,66,O
transporter,66,O
protein,66,O
of,66,O
unknown,66,O
function,66,O
.,66,O
The,67,O
most,67,O
common,67,O
phenotype,67,O
of,67,O
ALD,67,B-SpecificDisease
is,67,O
the,67,O
cerebral,67,O
form,67,O
(,67,O
45,67,O
%,67,O
),67,O
that,67,O
develops,67,O
in,67,O
boys,67,O
between,67,O
5-12,67,O
yr.,67,O
Adrenomyeloneuropathy,67,B-SpecificDisease
(,67,O
AMN,67,B-SpecificDisease
),67,O
involves,67,O
the,67,O
spinal,67,O
cord,67,O
and,67,O
peripheral,67,O
nerves,67,O
in,67,O
young,67,O
adults,67,O
(,67,O
35,67,O
%,67,O
),67,O
.,67,O
Adrenal,68,B-DiseaseClass
insufficiency,68,I-DiseaseClass
(,68,O
Addisons,68,B-SpecificDisease
disease,68,I-SpecificDisease
),68,O
is,68,O
frequently,68,O
associated,68,O
with,68,O
AMN,68,B-SpecificDisease
or,68,O
cerebral,68,B-SpecificDisease
ALD,68,I-SpecificDisease
and,68,O
may,68,O
remain,68,O
the,68,O
only,68,O
clinical,68,O
expression,68,O
of,68,O
ALD,68,B-SpecificDisease
(,68,O
8,68,O
%,68,O
of,68,O
cases,68,O
),68,O
.,68,O
The,69,O
prevalence,69,O
of,69,O
ALD,69,B-SpecificDisease
among,69,O
adults,69,O
with,69,O
Addisons,69,B-SpecificDisease
disease,69,I-SpecificDisease
remains,69,O
unknown,69,O
.,69,O
To,70,O
evaluate,70,O
this,70,O
prevalence,70,O
",",70,O
we,70,O
performed,70,O
biochemical,70,O
analysis,70,O
of,70,O
very,70,O
long,70,O
chain,70,O
fatty,70,O
acids,70,O
in,70,O
14,70,O
male,70,O
patients,70,O
(,70,O
age,70,O
ranging,70,O
from,70,O
12-45,70,O
yr,70,O
at,70,O
diagnosis,70,O
),70,O
previously,70,O
diagnosed,70,O
as,70,O
having,70,O
primary,70,O
idiopathic,70,O
adrenocortical,70,B-DiseaseClass
insufficiency,70,I-DiseaseClass
.,70,O
In,71,O
5,71,O
of,71,O
14,71,O
patients,71,O
(,71,O
35,71,O
%,71,O
),71,O
",",71,O
elevated,71,O
plasma,71,O
concentrations,71,O
of,71,O
very,71,O
long,71,O
chain,71,O
fatty,71,O
acids,71,O
were,71,O
detected,71,O
.,71,O
None,72,O
of,72,O
these,72,O
patients,72,O
had,72,O
adrenocortical,72,O
antibodies,72,O
.,72,O
By,73,O
electrophysiological,73,O
tests,73,O
and,73,O
magnetic,73,O
resonance,73,O
imaging,73,O
it,73,O
was,73,O
determined,73,O
that,73,O
two,73,O
patients,73,O
had,73,O
cerebral,73,B-SpecificDisease
ALD,73,I-SpecificDisease
",",73,O
one,73,O
had,73,O
adrenomyeloneuropathy,73,B-SpecificDisease
with,73,O
cerebral,73,O
involvement,73,O
",",73,O
and,73,O
two,73,O
had,73,O
preclinical,73,O
AMN,73,B-SpecificDisease
.,73,O
Our,74,O
data,74,O
support,74,O
the,74,O
hypothesis,74,O
that,74,O
ALD,74,B-SpecificDisease
is,74,O
a,74,O
frequent,74,O
cause,74,O
of,74,O
idiopathic,74,O
Addisons,74,B-SpecificDisease
disease,74,I-SpecificDisease
in,74,O
children,74,O
and,74,O
adults,74,O
..,74,O
Tumor,75,B-Modifier
suppression,75,O
and,75,O
apoptosis,75,O
of,75,O
human,75,O
prostate,75,B-SpecificDisease
carcinoma,75,I-SpecificDisease
mediated,75,O
by,75,O
a,75,O
genetic,75,O
locus,75,O
within,75,O
human,75,O
chromosome,75,O
10pter-q11,75,O
.,75,O
Prostate,76,B-SpecificDisease
cancer,76,I-SpecificDisease
is,76,O
the,76,O
second,76,O
leading,76,O
cause,76,O
of,76,O
male,76,O
cancer,76,B-Modifier
deaths,76,O
in,76,O
the,76,O
United,76,O
States,76,O
.,76,O
Yet,77,O
",",77,O
despite,77,O
a,77,O
large,77,O
international,77,O
effort,77,O
",",77,O
little,77,O
is,77,O
known,77,O
about,77,O
the,77,O
molecular,77,O
mechanisms,77,O
that,77,O
underlie,77,O
this,77,O
devastating,77,O
disease,77,O
.,77,O
Prostate,78,O
secretory,78,O
epithelial,78,O
cells,78,O
and,78,O
androgen-dependent,78,O
prostate,78,B-SpecificDisease
carcinomas,78,I-SpecificDisease
undergo,78,O
apoptosis,78,O
in,78,O
response,78,O
to,78,O
androgen,78,O
deprivation,78,O
and,78,O
",",78,O
furthermore,78,O
",",78,O
most,78,O
prostate,78,B-SpecificDisease
carcinomas,78,I-SpecificDisease
become,78,O
androgen,78,O
independent,78,O
and,78,O
refractory,78,O
to,78,O
further,78,O
therapeutic,78,O
manipulations,78,O
during,78,O
disease,78,O
progression,78,O
.,78,O
Definition,79,O
of,79,O
the,79,O
genetic,79,O
events,79,O
that,79,O
trigger,79,O
apoptosis,79,O
in,79,O
the,79,O
prostate,79,O
could,79,O
provide,79,O
important,79,O
insights,79,O
into,79,O
critical,79,O
pathways,79,O
in,79,O
normal,79,O
development,79,O
as,79,O
well,79,O
as,79,O
elucidate,79,O
the,79,O
perturbations,79,O
of,79,O
those,79,O
key,79,O
pathways,79,O
in,79,O
neoplastic,79,O
transformation,79,O
.,79,O
We,80,O
report,80,O
the,80,O
functional,80,O
definition,80,O
of,80,O
a,80,O
novel,80,O
genetic,80,O
locus,80,O
within,80,O
human,80,O
chromosome,80,O
10pter-q11,80,O
that,80,O
mediates,80,O
both,80,O
in,80,O
vivo,80,O
tumor,80,O
suppression,80,O
and,80,O
in,80,O
vitro,80,O
apoptosis,80,O
of,80,O
prostatic,80,B-Modifier
adenocarcinoma,80,I-Modifier
cells,80,O
.,80,O
A,81,O
defined,81,O
fragment,81,O
of,81,O
human,81,O
chromosome,81,O
10,81,O
was,81,O
transferred,81,O
via,81,O
microcell,81,O
fusion,81,O
into,81,O
a,81,O
prostate,81,B-Modifier
adenocarcinoma,81,I-Modifier
cell,81,O
line,81,O
.,81,O
Microcell,82,O
hybrids,82,O
containing,82,O
only,82,O
the,82,O
region,82,O
10pter-q11,82,O
were,82,O
suppressed,82,O
for,82,O
tumorigenicity,82,O
following,82,O
injection,82,O
of,82,O
microcell,82,O
hybrids,82,O
into,82,O
nude,82,O
mice,82,O
.,82,O
Furthermore,83,O
",",83,O
the,83,O
complemented,83,O
hybrids,83,O
undergo,83,O
programmed,83,O
cell,83,O
death,83,O
in,83,O
vitro,83,O
via,83,O
a,83,O
mechanism,83,O
that,83,O
does,83,O
not,83,O
require,83,O
nuclear,83,O
localization,83,O
of,83,O
p53,83,O
.,83,O
These,84,O
data,84,O
functionally,84,O
define,84,O
a,84,O
novel,84,O
genetic,84,O
locus,84,O
",",84,O
designated,84,O
PAC1,84,O
",",84,O
for,84,O
prostate,84,O
adenocarcinoma,84,O
1,84,O
",",84,O
involved,84,O
in,84,O
tumor,84,O
suppression,84,O
of,84,O
human,84,O
prostate,84,B-SpecificDisease
carcinoma,84,I-SpecificDisease
and,84,O
furthermore,84,O
strongly,84,O
suggest,84,O
that,84,O
the,84,O
cell,84,O
death,84,O
pathway,84,O
can,84,O
be,84,O
functionally,84,O
restored,84,O
in,84,O
prostatic,84,B-SpecificDisease
adenocarcinoma,84,I-SpecificDisease
..,84,O
Low,85,O
incidence,85,O
of,85,O
BRCA2,85,O
mutations,85,O
in,85,O
breast,85,B-SpecificDisease
carcinoma,85,I-SpecificDisease
and,85,O
other,85,O
cancers,85,B-DiseaseClass
.,85,O
Inherited,86,O
mutant,86,O
alleles,86,O
of,86,O
familial,86,O
tumour,86,B-Modifier
suppressor,86,O
genes,86,O
predispose,86,O
individuals,86,O
to,86,O
particular,86,O
types,86,O
of,86,O
cancer,86,B-DiseaseClass
.,86,O
In,87,O
addition,87,O
to,87,O
an,87,O
involvement,87,O
in,87,O
inherited,87,O
susceptibility,87,O
to,87,O
cancer,87,B-DiseaseClass
",",87,O
these,87,O
tumour,87,B-Modifier
suppressor,87,O
genes,87,O
are,87,O
targets,87,O
for,87,O
somatic,87,O
mutations,87,O
in,87,O
sporadic,87,B-DiseaseClass
cancers,87,I-DiseaseClass
of,87,O
the,87,O
same,87,O
type,87,O
found,87,O
in,87,O
the,87,O
familial,87,O
forms,87,O
.,87,O
An,88,O
exception,88,O
is,88,O
BRCA1,88,O
",",88,O
which,88,O
contributes,88,O
to,88,O
a,88,O
significant,88,O
fraction,88,O
of,88,O
familial,88,B-CompositeMention
breast,88,I-CompositeMention
and,88,I-CompositeMention
ovarian,88,I-CompositeMention
cancer,88,I-CompositeMention
",",88,O
but,88,O
undergoes,88,O
mutation,88,O
at,88,O
very,88,O
low,88,O
rates,88,O
in,88,O
sporadic,88,O
breast,88,O
and,88,O
ovarian,88,O
cancers,88,O
.,88,O
This,89,O
finding,89,O
suggests,89,O
that,89,O
other,89,O
genes,89,O
may,89,O
be,89,O
the,89,O
principal,89,O
targets,89,O
for,89,O
somatic,89,O
mutation,89,O
in,89,O
breast,89,B-SpecificDisease
carcinoma,89,I-SpecificDisease
.,89,O
A,90,O
second,90,O
",",90,O
recently,90,O
identified,90,O
familial,90,B-Modifier
breast,90,I-Modifier
cancer,90,I-Modifier
gene,90,O
",",90,O
BRCA2,90,O
(,90,O
refs,90,O
5-8,90,O
),90,O
",",90,O
accounts,90,O
for,90,O
a,90,O
proportion,90,O
of,90,O
breast,90,B-SpecificDisease
cancer,90,I-SpecificDisease
roughly,90,O
equal,90,O
to,90,O
BRCA1,90,O
.,90,O
Like,91,O
BRCA1,91,O
",",91,O
BRCA2,91,O
behaves,91,O
as,91,O
a,91,O
dominantly,91,O
inherited,91,O
tumour,91,B-Modifier
suppressor,91,O
gene,91,O
.,91,O
Individuals,92,O
who,92,O
inherit,92,O
one,92,O
mutant,92,O
allele,92,O
are,92,O
at,92,O
increased,92,O
risk,92,O
for,92,O
breast,92,B-SpecificDisease
cancer,92,I-SpecificDisease
",",92,O
and,92,O
the,92,O
tumours,92,B-DiseaseClass
they,92,O
develop,92,O
lose,92,O
the,92,O
wild-type,92,O
allele,92,O
by,92,O
heterozygous,92,O
deletion,92,O
.,92,O
The,93,O
BRCA2,93,O
coding,93,O
sequence,93,O
is,93,O
huge,93,O
",",93,O
composed,93,O
of,93,O
26,93,O
exons,93,O
that,93,O
span,93,O
10,93,O
",",93,O
443,93,O
bp,93,O
.,93,O
Here,94,O
we,94,O
investigate,94,O
the,94,O
rate,94,O
of,94,O
BRCA2,94,O
mutation,94,O
in,94,O
sporadic,94,B-SpecificDisease
breast,94,I-SpecificDisease
cancers,94,I-SpecificDisease
and,94,O
in,94,O
a,94,O
set,94,O
of,94,O
cell,94,O
lines,94,O
that,94,O
represent,94,O
twelve,94,O
other,94,O
tumour,94,B-Modifier
types,94,O
.,94,O
Surprisingly,95,O
",",95,O
mutations,95,O
in,95,O
BRCA2,95,O
are,95,O
infrequent,95,O
in,95,O
cancers,95,B-DiseaseClass
including,95,O
breast,95,B-SpecificDisease
carcinoma,95,I-SpecificDisease
.,95,O
However,96,O
",",96,O
a,96,O
probable,96,O
germline,96,O
mutation,96,O
in,96,O
a,96,O
pancreatic,96,B-Modifier
tumour,96,I-Modifier
cell,96,O
line,96,O
suggests,96,O
a,96,O
role,96,O
for,96,O
BRCA2,96,O
in,96,O
susceptibility,96,O
to,96,O
pancreatic,96,B-SpecificDisease
cancer,96,I-SpecificDisease
..,96,O
Founding,97,O
BRCA1,97,O
mutations,97,O
in,97,O
hereditary,97,B-CompositeMention
breast,97,I-CompositeMention
and,97,I-CompositeMention
ovarian,97,I-CompositeMention
cancer,97,I-CompositeMention
in,97,O
southern,97,O
Sweden,97,O
.,97,O
Nine,98,O
different,98,O
germ-line,98,O
mutations,98,O
in,98,O
the,98,O
BRCA1,98,O
breast,98,B-Modifier
and,98,I-Modifier
ovarian,98,I-Modifier
cancer,98,I-Modifier
susceptibility,98,O
gene,98,O
were,98,O
identified,98,O
in,98,O
15,98,O
of,98,O
47,98,O
kindreds,98,O
from,98,O
southern,98,O
Sweden,98,O
",",98,O
by,98,O
use,98,O
of,98,O
SSCP,98,O
and,98,O
heteroduplex,98,O
analysis,98,O
of,98,O
all,98,O
exons,98,O
and,98,O
flanking,98,O
intron,98,O
region,98,O
and,98,O
by,98,O
a,98,O
protein-truncation,98,O
test,98,O
for,98,O
exon,98,O
11,98,O
",",98,O
followed,98,O
by,98,O
direct,98,O
sequencing,98,O
.,98,O
All,99,O
but,99,O
one,99,O
of,99,O
the,99,O
mutations,99,O
are,99,O
predicted,99,O
to,99,O
give,99,O
rise,99,O
to,99,O
premature,99,O
translation,99,O
termination,99,O
and,99,O
include,99,O
seven,99,O
frameshift,99,O
insertions,99,O
or,99,O
deletions,99,O
",",99,O
a,99,O
nonsense,99,O
mutation,99,O
",",99,O
and,99,O
a,99,O
splice,99,O
acceptor,99,O
site,99,O
mutation,99,O
.,99,O
The,100,O
remaining,100,O
mutation,100,O
is,100,O
a,100,O
missense,100,O
mutation,100,O
(,100,O
Cys61Gly,100,O
),100,O
in,100,O
the,100,O
zinc-binding,100,O
motif,100,O
.,100,O
Four,101,O
novel,101,O
Swedish,101,O
founding,101,O
mutations,101,O
were,101,O
identified,101,O
the,101,O
nucleotide,101,O
2595,101,O
deletion,101,O
A,101,O
was,101,O
found,101,O
in,101,O
five,101,O
families,101,O
",",101,O
the,101,O
C,101,O
1806,101,O
T,101,O
nonsense,101,O
mutation,101,O
in,101,O
three,101,O
families,101,O
",",101,O
the,101,O
3166,101,O
insertion,101,O
TGAGA,101,O
in,101,O
three,101,O
families,101,O
",",101,O
and,101,O
the,101,O
nucleotide,101,O
1201,101,O
deletion,101,O
11,101,O
in,101,O
two,101,O
families,101,O
.,101,O
Analysis,102,O
of,102,O
the,102,O
intragenic,102,O
polymorphism,102,O
D17S855,102,O
supports,102,O
common,102,O
origins,102,O
of,102,O
the,102,O
mutations,102,O
.,102,O
Eleven,103,O
of,103,O
the,103,O
15,103,O
kindreds,103,O
manifesting,103,O
BRCA1,103,O
mutations,103,O
were,103,O
breast-ovarian,103,B-Modifier
cancer,103,I-Modifier
families,103,O
",",103,O
several,103,O
of,103,O
them,103,O
with,103,O
a,103,O
predominant,103,O
ovarian,103,B-Modifier
cancer,103,I-Modifier
phenotype,103,O
.,103,O
The,104,O
set,104,O
of,104,O
32,104,O
families,104,O
in,104,O
which,104,O
no,104,O
BRCA1,104,O
alterations,104,O
were,104,O
detected,104,O
included,104,O
1,104,O
breast-ovarian,104,B-Modifier
cancer,104,I-Modifier
kindred,104,O
manifesting,104,O
clear,104,O
linkage,104,O
to,104,O
the,104,O
BRCA1,104,O
region,104,O
and,104,O
loss,104,O
of,104,O
the,104,O
wild-type,104,O
chromosome,104,O
in,104,O
associated,104,O
tumors,104,B-DiseaseClass
.,104,O
Other,105,O
tumor,105,B-Modifier
types,105,O
found,105,O
in,105,O
BRCA1,105,O
mutation/haplotype,105,O
carriers,105,O
included,105,O
prostatic,105,O
",",105,O
pancreas,105,O
",",105,O
skin,105,O
",",105,O
and,105,O
lung,105,O
cancer,105,O
",",105,O
a,105,O
malignant,105,B-SpecificDisease
melanoma,105,I-SpecificDisease
",",105,O
an,105,O
oligodendroglioma,105,B-SpecificDisease
",",105,O
and,105,O
a,105,O
carcinosarcoma,105,B-SpecificDisease
.,105,O
In,106,O
all,106,O
",",106,O
12,106,O
of,106,O
16,106,O
kindreds,106,O
manifesting,106,O
BRCA1,106,O
mutation,106,O
or,106,O
linkage,106,O
contained,106,O
ovarian,106,B-SpecificDisease
cancer,106,I-SpecificDisease
",",106,O
as,106,O
compared,106,O
with,106,O
only,106,O
6,106,O
of,106,O
the,106,O
remaining,106,O
31,106,O
families,106,O
(,106,O
P,106,O
<,106,O
.,106,O
001,107,O
),107,O
.,107,O
The,108,O
present,108,O
study,108,O
confirms,108,O
the,108,O
involvement,108,O
of,108,O
BRCA1,108,O
in,108,O
disease,108,O
predisposition,108,O
for,108,O
a,108,O
subset,108,O
of,108,O
hereditary,108,B-Modifier
breast,108,I-Modifier
cancer,108,I-Modifier
families,108,O
often,108,O
characterized,108,O
by,108,O
ovarian,108,B-SpecificDisease
cancers,108,I-SpecificDisease
.,108,O
Rapid,109,O
detection,109,O
of,109,O
regionally,109,O
clustered,109,O
germ-line,109,O
BRCA1,109,O
mutations,109,O
by,109,O
multiplex,109,O
heteroduplex,109,O
analysis,109,O
.,109,O
UKCCCR,110,O
Familial,110,O
Ovarian,110,B-Modifier
Cancer,110,I-Modifier
Study,110,O
Group,110,O
.,110,O
Germ-line,111,O
mutations,111,O
of,111,O
the,111,O
BRCA1,111,O
gene,111,O
are,111,O
responsible,111,O
for,111,O
a,111,O
substantial,111,O
proportion,111,O
of,111,O
families,111,O
with,111,O
multiple,111,O
cases,111,O
of,111,O
early-onset,111,O
breast,111,B-CompositeMention
and/or,111,I-CompositeMention
ovarian,111,I-CompositeMention
cancer,111,I-CompositeMention
.,111,O
Since,112,O
the,112,O
isolation,112,O
of,112,O
BRCA1,112,O
last,112,O
year,112,O
",",112,O
>,112,O
65,112,O
distinct,112,O
mutations,112,O
scattered,112,O
throughout,112,O
the,112,O
coding,112,O
region,112,O
have,112,O
been,112,O
detected,112,O
",",112,O
making,112,O
analysis,112,O
of,112,O
the,112,O
gene,112,O
time,112,O
consuming,112,O
and,112,O
technically,112,O
challenging,112,O
.,112,O
We,113,O
have,113,O
developed,113,O
a,113,O
multiplex,113,O
heteroduplex,113,O
analysis,113,O
that,113,O
is,113,O
designed,113,O
to,113,O
analyze,113,O
one-quarter,113,O
of,113,O
the,113,O
coding,113,O
sequence,113,O
in,113,O
a,113,O
single-step,113,O
screening,113,O
procedure,113,O
and,113,O
that,113,O
will,113,O
detect,113,O
approximately,113,O
50,113,O
%,113,O
of,113,O
all,113,O
BRCA1,113,O
mutations,113,O
so,113,O
far,113,O
reported,113,O
in,113,O
breast/ovarian,113,B-Modifier
cancer,113,I-Modifier
families,113,O
.,113,O
We,114,O
have,114,O
used,114,O
this,114,O
technique,114,O
to,114,O
analyze,114,O
BRCA1,114,O
in,114,O
162,114,O
families,114,O
with,114,O
a,114,O
history,114,O
of,114,O
breast,114,B-CompositeMention
and/or,114,I-CompositeMention
ovarian,114,I-CompositeMention
cancer,114,I-CompositeMention
and,114,O
identified,114,O
12,114,O
distinct,114,O
mutations,114,O
in,114,O
35,114,O
families,114,O
..,114,O
A,115,O
previously,115,O
undescribed,115,O
mutation,115,O
within,115,O
the,115,O
tetramerisation,115,O
domain,115,O
of,115,O
TP53,115,O
in,115,O
a,115,O
family,115,O
with,115,O
Li-Fraumeni,115,B-SpecificDisease
syndrome,115,I-SpecificDisease
.,115,O
We,116,O
report,116,O
details,116,O
of,116,O
a,116,O
family,116,O
with,116,O
classic,116,O
Li-Fraumeni,116,B-SpecificDisease
syndrome,116,I-SpecificDisease
in,116,O
which,116,O
there,116,O
is,116,O
a,116,O
mutation,116,O
in,116,O
codon,116,O
344,116,O
of,116,O
the,116,O
tumour,116,B-Modifier
suppressor,116,O
gene,116,O
TP53,116,O
.,116,O
Codon,117,O
344,117,O
is,117,O
a,117,O
key,117,O
residue,117,O
within,117,O
the,117,O
tetramerisation,117,O
domain,117,O
",",117,O
and,117,O
the,117,O
amino,117,O
acid,117,O
substitution,117,O
of,117,O
a,117,O
proline,117,O
for,117,O
a,117,O
leucine,117,O
is,117,O
predicted,117,O
to,117,O
have,117,O
profound,117,O
implications,117,O
for,117,O
tetramerisation,117,O
and,117,O
potentially,117,O
DNA,117,O
binding,117,O
.,117,O
This,118,O
is,118,O
the,118,O
first,118,O
report,118,O
of,118,O
a,118,O
mutation,118,O
at,118,O
this,118,O
residue,118,O
in,118,O
either,118,O
sporadic,118,B-DiseaseClass
tumours,118,I-DiseaseClass
or,118,O
in,118,O
the,118,O
germline,118,O
and,118,O
the,118,O
first,118,O
report,118,O
of,118,O
a,118,O
germline,118,O
mutation,118,O
within,118,O
the,118,O
tetramerisation,118,O
domain,118,O
.,118,O
The,119,O
family,119,O
does,119,O
not,119,O
appear,119,O
to,119,O
be,119,O
remarkable,119,O
in,119,O
the,119,O
spectrum,119,O
of,119,O
tumours,119,B-DiseaseClass
",",119,O
and,119,O
there,119,O
is,119,O
loss,119,O
of,119,O
the,119,O
wild-type,119,O
allele,119,O
in,119,O
a,119,O
leiomyosarcoma,119,B-SpecificDisease
from,119,O
the,119,O
proband,119,O
.,119,O
A,120,O
cell,120,O
line,120,O
has,120,O
been,120,O
established,120,O
from,120,O
the,120,O
tumour,120,B-DiseaseClass
of,120,O
the,120,O
proband,120,O
and,120,O
cytogenetic,120,O
and,120,O
molecular,120,O
studies,120,O
carried,120,O
out,120,O
",",120,O
providing,120,O
an,120,O
extensive,120,O
analysis,120,O
in,120,O
this,120,O
family,120,O
..,120,O
The,121,O
spectrum,121,O
of,121,O
RB1,121,O
germ-line,121,O
mutations,121,O
in,121,O
hereditary,121,B-SpecificDisease
retinoblastoma,121,I-SpecificDisease
.,121,O
We,122,O
have,122,O
searched,122,O
for,122,O
germ-line,122,O
RB1,122,O
mutations,122,O
in,122,O
119,122,O
patients,122,O
with,122,O
hereditary,122,B-SpecificDisease
retinoblastoma,122,I-SpecificDisease
.,122,O
Previous,123,O
investigations,123,O
by,123,O
Southern,123,O
blot,123,O
hybridization,123,O
and,123,O
PCR,123,O
fragment-length,123,O
analysis,123,O
had,123,O
revealed,123,O
mutations,123,O
in,123,O
48,123,O
patients,123,O
.,123,O
Here,124,O
we,124,O
report,124,O
on,124,O
the,124,O
analysis,124,O
of,124,O
the,124,O
remaining,124,O
71,124,O
patients,124,O
.,124,O
By,125,O
applying,125,O
heteroduplex,125,O
analysis,125,O
",",125,O
nonisotopic,125,O
SSCP,125,O
",",125,O
and,125,O
direct,125,O
sequencing,125,O
",",125,O
we,125,O
detected,125,O
germ-line,125,O
mutations,125,O
resulting,125,O
in,125,O
premature,125,O
termination,125,O
codons,125,O
or,125,O
disruption,125,O
of,125,O
splice,125,O
signals,125,O
in,125,O
51,125,O
(,125,O
72,125,O
%,125,O
),125,O
of,125,O
the,125,O
71,125,O
patients,125,O
.,125,O
Four,126,O
patients,126,O
also,126,O
showed,126,O
rare,126,O
sequence,126,O
variants,126,O
.,126,O
No,127,O
region,127,O
of,127,O
the,127,O
RB1,127,O
gene,127,O
was,127,O
preferentially,127,O
involved,127,O
in,127,O
single,127,O
base,127,O
substitutions,127,O
.,127,O
Recurrent,128,O
transitions,128,O
were,128,O
observed,128,O
at,128,O
most,128,O
of,128,O
the,128,O
14,128,O
codons,128,O
within,128,O
the,128,O
RB1,128,O
.,128,O
No,129,O
mutation,129,O
was,129,O
observed,129,O
in,129,O
exons,129,O
25-27,129,O
",",129,O
although,129,O
this,129,O
region,129,O
contains,129,O
two,129,O
CGA,129,O
codons,129,O
.,129,O
This,130,O
suggests,130,O
that,130,O
mutations,130,O
within,130,O
the,130,O
3-terminal,130,O
region,130,O
of,130,O
the,130,O
RB1,130,O
gene,130,O
may,130,O
not,130,O
be,130,O
oncogenic,130,O
.,130,O
When,131,O
these,131,O
data,131,O
were,131,O
combined,131,O
with,131,O
the,131,O
results,131,O
of,131,O
our,131,O
previous,131,O
investigations,131,O
",",131,O
mutations,131,O
were,131,O
identified,131,O
in,131,O
a,131,O
total,131,O
of,131,O
99,131,O
(,131,O
83,131,O
%,131,O
),131,O
of,131,O
119,131,O
patients,131,O
.,131,O
The,132,O
spectrum,132,O
comprises,132,O
15,132,O
%,132,O
large,132,O
deletions,132,O
",",132,O
26,132,O
%,132,O
small,132,O
length,132,O
alterations,132,O
",",132,O
and,132,O
42,132,O
%,132,O
base,132,O
substitutions,132,O
.,132,O
No,133,O
correlation,133,O
between,133,O
the,133,O
location,133,O
of,133,O
frameshift,133,O
or,133,O
nonsense,133,O
mutations,133,O
and,133,O
phenotypic,133,O
features,133,O
",",133,O
including,133,O
age,133,O
at,133,O
diagnosis,133,O
",",133,O
the,133,O
number,133,O
of,133,O
tumor,133,B-Modifier
foci,133,O
",",133,O
and,133,O
manifestation,133,O
of,133,O
nonocular,133,B-DiseaseClass
tumors,133,I-DiseaseClass
was,133,O
observed,133,O
..,133,O
Phenotypic,134,O
characterization,134,O
of,134,O
individuals,134,O
with,134,O
30-40,134,O
CAG,134,O
repeats,134,O
in,134,O
the,134,O
Huntington,134,B-Modifier
disease,134,I-Modifier
(,134,O
HD,134,B-Modifier
),134,O
gene,134,O
reveals,134,O
HD,134,B-Modifier
cases,134,O
with,134,O
36,134,O
repeats,134,O
and,134,O
apparently,134,O
normal,134,O
elderly,134,O
individuals,134,O
with,134,O
36-39,134,O
repeats,134,O
.,134,O
Abnormal,135,O
CAG,135,O
expansions,135,O
in,135,O
the,135,O
IT-15,135,O
gene,135,O
are,135,O
associated,135,O
with,135,O
Huntington,135,B-SpecificDisease
disease,135,I-SpecificDisease
(,135,O
HD,135,B-SpecificDisease
),135,O
.,135,O
In,136,O
the,136,O
diagnostic,136,O
setting,136,O
it,136,O
is,136,O
necessary,136,O
to,136,O
define,136,O
the,136,O
limits,136,O
of,136,O
the,136,O
CAG,136,O
size,136,O
ranges,136,O
on,136,O
normal,136,O
and,136,O
HD-associated,136,B-Modifier
chromosomes,136,O
.,136,O
Most,137,O
large,137,O
analyses,137,O
that,137,O
defined,137,O
the,137,O
limits,137,O
of,137,O
the,137,O
normal,137,O
and,137,O
pathological,137,O
size,137,O
ranges,137,O
employed,137,O
PCR,137,O
assays,137,O
",",137,O
which,137,O
included,137,O
the,137,O
CAG,137,O
repeats,137,O
and,137,O
a,137,O
CCG,137,O
repeat,137,O
tract,137,O
that,137,O
was,137,O
thought,137,O
to,137,O
be,137,O
invariant,137,O
.,137,O
Many,138,O
of,138,O
these,138,O
experiments,138,O
found,138,O
an,138,O
overlap,138,O
between,138,O
the,138,O
normal,138,O
and,138,O
disease,138,O
size,138,O
ranges,138,O
.,138,O
Subsequent,139,O
findings,139,O
that,139,O
the,139,O
CCG,139,O
repeats,139,O
vary,139,O
by,139,O
8,139,O
trinucleotide,139,O
lengths,139,O
suggested,139,O
that,139,O
the,139,O
limits,139,O
of,139,O
the,139,O
normal,139,O
and,139,O
disease,139,O
size,139,O
ranges,139,O
should,139,O
be,139,O
reevaluated,139,O
with,139,O
assays,139,O
that,139,O
exclude,139,O
the,139,O
CCG,139,O
polymorphism,139,O
.,139,O
Since,140,O
patients,140,O
with,140,O
between,140,O
30,140,O
and,140,O
40,140,O
repeats,140,O
are,140,O
rare,140,O
",",140,O
a,140,O
consortium,140,O
was,140,O
assembled,140,O
to,140,O
collect,140,O
such,140,O
individuals,140,O
.,140,O
All,141,O
178,141,O
samples,141,O
were,141,O
reanalyzed,141,O
in,141,O
Cambridge,141,O
by,141,O
using,141,O
assays,141,O
specific,141,O
for,141,O
the,141,O
CAG,141,O
repeats,141,O
.,141,O
We,142,O
have,142,O
optimized,142,O
methods,142,O
for,142,O
reliable,142,O
sizing,142,O
of,142,O
CAG,142,O
repeats,142,O
and,142,O
show,142,O
cases,142,O
that,142,O
demonstrate,142,O
the,142,O
dangers,142,O
of,142,O
using,142,O
PCR,142,O
assays,142,O
that,142,O
include,142,O
both,142,O
the,142,O
CAG,142,O
and,142,O
CCG,142,O
polymorphisms,142,O
.,142,O
Seven,143,O
HD,143,B-Modifier
patients,143,O
had,143,O
36,143,O
repeats,143,O
",",143,O
which,143,O
confirms,143,O
that,143,O
this,143,O
allele,143,O
is,143,O
associated,143,O
with,143,O
disease,143,O
.,143,O
Individuals,144,O
without,144,O
apparent,144,O
symptoms,144,O
or,144,O
signs,144,O
of,144,O
HD,144,B-SpecificDisease
were,144,O
found,144,O
at,144,O
36,144,O
repeats,144,O
(,144,O
aged,144,O
74,144,O
",",144,O
78,144,O
",",144,O
79,144,O
",",144,O
and,144,O
87,144,O
years,144,O
),144,O
",",144,O
37,144,O
repeats,144,O
(,144,O
aged,144,O
69,144,O
years,144,O
),144,O
",",144,O
38,144,O
repeats,144,O
(,144,O
aged,144,O
69,144,O
and,144,O
90,144,O
years,144,O
),144,O
",",144,O
and,144,O
39,144,O
repeats,144,O
(,144,O
aged,144,O
67,144,O
",",144,O
90,144,O
",",144,O
and,144,O
95,144,O
years,144,O
),144,O
.,144,O
The,145,O
detailed,145,O
case,145,O
histories,145,O
of,145,O
an,145,O
exceptional,145,O
case,145,O
from,145,O
this,145,O
series,145,O
will,145,O
be,145,O
presented,145,O
a,145,O
95-year-old,145,O
man,145,O
with,145,O
39,145,O
repeats,145,O
who,145,O
did,145,O
not,145,O
have,145,O
classical,145,O
features,145,O
of,145,O
HD,145,B-SpecificDisease
.,145,O
The,146,O
apparently,146,O
healthy,146,O
survival,146,O
into,146,O
old,146,O
age,146,O
of,146,O
some,146,O
individuals,146,O
with,146,O
36-39,146,O
repeats,146,O
suggests,146,O
that,146,O
the,146,O
HD,146,B-Modifier
mutation,146,O
may,146,O
not,146,O
always,146,O
be,146,O
fully,146,O
penetrant,146,O
..,146,O
Identification,147,O
and,147,O
expression,147,O
of,147,O
eight,147,O
novel,147,O
mutations,147,O
among,147,O
non-Jewish,147,O
patients,147,O
with,147,O
Canavan,147,B-SpecificDisease
disease,147,I-SpecificDisease
.,147,O
Canavan,148,B-SpecificDisease
disease,148,I-SpecificDisease
is,148,O
inherited,148,O
as,148,O
an,148,O
autosomal,148,O
recessive,148,O
trait,148,O
that,148,O
is,148,O
caused,148,O
by,148,O
the,148,O
deficiency,148,B-SpecificDisease
of,148,I-SpecificDisease
aspartoacylase,148,I-SpecificDisease
(,148,O
ASPA,148,O
),148,O
.,148,O
The,149,O
majority,149,O
of,149,O
patients,149,O
with,149,O
Canavan,149,B-SpecificDisease
disease,149,I-SpecificDisease
are,149,O
from,149,O
an,149,O
Ashkenazi,149,O
Jewish,149,O
background,149,O
.,149,O
Mutations,150,O
in,150,O
ASPA,150,O
that,150,O
lead,150,O
to,150,O
loss,150,O
of,150,O
enzymatic,150,O
activity,150,O
have,150,O
been,150,O
identified,150,O
",",150,O
and,150,O
E285A,150,O
and,150,O
Y231X,150,O
are,150,O
the,150,O
two,150,O
predominant,150,O
mutations,150,O
that,150,O
account,150,O
for,150,O
97,150,O
%,150,O
of,150,O
the,150,O
mutant,150,O
chromosomes,150,O
in,150,O
Ashkenazi,150,O
Jewish,150,O
patients,150,O
.,150,O
The,151,O
current,151,O
study,151,O
was,151,O
aimed,151,O
at,151,O
finding,151,O
the,151,O
molecular,151,O
basis,151,O
of,151,O
Canavan,151,B-SpecificDisease
disease,151,I-SpecificDisease
in,151,O
25,151,O
independent,151,O
patients,151,O
of,151,O
non-Jewish,151,O
background,151,O
.,151,O
Eight,152,O
novel,152,O
and,152,O
three,152,O
previously,152,O
characterized,152,O
mutations,152,O
accounted,152,O
for,152,O
80,152,O
%,152,O
(,152,O
40/50,152,O
),152,O
of,152,O
mutant,152,O
chromosomes,152,O
.,152,O
The,153,O
A305E,153,O
missense,153,O
mutation,153,O
accounted,153,O
for,153,O
48,153,O
%,153,O
(,153,O
24/50,153,O
),153,O
of,153,O
mutant,153,O
chromosomes,153,O
in,153,O
patients,153,O
of,153,O
western,153,O
European,153,O
descent,153,O
",",153,O
while,153,O
the,153,O
two,153,O
predominant,153,O
Jewish,153,O
mutations,153,O
each,153,O
accounted,153,O
for,153,O
a,153,O
single,153,O
mutant,153,O
chromosome,153,O
.,153,O
The,154,O
eight,154,O
novel,154,O
mutations,154,O
identified,154,O
included,154,O
1-,154,O
and,154,O
4-bp,154,O
deletions,154,O
(,154,O
32,154,O
deltaT,154,O
and,154,O
876,154,O
deltaAGAA,154,O
",",154,O
respectively,154,O
),154,O
and,154,O
I16T,154,O
",",154,O
G27R,154,O
",",154,O
D114E,154,O
",",154,O
G123E,154,O
",",154,O
C152Y,154,O
",",154,O
and,154,O
R168C,154,O
missense,154,O
mutations,154,O
.,154,O
The,155,O
homozygous,155,O
32,155,O
deltaT,155,O
deletion,155,O
was,155,O
identified,155,O
in,155,O
the,155,O
only,155,O
known,155,O
patient,155,O
of,155,O
African-American,155,O
origin,155,O
with,155,O
Canavan,155,B-SpecificDisease
disease,155,I-SpecificDisease
.,155,O
The,156,O
heterozygosity,156,O
for,156,O
876,156,O
deltaAGAA,156,O
mutation,156,O
was,156,O
identified,156,O
in,156,O
three,156,O
independent,156,O
patients,156,O
from,156,O
England,156,O
.,156,O
Six,157,O
single-base,157,O
changes,157,O
leading,157,O
to,157,O
missense,157,O
mutations,157,O
were,157,O
identified,157,O
in,157,O
patients,157,O
from,157,O
Turkey,157,O
(,157,O
D114E,157,O
",",157,O
R168C,157,O
),157,O
",",157,O
The,157,O
Netherlands,157,O
(,157,O
I16T,157,O
),157,O
",",157,O
Germany,157,O
(,157,O
G27R,157,O
),157,O
",",157,O
Ireland,157,O
(,157,O
C152Y,157,O
),157,O
",",157,O
and,157,O
Canada,157,O
(,157,O
G123E,157,O
),157,O
.,157,O
A,158,O
PCR-based,158,O
protocol,158,O
is,158,O
described,158,O
that,158,O
was,158,O
used,158,O
to,158,O
introduce,158,O
mutations,158,O
in,158,O
wild-type,158,O
cDNA,158,O
.,158,O
In,159,O
vitro,159,O
expression,159,O
of,159,O
mutant,159,O
cDNA,159,O
clones,159,O
demonstrated,159,O
that,159,O
all,159,O
of,159,O
these,159,O
mutations,159,O
led,159,O
to,159,O
a,159,O
deficiency,159,B-SpecificDisease
of,159,I-SpecificDisease
ASPA,159,I-SpecificDisease
and,159,O
should,159,O
therefore,159,O
result,159,O
in,159,O
Canavan,159,B-SpecificDisease
disease,159,I-SpecificDisease
..,159,O
Identification,160,O
and,160,O
chromosomal,160,O
localization,160,O
of,160,O
Atm,160,O
",",160,O
the,160,O
mouse,160,O
homolog,160,O
of,160,O
the,160,O
ataxia-telangiectasia,160,B-Modifier
gene,160,O
.,160,O
Atm,161,O
",",161,O
the,161,O
mouse,161,O
homolog,161,O
of,161,O
the,161,O
human,161,O
ATM,161,O
gene,161,O
defective,161,O
in,161,O
ataxia-telangiectasia,161,B-SpecificDisease
(,161,O
A-T,161,B-SpecificDisease
),161,O
",",161,O
has,161,O
been,161,O
identified,161,O
.,161,O
The,162,O
entire,162,O
coding,162,O
sequence,162,O
of,162,O
the,162,O
Atm,162,O
transcript,162,O
was,162,O
cloned,162,O
and,162,O
found,162,O
to,162,O
contain,162,O
an,162,O
open,162,O
reading,162,O
frame,162,O
encoding,162,O
a,162,O
protein,162,O
of,162,O
3066,162,O
amino,162,O
acids,162,O
with,162,O
84,162,O
%,162,O
overall,162,O
identity,162,O
and,162,O
91,162,O
%,162,O
similarity,162,O
to,162,O
the,162,O
human,162,O
ATM,162,O
protein,162,O
.,162,O
Variable,163,O
levels,163,O
of,163,O
expression,163,O
of,163,O
Atm,163,O
were,163,O
observed,163,O
in,163,O
different,163,O
tissues,163,O
.,163,O
Fluorescence,164,O
in,164,O
situ,164,O
hybridization,164,O
and,164,O
linkage,164,O
analysis,164,O
located,164,O
the,164,O
Atm,164,O
gene,164,O
on,164,O
mouse,164,O
chromosome,164,O
9,164,O
",",164,O
band,164,O
9C,164,O
",",164,O
in,164,O
a,164,O
region,164,O
homologous,164,O
to,164,O
the,164,O
ATM,164,O
region,164,O
on,164,O
human,164,O
chromosome,164,O
11q22-q23,164,O
..,164,O
The,165,O
mouse,165,O
homolog,165,O
of,165,O
the,165,O
Wiskott-Aldrich,165,B-Modifier
syndrome,165,I-Modifier
protein,165,O
(,165,O
WASP,165,O
),165,O
gene,165,O
is,165,O
highly,165,O
conserved,165,O
and,165,O
maps,165,O
near,165,O
the,165,O
scurfy,165,O
(,165,O
sf,165,O
),165,O
mutation,165,O
on,165,O
the,165,O
X,165,O
chromosome,165,O
.,165,O
The,166,O
mouse,166,O
WASP,166,O
gene,166,O
",",166,O
the,166,O
homolog,166,O
of,166,O
the,166,O
gene,166,O
mutated,166,O
in,166,O
Wiskott-Aldrich,166,B-SpecificDisease
syndrome,166,I-SpecificDisease
",",166,O
has,166,O
been,166,O
isolated,166,O
and,166,O
sequenced,166,O
.,166,O
the,167,O
predicted,167,O
amino,167,O
acid,167,O
sequence,167,O
is,167,O
86,167,O
%,167,O
identical,167,O
to,167,O
the,167,O
human,167,O
WASP,167,O
sequence,167,O
.,167,O
A,168,O
distinct,168,O
feature,168,O
of,168,O
the,168,O
mouse,168,O
gene,168,O
is,168,O
an,168,O
expanded,168,O
polymorphic,168,O
GGA,168,O
trinucleotide,168,O
repeat,168,O
that,168,O
codes,168,O
for,168,O
polyglycine,168,O
and,168,O
varies,168,O
from,168,O
15,168,O
to,168,O
17,168,O
triplets,168,O
in,168,O
different,168,O
Mus,168,O
musculus,168,O
strains,168,O
.,168,O
The,169,O
genomic,169,O
structure,169,O
of,169,O
the,169,O
mouse,169,O
WASP,169,O
gene,169,O
is,169,O
expressed,169,O
as,169,O
an,169,O
approximately,169,O
2,169,O
.,169,O
4-kb,170,O
mRNA,170,O
in,170,O
thymus,170,O
and,170,O
spleen,170,O
.,170,O
Chromosomal,171,O
mapping,171,O
in,171,O
an,171,O
interspecific,171,O
M.,171,O
Musculus/M,171,O
.,171,O
spretus,172,O
backcross,172,O
placed,172,O
the,172,O
Wasp,172,O
locus,172,O
near,172,O
the,172,O
centromere,172,O
of,172,O
the,172,O
mouse,172,O
X,172,O
chromosome,172,O
",",172,O
inseparable,172,O
from,172,O
Gata1,172,O
",",172,O
Tcfe3,172,O
",",172,O
and,172,O
scurfy,172,O
(,172,O
sf,172,O
),172,O
.,172,O
This,173,O
localization,173,O
makes,173,O
Wasp,173,O
a,173,O
candidate,173,O
for,173,O
involvement,173,O
in,173,O
scurfy,173,O
",",173,O
a,173,O
T,173,O
cell-mediated,173,O
fatal,173,B-DiseaseClass
lymphoreticular,173,I-DiseaseClass
disease,173,I-DiseaseClass
of,173,O
mice,173,O
that,173,O
has,173,O
previously,173,O
been,173,O
proposed,173,O
as,173,O
a,173,O
mouse,173,O
homolog,173,O
of,173,O
Wiskott-Aldrich,173,B-SpecificDisease
syndrome,173,I-SpecificDisease
.,173,O
Northern,174,O
analysis,174,O
of,174,O
sf,174,O
tissue,174,O
samples,174,O
indicated,174,O
the,174,O
presence,174,O
of,174,O
WASP,174,O
mRNA,174,O
in,174,O
liver,174,O
and,174,O
skin,174,O
",",174,O
presumably,174,O
as,174,O
a,174,O
consequence,174,O
of,174,O
lymphocytic,174,O
infiltration,174,O
",",174,O
but,174,O
non,174,O
abnormalities,174,O
in,174,O
the,174,O
amount,174,O
or,174,O
size,174,O
of,174,O
mRNA,174,O
present,174,O
.,174,O
Colchicine,175,O
in,175,O
breast,175,O
milk,175,O
of,175,O
patients,175,O
with,175,O
familial,175,B-SpecificDisease
Mediterranean,175,I-SpecificDisease
fever,175,I-SpecificDisease
.,175,O
OBJECTIVE,176,O
.,176,O
To,177,O
clarify,177,O
whether,177,O
colchicine,177,O
is,177,O
excreted,177,O
in,177,O
breast,177,O
milk,177,O
",",177,O
and,177,O
to,177,O
compare,177,O
its,177,O
concentrations,177,O
in,177,O
the,177,O
serum,177,O
and,177,O
breast,177,O
milk,177,O
of,177,O
lactating,177,O
women,177,O
who,177,O
have,177,O
familial,177,B-SpecificDisease
Mediterranean,177,I-SpecificDisease
fever,177,I-SpecificDisease
(,177,O
FMF,177,B-SpecificDisease
),177,O
.,177,O
METHODS,178,O
.,178,O
Using,179,O
a,179,O
specific,179,O
radioimmunoassay,179,O
",",179,O
we,179,O
determined,179,O
colchicine,179,O
concentrations,179,O
in,179,O
the,179,O
serum,179,O
and,179,O
breast,179,O
milk,179,O
of,179,O
4,179,O
patients,179,O
at,179,O
various,179,O
time,179,O
points,179,O
",",179,O
following,179,O
oral,179,O
administration,179,O
of,179,O
the,179,O
drug,179,O
.,179,O
The,180,O
study,180,O
evaluated,180,O
4,180,O
patients,180,O
with,180,O
FMF,180,B-SpecificDisease
who,180,O
had,180,O
been,180,O
taking,180,O
colchicine,180,O
on,180,O
a,180,O
long-term,180,O
basis,180,O
.,180,O
RESULTS,181,O
.,181,O
Colchicine,182,O
was,182,O
found,182,O
to,182,O
be,182,O
excreted,182,O
in,182,O
breast,182,O
milk,182,O
.,182,O
Its,183,O
levels,183,O
ranged,183,O
between,183,O
1,183,O
.,183,O
9,184,O
and,184,O
8,184,O
.,184,O
6,185,O
ng/ml,185,O
",",185,O
which,185,O
were,185,O
similar,185,O
to,185,O
those,185,O
found,185,O
in,185,O
the,185,O
serum,185,O
(,185,O
parallel,185,O
concentration,185,O
time,185,O
curves,185,O
),185,O
.,185,O
However,186,O
",",186,O
there,186,O
appeared,186,O
to,186,O
be,186,O
a,186,O
considerable,186,O
variation,186,O
in,186,O
colchicine,186,O
milk,186,O
concentration,186,O
among,186,O
the,186,O
different,186,O
patients,186,O
",",186,O
which,186,O
might,186,O
be,186,O
related,186,O
to,186,O
individual,186,O
breast,186,O
milk,186,O
composition,186,O
and,186,O
",",186,O
possibly,186,O
",",186,O
to,186,O
other,186,O
nutritional,186,O
or,186,O
metabolic,186,O
factors,186,O
.,186,O
CONCLUSION,187,O
.,187,O
The,188,O
extensive,188,O
peripheral,188,O
tissue,188,O
binding,188,O
and,188,O
relatively,188,O
low,188,O
concentration,188,O
of,188,O
colchicine,188,O
in,188,O
breast,188,O
milk,188,O
suggests,188,O
that,188,O
the,188,O
amount,188,O
ingested,188,O
by,188,O
the,188,O
infant,188,O
is,188,O
small,188,O
.,188,O
Furthermore,189,O
",",189,O
based,189,O
on,189,O
our,189,O
clinical,189,O
experience,189,O
",",189,O
nursing,189,O
appears,189,O
to,189,O
be,189,O
safe,189,O
for,189,O
lactating,189,O
women,189,O
with,189,O
FMF,189,B-SpecificDisease
who,189,O
continue,189,O
to,189,O
take,189,O
colchicine,189,O
.,189,O
Abnormal,190,O
myotonic,190,B-Modifier
dystrophy,190,I-Modifier
protein,190,O
kinase,190,O
levels,190,O
produce,190,O
only,190,O
mild,190,O
myopathy,190,B-DiseaseClass
in,190,O
mice,190,O
.,190,O
Myotonic,191,B-SpecificDisease
dystrophy,191,I-SpecificDisease
(,191,O
DM,191,B-SpecificDisease
),191,O
is,191,O
commonly,191,O
associated,191,O
with,191,O
CTG,191,O
repeat,191,O
expansions,191,O
within,191,O
the,191,O
gene,191,O
for,191,O
DM-protein,191,O
kinase,191,O
(,191,O
DMPK,191,O
),191,O
.,191,O
The,192,O
effect,192,O
of,192,O
altered,192,O
expression,192,O
levels,192,O
of,192,O
DMPK,192,O
",",192,O
which,192,O
is,192,O
ubiquitously,192,O
expressed,192,O
in,192,O
all,192,O
muscle,192,O
cell,192,O
lineages,192,O
during,192,O
development,192,O
",",192,O
was,192,O
examined,192,O
by,192,O
disrupting,192,O
the,192,O
endogenous,192,O
Dmpk,192,O
gene,192,O
and,192,O
overexpressing,192,O
a,192,O
normal,192,O
human,192,O
DMPK,192,O
transgene,192,O
in,192,O
mice,192,O
.,192,O
Nullizygous,193,O
(,193,O
-/-,193,O
),193,O
mice,193,O
showed,193,O
only,193,O
inconsistent,193,O
and,193,O
minor,193,O
size,193,O
changes,193,O
in,193,O
head,193,O
and,193,O
neck,193,O
muscle,193,O
fibres,193,O
at,193,O
older,193,O
age,193,O
",",193,O
animals,193,O
with,193,O
the,193,O
highest,193,O
DMPK,193,O
transgene,193,O
expression,193,O
showed,193,O
hypertrophic,193,B-SpecificDisease
cardiomyopathy,193,I-SpecificDisease
and,193,O
enhanced,193,O
neonatal,193,O
mortality,193,O
.,193,O
However,194,O
",",194,O
both,194,O
models,194,O
lack,194,O
other,194,O
frequent,194,O
DM,194,B-Modifier
symptoms,194,O
including,194,O
the,194,O
fibre-type,194,O
dependent,194,O
atrophy,194,B-SpecificDisease
",",194,O
myotonia,194,B-SpecificDisease
",",194,O
cataract,194,B-SpecificDisease
and,194,O
male-infertility,194,B-SpecificDisease
.,194,O
These,195,O
results,195,O
strengthen,195,O
the,195,O
contention,195,O
that,195,O
simple,195,O
loss-,195,O
or,195,O
gain-of-expression,195,O
of,195,O
DMPK,195,O
is,195,O
not,195,O
the,195,O
only,195,O
crucial,195,O
requirement,195,O
for,195,O
development,195,O
of,195,O
the,195,O
disease,195,O
..,195,O
Mice,196,O
lacking,196,O
the,196,O
myotonic,196,B-Modifier
dystrophy,196,I-Modifier
protein,196,O
kinase,196,O
develop,196,O
a,196,O
late,196,O
onset,196,O
progressive,196,O
myopathy,196,B-SpecificDisease
.,196,O
Myotonic,197,B-SpecificDisease
dystrophy,197,I-SpecificDisease
(,197,O
DM,197,B-SpecificDisease
),197,O
is,197,O
an,197,O
autosomal,197,B-DiseaseClass
dominant,197,I-DiseaseClass
disorder,197,I-DiseaseClass
resulting,197,O
from,197,O
the,197,O
expansion,197,O
of,197,O
a,197,O
CTG,197,O
repeat,197,O
in,197,O
the,197,O
3,197,O
untranslated,197,O
region,197,O
of,197,O
a,197,O
putative,197,O
protein,197,O
kinase,197,O
(,197,O
DMPK,197,O
),197,O
.,197,O
To,198,O
elucidate,198,O
the,198,O
role,198,O
of,198,O
DMPK,198,O
in,198,O
DM,198,B-Modifier
pathogenesis,198,O
we,198,O
have,198,O
developed,198,O
Dmpk,198,B-SpecificDisease
deficient,198,I-SpecificDisease
(,198,O
Dmpk-/-,198,O
),198,O
mice,198,O
.,198,O
Dmpk-/-mice,199,O
develop,199,O
a,199,O
late-onset,199,O
",",199,O
progressive,199,B-SpecificDisease
skeletal,199,I-SpecificDisease
myopathy,199,I-SpecificDisease
that,199,O
shares,199,O
some,199,O
pathological,199,O
features,199,O
with,199,O
DM,199,B-SpecificDisease
.,199,O
Muscles,200,O
from,200,O
mature,200,O
mice,200,O
show,200,O
variation,200,O
in,200,O
fibre,200,O
size,200,O
",",200,O
increased,200,O
fibre,200,B-SpecificDisease
degeneration,200,I-SpecificDisease
and,200,O
fibrosis,200,B-SpecificDisease
.,200,O
Adult,201,O
Dmpk-/-mice,201,O
show,201,O
ultrastructural,201,O
changes,201,O
in,201,O
muscle,201,O
and,201,O
a,201,O
50,201,O
%,201,O
decrease,201,O
in,201,O
force,201,O
generation,201,O
compared,201,O
to,201,O
young,201,O
mice,201,O
.,201,O
Our,202,O
results,202,O
indicate,202,O
that,202,O
DMPK,202,O
may,202,O
be,202,O
necessary,202,O
for,202,O
the,202,O
maintenance,202,O
of,202,O
skeletal,202,O
muscle,202,O
structure,202,O
and,202,O
function,202,O
and,202,O
suggest,202,O
that,202,O
a,202,O
decrease,202,O
in,202,O
DMPK,202,O
levels,202,O
may,202,O
contribute,202,O
to,202,O
DM,202,B-Modifier
pathology,202,O
..,202,O
The,203,O
tumor,203,B-Modifier
suppressor,203,O
gene,203,O
Brca1,203,O
is,203,O
required,203,O
for,203,O
embryonic,203,O
cellular,203,O
proliferation,203,O
in,203,O
the,203,O
mouse,203,O
.,203,O
Mutations,204,O
of,204,O
the,204,O
BRCA1,204,O
gone,204,O
in,204,O
humans,204,O
are,204,O
associated,204,O
with,204,O
predisposition,204,O
to,204,O
breast,204,O
and,204,O
ovarian,204,O
cancers,204,O
.,204,O
We,205,O
show,205,O
here,205,O
that,205,O
Brca1,205,O
+/-,205,O
mice,205,O
are,205,O
normal,205,O
and,205,O
fertile,205,O
and,205,O
lack,205,O
tumors,205,B-DiseaseClass
by,205,O
age,205,O
eleven,205,O
months,205,O
.,205,O
Homozygous,206,O
Brca1,206,O
(,206,O
5-6,206,O
),206,O
mutant,206,O
mice,206,O
die,206,O
before,206,O
day,206,O
7,206,O
.,206,O
5,207,O
of,207,O
embryogenesis,207,O
.,207,O
Mutant,208,O
embryos,208,O
are,208,O
poorly,208,O
developed,208,O
",",208,O
with,208,O
no,208,O
evidence,208,O
of,208,O
mesoderm,208,O
formation,208,O
.,208,O
The,209,O
extraembryonic,209,O
region,209,O
is,209,O
abnormal,209,O
",",209,O
but,209,O
aggregation,209,O
with,209,O
wild-type,209,O
tetraploid,209,O
embryos,209,O
does,209,O
not,209,O
rescue,209,O
the,209,O
lethality,209,O
.,209,O
In,210,O
vivo,210,O
",",210,O
mutant,210,O
embryos,210,O
do,210,O
not,210,O
exhibit,210,O
increased,210,O
apoptosis,210,O
but,210,O
show,210,O
reduced,210,O
cell,210,O
proliferation,210,O
accompanied,210,O
by,210,O
decreased,210,O
expression,210,O
of,210,O
cyclin,210,O
E,210,O
and,210,O
mdm-2,210,O
",",210,O
a,210,O
regulator,210,O
of,210,O
p53,210,O
activity,210,O
.,210,O
The,211,O
expression,211,O
of,211,O
cyclin-dependent,211,O
kinase,211,O
inhibitor,211,O
p21,211,O
is,211,O
dramatically,211,O
increased,211,O
in,211,O
the,211,O
mutant,211,O
embryos,211,O
.,211,O
Buttressing,212,O
these,212,O
in,212,O
vivo,212,O
observations,212,O
is,212,O
the,212,O
fact,212,O
that,212,O
mutant,212,O
blastocyst,212,O
growth,212,O
is,212,O
grossly,212,O
impaired,212,O
in,212,O
vitro,212,O
.,212,O
Thus,213,O
",",213,O
the,213,O
death,213,O
of,213,O
Brca1,213,O
(,213,O
5-6,213,O
),213,O
mutant,213,O
embryos,213,O
prior,213,O
to,213,O
gastrulation,213,O
may,213,O
be,213,O
due,213,O
to,213,O
a,213,O
failure,213,O
of,213,O
the,213,O
proliferative,213,O
burst,213,O
required,213,O
for,213,O
the,213,O
development,213,O
of,213,O
the,213,O
different,213,O
germ,213,O
layers,213,O
.,213,O
Increased,214,O
coronary,214,B-SpecificDisease
heart,214,I-SpecificDisease
disease,214,I-SpecificDisease
in,214,O
Japanese-American,214,O
men,214,O
with,214,O
mutation,214,O
in,214,O
the,214,O
cholesteryl,214,O
ester,214,O
transfer,214,O
protein,214,O
gene,214,O
despite,214,O
increased,214,O
HDL,214,O
levels,214,O
.,214,O
Plasma,215,O
high,215,O
density,215,O
lipoprotein,215,O
(,215,O
HDL,215,O
),215,O
levels,215,O
are,215,O
strongly,215,O
genetically,215,O
determined,215,O
and,215,O
show,215,O
a,215,O
general,215,O
inverse,215,O
relationship,215,O
with,215,O
coronary,215,B-SpecificDisease
heart,215,I-SpecificDisease
disease,215,I-SpecificDisease
(,215,O
CHD,215,B-SpecificDisease
),215,O
.,215,O
The,216,O
cholesteryl,216,O
ester,216,O
transfer,216,O
protein,216,O
(,216,O
CETP,216,O
),216,O
mediates,216,O
the,216,O
transfer,216,O
of,216,O
cholesteryl,216,O
esters,216,O
from,216,O
HDL,216,O
to,216,O
other,216,O
lipoproteins,216,O
and,216,O
is,216,O
a,216,O
key,216,O
participant,216,O
in,216,O
the,216,O
reverse,216,O
transport,216,O
of,216,O
cholesterol,216,O
from,216,O
the,216,O
periphery,216,O
to,216,O
the,216,O
liver,216,O
.,216,O
A,217,O
high,217,O
prevalence,217,O
of,217,O
two,217,O
different,217,O
CETP,217,O
gene,217,O
mutations,217,O
(,217,O
D442G,217,O
",",217,O
5,217,O
.,217,O
1,218,O
%,218,O
;,218,O
intron,218,O
14G,218,O
A,218,O
",",218,O
0,218,O
.,218,O
5,219,O
%,219,O
),219,O
",",219,O
was,219,O
found,219,O
in,219,O
3,219,O
",",219,O
469,219,O
men,219,O
of,219,O
Japanese,219,O
ancestry,219,O
in,219,O
the,219,O
Honolulu,219,O
Heart,219,O
Program,219,O
and,219,O
mutations,219,O
were,219,O
associated,219,O
with,219,O
decreased,219,O
CETP,219,O
(,219,O
-35,219,O
%,219,O
),219,O
and,219,O
increased,219,O
HDL,219,O
chol,219,O
levels,219,O
(,219,O
+,219,O
10,219,O
%,219,O
for,219,O
D442G,219,O
),219,O
.,219,O
However,220,O
",",220,O
the,220,O
overall,220,O
prevalence,220,O
of,220,O
definite,220,O
CHD,220,B-SpecificDisease
was,220,O
21,220,O
%,220,O
in,220,O
men,220,O
with,220,O
mutations,220,O
and,220,O
16,220,O
%,220,O
in,220,O
men,220,O
without,220,O
mutations,220,O
.,220,O
The,221,O
relative,221,O
risk,221,O
(,221,O
RR,221,O
),221,O
of,221,O
CHD,221,B-SpecificDisease
was,221,O
1,221,O
.,221,O
43,222,O
in,222,O
men,222,O
with,222,O
mutations,222,O
(,222,O
P,222,O
<,222,O
.,222,O
05,223,O
),223,O
;,223,O
after,223,O
adjustment,223,O
for,223,O
CHD,223,B-Modifier
risk,223,O
factors,223,O
",",223,O
the,223,O
RR,223,O
was,223,O
1,223,O
.,223,O
55,224,O
(,224,O
P,224,O
=,224,O
.,224,O
02,225,O
),225,O
;,225,O
after,225,O
additional,225,O
adjustment,225,O
for,225,O
HDL,225,O
levels,225,O
",",225,O
the,225,O
RR,225,O
was,225,O
1,225,O
.,225,O
68,226,O
(,226,O
P,226,O
=,226,O
.,226,O
008,227,O
),227,O
.,227,O
Similar,228,O
RR,228,O
values,228,O
were,228,O
obtained,228,O
for,228,O
the,228,O
D442G,228,O
mutation,228,O
alone,228,O
.,228,O
Increased,229,O
CHD,229,B-SpecificDisease
in,229,O
men,229,O
with,229,O
mutations,229,O
was,229,O
primarily,229,O
observed,229,O
for,229,O
HDL,229,O
chol,229,O
41-60,229,O
mg/dl,229,O
;,229,O
for,229,O
HDL,229,O
chol,229,O
>,229,O
60,229,O
mg/dl,229,O
men,229,O
with,229,O
and,229,O
without,229,O
mutations,229,O
had,229,O
low,229,O
CHD,229,B-SpecificDisease
prevalence,229,O
.,229,O
Thus,230,O
",",230,O
genetic,230,O
CETP,230,B-SpecificDisease
deficiency,230,I-SpecificDisease
appears,230,O
to,230,O
be,230,O
an,230,O
independent,230,O
risk,230,O
factor,230,O
for,230,O
CHD,230,B-SpecificDisease
",",230,O
primarily,230,O
due,230,O
to,230,O
increased,230,O
CHD,230,B-Modifier
prevalence,230,O
in,230,O
men,230,O
with,230,O
the,230,O
D442G,230,O
mutation,230,O
and,230,O
HDL,230,O
cholesterol,230,O
between,230,O
41,230,O
and,230,O
60,230,O
mg/dl,230,O
.,230,O
The,231,O
findings,231,O
suggest,231,O
that,231,O
both,231,O
HDL,231,O
concentration,231,O
and,231,O
the,231,O
dynamics,231,O
of,231,O
cholesterol,231,O
transport,231,O
through,231,O
HDL,231,O
(,231,O
i.,231,O
e.,231,O
",",231,O
reverse,231,O
cholesterol,231,O
transport,231,O
),231,O
determine,231,O
the,231,O
anti-atherogenicity,231,O
of,231,O
the,231,O
HDL,231,O
fraction,231,O
.,231,O
Mapping,232,O
the,232,O
homolog,232,O
of,232,O
the,232,O
human,232,O
Rb1,232,O
gene,232,O
to,232,O
chromosome,232,O
14,232,O
of,232,O
higher,232,O
primates,232,O
.,232,O
The,233,O
Rb1,233,O
gene,233,O
has,233,O
been,233,O
implicated,233,O
with,233,O
retinoblastoma,233,B-SpecificDisease
and,233,O
is,233,O
located,233,O
on,233,O
human,233,O
Chromosome,233,O
(,233,O
Chr,233,O
),233,O
13q14,233,O
.,233,O
2,234,O
2,234,O
.,234,O
A,235,O
unique,235,O
sequence,235,O
human,235,O
Rb1,235,O
cosmid,235,O
DNA,235,O
probe,235,O
has,235,O
been,235,O
used,235,O
to,235,O
localize,235,O
this,235,O
region,235,O
on,235,O
apes,235,O
Chr,235,O
14,235,O
by,235,O
the,235,O
FISH,235,O
technique,235,O
.,235,O
The,236,O
conservation,236,O
of,236,O
the,236,O
Rb1,236,O
gene,236,O
in,236,O
higher,236,O
primates,236,O
at,236,O
the,236,O
corresponding,236,O
equivalent,236,O
chromosome,236,O
locus,236,O
(,236,O
14q14,236,O
),236,O
of,236,O
the,236,O
human,236,O
may,236,O
serve,236,O
as,236,O
a,236,O
phylogenetic,236,O
marker,236,O
to,236,O
further,236,O
trace,236,O
the,236,O
evolutionary,236,O
pathway,236,O
of,236,O
human,236,O
descent,236,O
.,236,O
Wiskott-Aldrich,237,B-SpecificDisease
syndrome,237,I-SpecificDisease
:,237,O
no,237,O
strict,237,O
genotype-phenotype,237,O
correlations,237,O
but,237,O
clustering,237,O
of,237,O
missense,237,O
mutations,237,O
in,237,O
the,237,O
amino-terminal,237,O
part,237,O
of,237,O
the,237,O
WASP,237,O
gene,237,O
product,237,O
.,237,O
The,238,O
Wiskott-Aldrich,238,B-Modifier
syndrome,238,I-Modifier
protein,238,O
(,238,O
WASP,238,O
),238,O
gene,238,O
was,238,O
found,238,O
to,238,O
be,238,O
mutated,238,O
in,238,O
patients,238,O
presenting,238,O
with,238,O
WAS,238,B-SpecificDisease
and,238,O
in,238,O
patients,238,O
showing,238,O
X-linked,238,B-SpecificDisease
thrombocytopenia,238,I-SpecificDisease
.,238,O
Mutation,239,O
analysis,239,O
in,239,O
19,239,O
families,239,O
of,239,O
German,239,O
",",239,O
Swiss,239,O
and,239,O
Turkish,239,O
descent,239,O
by,239,O
single-strand,239,O
conformation,239,O
polymorphism,239,O
and,239,O
sequencing,239,O
resulted,239,O
in,239,O
the,239,O
detection,239,O
of,239,O
seven,239,O
novel,239,O
and,239,O
10,239,O
known,239,O
mutations,239,O
.,239,O
A,240,O
striking,240,O
clustering,240,O
of,240,O
missense,240,O
mutations,240,O
in,240,O
the,240,O
first,240,O
four,240,O
exons,240,O
contrasted,240,O
with,240,O
a,240,O
random,240,O
distribution,240,O
of,240,O
nonsense,240,O
mutations,240,O
.,240,O
More,241,O
than,241,O
85,241,O
%,241,O
of,241,O
all,241,O
known,241,O
missense,241,O
mutations,241,O
were,241,O
localized,241,O
in,241,O
the,241,O
amino-terminal,241,O
stretch,241,O
of,241,O
the,241,O
WASP,241,O
gene,241,O
product,241,O
;,241,O
this,241,O
region,241,O
contained,241,O
a,241,O
mutational,241,O
hot,241,O
spot,241,O
at,241,O
codon,241,O
86,241,O
.,241,O
No,242,O
genotype-phenotype,242,O
correlation,242,O
emerged,242,O
after,242,O
a,242,O
comparison,242,O
of,242,O
the,242,O
identified,242,O
mutations,242,O
with,242,O
the,242,O
resulting,242,O
clinical,242,O
picture,242,O
for,242,O
a,242,O
classical,242,O
WAS,242,B-Modifier
phenotype,242,O
.,242,O
A,243,O
substitution,243,O
at,243,O
codon,243,O
86,243,O
resulted,243,O
in,243,O
an,243,O
extremely,243,O
variable,243,O
expression,243,O
of,243,O
the,243,O
disease,243,O
in,243,O
a,243,O
large,243,O
Swiss,243,O
family,243,O
.,243,O
An,244,O
extended,244,O
homology,244,O
search,244,O
revealed,244,O
a,244,O
distant,244,O
relationship,244,O
of,244,O
this,244,O
stretch,244,O
to,244,O
the,244,O
vasodilator-stimulated,244,O
phosphoprotein,244,O
(,244,O
VASP,244,O
),244,O
",",244,O
which,244,O
is,244,O
involved,244,O
in,244,O
the,244,O
maintenance,244,O
of,244,O
cyto-architecture,244,O
by,244,O
interacting,244,O
with,244,O
actin-like,244,O
filaments,244,O
..,244,O
Influence,245,O
of,245,O
PAX6,245,O
gene,245,O
dosage,245,O
on,245,O
development,245,O
:,245,O
overexpression,245,O
causes,245,O
severe,245,O
eye,245,B-DiseaseClass
abnormalities,245,I-DiseaseClass
.,245,O
Aniridia,246,B-SpecificDisease
in,246,O
man,246,O
and,246,O
Small,246,O
eye,246,O
in,246,O
mice,246,O
are,246,O
semidominant,246,B-DiseaseClass
developmental,246,I-DiseaseClass
disorders,246,I-DiseaseClass
caused,246,O
by,246,O
mutations,246,O
within,246,O
the,246,O
paired,246,O
box,246,O
gene,246,O
PAX6,246,O
.,246,O
Whereas,247,O
heterozygotes,247,O
suffer,247,O
from,247,O
iris,247,B-SpecificDisease
hypoplasia,247,I-SpecificDisease
",",247,O
homozygous,247,O
mice,247,O
lack,247,O
eyes,247,O
and,247,O
nasal,247,O
cavities,247,O
and,247,O
exhibit,247,O
brain,247,B-DiseaseClass
abnormalities,247,I-DiseaseClass
.,247,O
To,248,O
investigate,248,O
the,248,O
role,248,O
of,248,O
gene,248,O
dosage,248,O
in,248,O
more,248,O
detail,248,O
",",248,O
we,248,O
have,248,O
generated,248,O
yeast,248,O
artificial,248,O
chromosome,248,O
transgenic,248,O
mice,248,O
carrying,248,O
the,248,O
human,248,O
PAX6,248,O
locus,248,O
.,248,O
When,249,O
crossed,249,O
onto,249,O
the,249,O
Small,249,O
eye,249,O
background,249,O
",",249,O
the,249,O
transgene,249,O
rescues,249,O
the,249,O
mutant,249,O
phenotype,249,O
.,249,O
Strikingly,250,O
",",250,O
mice,250,O
carrying,250,O
multiple,250,O
copies,250,O
on,250,O
a,250,O
wild-type,250,O
background,250,O
show,250,O
specific,250,O
developmental,250,B-DiseaseClass
abnormalities,250,I-DiseaseClass
of,250,I-DiseaseClass
the,250,I-DiseaseClass
eye,250,I-DiseaseClass
",",250,O
but,250,O
not,250,O
of,250,O
other,250,O
tissues,250,O
expressing,250,O
the,250,O
gene,250,O
.,250,O
Thus,251,O
",",251,O
at,251,O
least,251,O
five,251,O
different,251,O
eye,251,O
phenotypes,251,O
are,251,O
associated,251,O
with,251,O
changes,251,O
in,251,O
PAX6,251,O
expression,251,O
.,251,O
We,252,O
provide,252,O
evidence,252,O
that,252,O
not,252,O
only,252,O
reduced,252,O
",",252,O
but,252,O
also,252,O
increased,252,O
levels,252,O
of,252,O
transcriptional,252,O
regulators,252,O
can,252,O
cause,252,O
developmental,252,B-DiseaseClass
defects,252,I-DiseaseClass
..,252,O
Heterodimer,253,O
formation,253,O
and,253,O
activity,253,O
in,253,O
the,253,O
human,253,O
enzyme,253,O
galactose-1-phosphate,253,O
uridylyltransferase,253,O
.,253,O
One,254,O
of,254,O
the,254,O
fundamental,254,O
questions,254,O
concerning,254,O
expression,254,O
and,254,O
function,254,O
of,254,O
dimeric,254,O
enzymes,254,O
involves,254,O
the,254,O
impact,254,O
of,254,O
naturally,254,O
occurring,254,O
mutations,254,O
on,254,O
subunit,254,O
assembly,254,O
and,254,O
heterodimer,254,O
activity,254,O
.,254,O
This,255,O
question,255,O
is,255,O
of,255,O
particular,255,O
interest,255,O
for,255,O
the,255,O
human,255,O
enzyme,255,O
galactose-l-phosphate,255,O
uridylyl-transferase,255,O
(,255,O
GALT,255,O
),255,O
",",255,O
impairment,255,O
of,255,O
which,255,O
results,255,O
in,255,O
the,255,O
inherited,255,B-DiseaseClass
metabolic,255,I-DiseaseClass
disorder,255,I-DiseaseClass
galactosemia,255,B-SpecificDisease
",",255,O
because,255,O
many,255,O
if,255,O
not,255,O
most,255,O
patients,255,O
studied,255,O
to,255,O
date,255,O
are,255,O
compound,255,O
heterozygotes,255,O
rather,255,O
than,255,O
true,255,O
molecular,255,O
homozygotes,255,O
.,255,O
Furthermore,256,O
",",256,O
the,256,O
broad,256,O
range,256,O
of,256,O
phenotypic,256,O
severity,256,O
observed,256,O
in,256,O
these,256,O
patients,256,O
raises,256,O
the,256,O
possibility,256,O
that,256,O
allelic,256,O
combination,256,O
",",256,O
not,256,O
just,256,O
allelic,256,O
constitution,256,O
",",256,O
may,256,O
play,256,O
some,256,O
role,256,O
in,256,O
determining,256,O
outcome,256,O
.,256,O
In,257,O
the,257,O
work,257,O
described,257,O
herein,257,O
",",257,O
we,257,O
have,257,O
selected,257,O
two,257,O
distinct,257,O
naturally,257,O
occurring,257,O
null,257,O
mutations,257,O
of,257,O
GALT,257,O
",",257,O
Q188R,257,O
and,257,O
R333W,257,O
",",257,O
and,257,O
asked,257,O
the,257,O
questions,257,O
(,257,O
i,257,O
),257,O
what,257,O
are,257,O
the,257,O
impacts,257,O
of,257,O
these,257,O
mutations,257,O
on,257,O
subunit,257,O
assembly,257,O
",",257,O
and,257,O
(,257,O
ii,257,O
),257,O
if,257,O
heterodimers,257,O
do,257,O
form,257,O
",",257,O
are,257,O
they,257,O
active,257,O
?,257,O
To,258,O
answer,258,O
these,258,O
questions,258,O
",",258,O
we,258,O
have,258,O
established,258,O
a,258,O
yeast,258,O
system,258,O
for,258,O
the,258,O
coexpression,258,O
of,258,O
epitope-tagged,258,O
alleles,258,O
of,258,O
human,258,O
GALT,258,O
and,258,O
investigated,258,O
both,258,O
the,258,O
extent,258,O
of,258,O
specific,258,O
GALT,258,O
subunit,258,O
interactions,258,O
and,258,O
the,258,O
activity,258,O
of,258,O
defined,258,O
heterodimer,258,O
pools,258,O
.,258,O
We,259,O
have,259,O
found,259,O
that,259,O
both,259,O
homodimers,259,O
and,259,O
heterodimers,259,O
do,259,O
form,259,O
involving,259,O
each,259,O
of,259,O
the,259,O
mutant,259,O
subunits,259,O
tested,259,O
and,259,O
that,259,O
both,259,O
heterodimer,259,O
pools,259,O
retain,259,O
substantial,259,O
enzymatic,259,O
activity,259,O
.,259,O
These,260,O
results,260,O
are,260,O
significant,260,O
not,260,O
only,260,O
in,260,O
terms,260,O
of,260,O
their,260,O
implications,260,O
for,260,O
furthering,260,O
our,260,O
understanding,260,O
of,260,O
galactosemia,260,B-SpecificDisease
and,260,O
GALT,260,O
holoenzyme,260,O
structure-function,260,O
relationships,260,O
but,260,O
also,260,O
because,260,O
the,260,O
system,260,O
described,260,O
may,260,O
serve,260,O
as,260,O
a,260,O
model,260,O
for,260,O
similar,260,O
studies,260,O
of,260,O
other,260,O
complexes,260,O
composed,260,O
of,260,O
multiple,260,O
subunits,260,O
..,260,O
Cleavage,261,O
of,261,O
huntingtin,261,O
by,261,O
apopain,261,O
",",261,O
a,261,O
proapoptotic,261,O
cysteine,261,O
protease,261,O
",",261,O
is,261,O
modulated,261,O
by,261,O
the,261,O
polyglutamine,261,O
tract,261,O
.,261,O
Apoptosis,262,O
has,262,O
recently,262,O
been,262,O
recognized,262,O
as,262,O
a,262,O
mode,262,O
of,262,O
cell,262,O
death,262,O
in,262,O
Huntington,262,B-SpecificDisease
disease,262,I-SpecificDisease
(,262,O
HD,262,B-SpecificDisease
),262,O
.,262,O
Apopain,263,O
",",263,O
a,263,O
human,263,O
counterpart,263,O
of,263,O
the,263,O
nematode,263,O
cysteine,263,O
protease,263,O
death-gene,263,O
product,263,O
",",263,O
CED-3,263,O
",",263,O
has,263,O
a,263,O
key,263,O
role,263,O
in,263,O
proteolytic,263,O
events,263,O
leading,263,O
to,263,O
apoptosis,263,O
.,263,O
Here,264,O
we,264,O
show,264,O
that,264,O
apoptotic,264,O
extracts,264,O
and,264,O
apopain,264,O
itself,264,O
specifically,264,O
cleave,264,O
the,264,O
HD,264,B-Modifier
gene,264,O
product,264,O
",",264,O
huntingtin,264,O
.,264,O
The,265,O
rate,265,O
of,265,O
cleavage,265,O
increases,265,O
with,265,O
the,265,O
length,265,O
of,265,O
the,265,O
huntingtin,265,O
polyglutamine,265,O
tract,265,O
",",265,O
providing,265,O
an,265,O
explanation,265,O
for,265,O
the,265,O
gain-of-function,265,O
associated,265,O
with,265,O
CAG,265,O
expansion,265,O
.,265,O
Our,266,O
results,266,O
show,266,O
that,266,O
huntingtin,266,O
is,266,O
cleaved,266,O
by,266,O
cysteine,266,O
proteases,266,O
and,266,O
suggest,266,O
that,266,O
HD,266,B-SpecificDisease
might,266,O
be,266,O
a,266,O
disorder,266,B-DiseaseClass
of,266,I-DiseaseClass
inappropriate,266,I-DiseaseClass
apoptosis,266,I-DiseaseClass
..,266,O
The,267,O
5,267,O
',267,O
end,267,O
of,267,O
the,267,O
BRCA1,267,O
gene,267,O
lies,267,O
within,267,O
a,267,O
duplicated,267,O
region,267,O
of,267,O
human,267,O
chromosome,267,O
17q21,267,O
.,267,O
To,268,O
begin,268,O
to,268,O
address,268,O
the,268,O
hypothesis,268,O
that,268,O
abnormal,268,O
regulation,268,O
of,268,O
the,268,O
breast/ovarian,268,B-Modifier
cancer,268,I-Modifier
susceptibility,268,O
gene,268,O
BRCA1,268,O
is,268,O
a,268,O
critical,268,O
step,268,O
in,268,O
sporadic,268,O
breast/ovarian,268,O
tumorigenesis,268,O
",",268,O
we,268,O
have,268,O
determined,268,O
the,268,O
detailed,268,O
structure,268,O
of,268,O
the,268,O
BRCA1,268,O
genomic,268,O
region,268,O
.,268,O
We,269,O
show,269,O
that,269,O
this,269,O
region,269,O
of,269,O
the,269,O
genome,269,O
contains,269,O
a,269,O
tandem,269,O
duplication,269,O
of,269,O
approximately,269,O
30,269,O
kilobases,269,O
",",269,O
which,269,O
results,269,O
in,269,O
two,269,O
copies,269,O
of,269,O
BRCA1,269,O
exons,269,O
1,269,O
and,269,O
2,269,O
",",269,O
of,269,O
exons,269,O
1,269,O
and,269,O
3,269,O
of,269,O
the,269,O
adjacent,269,O
1A1-3B,269,O
gene,269,O
and,269,O
of,269,O
the,269,O
previously,269,O
reported,269,O
295,269,O
base,269,O
pair,269,O
intergenic,269,O
region,269,O
.,269,O
Sequence,270,O
analysis,270,O
of,270,O
the,270,O
duplicated,270,O
exons,270,O
of,270,O
BRCA1,270,O
and,270,O
1A1-3B,270,O
and,270,O
flanking,270,O
genomic,270,O
DNA,270,O
reveals,270,O
maintenance,270,O
of,270,O
the,270,O
intron-exon,270,O
structure,270,O
and,270,O
a,270,O
high,270,O
degree,270,O
of,270,O
nucleotide,270,O
sequence,270,O
identity,270,O
",",270,O
suggesting,270,O
that,270,O
these,270,O
are,270,O
non-processed,270,O
pseudogenes,270,O
and,270,O
that,270,O
the,270,O
duplication,270,O
is,270,O
a,270,O
recent,270,O
event,270,O
in,270,O
evolutionary,270,O
terms,270,O
.,270,O
We,271,O
also,271,O
show,271,O
that,271,O
a,271,O
processed,271,O
pseudogene,271,O
of,271,O
the,271,O
acidic,271,O
ribosomal,271,O
phosphoprotein,271,O
P1,271,O
(,271,O
ARPP1,271,O
),271,O
is,271,O
inserted,271,O
directly,271,O
upstream,271,O
of,271,O
pseudo-BRCA1,271,O
exon,271,O
1A,271,O
.,271,O
We,272,O
believe,272,O
that,272,O
these,272,O
findings,272,O
could,272,O
not,272,O
only,272,O
confound,272,O
BRCA1,272,O
mutation,272,O
analysis,272,O
",",272,O
but,272,O
could,272,O
have,272,O
implications,272,O
for,272,O
the,272,O
normal,272,O
and,272,O
abnormal,272,O
regulation,272,O
of,272,O
BRCA1,272,O
transcription,272,O
",",272,O
translation,272,O
and,272,O
function,272,O
..,272,O
Deletion,273,O
of,273,O
small,273,O
nuclear,273,O
ribonucleoprotein,273,O
polypeptide,273,O
N,273,O
(,273,O
SNRPN,273,O
),273,O
in,273,O
Prader-Willi,273,B-SpecificDisease
syndrome,273,I-SpecificDisease
detected,273,O
by,273,O
fluorescence,273,O
in,273,O
situ,273,O
hybridization,273,O
:,273,O
two,273,O
sibs,273,O
with,273,O
the,273,O
typical,273,O
phenotype,273,O
without,273,O
a,273,O
cytogenetic,273,O
deletion,273,O
in,273,O
chromosome,273,O
15q,273,O
.,273,O
The,274,O
small,274,O
nuclear,274,O
ribonucleoprotein,274,O
polypeptide,274,O
N,274,O
(,274,O
SNRPN,274,O
),274,O
gene,274,O
is,274,O
regarded,274,O
as,274,O
one,274,O
of,274,O
the,274,O
candidates,274,O
for,274,O
Prader-Willi,274,B-SpecificDisease
syndrome,274,I-SpecificDisease
(,274,O
PWS,274,B-SpecificDisease
),274,O
.,274,O
We,275,O
describe,275,O
two,275,O
sibs,275,O
with,275,O
typical,275,O
PWS,275,B-SpecificDisease
presenting,275,O
deletion,275,O
of,275,O
SNRPN,275,O
detected,275,O
by,275,O
fluorescence,275,O
in,275,O
situ,275,O
hybridization,275,O
(,275,O
FISH,275,O
),275,O
.,275,O
Neither,276,O
a,276,O
cytogenetically,276,O
detectable,276,O
15q12,276,O
deletion,276,O
nor,276,O
a,276,O
deletion,276,O
for,276,O
the,276,O
D15S11,276,O
",",276,O
D15S10,276,O
",",276,O
and,276,O
GABRB3,276,O
cosmid,276,O
probes,276,O
were,276,O
found,276,O
in,276,O
either,276,O
patient,276,O
.,276,O
This,277,O
implies,277,O
a,277,O
smaller,277,O
deletion,277,O
limited,277,O
to,277,O
the,277,O
PWS,277,B-Modifier
critical,277,O
region,277,O
.,277,O
FISH,278,O
with,278,O
a,278,O
SNRPN,278,O
probe,278,O
will,278,O
permit,278,O
analysis,278,O
of,278,O
PWS,278,B-Modifier
patients,278,O
with,278,O
limited,278,O
deletions,278,O
not,278,O
detectable,278,O
with,278,O
other,278,O
probes,278,O
..,278,O
Expression,279,O
of,279,O
the,279,O
von,279,B-Modifier
Hippel-Lindau,279,I-Modifier
disease,279,I-Modifier
tumour,279,I-Modifier
suppressor,279,O
gene,279,O
during,279,O
human,279,O
embryogenesis,279,O
.,279,O
The,280,O
von,280,B-Modifier
Hippel-Lindau,280,I-Modifier
(,280,I-Modifier
VHL,280,I-Modifier
),280,I-Modifier
disease,280,I-Modifier
product,280,O
is,280,O
thought,280,O
to,280,O
down-regulate,280,O
transcription,280,O
by,280,O
antagonizing,280,O
elongin-enhanced,280,O
transcriptional,280,O
elongation,280,O
.,280,O
Germline,281,O
VHL,281,B-Modifier
gene,281,O
mutations,281,O
predispose,281,O
to,281,O
the,281,O
development,281,O
of,281,O
retinal,281,O
",",281,O
cerebellar,281,O
and,281,O
spinal,281,O
haemangioblastomas,281,O
",",281,O
renal,281,B-SpecificDisease
cell,281,I-SpecificDisease
carcinoma,281,I-SpecificDisease
and,281,O
phaeochromocytoma,281,B-SpecificDisease
.,281,O
In,282,O
addition,282,O
",",282,O
somatic,282,O
Inactivation,282,O
of,282,O
the,282,O
VHL,282,B-Modifier
gene,282,O
is,282,O
frequent,282,O
in,282,O
sporadic,282,B-SpecificDisease
renal,282,I-SpecificDisease
cell,282,I-SpecificDisease
carcinoma,282,I-SpecificDisease
and,282,O
haemangioblastoma,282,B-SpecificDisease
.,282,O
Regulation,283,O
of,283,O
transcript,283,O
elongation,283,O
is,283,O
an,283,O
important,283,O
control,283,O
mechanism,283,O
for,283,O
gene,283,O
expression,283,O
and,283,O
the,283,O
VHL,283,B-Modifier
gene,283,O
might,283,O
modify,283,O
the,283,O
expression,283,O
of,283,O
proto-oncogenes,283,O
and,283,O
growth,283,O
suppressor,283,O
genes,283,O
during,283,O
embryogenesis,283,O
.,283,O
We,284,O
therefore,284,O
investigated,284,O
the,284,O
expression,284,O
of,284,O
VHL,284,B-Modifier
mRNA,284,O
during,284,O
human,284,O
embryogenesis,284,O
by,284,O
in,284,O
situ,284,O
hybridization,284,O
studies,284,O
at,284,O
4,284,O
",",284,O
6,284,O
and,284,O
10,284,O
weeks,284,O
post,284,O
conception,284,O
.,284,O
Although,285,O
VHL,285,B-Modifier
mRNA,285,O
was,285,O
expressed,285,O
in,285,O
all,285,O
three,285,O
germ,285,O
layers,285,O
",",285,O
strong,285,O
expression,285,O
was,285,O
noted,285,O
in,285,O
the,285,O
central,285,O
nervous,285,O
system,285,O
",",285,O
kidneys,285,O
",",285,O
testis,285,O
and,285,O
lung,285,O
.,285,O
Within,286,O
the,286,O
kidney,286,O
",",286,O
VHL,286,B-Modifier
mRNA,286,O
was,286,O
differentially,286,O
expressed,286,O
within,286,O
renal,286,O
tubules,286,O
suggesting,286,O
that,286,O
the,286,O
VHL,286,B-Modifier
gene,286,O
product,286,O
may,286,O
have,286,O
a,286,O
specific,286,O
role,286,O
in,286,O
kidney,286,O
development,286,O
.,286,O
Two,287,O
alternatively,287,O
spliced,287,O
VHL,287,B-Modifier
mRNAs,287,O
characterized,287,O
by,287,O
inclusion,287,O
(,287,O
isoform,287,O
I,287,O
),287,O
or,287,O
exclusion,287,O
(,287,O
isoform,287,O
II,287,O
),287,O
of,287,O
exon,287,O
2,287,O
are,287,O
transcribed,287,O
in,287,O
adult,287,O
tissues,287,O
.,287,O
To,288,O
investigate,288,O
if,288,O
the,288,O
two,288,O
isoforms,288,O
are,288,O
differentially,288,O
expressed,288,O
during,288,O
embryogenesis,288,O
",",288,O
VHL,288,B-Modifier
mRNA,288,O
was,288,O
reverse,288,O
transcribed,288,O
from,288,O
13,288,O
fetal,288,O
tissues,288,O
(,288,O
8-10,288,O
weeks,288,O
gestation,288,O
),288,O
.,288,O
The,289,O
quantitative,289,O
distribution,289,O
of,289,O
VHL,289,B-Modifier
mRNA,289,O
within,289,O
fetal,289,O
tissues,289,O
reflected,289,O
that,289,O
seen,289,O
by,289,O
in,289,O
situ,289,O
hybridization,289,O
and,289,O
the,289,O
ratio,289,O
of,289,O
the,289,O
two,289,O
VHL,289,B-Modifier
isoforms,289,O
was,289,O
similar,289,O
between,289,O
tissues,289,O
.,289,O
Although,290,O
the,290,O
genes,290,O
regulated,290,O
by,290,O
the,290,O
VHL,290,B-Modifier
gene,290,O
product,290,O
have,290,O
not,290,O
yet,290,O
been,290,O
identified,290,O
",",290,O
our,290,O
findings,290,O
are,290,O
compatible,290,O
with,290,O
the,290,O
hypothesis,290,O
that,290,O
VHL-mediated,290,B-Modifier
control,290,O
of,290,O
transcriptional,290,O
elongation,290,O
may,290,O
have,290,O
a,290,O
role,290,O
in,290,O
normal,290,O
human,290,O
development,290,O
..,290,O
Genetic,291,O
heterogeneity,291,O
in,291,O
hereditary,291,B-SpecificDisease
breast,291,I-SpecificDisease
cancer,291,I-SpecificDisease
:,291,O
role,291,O
of,291,O
BRCA1,291,O
and,291,O
BRCA2,291,O
.,291,O
The,292,O
common,292,O
hereditary,292,O
forms,292,O
of,292,O
breast,292,B-SpecificDisease
cancer,292,I-SpecificDisease
have,292,O
been,292,O
largely,292,O
attributed,292,O
to,292,O
the,292,O
inheritance,292,O
of,292,O
mutations,292,O
in,292,O
the,292,O
BRCA1,292,O
or,292,O
BRCA2,292,O
genes,292,O
.,292,O
However,293,O
",",293,O
it,293,O
is,293,O
not,293,O
yet,293,O
clear,293,O
what,293,O
proportion,293,O
of,293,O
hereditary,293,B-SpecificDisease
breast,293,I-SpecificDisease
cancer,293,I-SpecificDisease
is,293,O
explained,293,O
by,293,O
BRCA1,293,O
and,293,O
BRCA2,293,O
or,293,O
by,293,O
some,293,O
other,293,O
unidentified,293,O
susceptibility,293,O
gene,293,O
(,293,O
s,293,O
),293,O
.,293,O
We,294,O
describe,294,O
the,294,O
proportion,294,O
of,294,O
hereditary,294,B-SpecificDisease
breast,294,I-SpecificDisease
cancer,294,I-SpecificDisease
explained,294,O
by,294,O
BRCA1,294,O
or,294,O
BRCA2,294,O
in,294,O
a,294,O
sample,294,O
of,294,O
North,294,O
American,294,O
hereditary,294,B-SpecificDisease
breast,294,I-SpecificDisease
cancers,294,I-SpecificDisease
and,294,O
assess,294,O
the,294,O
evidence,294,O
for,294,O
additional,294,O
susceptibility,294,O
genes,294,O
that,294,O
may,294,O
confer,294,O
hereditary,294,B-Modifier
breast,294,I-Modifier
or,294,I-Modifier
ovarian,294,I-Modifier
cancer,294,I-Modifier
risk,294,O
.,294,O
Twenty-three,295,O
families,295,O
were,295,O
identified,295,O
through,295,O
two,295,O
high-risk,295,O
breast,295,B-Modifier
cancer,295,I-Modifier
research,295,O
programs,295,O
.,295,O
Genetic,296,O
analysis,296,O
was,296,O
undertaken,296,O
to,296,O
establish,296,O
linkage,296,O
between,296,O
the,296,O
breast,296,O
or,296,O
ovarian,296,O
cancer,296,O
cases,296,O
and,296,O
markers,296,O
on,296,O
chromosomes,296,O
17q,296,O
(,296,O
BRCA1,296,O
),296,O
and,296,O
13q,296,O
(,296,O
BRCA2,296,O
),296,O
.,296,O
Mutation,297,O
analysis,297,O
in,297,O
the,297,O
BRCA1,297,O
and,297,O
BRCA2,297,O
genes,297,O
was,297,O
also,297,O
undertaken,297,O
in,297,O
all,297,O
families,297,O
.,297,O
The,298,O
pattern,298,O
of,298,O
hereditary,298,B-DiseaseClass
cancer,298,I-DiseaseClass
in,298,O
14,298,O
(,298,O
61,298,O
%,298,O
),298,O
of,298,O
the,298,O
23,298,O
families,298,O
studied,298,O
was,298,O
attributed,298,O
to,298,O
BRCA1,298,O
by,298,O
a,298,O
combination,298,O
of,298,O
linkage,298,O
and,298,O
mutation,298,O
analyses,298,O
.,298,O
No,299,O
families,299,O
were,299,O
attributed,299,O
to,299,O
BRCA2,299,O
.,299,O
Five,300,O
families,300,O
(,300,O
22,300,O
%,300,O
),300,O
provided,300,O
evidence,300,O
against,300,O
linkage,300,O
to,300,O
both,300,O
BRCA1,300,O
and,300,O
BRCA2,300,O
.,300,O
No,301,O
BRCA1,301,O
or,301,O
BRCA2,301,O
mutations,301,O
were,301,O
detected,301,O
in,301,O
these,301,O
five,301,O
families,301,O
.,301,O
The,302,O
BRCA1,302,O
or,302,O
BRCA2,302,O
status,302,O
of,302,O
four,302,O
families,302,O
(,302,O
17,302,O
%,302,O
),302,O
could,302,O
not,302,O
be,302,O
determined,302,O
.,302,O
BRCA1,303,O
and,303,O
BRCA2,303,O
probably,303,O
explain,303,O
the,303,O
majority,303,O
of,303,O
hereditary,303,B-SpecificDisease
breast,303,I-SpecificDisease
cancer,303,I-SpecificDisease
that,303,O
exists,303,O
in,303,O
the,303,O
North,303,O
American,303,O
population,303,O
.,303,O
However,304,O
",",304,O
one,304,O
or,304,O
more,304,O
additional,304,O
genes,304,O
may,304,O
yet,304,O
be,304,O
found,304,O
that,304,O
explain,304,O
some,304,O
proportion,304,O
of,304,O
hereditary,304,B-SpecificDisease
breast,304,I-SpecificDisease
cancer,304,I-SpecificDisease
..,304,O
An,305,O
intronic,305,O
mutation,305,O
in,305,O
a,305,O
lariat,305,O
branchpoint,305,O
sequence,305,O
is,305,O
a,305,O
direct,305,O
cause,305,O
of,305,O
an,305,O
inherited,305,B-DiseaseClass
human,305,I-DiseaseClass
disorder,305,I-DiseaseClass
(,305,O
fish-eye,305,B-SpecificDisease
disease,305,I-SpecificDisease
),305,O
.,305,O
The,306,O
first,306,O
step,306,O
in,306,O
the,306,O
splicing,306,O
of,306,O
an,306,O
intron,306,O
from,306,O
nuclear,306,O
precursors,306,O
of,306,O
mRNA,306,O
results,306,O
in,306,O
the,306,O
formation,306,O
of,306,O
a,306,O
lariat,306,O
structure,306,O
.,306,O
A,307,O
distinct,307,O
intronic,307,O
nucleotide,307,O
sequence,307,O
",",307,O
known,307,O
as,307,O
the,307,O
branchpoint,307,O
region,307,O
",",307,O
plays,307,O
a,307,O
central,307,O
role,307,O
in,307,O
this,307,O
process,307,O
.,307,O
We,308,O
here,308,O
describe,308,O
a,308,O
point,308,O
mutation,308,O
in,308,O
such,308,O
a,308,O
sequence,308,O
.,308,O
Three,309,O
sisters,309,O
were,309,O
shown,309,O
to,309,O
suffer,309,O
from,309,O
fish-eye,309,B-SpecificDisease
disease,309,I-SpecificDisease
(,309,O
FED,309,B-SpecificDisease
),309,O
",",309,O
a,309,O
disorder,309,O
which,309,O
is,309,O
caused,309,O
by,309,O
mutations,309,O
in,309,O
the,309,O
gene,309,O
coding,309,O
for,309,O
lecithin,309,O
cholesterol,309,O
acyltransferase,309,O
(,309,O
LCAT,309,O
),309,O
.,309,O
Sequencing,310,O
of,310,O
the,310,O
LCAT,310,O
gene,310,O
of,310,O
all,310,O
three,310,O
probands,310,O
revealed,310,O
compound,310,O
heterozygosity,310,O
for,310,O
a,310,O
missense,310,O
mutation,310,O
in,310,O
exon,310,O
4,310,O
which,310,O
is,310,O
reported,310,O
to,310,O
underlie,310,O
the,310,O
FED,310,B-Modifier
phenotype,310,O
",",310,O
and,310,O
a,310,O
point,310,O
mutation,310,O
located,310,O
in,310,O
intron,310,O
4,310,O
(,310,O
IVS4,310,O
T-22C,310,O
),310,O
.,310,O
By,311,O
performing,311,O
in,311,O
vitro,311,O
expression,311,O
of,311,O
LCAT,311,O
minigenes,311,O
and,311,O
reverse,311,O
transcriptase,311,O
PCR,311,O
on,311,O
mRNA,311,O
isolated,311,O
from,311,O
leukocytes,311,O
of,311,O
the,311,O
patient,311,O
",",311,O
this,311,O
gene,311,O
defect,311,O
was,311,O
shown,311,O
to,311,O
cause,311,O
a,311,O
null,311,O
allele,311,O
as,311,O
the,311,O
result,311,O
of,311,O
complete,311,O
intron,311,O
retention,311,O
.,311,O
In,312,O
conclusion,312,O
",",312,O
we,312,O
demonstrated,312,O
that,312,O
a,312,O
point,312,O
mutation,312,O
in,312,O
a,312,O
lariat,312,O
branchpoint,312,O
consensus,312,O
sequence,312,O
causes,312,O
a,312,O
null,312,O
allele,312,O
in,312,O
a,312,O
patient,312,O
with,312,O
FED,312,B-SpecificDisease
.,312,O
In,313,O
addition,313,O
",",313,O
our,313,O
finding,313,O
illustrates,313,O
the,313,O
importance,313,O
of,313,O
this,313,O
sequence,313,O
for,313,O
normal,313,O
human,313,O
mRNA,313,O
processing,313,O
.,313,O
Finally,314,O
",",314,O
this,314,O
report,314,O
provides,314,O
a,314,O
widely,314,O
applicable,314,O
strategy,314,O
which,314,O
ensures,314,O
fast,314,O
and,314,O
effective,314,O
screening,314,O
for,314,O
intronic,314,O
defects,314,O
that,314,O
underlie,314,O
differential,314,O
gene,314,O
expression,314,O
..,314,O
Mutations,315,O
associated,315,O
with,315,O
variant,315,O
phenotypes,315,O
in,315,O
ataxia-telangiectasia,315,B-SpecificDisease
.,315,O
We,316,O
have,316,O
identified,316,O
14,316,O
families,316,O
with,316,O
ataxia-telangiectasia,316,B-SpecificDisease
(,316,O
A-T,316,B-SpecificDisease
),316,O
in,316,O
which,316,O
mutation,316,O
of,316,O
the,316,O
ATM,316,O
gene,316,O
is,316,O
associated,316,O
with,316,O
a,316,O
less,316,O
severe,316,O
clinical,316,O
and,316,O
cellular,316,O
phenotype,316,O
(,316,O
approximately,316,O
10,316,O
%,316,O
-15,316,O
%,316,O
of,316,O
A-T,316,B-Modifier
families,316,O
identified,316,O
in,316,O
the,316,O
United,316,O
Kingdom,316,O
),316,O
.,316,O
In,317,O
10,317,O
of,317,O
these,317,O
families,317,O
",",317,O
all,317,O
the,317,O
homozygotes,317,O
have,317,O
a,317,O
137-bp,317,O
insertion,317,O
in,317,O
their,317,O
cDNA,317,O
caused,317,O
by,317,O
a,317,O
point,317,O
mutation,317,O
in,317,O
a,317,O
sequence,317,O
resembling,317,O
a,317,O
splice-donor,317,O
site,317,O
.,317,O
The,318,O
second,318,O
A-T,318,B-Modifier
allele,318,O
has,318,O
a,318,O
different,318,O
mutation,318,O
in,318,O
each,318,O
patient,318,O
.,318,O
We,319,O
show,319,O
that,319,O
the,319,O
less,319,O
severe,319,O
phenotype,319,O
in,319,O
these,319,O
patients,319,O
is,319,O
caused,319,O
by,319,O
some,319,O
degree,319,O
of,319,O
normal,319,O
splicing,319,O
",",319,O
which,319,O
occurs,319,O
as,319,O
an,319,O
alternative,319,O
product,319,O
from,319,O
the,319,O
insertion-containing,319,O
allele,319,O
.,319,O
The,320,O
level,320,O
of,320,O
the,320,O
137-bp,320,O
PCR,320,O
product,320,O
containing,320,O
the,320,O
insertion,320,O
was,320,O
lowest,320,O
in,320,O
two,320,O
patients,320,O
who,320,O
showed,320,O
a,320,O
later,320,O
onset,320,O
of,320,O
cerebellar,320,B-SpecificDisease
ataxia,320,I-SpecificDisease
.,320,O
A,321,O
further,321,O
four,321,O
families,321,O
who,321,O
do,321,O
not,321,O
have,321,O
this,321,O
insertion,321,O
have,321,O
been,321,O
identified,321,O
.,321,O
Mutations,322,O
detected,322,O
in,322,O
two,322,O
of,322,O
four,322,O
of,322,O
these,322,O
are,322,O
missense,322,O
mutations,322,O
",",322,O
normally,322,O
rare,322,O
in,322,O
A-T,322,B-Modifier
patients,322,O
.,322,O
The,323,O
demonstration,323,O
of,323,O
mutations,323,O
giving,323,O
rise,323,O
to,323,O
a,323,O
slightly,323,O
milder,323,O
phenotype,323,O
in,323,O
A-T,323,B-SpecificDisease
raises,323,O
the,323,O
interesting,323,O
question,323,O
of,323,O
what,323,O
range,323,O
of,323,O
phenotypes,323,O
might,323,O
occur,323,O
in,323,O
individuals,323,O
in,323,O
whom,323,O
both,323,O
mutations,323,O
are,323,O
milder,323,O
.,323,O
One,324,O
possibility,324,O
might,324,O
be,324,O
that,324,O
individuals,324,O
who,324,O
are,324,O
compound,324,O
heterozygotes,324,O
for,324,O
ATM,324,O
mutations,324,O
are,324,O
more,324,O
common,324,O
than,324,O
we,324,O
realize,324,O
..,324,O
Mutation,325,O
of,325,O
the,325,O
VHL,325,O
gene,325,O
is,325,O
associated,325,O
exclusively,325,O
with,325,O
the,325,O
development,325,O
of,325,O
non-papillary,325,B-SpecificDisease
renal,325,I-SpecificDisease
cell,325,I-SpecificDisease
carcinomas,325,I-SpecificDisease
.,325,O
To,326,O
define,326,O
the,326,O
possible,326,O
role,326,O
of,326,O
the,326,O
VHL,326,B-Modifier
gene,326,O
in,326,O
the,326,O
development,326,O
of,326,O
sporadic,326,B-SpecificDisease
renal,326,I-SpecificDisease
cell,326,I-SpecificDisease
carcinomas,326,I-SpecificDisease
",",326,O
91,326,O
different,326,O
parenchymal,326,B-DiseaseClass
tumours,326,I-DiseaseClass
of,326,I-DiseaseClass
the,326,I-DiseaseClass
kidney,326,I-DiseaseClass
have,326,O
been,326,O
investigated,326,O
for,326,O
mutation,326,O
of,326,O
the,326,O
VHL,326,B-Modifier
gene,326,O
by,326,O
single,326,O
strand,326,O
conformation,326,O
polymorphism,326,O
(,326,O
SSCP,326,O
),326,O
and/or,326,O
heteroduplex,326,O
(,326,O
HD,326,O
),326,O
techniques,326,O
.,326,O
Chromosome,327,O
3p,327,O
deletion,327,O
was,327,O
detected,327,O
in,327,O
98,327,O
per,327,O
cent,327,O
of,327,O
non-papillary,327,B-SpecificDisease
renal,327,I-SpecificDisease
cell,327,I-SpecificDisease
carcinomas,327,I-SpecificDisease
and,327,O
in,327,O
25,327,O
per,327,O
cent,327,O
of,327,O
chromophobe,327,O
renal,327,B-SpecificDisease
cell,327,I-SpecificDisease
carcinomas,327,I-SpecificDisease
.,327,O
In,328,O
22,328,O
of,328,O
the,328,O
43,328,O
non-papillary,328,B-SpecificDisease
renal,328,I-SpecificDisease
cell,328,I-SpecificDisease
carcinomas,328,I-SpecificDisease
",",328,O
abnormally,328,O
migrating,328,O
DNA,328,O
bands,328,O
were,328,O
detected,328,O
by,328,O
SSCP,328,O
and/or,328,O
HD,328,O
analysis,328,O
.,328,O
No,329,O
mobility,329,O
shift,329,O
was,329,O
seen,329,O
in,329,O
any,329,O
of,329,O
the,329,O
23,329,O
chromophobe,329,O
renal,329,B-SpecificDisease
cell,329,I-SpecificDisease
carcinomas,329,I-SpecificDisease
.,329,O
In,330,O
addition,330,O
",",330,O
15,330,O
papillary,330,B-SpecificDisease
renal,330,I-SpecificDisease
cell,330,I-SpecificDisease
tumours,330,I-SpecificDisease
and,330,O
ten,330,O
renal,330,B-SpecificDisease
oncocytomas,330,I-SpecificDisease
",",330,O
which,330,O
are,330,O
characterized,330,O
by,330,O
genetic,330,O
changes,330,O
other,330,O
than,330,O
loss,330,O
of,330,O
chromosome,330,O
3p,330,O
sequences,330,O
",",330,O
were,330,O
analysed,330,O
for,330,O
mutation,330,O
of,330,O
the,330,O
VHL,330,B-Modifier
gene,330,O
.,330,O
None,331,O
of,331,O
these,331,O
tumours,331,B-DiseaseClass
showed,331,O
abnormal,331,O
migration,331,O
patterns,331,O
.,331,O
The,332,O
results,332,O
indicate,332,O
that,332,O
mutation,332,O
of,332,O
the,332,O
VHL,332,B-Modifier
gene,332,O
is,332,O
associated,332,O
exclusively,332,O
with,332,O
the,332,O
development,332,O
of,332,O
non-papillary,332,B-SpecificDisease
renal,332,I-SpecificDisease
cell,332,I-SpecificDisease
carcinoma,332,I-SpecificDisease
..,332,O
The,333,O
Emery-Dreifuss,333,B-Modifier
muscular,333,I-Modifier
dystrophy,333,I-Modifier
protein,333,O
",",333,O
emerin,333,O
",",333,O
is,333,O
a,333,O
nuclear,333,O
membrane,333,O
protein,333,O
.,333,O
A,334,O
large,334,O
fragment,334,O
of,334,O
emerin,334,O
cDNA,334,O
was,334,O
prepared,334,O
by,334,O
PCR,334,O
and,334,O
expressed,334,O
as,334,O
a,334,O
recombinant,334,O
protein,334,O
in,334,O
Escherichia,334,O
coli,334,O
.,334,O
Using,335,O
this,335,O
as,335,O
immunogen,335,O
",",335,O
we,335,O
prepared,335,O
a,335,O
panel,335,O
of,335,O
12,335,O
monoclonal,335,O
antibodies,335,O
which,335,O
recognise,335,O
at,335,O
least,335,O
four,335,O
different,335,O
epitopes,335,O
on,335,O
emerin,335,O
in,335,O
order,335,O
to,335,O
ensure,335,O
that,335,O
emerin,335,O
can,335,O
be,335,O
distinguished,335,O
from,335,O
non-specific,335,O
cross-reacting,335,O
proteins,335,O
.,335,O
All,336,O
the,336,O
mAbs,336,O
recognised,336,O
a,336,O
34,336,O
kDa,336,O
protein,336,O
in,336,O
all,336,O
tissues,336,O
tested,336,O
",",336,O
though,336,O
minor,336,O
emerin-related,336,O
bands,336,O
were,336,O
also,336,O
detected,336,O
in,336,O
some,336,O
tissues,336,O
.,336,O
Immunofluorescence,337,O
microscopy,337,O
showed,337,O
that,337,O
emerin,337,O
is,337,O
located,337,O
at,337,O
the,337,O
nuclear,337,O
rim,337,O
in,337,O
all,337,O
tissues,337,O
examined,337,O
.,337,O
A,338,O
muscle,338,O
biopsy,338,O
from,338,O
an,338,O
Emery-Dreifuss,338,B-Modifier
muscular,338,I-Modifier
dystrophy,338,I-Modifier
(,338,O
EMDM,338,B-Modifier
),338,O
patient,338,O
showed,338,O
complete,338,O
absence,338,O
of,338,O
emerin,338,O
by,338,O
both,338,O
Western,338,O
blotting,338,O
and,338,O
immunohistochemistry,338,O
",",338,O
suggesting,338,O
a,338,O
simple,338,O
diagnostic,338,O
antibody,338,O
test,338,O
for,338,O
EDMD,338,B-Modifier
families,338,O
.,338,O
Biochemical,339,O
fractionation,339,O
of,339,O
brain,339,O
and,339,O
liver,339,O
tissues,339,O
showed,339,O
that,339,O
emerin,339,O
was,339,O
present,339,O
in,339,O
nuclei,339,O
purified,339,O
by,339,O
centrifugation,339,O
through,339,O
65,339,O
%,339,O
sucrose,339,O
and,339,O
was,339,O
absent,339,O
from,339,O
soluble,339,O
fractions,339,O
(,339,O
post-100,339,O
",",339,O
000,339,O
g,339,O
),339,O
.,339,O
From,340,O
these,340,O
results,340,O
",",340,O
together,340,O
with,340,O
sequence,340,O
and,340,O
structural,340,O
homologies,340,O
between,340,O
emerin,340,O
",",340,O
thymopoietins,340,O
and,340,O
the,340,O
nuclear,340,O
lamina-associated,340,O
protein,340,O
",",340,O
LAP2,340,O
",",340,O
we,340,O
suggest,340,O
that,340,O
emerin,340,O
will,340,O
prove,340,O
to,340,O
be,340,O
one,340,O
member,340,O
of,340,O
a,340,O
family,340,O
of,340,O
inner,340,O
nuclear,340,O
membrane,340,O
proteins,340,O
..,340,O
Mutation,341,O
of,341,O
MSH3,341,O
in,341,O
endometrial,341,B-SpecificDisease
cancer,341,I-SpecificDisease
and,341,O
evidence,341,O
for,341,O
its,341,O
functional,341,O
role,341,O
in,341,O
heteroduplex,341,O
repair,341,O
.,341,O
Many,342,O
human,342,O
tumours,342,B-DiseaseClass
have,342,O
length,342,O
alterations,342,O
in,342,O
repetitive,342,O
sequence,342,O
elements,342,O
.,342,O
Although,343,O
this,343,O
microsatellite,343,B-SpecificDisease
instability,343,I-SpecificDisease
has,343,O
been,343,O
attributed,343,O
to,343,O
mutations,343,O
in,343,O
four,343,O
DNA,343,O
mismatch,343,O
repair,343,O
genes,343,O
in,343,O
hereditary,343,B-Modifier
nonpolyposis,343,I-Modifier
colorectal,343,I-Modifier
cancer,343,I-Modifier
(,343,O
HNPCC,343,B-Modifier
),343,O
kindreds,343,O
",",343,O
many,343,O
sporadic,343,B-DiseaseClass
tumours,343,I-DiseaseClass
exhibit,343,O
instability,343,O
but,343,O
no,343,O
detectable,343,O
mutations,343,O
in,343,O
these,343,O
genes,343,O
.,343,O
It,344,O
is,344,O
therefore,344,O
of,344,O
interest,344,O
to,344,O
identify,344,O
other,344,O
genes,344,O
that,344,O
contribute,344,O
to,344,O
this,344,O
instability,344,O
.,344,O
In,345,O
yeast,345,O
",",345,O
mutations,345,O
in,345,O
several,345,O
genes,345,O
",",345,O
including,345,O
RTH,345,O
and,345,O
MSH3,345,O
",",345,O
cause,345,O
microsatellite,345,O
instability,345,O
.,345,O
Thus,346,O
",",346,O
we,346,O
screened,346,O
16,346,O
endometrial,346,B-SpecificDisease
carcinomas,346,I-SpecificDisease
with,346,O
microsatellite,346,O
instability,346,O
for,346,O
alterations,346,O
in,346,O
FEN1,346,O
(,346,O
the,346,O
human,346,O
homolog,346,O
of,346,O
RTH,346,O
),346,O
and,346,O
in,346,O
MSH3,346,O
(,346,O
refs,346,O
12-14,346,O
),346,O
.,346,O
Although,347,O
we,347,O
found,347,O
no,347,O
FEN1,347,O
mutations,347,O
",",347,O
a,347,O
frameshift,347,O
mutation,347,O
in,347,O
MSH3,347,O
was,347,O
observed,347,O
in,347,O
an,347,O
endometrial,347,B-SpecificDisease
carcinoma,347,I-SpecificDisease
and,347,O
in,347,O
an,347,O
endometrial,347,B-Modifier
carcinoma,347,I-Modifier
cell,347,O
line,347,O
.,347,O
Extracts,348,O
of,348,O
the,348,O
cell,348,O
line,348,O
were,348,O
deficient,348,O
in,348,O
repair,348,O
of,348,O
DNA,348,O
substrates,348,O
containing,348,O
mismatches,348,O
or,348,O
extra,348,O
nucleotides,348,O
.,348,O
Introducing,349,O
chromosome,349,O
5,349,O
",",349,O
encoding,349,O
the,349,O
MSH3,349,O
gene,349,O
",",349,O
into,349,O
the,349,O
mutant,349,O
cell,349,O
line,349,O
increased,349,O
the,349,O
stability,349,O
of,349,O
some,349,O
but,349,O
not,349,O
all,349,O
microsatellites,349,O
.,349,O
Extracts,350,O
of,350,O
these,350,O
cells,350,O
repaired,350,O
certain,350,O
substrates,350,O
containing,350,O
extra,350,O
nucleotides,350,O
",",350,O
but,350,O
were,350,O
deficient,350,O
in,350,O
repair,350,O
of,350,O
those,350,O
containing,350,O
mismatches,350,O
or,350,O
other,350,O
extra,350,O
nucleotides,350,O
.,350,O
A,351,O
subsequent,351,O
search,351,O
revealed,351,O
a,351,O
second,351,O
gene,351,O
mutation,351,O
in,351,O
HHUA,351,O
cells,351,O
",",351,O
a,351,O
missense,351,O
mutation,351,O
in,351,O
the,351,O
MSH6,351,O
gene,351,O
.,351,O
Together,352,O
the,352,O
data,352,O
suggest,352,O
that,352,O
the,352,O
MSH3,352,O
gene,352,O
encodes,352,O
a,352,O
product,352,O
that,352,O
functions,352,O
in,352,O
repair,352,O
of,352,O
some,352,O
but,352,O
not,352,O
all,352,O
pre-mutational,352,O
intermediates,352,O
",",352,O
its,352,O
mutation,352,O
in,352,O
tumours,352,B-DiseaseClass
can,352,O
result,352,O
in,352,O
genomic,352,O
instability,352,O
and,352,O
",",352,O
as,352,O
in,352,O
yeast,352,O
",",352,O
MSH3,352,O
and,352,O
MSH6,352,O
are,352,O
partially,352,O
redundant,352,O
for,352,O
mismatch,352,O
repair,352,O
..,352,O
Comparative,353,O
genome,353,O
mapping,353,O
of,353,O
the,353,O
ataxia-telangiectasia,353,B-Modifier
region,353,O
in,353,O
mouse,353,O
",",353,O
rat,353,O
",",353,O
and,353,O
Syrian,353,O
hamster,353,O
.,353,O
Chromosomal,354,O
locations,354,O
of,354,O
the,354,O
Atm,354,O
(,354,O
ataxia-telangiectasia,354,B-Modifier
(,354,O
AT,354,B-Modifier
),354,O
-mutated,354,O
),354,O
and,354,O
Acat1,354,O
(,354,O
mitochondrial,354,O
acetoacetyl-CoA,354,O
thiolase,354,O
),354,O
genes,354,O
in,354,O
mouse,354,O
",",354,O
rat,354,O
",",354,O
and,354,O
Syrian,354,O
hamster,354,O
were,354,O
determined,354,O
by,354,O
direct,354,O
R-banding,354,O
FISH,354,O
.,354,O
Both,355,O
genes,355,O
were,355,O
colocalized,355,O
to,355,O
the,355,O
C-D,355,O
band,355,O
of,355,O
mouse,355,O
chromosome,355,O
9,355,O
",",355,O
the,355,O
proximal,355,O
end,355,O
of,355,O
q24,355,O
.,355,O
1,356,O
of,356,O
rat,356,O
chromosome,356,O
8,356,O
",",356,O
and,356,O
qa4-qa5,356,O
of,356,O
Syrian,356,O
hamster,356,O
chromosome,356,O
12,356,O
.,356,O
The,357,O
regions,357,O
in,357,O
the,357,O
mouse,357,O
and,357,O
rat,357,O
were,357,O
homologous,357,O
to,357,O
human,357,O
chromosome,357,O
11q,357,O
.,357,O
Fine,358,O
genetic,358,O
linkage,358,O
mapping,358,O
of,358,O
the,358,O
mouse,358,O
AT,358,B-Modifier
region,358,O
was,358,O
performed,358,O
using,358,O
the,358,O
interspecific,358,O
backcross,358,O
mice,358,O
.,358,O
Atm,359,O
",",359,O
Acat1,359,O
",",359,O
and,359,O
Npat,359,O
",",359,O
which,359,O
is,359,O
a,359,O
new,359,O
gene,359,O
isolated,359,O
from,359,O
the,359,O
AT,359,O
region,359,O
",",359,O
and,359,O
12,359,O
flanking,359,O
microsatellite,359,O
DNA,359,O
markers,359,O
were,359,O
examined,359,O
.,359,O
No,360,O
recombinations,360,O
were,360,O
found,360,O
among,360,O
the,360,O
Atm,360,O
",",360,O
Npat,360,O
",",360,O
Acat1,360,O
",",360,O
and,360,O
D9Mit6,360,O
loci,360,O
",",360,O
and,360,O
these,360,O
loci,360,O
were,360,O
mapped,360,O
2,360,O
.,360,O
0,361,O
cM,361,O
distal,361,O
to,361,O
D9Mit99,361,O
and,361,O
1,361,O
.,361,O
3,362,O
cM,362,O
proximal,362,O
to,362,O
D9Mit102,362,O
.,362,O
Comparison,363,O
of,363,O
the,363,O
linkage,363,O
map,363,O
of,363,O
mouse,363,O
chromosome,363,O
9,363,O
(,363,O
MMU9,363,O
),363,O
and,363,O
that,363,O
of,363,O
human,363,O
chromosome,363,O
11,363,O
(,363,O
HSA11,363,O
),363,O
indicates,363,O
that,363,O
there,363,O
is,363,O
a,363,O
chromosomal,363,O
rearrangement,363,O
due,363,O
to,363,O
an,363,O
inversion,363,O
between,363,O
Ets1,363,O
and,363,O
Atm-Npat-Acat1,363,O
and,363,O
that,363,O
the,363,O
inversion,363,O
of,363,O
MMU9,363,O
originated,363,O
from,363,O
the,363,O
chromosomal,363,O
breakage,363,O
at,363,O
the,363,O
boundary,363,O
between,363,O
Gria4,363,O
and,363,O
Atm-Npat-Acat1,363,O
on,363,O
HSA11,363,O
.,363,O
This,364,O
type,364,O
of,364,O
inversion,364,O
appeared,364,O
to,364,O
be,364,O
conserved,364,O
in,364,O
the,364,O
three,364,O
rodent,364,O
species,364,O
",",364,O
mouse,364,O
",",364,O
rat,364,O
",",364,O
and,364,O
Syrian,364,O
hamster,364,O
",",364,O
using,364,O
additional,364,O
comparative,364,O
mapping,364,O
data,364,O
with,364,O
the,364,O
Rck,364,O
gene,364,O
An,365,O
animal,365,O
model,365,O
for,365,O
Norrie,365,B-SpecificDisease
disease,365,I-SpecificDisease
(,365,O
ND,365,B-SpecificDisease
),365,O
:,365,O
gene,365,O
targeting,365,O
of,365,O
the,365,O
mouse,365,O
ND,365,B-Modifier
gene,365,O
.,365,O
In,366,O
order,366,O
to,366,O
elucidate,366,O
the,366,O
cellular,366,O
and,366,O
molecular,366,O
processes,366,O
which,366,O
are,366,O
involved,366,O
in,366,O
Norrie,366,B-SpecificDisease
disease,366,I-SpecificDisease
(,366,O
ND,366,B-SpecificDisease
),366,O
",",366,O
we,366,O
have,366,O
used,366,O
gene,366,O
targeting,366,O
technology,366,O
to,366,O
generate,366,O
ND,366,B-Modifier
mutant,366,O
mice,366,O
.,366,O
The,367,O
murine,367,O
homologue,367,O
of,367,O
the,367,O
ND,367,B-Modifier
gene,367,O
was,367,O
cloned,367,O
and,367,O
shown,367,O
to,367,O
encode,367,O
a,367,O
polypeptide,367,O
that,367,O
shares,367,O
94,367,O
%,367,O
of,367,O
the,367,O
amino,367,O
acid,367,O
sequence,367,O
with,367,O
its,367,O
human,367,O
counterpart,367,O
.,367,O
RNA,368,O
in,368,O
situ,368,O
hybridization,368,O
revealed,368,O
expression,368,O
in,368,O
retina,368,O
",",368,O
brain,368,O
and,368,O
the,368,O
olfactory,368,O
bulb,368,O
and,368,O
epithelium,368,O
of,368,O
2,368,O
week,368,O
old,368,O
mice,368,O
.,368,O
Hemizygous,369,O
mice,369,O
carrying,369,O
a,369,O
replacement,369,O
mutation,369,O
in,369,O
exon,369,O
2,369,O
of,369,O
the,369,O
ND,369,B-Modifier
gene,369,O
developed,369,O
retrolental,369,O
structures,369,O
in,369,O
the,369,O
vitreous,369,O
body,369,O
and,369,O
showed,369,O
an,369,O
overall,369,O
disorganization,369,O
of,369,O
the,369,O
retinal,369,O
ganglion,369,O
cell,369,O
layer,369,O
.,369,O
The,370,O
outer,370,O
plexiform,370,O
layer,370,O
disappears,370,O
occasionally,370,O
",",370,O
resulting,370,O
in,370,O
a,370,O
juxtaposed,370,O
inner,370,O
and,370,O
outer,370,O
nuclear,370,O
layer,370,O
.,370,O
At,371,O
the,371,O
same,371,O
regions,371,O
",",371,O
the,371,O
outer,371,O
segments,371,O
of,371,O
the,371,O
photoreceptor,371,O
cell,371,O
layer,371,O
are,371,O
no,371,O
longer,371,O
present,371,O
.,371,O
These,372,O
ocular,372,O
findings,372,O
are,372,O
consistent,372,O
with,372,O
observations,372,O
in,372,O
ND,372,B-Modifier
patients,372,O
and,372,O
the,372,O
generated,372,O
mouse,372,O
line,372,O
provides,372,O
a,372,O
faithful,372,O
model,372,O
for,372,O
study,372,O
of,372,O
early,372,O
pathogenic,372,O
events,372,O
in,372,O
this,372,O
severe,372,O
X-linked,372,B-DiseaseClass
recessive,372,I-DiseaseClass
neurological,372,I-DiseaseClass
disorder,372,I-DiseaseClass
..,372,O
The,373,O
hybrid,373,O
PAX3-FKHR,373,O
fusion,373,O
protein,373,O
of,373,O
alveolar,373,B-SpecificDisease
rhabdomyosarcoma,373,I-SpecificDisease
transforms,373,O
fibroblasts,373,O
in,373,O
culture,373,O
.,373,O
Pediatric,374,B-SpecificDisease
alveolar,374,I-SpecificDisease
rhabdomyosarcoma,374,I-SpecificDisease
is,374,O
characterized,374,O
by,374,O
a,374,O
chromosomal,374,O
translocation,374,O
that,374,O
fuses,374,O
parts,374,O
of,374,O
the,374,O
PAX3,374,O
and,374,O
FKHR,374,O
genes,374,O
.,374,O
PAX3,375,O
codes,375,O
for,375,O
a,375,O
transcriptional,375,O
regulator,375,O
that,375,O
controls,375,O
developmental,375,O
programs,375,O
",",375,O
and,375,O
FKHR,375,O
codes,375,O
for,375,O
a,375,O
forkhead-winged,375,O
helix,375,O
protein,375,O
",",375,O
also,375,O
a,375,O
likely,375,O
transcription,375,O
factor,375,O
.,375,O
The,376,O
PAX3-FKHR,376,O
fusion,376,O
product,376,O
retains,376,O
the,376,O
DNA,376,O
binding,376,O
domains,376,O
of,376,O
the,376,O
PAX3,376,O
protein,376,O
and,376,O
the,376,O
putative,376,O
activator,376,O
domain,376,O
of,376,O
the,376,O
FKHR,376,O
protein,376,O
.,376,O
The,377,O
PAX3-FKHR,377,O
protein,377,O
has,377,O
been,377,O
shown,377,O
to,377,O
function,377,O
as,377,O
a,377,O
transcriptional,377,O
activator,377,O
.,377,O
Using,378,O
the,378,O
RCAS,378,O
retroviral,378,O
vector,378,O
",",378,O
we,378,O
have,378,O
introduced,378,O
the,378,O
PAX3-FKHR,378,O
gene,378,O
into,378,O
chicken,378,O
embryo,378,O
fibroblasts,378,O
.,378,O
Expression,379,O
of,379,O
the,379,O
PAX3-FKHR,379,O
protein,379,O
in,379,O
these,379,O
cells,379,O
leads,379,O
to,379,O
transformation,379,O
the,379,O
cells,379,O
become,379,O
enlarged,379,O
",",379,O
grow,379,O
tightly,379,O
packed,379,O
and,379,O
in,379,O
multiple,379,O
layers,379,O
",",379,O
and,379,O
acquire,379,O
the,379,O
ability,379,O
for,379,O
anchorage-independent,379,O
growth,379,O
.,379,O
This,380,O
cellular,380,O
transformation,380,O
in,380,O
vitro,380,O
will,380,O
facilitate,380,O
studies,380,O
on,380,O
the,380,O
mechanism,380,O
of,380,O
PAX3-FKHR-induced,380,O
oncogenesis,380,O
..,380,O
Somatic-cell,381,O
selection,381,O
is,381,O
a,381,O
major,381,O
determinant,381,O
of,381,O
the,381,O
blood-cell,381,O
phenotype,381,O
in,381,O
heterozygotes,381,O
for,381,O
glucose-6-phosphate,381,O
dehydrogenase,381,O
mutations,381,O
causing,381,O
severe,381,O
enzyme,381,B-DiseaseClass
deficiency,381,I-DiseaseClass
.,381,O
X-chromosome,382,O
inactivation,382,O
in,382,O
mammals,382,O
is,382,O
regarded,382,O
as,382,O
an,382,O
essentially,382,O
random,382,O
process,382,O
",",382,O
but,382,O
the,382,O
resulting,382,O
somatic-cell,382,O
mosaicism,382,O
creates,382,O
the,382,O
opportunity,382,O
for,382,O
cell,382,O
selection,382,O
.,382,O
In,383,O
most,383,O
people,383,O
with,383,O
red-blood-cell,383,O
glucose-6-phosphate,383,B-SpecificDisease
dehydrogenase,383,I-SpecificDisease
(,383,I-SpecificDisease
G6PD,383,I-SpecificDisease
),383,I-SpecificDisease
deficiency,383,I-SpecificDisease
",",383,O
the,383,O
enzyme-deficient,383,O
phenotype,383,O
is,383,O
only,383,O
moderately,383,O
expressed,383,O
in,383,O
nucleated,383,O
cells,383,O
.,383,O
However,384,O
",",384,O
in,384,O
a,384,O
small,384,O
subset,384,O
of,384,O
hemizygous,384,O
males,384,O
who,384,O
suffer,384,O
from,384,O
chronic,384,B-SpecificDisease
nonspherocytic,384,I-SpecificDisease
hemolytic,384,I-SpecificDisease
anemia,384,I-SpecificDisease
",",384,O
the,384,O
underlying,384,O
mutations,384,O
(,384,O
designated,384,O
class,384,O
I,384,O
),384,O
cause,384,O
more-severe,384,O
G6PD,384,B-SpecificDisease
deficiency,384,I-SpecificDisease
",",384,O
and,384,O
this,384,O
might,384,O
provide,384,O
an,384,O
opportunity,384,O
for,384,O
selection,384,O
in,384,O
heterozygous,384,O
females,384,O
during,384,O
development,384,O
.,384,O
In,385,O
order,385,O
to,385,O
test,385,O
this,385,O
possibility,385,O
we,385,O
have,385,O
analyzed,385,O
four,385,O
heterozygotes,385,O
for,385,O
class,385,O
I,385,O
G6PD,385,O
mutations,385,O
two,385,O
with,385,O
G6PD,385,O
Portici,385,O
(,385,O
1178G,385,O
--,385,O
>,385,O
A,385,O
),385,O
and,385,O
two,385,O
with,385,O
G6PD,385,O
Bari,385,O
(,385,O
1187C,385,O
--,385,O
>,385,O
T,385,O
),385,O
.,385,O
We,386,O
found,386,O
that,386,O
in,386,O
fractionated,386,O
blood,386,O
cell,386,O
types,386,O
(,386,O
including,386,O
erythroid,386,O
",",386,O
myeloid,386,O
",",386,O
and,386,O
lymphoid,386,O
cell,386,O
lineages,386,O
),386,O
there,386,O
was,386,O
a,386,O
significant,386,O
excess,386,O
of,386,O
G6PD-normal,386,O
cells,386,O
.,386,O
The,387,O
significant,387,O
concordance,387,O
that,387,O
we,387,O
have,387,O
observed,387,O
in,387,O
the,387,O
degree,387,O
of,387,O
imbalance,387,O
in,387,O
the,387,O
different,387,O
blood-cell,387,O
lineages,387,O
indicates,387,O
that,387,O
a,387,O
selective,387,O
mechanism,387,O
is,387,O
likely,387,O
to,387,O
operate,387,O
at,387,O
the,387,O
level,387,O
of,387,O
pluripotent,387,O
blood,387,O
stem,387,O
cells,387,O
.,387,O
Thus,388,O
",",388,O
it,388,O
appears,388,O
that,388,O
severe,388,O
G6PD,388,B-SpecificDisease
deficiency,388,I-SpecificDisease
affects,388,O
adversely,388,O
the,388,O
proliferation,388,O
or,388,O
the,388,O
survival,388,O
of,388,O
nucleated,388,O
blood,388,O
cells,388,O
and,388,O
that,388,O
this,388,O
phenotypic,388,O
characteristic,388,O
is,388,O
critical,388,O
during,388,O
hematopoiesis,388,O
..,388,O
Analysis,389,O
of,389,O
meiotic,389,O
segregation,389,O
",",389,O
using,389,O
single-sperm,389,O
typing,389,O
:,389,O
meiotic,389,O
drive,389,O
at,389,O
the,389,O
myotonic,389,B-Modifier
dystrophy,389,I-Modifier
locus,389,O
.,389,O
Meiotic,390,O
drive,390,O
at,390,O
the,390,O
myotonic,390,B-Modifier
dystrophy,390,I-Modifier
(,390,O
DM,390,B-Modifier
),390,O
locus,390,O
has,390,O
recently,390,O
been,390,O
suggested,390,O
as,390,O
being,390,O
responsible,390,O
for,390,O
maintaining,390,O
the,390,O
frequency,390,O
",",390,O
in,390,O
the,390,O
human,390,O
population,390,O
",",390,O
of,390,O
DM,390,B-Modifier
chromosomes,390,O
capable,390,O
of,390,O
expansion,390,O
to,390,O
the,390,O
disease,390,O
state,390,O
.,390,O
In,391,O
order,391,O
to,391,O
test,391,O
this,391,O
hypothesis,391,O
",",391,O
we,391,O
have,391,O
studied,391,O
samples,391,O
of,391,O
single,391,O
sperm,391,O
from,391,O
three,391,O
individuals,391,O
heterozygous,391,O
at,391,O
the,391,O
DM,391,B-Modifier
locus,391,O
",",391,O
each,391,O
with,391,O
one,391,O
allele,391,O
larger,391,O
and,391,O
one,391,O
allele,391,O
smaller,391,O
than,391,O
19,391,O
CTG,391,O
repeats,391,O
.,391,O
To,392,O
guard,392,O
against,392,O
the,392,O
possible,392,O
problem,392,O
of,392,O
differential,392,O
PCR,392,O
amplification,392,O
rates,392,O
based,392,O
on,392,O
the,392,O
lengths,392,O
of,392,O
the,392,O
alleles,392,O
",",392,O
the,392,O
sperm,392,O
were,392,O
also,392,O
typed,392,O
at,392,O
another,392,O
closely,392,O
linked,392,O
marker,392,O
whose,392,O
allele,392,O
size,392,O
was,392,O
unrelated,392,O
to,392,O
the,392,O
allele,392,O
size,392,O
at,392,O
the,392,O
DM,392,B-Modifier
locus,392,O
.,392,O
Using,393,O
statistical,393,O
models,393,O
specifically,393,O
designed,393,O
to,393,O
study,393,O
single-sperm,393,O
segregation,393,O
data,393,O
",",393,O
we,393,O
find,393,O
no,393,O
evidence,393,O
of,393,O
meiotic,393,O
segregation,393,O
distortion,393,O
.,393,O
The,394,O
upper,394,O
limit,394,O
of,394,O
the,394,O
two-sided,394,O
95,394,O
%,394,O
confidence,394,O
interval,394,O
for,394,O
the,394,O
estimate,394,O
of,394,O
the,394,O
common,394,O
segregation,394,O
probability,394,O
for,394,O
the,394,O
three,394,O
donors,394,O
is,394,O
at,394,O
or,394,O
below,394,O
.,394,O
515,395,O
for,395,O
all,395,O
models,395,O
considered,395,O
",",395,O
and,395,O
no,395,O
statistically,395,O
significant,395,O
difference,395,O
from,395,O
.,395,O
5,396,O
is,396,O
detected,396,O
in,396,O
any,396,O
of,396,O
the,396,O
models,396,O
.,396,O
This,397,O
suggests,397,O
that,397,O
any,397,O
greater,397,O
amount,397,O
of,397,O
segregation,397,O
distortion,397,O
at,397,O
the,397,O
myotonic,397,B-Modifier
dystrophy,397,I-Modifier
locus,397,O
must,397,O
result,397,O
from,397,O
events,397,O
following,397,O
sperm,397,O
ejaculation,397,O
.,397,O
LPP,398,O
",",398,O
the,398,O
preferred,398,O
fusion,398,O
partner,398,O
gene,398,O
of,398,O
HMGIC,398,O
in,398,O
lipomas,398,B-DiseaseClass
",",398,O
is,398,O
a,398,O
novel,398,O
member,398,O
of,398,O
the,398,O
LIM,398,O
protein,398,O
gene,398,O
family,398,O
.,398,O
A,399,O
major,399,O
cytogenetic,399,O
subgroup,399,O
of,399,O
lipomas,399,B-DiseaseClass
is,399,O
characterized,399,O
by,399,O
recurrent,399,O
chromosome,399,O
aberrations,399,O
",",399,O
mainly,399,O
translocations,399,O
",",399,O
that,399,O
involve,399,O
chromosome,399,O
segment,399,O
12q13-q15,399,O
.,399,O
Multiple,400,O
chromosomes,400,O
have,400,O
been,400,O
found,400,O
as,400,O
the,400,O
translocation,400,O
partners,400,O
of,400,O
chromosome,400,O
12,400,O
but,400,O
3q27-q28,400,O
is,400,O
preferentially,400,O
involved,400,O
.,400,O
In,401,O
previous,401,O
studies,401,O
",",401,O
it,401,O
has,401,O
been,401,O
shown,401,O
that,401,O
the,401,O
high,401,O
mobility,401,O
group,401,O
(,401,O
HMG,401,O
),401,O
protein,401,O
gene,401,O
HMGIC,401,O
at,401,O
12q15,401,O
is,401,O
consistently,401,O
rearranged,401,O
as,401,O
a,401,O
consequence,401,O
of,401,O
these,401,O
translocations,401,O
.,401,O
Here,402,O
",",402,O
we,402,O
report,402,O
the,402,O
identification,402,O
and,402,O
characterization,402,O
of,402,O
the,402,O
chromosome,402,O
3-derived,402,O
translocation,402,O
partner,402,O
gene,402,O
",",402,O
which,402,O
we,402,O
have,402,O
designated,402,O
LPP,402,O
(,402,O
lipoma,402,B-Modifier
preferred,402,O
partner,402,O
gene,402,O
),402,O
.,402,O
Using,403,O
3-RACE,403,O
analysis,403,O
of,403,O
HMGIC,403,O
fusion,403,O
transcripts,403,O
in,403,O
lipoma,403,B-Modifier
cell,403,O
line,403,O
Li-501/SV40,403,O
",",403,O
ectopic,403,O
genetic,403,O
sequences,403,O
were,403,O
obtained,403,O
",",403,O
which,403,O
by,403,O
CASH,403,O
(,403,O
chromosome,403,O
assignment,403,O
using,403,O
somatic,403,O
cell,403,O
hybrids,403,O
),403,O
and,403,O
FISH,403,O
(,403,O
fluorescence,403,O
in,403,O
situ,403,O
hybridization,403,O
),403,O
analysis,403,O
were,403,O
found,403,O
to,403,O
originate,403,O
from,403,O
chromosome,403,O
segment,403,O
3q27-q28,403,O
.,403,O
In,404,O
Northern,404,O
blot,404,O
analysis,404,O
",",404,O
an,404,O
mRNA,404,O
of,404,O
over,404,O
10,404,O
kb,404,O
was,404,O
detected,404,O
by,404,O
these,404,O
ectopic,404,O
sequences,404,O
in,404,O
a,404,O
variety,404,O
of,404,O
human,404,O
tissues,404,O
but,404,O
not,404,O
in,404,O
brain,404,O
and,404,O
peripheral,404,O
blood,404,O
leukocytes,404,O
.,404,O
Upon,405,O
partial,405,O
cDNA,405,O
cloning,405,O
",",405,O
features,405,O
of,405,O
the,405,O
genetic,405,O
organization,405,O
of,405,O
LPP,405,O
were,405,O
established,405,O
.,405,O
The,406,O
gene,406,O
was,406,O
found,406,O
to,406,O
span,406,O
a,406,O
genomic,406,O
region,406,O
of,406,O
over,406,O
400,406,O
kb,406,O
.,406,O
Nucleotide,407,O
sequence,407,O
analysis,407,O
of,407,O
a,407,O
composite,407,O
cDNA,407,O
of,407,O
LPP,407,O
revealed,407,O
an,407,O
open,407,O
reading,407,O
frame,407,O
of,407,O
1836,407,O
nucleotides,407,O
encoding,407,O
a,407,O
proline-rich,407,O
protein,407,O
containing,407,O
a,407,O
leucine-zipper,407,O
motif,407,O
in,407,O
its,407,O
amino-terminal,407,O
region,407,O
and,407,O
three,407,O
LIM,407,O
domains,407,O
in,407,O
its,407,O
carboxy-terminal,407,O
region,407,O
.,407,O
The,408,O
LPP-encoded,408,O
protein,408,O
should,408,O
be,408,O
classified,408,O
as,408,O
a,408,O
novel,408,O
member,408,O
of,408,O
the,408,O
group,408,O
3,408,O
proteins,408,O
of,408,O
the,408,O
LIM,408,O
protein,408,O
gene,408,O
family,408,O
.,408,O
Using,409,O
reverse,409,O
transcriptase,409,O
combined,409,O
with,409,O
polymerase,409,O
chain,409,O
reactions,409,O
in,409,O
the,409,O
analysis,409,O
of,409,O
a,409,O
number,409,O
of,409,O
lipoma,409,B-Modifier
cell,409,O
lines,409,O
and,409,O
primary,409,B-DiseaseClass
lipomas,409,I-DiseaseClass
",",409,O
it,409,O
appeared,409,O
that,409,O
LPP,409,O
is,409,O
frequently,409,O
rearranged,409,O
also,409,O
in,409,O
cases,409,O
without,409,O
a,409,O
cytogenetically,409,O
detectable,409,O
involvement,409,O
of,409,O
3q27-q28,409,O
.,409,O
Two,410,O
alternative,410,O
HMGIC/LPP,410,O
hybrid,410,O
transcripts,410,O
have,410,O
been,410,O
detected,410,O
;,410,O
the,410,O
difference,410,O
between,410,O
them,410,O
is,410,O
mainly,410,O
the,410,O
presence,410,O
of,410,O
either,410,O
two,410,O
or,410,O
three,410,O
LIM,410,O
domains,410,O
in,410,O
the,410,O
predicted,410,O
HMGI-C/LPP,410,O
fusion,410,O
proteins,410,O
..,410,O
Absence,411,O
of,411,O
disease,411,O
phenotype,411,O
and,411,O
intergenerational,411,O
stability,411,O
of,411,O
the,411,O
CAG,411,O
repeat,411,O
in,411,O
transgenic,411,O
mice,411,O
expressing,411,O
the,411,O
human,411,O
Huntington,411,B-Modifier
disease,411,I-Modifier
transcript,411,O
.,411,O
The,412,O
mutation,412,O
underlying,412,O
Huntington,412,B-SpecificDisease
disease,412,I-SpecificDisease
(,412,O
HD,412,B-SpecificDisease
),412,O
is,412,O
CAG,412,O
expansion,412,O
in,412,O
the,412,O
first,412,O
exon,412,O
of,412,O
the,412,O
HD,412,B-Modifier
gene,412,O
.,412,O
In,413,O
order,413,O
to,413,O
investigate,413,O
the,413,O
role,413,O
of,413,O
CAG,413,O
expansion,413,O
in,413,O
the,413,O
pathogenesis,413,O
of,413,O
HD,413,B-SpecificDisease
",",413,O
we,413,O
have,413,O
produced,413,O
transgenic,413,O
mice,413,O
containing,413,O
the,413,O
full,413,O
length,413,O
human,413,O
HD,413,B-Modifier
cDNA,413,O
with,413,O
44,413,O
CAG,413,O
repeats,413,O
.,413,O
By,414,O
1,414,O
year,414,O
",",414,O
these,414,O
mice,414,O
have,414,O
no,414,O
behavioral,414,B-DiseaseClass
abnormalities,414,I-DiseaseClass
and,414,O
morphometric,414,O
analysis,414,O
at,414,O
6,414,O
(,414,O
one,414,O
animal,414,O
),414,O
and,414,O
9,414,O
(,414,O
two,414,O
animals,414,O
),414,O
months,414,O
age,414,O
revealed,414,O
no,414,O
changes,414,O
.,414,O
Despite,415,O
high,415,O
levels,415,O
of,415,O
mRNA,415,O
expression,415,O
",",415,O
there,415,O
was,415,O
no,415,O
evidence,415,O
of,415,O
the,415,O
HD,415,B-Modifier
gene,415,O
product,415,O
in,415,O
any,415,O
of,415,O
these,415,O
transgenic,415,O
mice,415,O
.,415,O
In,416,O
vitro,416,O
transfection,416,O
studies,416,O
indicated,416,O
that,416,O
the,416,O
inclusion,416,O
of,416,O
120,416,O
bp,416,O
of,416,O
the,416,O
5,416,O
UTR,416,O
in,416,O
the,416,O
cDNA,416,O
construct,416,O
and,416,O
the,416,O
presence,416,O
of,416,O
a,416,O
frameshift,416,O
mutation,416,O
at,416,O
nucleotide,416,O
2349,416,O
prevented,416,O
expression,416,O
of,416,O
the,416,O
HD,416,B-Modifier
cDNA,416,O
.,416,O
These,417,O
findings,417,O
suggest,417,O
that,417,O
the,417,O
pathogenesis,417,O
of,417,O
HD,417,B-SpecificDisease
is,417,O
not,417,O
mediated,417,O
through,417,O
DNA-protein,417,O
interaction,417,O
and,417,O
that,417,O
presence,417,O
of,417,O
the,417,O
RNA,417,O
transcript,417,O
with,417,O
an,417,O
expanded,417,O
CAG,417,O
repeat,417,O
is,417,O
insufficient,417,O
to,417,O
cause,417,O
the,417,O
disease,417,O
.,417,O
Rather,418,O
",",418,O
translation,418,O
of,418,O
the,418,O
CAG,418,O
is,418,O
crucial,418,O
for,418,O
the,418,O
pathogenesis,418,O
of,418,O
HD,418,B-SpecificDisease
.,418,O
In,419,O
contrast,419,O
to,419,O
that,419,O
seen,419,O
in,419,O
humans,419,O
",",419,O
the,419,O
CAG,419,O
repeat,419,O
in,419,O
these,419,O
mice,419,O
was,419,O
remarkably,419,O
stable,419,O
in,419,O
97,419,O
meioses,419,O
.,419,O
This,420,O
suggests,420,O
that,420,O
genomic,420,O
sequences,420,O
may,420,O
play,420,O
a,420,O
critical,420,O
role,420,O
in,420,O
influencing,420,O
repeat,420,O
instability,420,O
..,420,O
FISH,421,O
studies,421,O
in,421,O
a,421,O
patient,421,O
with,421,O
sporadic,421,B-SpecificDisease
aniridia,421,I-SpecificDisease
and,421,O
t,421,O
(,421,O
7,421,O
;,421,O
11,421,O
),421,O
(,421,O
q31.2,421,O
;,421,O
p13,421,O
),421,O
.,421,O
A,422,O
2,422,O
year,422,O
old,422,O
female,422,O
presenting,422,O
with,422,O
bilateral,422,B-SpecificDisease
sporadic,422,I-SpecificDisease
aniridia,422,I-SpecificDisease
was,422,O
found,422,O
to,422,O
have,422,O
an,422,O
apparently,422,O
balanced,422,O
reciprocal,422,O
translocation,422,O
with,422,O
a,422,O
chromosome,422,O
11,422,O
breakpoint,422,O
within,422,O
band,422,O
p13,422,O
.,422,O
Fluorescence,423,O
in,423,O
situ,423,O
hybridisation,423,O
(,423,O
FISH,423,O
),423,O
studies,423,O
with,423,O
distal,423,O
11p13,423,O
specific,423,O
cosmids,423,O
showed,423,O
that,423,O
the,423,O
chromosome,423,O
11,423,O
breakpoint,423,O
lay,423,O
between,423,O
the,423,O
aniridia,423,B-SpecificDisease
(,423,O
PAX6,423,O
),423,O
locus,423,O
and,423,O
a,423,O
region,423,O
approximately,423,O
100,423,O
kb,423,O
distal,423,O
to,423,O
PAX6,423,O
defined,423,O
by,423,O
the,423,O
cosmid,423,O
FO2121,423,O
.,423,O
Although,424,O
this,424,O
patient,424,O
did,424,O
not,424,O
have,424,O
a,424,O
detectable,424,O
deletion,424,O
within,424,O
PAX6,424,O
",",424,O
her,424,O
aniridia,424,B-SpecificDisease
may,424,O
have,424,O
resulted,424,O
from,424,O
a,424,O
disruption,424,O
of,424,O
the,424,O
distal,424,O
chromatin,424,O
domain,424,O
containing,424,O
either,424,O
enhancers,424,O
or,424,O
regulators,424,O
for,424,O
PAX6,424,O
.,424,O
This,425,O
case,425,O
may,425,O
therefore,425,O
be,425,O
another,425,O
example,425,O
of,425,O
aniridia,425,B-SpecificDisease
caused,425,O
by,425,O
a,425,O
position,425,O
effect,425,O
as,425,O
recently,425,O
described,425,O
in,425,O
two,425,O
familial,425,B-Modifier
aniridia,425,I-Modifier
patients,425,O
in,425,O
which,425,O
the,425,O
phenotype,425,O
cosegregated,425,O
with,425,O
chromosome,425,B-DiseaseClass
abnormalities,425,I-DiseaseClass
with,425,O
11p13,425,O
breakpoints,425,O
..,425,O
Muscle,426,O
expression,426,O
of,426,O
glucose-6-phosphate,426,B-SpecificDisease
dehydrogenase,426,I-SpecificDisease
deficiency,426,I-SpecificDisease
in,426,O
different,426,O
variants,426,O
.,426,O
Muscle,427,O
expression,427,O
of,427,O
G6PD,427,B-SpecificDisease
deficiency,427,I-SpecificDisease
has,427,O
been,427,O
investigated,427,O
in,427,O
Mediterranean,427,O
",",427,O
Seattle-like,427,O
and,427,O
A-variants,427,O
.,427,O
G6PD,428,O
activity,428,O
was,428,O
detected,428,O
in,428,O
samples,428,O
obtained,428,O
from,428,O
biopsies,428,O
on,428,O
the,428,O
quadriceps,428,O
muscle,428,O
of,428,O
seven,428,O
males,428,O
and,428,O
one,428,O
female,428,O
.,428,O
The,429,O
type,429,O
of,429,O
genetic,429,O
variant,429,O
was,429,O
determined,429,O
by,429,O
molecular,429,O
analysis,429,O
of,429,O
DNA,429,O
",",429,O
extracted,429,O
from,429,O
blood,429,O
samples,429,O
.,429,O
All,430,O
variants,430,O
showed,430,O
the,430,O
enzyme,430,O
defect,430,O
in,430,O
muscle,430,O
.,430,O
A,431,O
statistically,431,O
significant,431,O
relationship,431,O
was,431,O
found,431,O
in,431,O
the,431,O
activity,431,O
of,431,O
G6PD,431,O
between,431,O
erythrocytes,431,O
and,431,O
muscle,431,O
of,431,O
the,431,O
male,431,O
subjects,431,O
(,431,O
r,431,O
=,431,O
0,431,O
.,431,O
968,432,O
;,432,O
p,432,O
=,432,O
0,432,O
.,432,O
00008,433,O
),433,O
.,433,O
The,434,O
equation,434,O
for,434,O
the,434,O
best,434,O
fit,434,O
line,434,O
was,434,O
Y,434,O
=,434,O
0,434,O
.,434,O
390X,435,O
+,435,O
0,435,O
.,435,O
198,436,O
198,436,O
.,436,O
The,437,O
results,437,O
suggest,437,O
that,437,O
",",437,O
for,437,O
a,437,O
given,437,O
variant,437,O
",",437,O
the,437,O
extent,437,O
of,437,O
the,437,O
enzyme,437,O
defect,437,O
in,437,O
muscle,437,O
may,437,O
be,437,O
determined,437,O
",",437,O
using,437,O
this,437,O
equation,437,O
",",437,O
from,437,O
the,437,O
G6PD,437,O
activity,437,O
of,437,O
erythrocytes,437,O
Gene,438,O
therapy,438,O
for,438,O
phenylketonuria,438,B-SpecificDisease
.,438,O
Classical,439,O
phenylketonuria,439,B-SpecificDisease
(,439,O
PKU,439,B-SpecificDisease
),439,O
is,439,O
an,439,O
autosomal,439,B-DiseaseClass
recessive,439,I-DiseaseClass
disorder,439,I-DiseaseClass
caused,439,O
by,439,O
a,439,O
deficiency,439,B-SpecificDisease
of,439,I-SpecificDisease
hepatic,439,I-SpecificDisease
phenylalanine,439,I-SpecificDisease
hydroxylase,439,I-SpecificDisease
(,439,O
PAH,439,O
),439,O
.,439,O
Limitations,440,O
of,440,O
the,440,O
current,440,O
dietary,440,O
treatment,440,O
for,440,O
PKU,440,B-SpecificDisease
have,440,O
led,440,O
to,440,O
the,440,O
development,440,O
of,440,O
potential,440,O
treatments,440,O
based,440,O
on,440,O
somatic,440,O
gene,440,O
transfer,440,O
.,440,O
Three,441,O
different,441,O
vector,441,O
systems,441,O
have,441,O
been,441,O
examined,441,O
.,441,O
Vectors,442,O
derived,442,O
from,442,O
a,442,O
recombinant,442,O
retrovirus,442,O
or,442,O
a,442,O
DNA/protein,442,O
complex,442,O
can,442,O
efficiently,442,O
transduce,442,O
the,442,O
PAH,442,O
cDNA,442,O
into,442,O
PAH-deficient,442,B-Modifier
hepatocytes,442,O
in,442,O
vitro,442,O
",",442,O
but,442,O
the,442,O
application,442,O
of,442,O
these,442,O
vector,442,O
systems,442,O
is,442,O
presently,442,O
limited,442,O
by,442,O
their,442,O
low,442,O
transduction,442,O
efficiency,442,O
in,442,O
vivo,442,O
.,442,O
In,443,O
contrast,443,O
",",443,O
a,443,O
vector,443,O
derived,443,O
from,443,O
a,443,O
recombinant,443,O
adenovirus,443,O
can,443,O
restore,443,O
10,443,O
%,443,O
-80,443,O
%,443,O
of,443,O
normal,443,O
hepatic,443,O
PAH,443,O
activity,443,O
into,443,O
PAH-deficient,443,B-Modifier
mice,443,O
",",443,O
which,443,O
completely,443,O
normalizes,443,O
serum,443,O
phenylalanine,443,O
levels,443,O
.,443,O
This,444,O
treatment,444,O
is,444,O
transient,444,O
and,444,O
can,444,O
not,444,O
be,444,O
effectively,444,O
re-administered,444,O
due,444,O
to,444,O
the,444,O
presence,444,O
of,444,O
neutralizing,444,O
antibodies,444,O
directed,444,O
against,444,O
the,444,O
recombinant,444,O
adenoviral,444,O
vector,444,O
.,444,O
However,445,O
",",445,O
these,445,O
findings,445,O
suggest,445,O
that,445,O
PKU,445,B-SpecificDisease
can,445,O
be,445,O
completely,445,O
corrected,445,O
by,445,O
somatic,445,O
gene,445,O
therapy,445,O
",",445,O
and,445,O
provide,445,O
some,445,O
direction,445,O
for,445,O
the,445,O
future,445,O
development,445,O
of,445,O
adenoviral,445,O
vectors,445,O
..,445,O
Exon-intron,446,O
structure,446,O
of,446,O
the,446,O
human,446,O
neuronal,446,O
nicotinic,446,O
acetylcholine,446,O
receptor,446,O
alpha,446,O
4,446,O
subunit,446,O
(,446,O
CHRNA4,446,O
),446,O
.,446,O
The,447,O
human,447,O
neuronal,447,O
nicotinic,447,O
acetylcholine,447,O
receptor,447,O
alpha,447,O
4,447,O
subunit,447,O
gene,447,O
(,447,O
CHRNA4,447,O
),447,O
is,447,O
located,447,O
in,447,O
the,447,O
candidate,447,O
region,447,O
for,447,O
three,447,O
different,447,O
phenotypes,447,O
benign,447,B-SpecificDisease
familial,447,I-SpecificDisease
neonatal,447,I-SpecificDisease
convulsions,447,I-SpecificDisease
",",447,O
autosomal,447,B-SpecificDisease
dominant,447,I-SpecificDisease
nocturnal,447,I-SpecificDisease
frontal,447,I-SpecificDisease
lobe,447,I-SpecificDisease
epilepsy,447,I-SpecificDisease
",",447,O
and,447,O
low-voltage,447,O
EEG,447,O
.,447,O
Recently,448,O
",",448,O
a,448,O
missense,448,O
mutation,448,O
in,448,O
transmembrane,448,O
domain,448,O
2,448,O
of,448,O
CHRNA4,448,O
was,448,O
found,448,O
to,448,O
be,448,O
associated,448,O
with,448,O
autosomal,448,B-SpecificDisease
dominant,448,I-SpecificDisease
nocturnal,448,I-SpecificDisease
frontal,448,I-SpecificDisease
lobe,448,I-SpecificDisease
epilepsy,448,I-SpecificDisease
in,448,O
one,448,O
extended,448,O
pedigree,448,O
.,448,O
We,449,O
have,449,O
determined,449,O
the,449,O
genomic,449,O
organization,449,O
of,449,O
CHRNA4,449,O
",",449,O
which,449,O
consists,449,O
of,449,O
six,449,O
exons,449,O
distributed,449,O
over,449,O
approximately,449,O
17,449,O
kb,449,O
of,449,O
genomic,449,O
DNA,449,O
.,449,O
The,450,O
nucleotide,450,O
sequence,450,O
obtained,450,O
from,450,O
the,450,O
genomic,450,O
regions,450,O
adjacent,450,O
to,450,O
the,450,O
exon,450,O
boundaries,450,O
enabled,450,O
us,450,O
to,450,O
develop,450,O
a,450,O
set,450,O
of,450,O
primer,450,O
pairs,450,O
for,450,O
PCR,450,O
amplification,450,O
of,450,O
the,450,O
complete,450,O
coding,450,O
region,450,O
.,450,O
The,451,O
sequence,451,O
analysis,451,O
provides,451,O
the,451,O
basis,451,O
for,451,O
a,451,O
comprehensive,451,O
mutation,451,O
screening,451,O
of,451,O
CHRNA4,451,O
in,451,O
the,451,O
above-mentioned,451,O
phenotypes,451,O
and,451,O
possibly,451,O
in,451,O
other,451,O
types,451,O
of,451,O
idiopathic,451,B-DiseaseClass
epilepsies,451,I-DiseaseClass
..,451,O
Ashkenazi,452,O
Jewish,452,O
population,452,O
frequencies,452,O
for,452,O
common,452,O
mutations,452,O
in,452,O
BRCA1,452,O
and,452,O
BRCA2,452,O
.,452,O
BRCA1,453,O
and,453,O
BRCA2,453,O
are,453,O
the,453,O
two,453,O
major,453,O
identified,453,O
causes,453,O
of,453,O
inherited,453,B-SpecificDisease
breast,453,I-SpecificDisease
cancer,453,I-SpecificDisease
",",453,O
with,453,O
mutations,453,O
in,453,O
either,453,O
gene,453,O
conferring,453,O
up,453,O
to,453,O
80-90,453,O
%,453,O
lifetime,453,O
risk,453,O
of,453,O
breast,453,B-SpecificDisease
cancer,453,I-SpecificDisease
in,453,O
carrier,453,O
females,453,O
.,453,O
Mutations,454,O
in,454,O
BRCA1,454,O
account,454,O
for,454,O
approximately,454,O
45,454,O
%,454,O
of,454,O
familial,454,B-SpecificDisease
breast,454,I-SpecificDisease
cancer,454,I-SpecificDisease
and,454,O
90,454,O
%,454,O
of,454,O
inherited,454,B-CompositeMention
breast/ovarian,454,I-CompositeMention
cancer,454,I-CompositeMention
",",454,O
whereas,454,O
mutations,454,O
in,454,O
BRCA2,454,O
account,454,O
for,454,O
a,454,O
comparable,454,O
percentage,454,O
of,454,O
inherited,454,B-Modifier
breast,454,I-Modifier
cancer,454,I-Modifier
cases,454,O
.,454,O
Over,455,O
85,455,O
distinct,455,O
BRCA1,455,O
mutations,455,O
and,455,O
a,455,O
growing,455,O
list,455,O
of,455,O
BRCA2,455,O
mutations,455,O
have,455,O
been,455,O
identified,455,O
",",455,O
with,455,O
the,455,O
majority,455,O
resulting,455,O
in,455,O
protein,455,O
truncation,455,O
.,455,O
A,456,O
specific,456,O
BRCA1,456,O
mutation,456,O
",",456,O
185delAG,456,O
",",456,O
has,456,O
a,456,O
reported,456,O
increased,456,O
carrier,456,O
frequency,456,O
of,456,O
approximately,456,O
0,456,O
.,456,O
9,457,O
%,457,O
in,457,O
the,457,O
Ashkenazi,457,O
Jewish,457,O
population,457,O
",",457,O
but,457,O
is,457,O
also,457,O
found,457,O
in,457,O
rare,457,O
non-Jewish,457,O
patients,457,O
with,457,O
a,457,O
different,457,O
haplotype,457,O
.,457,O
The,458,O
6174delT,458,O
mutation,458,O
in,458,O
BRCA2,458,O
was,458,O
recently,458,O
identified,458,O
as,458,O
a,458,O
frequent,458,O
mutation,458,O
in,458,O
8,458,O
out,458,O
of,458,O
107,458,O
Ashkenazi,458,O
Jewish,458,O
women,458,O
diagnosed,458,O
with,458,O
breast,458,B-SpecificDisease
cancer,458,I-SpecificDisease
by,458,O
age,458,O
50,458,O
(,458,O
ref,458,O
.,458,O
8,459,O
),459,O
",",459,O
as,459,O
well,459,O
as,459,O
in,459,O
three,459,O
Ashkenazi,459,O
male,459,B-Modifier
breast,459,I-Modifier
cancer,459,I-Modifier
patients,459,O
.,459,O
We,460,O
have,460,O
conducted,460,O
a,460,O
large-scale,460,O
population,460,O
study,460,O
to,460,O
investigate,460,O
the,460,O
prevalence,460,O
of,460,O
specific,460,O
BRCA1,460,O
and,460,O
BRCA2,460,O
mutations,460,O
in,460,O
Ashkenazi,460,O
Jewish,460,O
individuals,460,O
who,460,O
were,460,O
unselected,460,O
for,460,O
breast,460,B-SpecificDisease
cancer,460,I-SpecificDisease
.,460,O
BRCA1,461,O
mutation,461,O
screening,461,O
on,461,O
approximately,461,O
3,461,O
",",461,O
000,461,O
Ashkenazi,461,O
Jewish,461,O
samples,461,O
determined,461,O
a,461,O
carrier,461,O
frequency,461,O
of,461,O
1,461,O
.,461,O
09,462,O
%,462,O
for,462,O
the,462,O
185delAG,462,O
mutation,462,O
and,462,O
0,462,O
.,462,O
13,463,O
%,463,O
for,463,O
the,463,O
5382insC,463,O
mutation,463,O
.,463,O
BRCA2,464,O
analysis,464,O
on,464,O
3,464,O
",",464,O
085,464,O
individuals,464,O
from,464,O
the,464,O
same,464,O
population,464,O
showed,464,O
a,464,O
carrier,464,O
frequency,464,O
of,464,O
1,464,O
.,464,O
52,465,O
%,465,O
for,465,O
the,465,O
6174delT,465,O
mutation,465,O
.,465,O
This,466,O
expanded,466,O
population-based,466,O
study,466,O
confirms,466,O
that,466,O
the,466,O
BRCA1,466,O
185delAG,466,O
mutation,466,O
and,466,O
the,466,O
BRCA2,466,O
6174delT,466,O
mutation,466,O
constitute,466,O
the,466,O
two,466,O
most,466,O
frequent,466,O
mutation,466,O
alleles,466,O
predisposing,466,O
to,466,O
hereditary,466,B-SpecificDisease
breast,466,I-SpecificDisease
cancer,466,I-SpecificDisease
among,466,O
the,466,O
Ashkenazim,466,O
",",466,O
and,466,O
suggests,466,O
a,466,O
relatively,466,O
lower,466,O
penetrance,466,O
for,466,O
the,466,O
6174delT,466,O
mutation,466,O
in,466,O
BRCA2,466,O
Dual,467,O
roles,467,O
of,467,O
ATM,467,O
in,467,O
the,467,O
cellular,467,O
response,467,O
to,467,O
radiation,467,O
and,467,O
in,467,O
cell,467,O
growth,467,O
control,467,O
.,467,O
The,468,O
gene,468,O
mutated,468,O
in,468,O
ataxia-telangiectasia,468,B-Modifier
(,468,O
AT,468,B-Modifier
),468,O
patients,468,O
",",468,O
denoted,468,O
ATM,468,O
",",468,O
encodes,468,O
a,468,O
putative,468,O
protein,468,O
or,468,O
lipid,468,O
kinase,468,O
.,468,O
To,469,O
elucidate,469,O
the,469,O
functions,469,O
of,469,O
ATM,469,O
",",469,O
we,469,O
disrupted,469,O
the,469,O
mouse,469,O
ATM,469,O
gene,469,O
through,469,O
homologous,469,O
recombination,469,O
in,469,O
mice,469,O
.,469,O
Consistent,470,O
with,470,O
cellular,470,O
defects,470,O
of,470,O
AT,470,B-Modifier
patients,470,O
",",470,O
the,470,O
ATM-/-,470,O
cells,470,O
are,470,O
hypersensitive,470,O
to,470,O
gamma-irradiation,470,O
and,470,O
defective,470,O
in,470,O
cell-cycle,470,O
arrest,470,O
following,470,O
radiation,470,O
",",470,O
correlating,470,O
with,470,O
a,470,O
defective,470,O
up-regulation,470,O
of,470,O
p53,470,O
.,470,O
In,471,O
addition,471,O
",",471,O
ATM-/-,471,O
mouse,471,O
thymocytes,471,O
are,471,O
more,471,O
resistant,471,O
to,471,O
apoptosis,471,O
induced,471,O
by,471,O
gamma-irradiation,471,O
than,471,O
normal,471,O
thymocytes,471,O
.,471,O
ATM-/-,472,O
fibroblasts,472,O
are,472,O
inefficient,472,O
in,472,O
G1,472,O
to,472,O
S-phase,472,O
progression,472,O
following,472,O
serum,472,O
stimulation,472,O
and,472,O
senesce,472,O
after,472,O
only,472,O
a,472,O
few,472,O
passages,472,O
in,472,O
culture,472,O
.,472,O
They,473,O
have,473,O
an,473,O
increased,473,O
constitutive,473,O
level,473,O
of,473,O
p21CP1/WAF1,473,O
.,473,O
The,474,O
ATM,474,O
protein,474,O
is,474,O
therefore,474,O
critical,474,O
both,474,O
for,474,O
cellular,474,O
responses,474,O
to,474,O
ionizing,474,O
radiation,474,O
and,474,O
for,474,O
normal,474,O
cell-cycle,474,O
progression,474,O
.,474,O
ATM,475,O
+/-,475,O
fibroblasts,475,O
and,475,O
thymocytes,475,O
showed,475,O
intermediately,475,O
defective,475,O
responses,475,O
to,475,O
irradiation,475,O
but,475,O
no,475,O
growth,475,O
defect,475,O
",",475,O
suggesting,475,O
that,475,O
the,475,O
increased,475,O
cancer,475,B-Modifier
risk,475,O
of,475,O
AT,475,B-Modifier
heterozygotes,475,O
could,475,O
be,475,O
attributable,475,O
to,475,O
poor,475,O
checkpoint,475,O
function,475,O
..,475,O
Targeted,476,O
disruption,476,O
of,476,O
ATM,476,O
leads,476,O
to,476,O
growth,476,B-DiseaseClass
retardation,476,I-DiseaseClass
",",476,O
chromosomal,476,B-SpecificDisease
fragmentation,476,I-SpecificDisease
during,476,I-SpecificDisease
meiosis,476,I-SpecificDisease
",",476,O
immune,476,B-DiseaseClass
defects,476,I-DiseaseClass
",",476,O
and,476,O
thymic,476,B-SpecificDisease
lymphoma,476,I-SpecificDisease
.,476,O
ATM,477,O
",",477,O
the,477,O
gene,477,O
mutated,477,O
in,477,O
the,477,O
inherited,477,B-DiseaseClass
human,477,I-DiseaseClass
disease,477,I-DiseaseClass
ataxia-telangiectasia,477,B-SpecificDisease
",",477,O
is,477,O
a,477,O
member,477,O
of,477,O
a,477,O
family,477,O
of,477,O
kinases,477,O
involved,477,O
in,477,O
DNA,477,O
metabolism,477,O
and,477,O
cell-cycle,477,O
checkpoint,477,O
control,477,O
.,477,O
To,478,O
help,478,O
clarify,478,O
the,478,O
physiological,478,O
roles,478,O
of,478,O
the,478,O
ATM,478,O
protein,478,O
",",478,O
we,478,O
disrupted,478,O
the,478,O
ATM,478,O
gene,478,O
in,478,O
mice,478,O
through,478,O
homologous,478,O
recombination,478,O
.,478,O
Initial,479,O
evaluation,479,O
of,479,O
the,479,O
ATM,479,O
knockout,479,O
animals,479,O
indicates,479,O
that,479,O
inactivation,479,O
of,479,O
the,479,O
mouse,479,O
ATM,479,O
gene,479,O
recreates,479,O
much,479,O
of,479,O
the,479,O
phenotype,479,O
of,479,O
ataxia-telangiectasia,479,B-SpecificDisease
.,479,O
The,480,O
homozygous,480,O
mutant,480,O
(,480,O
ATM-/-,480,O
),480,O
mice,480,O
are,480,O
viable,480,O
",",480,O
growth-retarded,480,O
",",480,O
and,480,O
infertile,480,O
.,480,O
The,481,O
infertility,481,B-SpecificDisease
of,481,O
ATM-/-,481,O
mice,481,O
results,481,O
from,481,O
meiotic,481,O
failure,481,O
.,481,O
Meiosis,482,O
is,482,O
arrested,482,O
at,482,O
the,482,O
zygotene/pachytene,482,O
stage,482,O
of,482,O
prophase,482,O
I,482,O
as,482,O
a,482,O
result,482,O
of,482,O
abnormal,482,O
chromosomal,482,O
synapsis,482,O
and,482,O
subsequent,482,O
chromosome,482,O
fragmentation,482,O
.,482,O
Immune,483,B-DiseaseClass
defects,483,I-DiseaseClass
also,483,O
are,483,O
evident,483,O
in,483,O
ATM-/-,483,O
mice,483,O
",",483,O
including,483,O
reduced,483,O
numbers,483,O
of,483,O
B220,483,O
+,483,O
CD43-,483,O
pre-B,483,O
cells,483,O
",",483,O
thymocytes,483,O
",",483,O
and,483,O
peripheral,483,O
T,483,O
cells,483,O
",",483,O
as,483,O
well,483,O
as,483,O
functional,483,O
impairment,483,O
of,483,O
T-cell-dependent,483,O
immune,483,O
responses,483,O
.,483,O
The,484,O
cerebella,484,O
of,484,O
ATM-/-,484,O
mice,484,O
appear,484,O
normal,484,O
by,484,O
histologic,484,O
examination,484,O
at,484,O
3,484,O
to,484,O
4,484,O
months,484,O
and,484,O
the,484,O
mice,484,O
have,484,O
no,484,O
gross,484,O
behavioral,484,B-DiseaseClass
abnormalities,484,I-DiseaseClass
.,484,O
The,485,O
majority,485,O
of,485,O
mutant,485,O
mice,485,O
rapidly,485,O
develop,485,O
thymic,485,B-SpecificDisease
lymphomas,485,I-SpecificDisease
and,485,O
die,485,O
before,485,O
4,485,O
months,485,O
of,485,O
age,485,O
.,485,O
These,486,O
findings,486,O
indicate,486,O
that,486,O
the,486,O
ATM,486,O
gene,486,O
product,486,O
plays,486,O
an,486,O
essential,486,O
role,486,O
in,486,O
a,486,O
diverse,486,O
group,486,O
of,486,O
cellular,486,O
processes,486,O
",",486,O
including,486,O
meiosis,486,O
",",486,O
the,486,O
normal,486,O
growth,486,O
of,486,O
somatic,486,O
tissues,486,O
",",486,O
immune,486,O
development,486,O
",",486,O
and,486,O
tumor,486,B-Modifier
suppression,486,O
..,486,O
Cloning,487,O
and,487,O
characterization,487,O
of,487,O
human,487,O
very-long-chain,487,O
acyl-CoA,487,O
dehydrogenase,487,O
cDNA,487,O
",",487,O
chromosomal,487,O
assignment,487,O
of,487,O
the,487,O
gene,487,O
and,487,O
identification,487,O
in,487,O
four,487,O
patients,487,O
of,487,O
nine,487,O
different,487,O
mutations,487,O
within,487,O
the,487,O
VLCAD,487,O
gene,487,O
.,487,O
Very-long-chain,488,O
acyl-CoA,488,O
dehydrogenase,488,O
(,488,O
VLCAD,488,O
),488,O
is,488,O
one,488,O
of,488,O
four,488,O
straight-chain,488,O
acyl-CoA,488,O
dehydrogenase,488,O
(,488,O
ACD,488,O
),488,O
enzymes,488,O
",",488,O
which,488,O
are,488,O
all,488,O
nuclear,488,O
encoded,488,O
mitochondrial,488,O
flavoproteins,488,O
catalyzing,488,O
the,488,O
initial,488,O
step,488,O
in,488,O
fatty,488,O
acid,488,O
beta-oxidation,488,O
.,488,O
We,489,O
have,489,O
used,489,O
the,489,O
very,489,O
fast,489,O
",",489,O
Rapid,489,O
Amplification,489,O
of,489,O
cDNA,489,O
Ends,489,O
(,489,O
RACE,489,O
),489,O
based,489,O
strategy,489,O
to,489,O
obtain,489,O
the,489,O
sequence,489,O
of,489,O
cDNAs,489,O
encoding,489,O
human,489,O
VLCAD,489,O
from,489,O
placenta,489,O
and,489,O
fibroblasts,489,O
.,489,O
Alignment,490,O
of,490,O
the,490,O
predicted,490,O
amino,490,O
acid,490,O
sequence,490,O
of,490,O
human,490,O
VLCAD,490,O
with,490,O
those,490,O
of,490,O
the,490,O
other,490,O
human,490,O
ACD,490,O
enzymes,490,O
revealed,490,O
extensive,490,O
sequence,490,O
homology,490,O
.,490,O
Moreover,491,O
",",491,O
human,491,O
VLCAD,491,O
and,491,O
human,491,O
acyl-CoA,491,O
oxidase,491,O
showed,491,O
extensive,491,O
sequence,491,O
homology,491,O
corroborating,491,O
the,491,O
notion,491,O
that,491,O
these,491,O
genes,491,O
are,491,O
evolutionarily,491,O
related,491,O
.,491,O
Southern,492,O
blot,492,O
analysis,492,O
of,492,O
genomic,492,O
DNA,492,O
from,492,O
hybrid,492,O
cell,492,O
lines,492,O
was,492,O
used,492,O
to,492,O
localize,492,O
the,492,O
VLCAD,492,O
gene,492,O
to,492,O
human,492,O
chromosome,492,O
17p11,492,O
.,492,O
2-p11,493,O
.,493,O
13105,494,O
.,494,O
Using,495,O
Northern,495,O
and,495,O
Western,495,O
blot,495,O
analysis,495,O
to,495,O
investigate,495,O
the,495,O
tissue,495,O
specific,495,O
distribution,495,O
of,495,O
VLCAD,495,O
mRNA,495,O
and,495,O
protein,495,O
in,495,O
several,495,O
human,495,O
tissues,495,O
we,495,O
showed,495,O
that,495,O
VLCAD,495,O
is,495,O
most,495,O
abundant,495,O
in,495,O
heart,495,O
and,495,O
skeletal,495,O
muscle,495,O
.,495,O
This,496,O
agrees,496,O
well,496,O
with,496,O
the,496,O
fact,496,O
that,496,O
cardiac,496,O
and,496,O
muscle,496,O
symptoms,496,O
are,496,O
characteristic,496,O
for,496,O
patients,496,O
with,496,O
VLCAD,496,B-SpecificDisease
deficiency,496,I-SpecificDisease
.,496,O
Northern,497,O
blot,497,O
analysis,497,O
and,497,O
sequencing,497,O
of,497,O
cloned,497,O
PCR,497,O
amplified,497,O
VLCAD,497,O
cDNA,497,O
from,497,O
four,497,O
unrelated,497,O
patients,497,O
with,497,O
VLCAD,497,B-SpecificDisease
deficiency,497,I-SpecificDisease
showed,497,O
that,497,O
VLCAD,497,O
mRNA,497,O
was,497,O
undetectable,497,O
in,497,O
one,497,O
patient,497,O
and,497,O
that,497,O
the,497,O
other,497,O
three,497,O
have,497,O
mutations,497,O
in,497,O
both,497,O
VLCAD,497,O
alleles,497,O
.,497,O
Western,498,O
blot,498,O
analysis,498,O
of,498,O
patient,498,O
fibroblasts,498,O
showed,498,O
that,498,O
the,498,O
identified,498,O
mutations,498,O
result,498,O
in,498,O
severely,498,O
reduced,498,O
amounts,498,O
of,498,O
VLCAD,498,O
protein,498,O
.,498,O
Molecular,499,O
bases,499,O
of,499,O
combined,499,O
subtotal,499,O
deficiencies,499,O
of,499,O
C6,499,O
and,499,O
C7,499,O
:,499,O
their,499,O
effects,499,O
in,499,O
combination,499,O
with,499,O
other,499,O
C6,499,O
and,499,O
C7,499,O
deficiencies,499,O
.,499,O
Combined,500,O
subtotal,500,O
deficiency,500,O
of,500,O
C6,500,O
and,500,O
C7,500,O
",",500,O
in,500,O
which,500,O
both,500,O
proteins,500,O
are,500,O
expressed,500,O
at,500,O
very,500,O
low,500,O
levels,500,O
",",500,O
has,500,O
been,500,O
observed,500,O
in,500,O
homozygous,500,O
form,500,O
in,500,O
two,500,O
families,500,O
.,500,O
A,501,O
defect,501,O
at,501,O
the,501,O
5,501,O
splice,501,O
donor,501,O
site,501,O
of,501,O
intron,501,O
15,501,O
of,501,O
the,501,O
C6,501,O
gene,501,O
explains,501,O
the,501,O
low,501,O
molecular,501,O
weight,501,O
of,501,O
the,501,O
C6,501,O
protein,501,O
and,501,O
is,501,O
probably,501,O
responsible,501,O
for,501,O
its,501,O
low,501,O
expressed,501,O
concentration,501,O
.,501,O
The,502,O
C7,502,O
defect,502,O
is,502,O
more,502,O
enigmatic,502,O
the,502,O
protein,502,O
is,502,O
of,502,O
normal,502,O
molecular,502,O
weight,502,O
",",502,O
low,502,O
circulating,502,O
concentration,502,O
",",502,O
and,502,O
altered,502,O
isoelectric,502,O
point,502,O
.,502,O
An,503,O
Arg,503,O
>,503,O
Ser,503,O
codon,503,O
substitution,503,O
in,503,O
exon,503,O
11,503,O
is,503,O
the,503,O
only,503,O
molecular,503,O
alteration,503,O
within,503,O
the,503,O
mature,503,O
C7,503,O
protein,503,O
.,503,O
These,504,O
defects,504,O
are,504,O
associated,504,O
with,504,O
a,504,O
characteristic,504,O
set,504,O
of,504,O
polymorphic,504,O
DNA,504,O
markers,504,O
in,504,O
the,504,O
C6/C7,504,O
region,504,O
",",504,O
forming,504,O
a,504,O
distinct,504,O
haplotype,504,O
.,504,O
The,505,O
haplotype,505,O
has,505,O
been,505,O
found,505,O
in,505,O
combination,505,O
with,505,O
a,505,O
number,505,O
of,505,O
other,505,O
haplotypes,505,O
containing,505,O
defective,505,O
genes,505,O
that,505,O
lead,505,O
either,505,O
to,505,O
C6,505,O
or,505,O
C7,505,O
deficiency,505,O
",",505,O
but,505,O
with,505,O
different,505,O
consequences,505,O
.,505,O
Where,506,O
it,506,O
is,506,O
combined,506,O
with,506,O
a,506,O
C6-deficient,506,B-Modifier
gene,506,O
",",506,O
the,506,O
serum,506,O
C7,506,O
levels,506,O
can,506,O
be,506,O
surprisingly,506,O
high,506,O
",",506,O
possibly,506,O
because,506,O
there,506,O
is,506,O
no,506,O
C6,506,O
generating,506,O
C56,506,O
to,506,O
consume,506,O
the,506,O
C7,506,O
.,506,O
In,507,O
contrast,507,O
",",507,O
where,507,O
the,507,O
C7,507,O
genes,507,O
are,507,O
both,507,O
defective,507,O
(,507,O
but,507,O
still,507,O
partially,507,O
functional,507,O
),507,O
",",507,O
there,507,O
may,507,O
be,507,O
a,507,O
profound,507,O
deficit,507,O
of,507,O
circulating,507,O
C7,507,O
because,507,O
there,507,O
is,507,O
ample,507,O
C6,507,O
to,507,O
produce,507,O
C56,507,O
and,507,O
consume,507,O
the,507,O
already,507,O
small,507,O
amount,507,O
of,507,O
C7,507,O
.,507,O
Each,508,O
molecular,508,O
defect,508,O
has,508,O
also,508,O
been,508,O
found,508,O
in,508,O
isolation,508,O
and,508,O
has,508,O
the,508,O
expected,508,O
effect,508,O
..,508,O
Genetic,509,O
bases,509,O
of,509,O
human,509,O
complement,509,B-SpecificDisease
C7,509,I-SpecificDisease
deficiency,509,I-SpecificDisease
.,509,O
Complement,510,B-SpecificDisease
C7,510,I-SpecificDisease
deficiency,510,I-SpecificDisease
(,510,O
C7D,510,B-SpecificDisease
),510,O
is,510,O
associated,510,O
frequently,510,O
with,510,O
recurrent,510,O
bacterial,510,B-DiseaseClass
infections,510,I-DiseaseClass
",",510,O
especially,510,O
meningitis,510,B-DiseaseClass
caused,510,O
by,510,O
Neisseria,510,B-SpecificDisease
meningitidis,510,I-SpecificDisease
.,510,O
We,511,O
report,511,O
in,511,O
this,511,O
work,511,O
the,511,O
molecular,511,O
bases,511,O
of,511,O
C7D,511,B-SpecificDisease
in,511,O
two,511,O
unrelated,511,O
Japanese,511,O
males,511,O
.,511,O
We,512,O
used,512,O
exon-specific,512,O
PCR/single-strand,512,O
conformation,512,O
polymorphism,512,O
analysis,512,O
as,512,O
a,512,O
screening,512,O
step,512,O
for,512,O
mutations,512,O
.,512,O
Subsequent,513,O
direct,513,O
sequencing,513,O
of,513,O
the,513,O
target,513,O
exons,513,O
identified,513,O
homozygous,513,O
mutations,513,O
in,513,O
exon,513,O
16,513,O
of,513,O
case,513,O
1,513,O
and,513,O
in,513,O
exon,513,O
15,513,O
of,513,O
case,513,O
2,513,O
.,513,O
The,514,O
mutation,514,O
of,514,O
case,514,O
1,514,O
was,514,O
a,514,O
homozygous,514,O
T,514,O
to,514,O
A,514,O
transversion,514,O
at,514,O
nucleotide,514,O
2250,514,O
",",514,O
the,514,O
third,514,O
nucleotide,514,O
of,514,O
the,514,O
codon,514,O
TGT,514,O
for,514,O
Cys728,514,O
",",514,O
leading,514,O
to,514,O
a,514,O
stop,514,O
codon,514,O
TGA,514,O
(,514,O
C728X,514,O
),514,O
.,514,O
In,515,O
case,515,O
2,515,O
",",515,O
a,515,O
homozygous,515,O
2-bp,515,O
deletion,515,O
(,515,O
2137delTG/2138delGT/2139delTG,515,O
),515,O
caused,515,O
a,515,O
frameshift,515,O
",",515,O
generating,515,O
a,515,O
premature,515,O
termination,515,O
codon,515,O
4,515,O
to,515,O
6,515,O
nucleotides,515,O
downstream,515,O
.,515,O
Family,516,O
study,516,O
in,516,O
case,516,O
1,516,O
confirmed,516,O
the,516,O
genetic,516,O
nature,516,O
of,516,O
the,516,O
defect,516,O
.,516,O
Moreover,517,O
",",517,O
we,517,O
detected,517,O
a,517,O
novel,517,O
polymorphism,517,O
in,517,O
intron,517,O
11,517,O
that,517,O
presumably,517,O
is,517,O
linked,517,O
to,517,O
the,517,O
mutation,517,O
responsible,517,O
for,517,O
C7D,517,B-SpecificDisease
in,517,O
case,517,O
1,517,O
.,517,O
Our,518,O
results,518,O
indicate,518,O
that,518,O
the,518,O
pathogenesis,518,O
of,518,O
C7D,518,B-SpecificDisease
is,518,O
heterogeneous,518,O
like,518,O
most,518,O
of,518,O
the,518,O
other,518,O
deficiencies,518,B-DiseaseClass
of,518,I-DiseaseClass
complement,518,I-DiseaseClass
components,518,I-DiseaseClass
..,518,O
HPRT-APRT-deficient,519,B-Modifier
mice,519,O
are,519,O
not,519,O
a,519,O
model,519,O
for,519,O
lesch-nyhan,519,B-SpecificDisease
syndrome,519,I-SpecificDisease
.,519,O
Complete,520,B-SpecificDisease
hypoxanthine-guanine,520,I-SpecificDisease
phosphoribosyl-transferase,520,I-SpecificDisease
(,520,I-SpecificDisease
HPRT,520,I-SpecificDisease
),520,I-SpecificDisease
deficiency,520,I-SpecificDisease
in,520,O
humans,520,O
results,520,O
in,520,O
the,520,O
Lesch-Nyhan,520,B-SpecificDisease
syndrome,520,I-SpecificDisease
which,520,O
is,520,O
characterized,520,O
",",520,O
among,520,O
other,520,O
features,520,O
",",520,O
by,520,O
compulsive,520,O
self-injurious,520,O
behavior,520,O
.,520,O
HPRT-deficient,521,B-Modifier
mice,521,O
generated,521,O
using,521,O
mouse,521,O
embryonic,521,O
stem,521,O
cells,521,O
exhibit,521,O
none,521,O
of,521,O
the,521,O
behavioral,521,O
symptoms,521,O
associated,521,O
with,521,O
the,521,O
Lesch-Nyhan,521,B-SpecificDisease
syndrome,521,I-SpecificDisease
.,521,O
Administration,522,O
of,522,O
drugs,522,O
that,522,O
inhibit,522,O
adenine,522,O
phosphoribosyltransferase,522,O
(,522,O
APRT,522,O
),522,O
in,522,O
HPRT-deficient,522,B-Modifier
mice,522,O
has,522,O
produced,522,O
the,522,O
suggestion,522,O
that,522,O
deficiency,522,B-SpecificDisease
of,522,I-SpecificDisease
APRT,522,I-SpecificDisease
in,522,O
combination,522,O
with,522,O
HPRT-deficiency,522,B-SpecificDisease
in,522,O
mice,522,O
may,522,O
lead,522,O
to,522,O
self-mutilation,522,O
behavior,522,O
[,522,O
C.,522,O
L.,522,O
Wu,522,O
and,522,O
D.,522,O
W.,522,O
Melton,522,O
(,522,O
1993,522,O
),522,O
Nature,522,O
Genet,522,O
.,522,O
3,523,O
",",523,O
235-240,523,O
],523,O
.,523,O
To,524,O
test,524,O
this,524,O
proposition,524,O
",",524,O
we,524,O
bred,524,O
HPRT-APRT-deficient,524,B-Modifier
mice,524,O
.,524,O
Although,525,O
the,525,O
doubly-deficient,525,O
mice,525,O
excrete,525,O
adenine,525,O
and,525,O
its,525,O
highly,525,O
insoluble,525,O
derivative,525,O
",",525,O
2,525,O
",",525,O
8-dihydroxyadenine,525,O
",",525,O
which,525,O
are,525,O
also,525,O
associated,525,O
with,525,O
human,525,O
APRT,525,B-SpecificDisease
deficiency,525,I-SpecificDisease
",",525,O
additional,525,O
abnormalities,525,O
or,525,O
any,525,O
self-injurious,525,O
behavior,525,O
were,525,O
not,525,O
detected,525,O
.,525,O
Thus,526,O
",",526,O
APRT-HPRT-deficient,526,B-Modifier
mice,526,O
",",526,O
which,526,O
are,526,O
devoid,526,O
of,526,O
any,526,O
purine,526,O
salvage,526,O
pathways,526,O
",",526,O
show,526,O
no,526,O
novel,526,O
phenotype,526,O
and,526,O
are,526,O
not,526,O
a,526,O
model,526,O
for,526,O
the,526,O
behavioral,526,B-DiseaseClass
abnormalities,526,I-DiseaseClass
associated,526,O
with,526,O
the,526,O
Lesch-Nyhan,526,B-SpecificDisease
syndrome,526,I-SpecificDisease
as,526,O
previously,526,O
suggested,526,O
Somatic,527,O
alterations,527,O
of,527,O
the,527,O
DPC4,527,O
gene,527,O
in,527,O
human,527,O
colorectal,527,B-SpecificDisease
cancers,527,I-SpecificDisease
in,527,O
vivo,527,O
.,527,O
BACKGROUND,528,O
&,528,O
AIMS,528,O
The,528,O
chromosome,528,O
region,528,O
18q21,528,O
has,528,O
been,528,O
shown,528,O
to,528,O
be,528,O
frequently,528,O
deleted,528,O
in,528,O
colorectal,528,B-SpecificDisease
cancers,528,I-SpecificDisease
",",528,O
and,528,O
such,528,O
frequent,528,O
allelic,528,O
loss,528,O
is,528,O
a,528,O
hallmark,528,O
of,528,O
the,528,O
presence,528,O
of,528,O
a,528,O
tumor-suppressor,528,O
gene,528,O
.,528,O
The,529,O
DPC4,529,O
gene,529,O
",",529,O
which,529,O
is,529,O
located,529,O
at,529,O
18q21,529,O
",",529,O
has,529,O
been,529,O
identified,529,O
as,529,O
a,529,O
tumor-suppressor,529,O
gene,529,O
from,529,O
examination,529,O
of,529,O
pancreatic,529,B-SpecificDisease
cancers,529,I-SpecificDisease
.,529,O
The,530,O
aim,530,O
of,530,O
the,530,O
present,530,O
study,530,O
was,530,O
to,530,O
determine,530,O
if,530,O
it,530,O
might,530,O
also,530,O
be,530,O
altered,530,O
in,530,O
colorectal,530,B-SpecificDisease
cancers,530,I-SpecificDisease
.,530,O
METHODS,531,O
Mutation,531,O
analyses,531,O
of,531,O
the,531,O
DPC4,531,O
gene,531,O
were,531,O
performed,531,O
on,531,O
complementary,531,O
DNA,531,O
samples,531,O
from,531,O
31,531,O
primary,531,O
colorectal,531,B-Modifier
cancer,531,I-Modifier
specimens,531,O
using,531,O
a,531,O
combination,531,O
of,531,O
polymerase,531,O
chain,531,O
reaction,531,O
",",531,O
single-strand,531,O
conformation,531,O
polymorphism,531,O
",",531,O
and,531,O
DNA,531,O
sequencing,531,O
.,531,O
RESULTS,532,O
Four,532,O
missense,532,O
mutations,532,O
producing,532,O
amino,532,O
acid,532,O
substitutions,532,O
and,532,O
a,532,O
somatic,532,O
12-base,532,O
pair,532,O
deletion,532,O
in,532,O
the,532,O
coding,532,O
region,532,O
of,532,O
the,532,O
DPC4,532,O
gene,532,O
were,532,O
detected,532,O
in,532,O
the,532,O
31,532,O
cancers,532,B-DiseaseClass
(,532,O
16,532,O
%,532,O
;,532,O
5,532,O
of,532,O
31,532,O
),532,O
.,532,O
CONCLUSIONS,533,O
The,533,O
DPC4,533,O
gene,533,O
may,533,O
play,533,O
a,533,O
role,533,O
as,533,O
a,533,O
tumor-suppressor,533,O
gene,533,O
in,533,O
a,533,O
fraction,533,O
of,533,O
colorectal,533,B-SpecificDisease
cancers,533,I-SpecificDisease
;,533,O
however,533,O
",",533,O
while,533,O
allelic,533,O
loss,533,O
at,533,O
18q21,533,O
is,533,O
very,533,O
often,533,O
seen,533,O
in,533,O
colorectal,533,B-SpecificDisease
cancers,533,I-SpecificDisease
",",533,O
only,533,O
a,533,O
minority,533,O
show,533,O
DPC4,533,O
mutations,533,O
",",533,O
suggesting,533,O
that,533,O
there,533,O
might,533,O
be,533,O
another,533,O
tumor-suppressor,533,O
gene,533,O
in,533,O
this,533,O
chromosome,533,O
region,533,O
..,533,O
Pleiotropic,534,O
defects,534,O
in,534,O
ataxia-telangiectasia,534,B-Modifier
protein-deficient,534,O
mice,534,O
.,534,O
We,535,O
have,535,O
generated,535,O
a,535,O
mouse,535,O
model,535,O
for,535,O
ataxia-telangiectasia,535,B-SpecificDisease
by,535,O
using,535,O
gene,535,O
targeting,535,O
to,535,O
generate,535,O
mice,535,O
that,535,O
do,535,O
not,535,O
express,535,O
the,535,O
Atm,535,O
protein,535,O
.,535,O
Atm-deficient,536,O
mice,536,O
are,536,O
retarded,536,O
in,536,O
growth,536,O
",",536,O
do,536,O
not,536,O
produce,536,O
mature,536,O
sperm,536,O
",",536,O
and,536,O
exhibit,536,O
severe,536,O
defects,536,O
in,536,O
T,536,O
cell,536,O
maturation,536,O
while,536,O
going,536,O
on,536,O
to,536,O
develop,536,O
thymomas,536,B-SpecificDisease
.,536,O
Atm-deficient,537,O
fibroblasts,537,O
grow,537,O
poorly,537,O
in,537,O
culture,537,O
and,537,O
display,537,O
a,537,O
high,537,O
level,537,O
of,537,O
double-stranded,537,O
chromosome,537,O
breaks,537,O
.,537,O
Atm-deficient,538,O
thymocytes,538,O
undergo,538,O
spontaneous,538,O
apoptosis,538,O
in,538,O
vitro,538,O
significantly,538,O
more,538,O
than,538,O
controls,538,O
.,538,O
Atm-deficient,539,O
mice,539,O
then,539,O
exhibit,539,O
many,539,O
of,539,O
the,539,O
same,539,O
symptoms,539,O
found,539,O
in,539,O
ataxia-telangiectasia,539,B-Modifier
patients,539,O
and,539,O
in,539,O
cells,539,O
derived,539,O
from,539,O
them,539,O
.,539,O
Furthermore,540,O
",",540,O
we,540,O
demonstrate,540,O
that,540,O
the,540,O
Atm,540,O
protein,540,O
exists,540,O
as,540,O
two,540,O
discrete,540,O
molecular,540,O
species,540,O
",",540,O
and,540,O
that,540,O
loss,540,O
of,540,O
one,540,O
or,540,O
of,540,O
both,540,O
of,540,O
these,540,O
can,540,O
lead,540,O
to,540,O
the,540,O
development,540,O
of,540,O
the,540,O
disease,540,O
..,540,O
The,541,O
DCC,541,O
protein,541,O
and,541,O
prognosis,541,O
in,541,O
colorectal,541,B-SpecificDisease
cancer,541,I-SpecificDisease
.,541,O
BACKGROUND,542,O
Allelic,542,O
loss,542,O
of,542,O
chromosome,542,O
18q,542,O
predicts,542,O
a,542,O
poor,542,O
outcome,542,O
in,542,O
patients,542,O
with,542,O
stage,542,B-SpecificDisease
II,542,I-SpecificDisease
colorectal,542,I-SpecificDisease
cancer,542,I-SpecificDisease
.,542,O
Although,543,O
the,543,O
specific,543,O
gene,543,O
inactivated,543,O
by,543,O
this,543,O
allelic,543,O
loss,543,O
has,543,O
not,543,O
been,543,O
elucidated,543,O
",",543,O
the,543,O
DCC,543,O
(,543,O
deleted,543,O
in,543,O
colorectal,543,B-SpecificDisease
cancer,543,I-SpecificDisease
),543,O
gene,543,O
is,543,O
a,543,O
candidate,543,O
.,543,O
We,544,O
investigated,544,O
whether,544,O
the,544,O
expression,544,O
of,544,O
the,544,O
DCC,544,O
protein,544,O
in,544,O
tumor,544,B-Modifier
cells,544,O
is,544,O
a,544,O
prognostic,544,O
marker,544,O
in,544,O
colorectal,544,B-SpecificDisease
carcinoma,544,I-SpecificDisease
.,544,O
METHODS,545,O
The,545,O
expression,545,O
of,545,O
DCC,545,O
was,545,O
evaluated,545,O
immunohistochemically,545,O
in,545,O
132,545,O
paraffin-embedded,545,O
samples,545,O
from,545,O
patients,545,O
with,545,O
curatively,545,O
resected,545,O
stage,545,B-CompositeMention
II,545,I-CompositeMention
and,545,I-CompositeMention
III,545,I-CompositeMention
colorectal,545,I-CompositeMention
carcinomas,545,I-CompositeMention
.,545,O
The,546,O
Cox,546,O
proportional-hazards,546,O
model,546,O
was,546,O
used,546,O
to,546,O
adjust,546,O
for,546,O
covariates,546,O
including,546,O
age,546,O
",",546,O
sex,546,O
",",546,O
tumor,546,B-Modifier
site,546,O
",",546,O
degree,546,O
of,546,O
tumor,546,B-Modifier
differentiation,546,O
",",546,O
and,546,O
use,546,O
of,546,O
adjuvant,546,O
therapy,546,O
.,546,O
RESULTS,547,O
The,547,O
expression,547,O
of,547,O
DCC,547,O
was,547,O
a,547,O
strong,547,O
positive,547,O
predictive,547,O
factor,547,O
for,547,O
survival,547,O
in,547,O
both,547,O
stage,547,B-CompositeMention
II,547,I-CompositeMention
and,547,I-CompositeMention
stage,547,I-CompositeMention
III,547,I-CompositeMention
colorectal,547,I-CompositeMention
carcinomas,547,I-CompositeMention
.,547,O
In,548,O
patients,548,O
with,548,O
stage,548,O
II,548,O
disease,548,O
whose,548,O
tumors,548,B-DiseaseClass
expressed,548,O
DCC,548,O
",",548,O
the,548,O
five-year,548,O
survival,548,O
rate,548,O
was,548,O
94,548,O
.,548,O
3,549,O
percent,549,O
",",549,O
whereas,549,O
in,549,O
patients,549,O
with,549,O
DCC-negative,549,B-SpecificDisease
tumors,549,I-SpecificDisease
",",549,O
the,549,O
survival,549,O
rate,549,O
was,549,O
61,549,O
.,549,O
6,550,O
percent,550,O
(,550,O
P,550,O
<,550,O
0,550,O
.,550,O
001,551,O
),551,O
.,551,O
In,552,O
patients,552,O
with,552,O
stage,552,B-SpecificDisease
III,552,I-SpecificDisease
disease,552,I-SpecificDisease
",",552,O
the,552,O
respective,552,O
survival,552,O
rates,552,O
were,552,O
59,552,O
.,552,O
3,553,O
percent,553,O
and,553,O
33,553,O
.,553,O
2,554,O
percent,554,O
(,554,O
P,554,O
=,554,O
0,554,O
.,554,O
03,555,O
),555,O
.,555,O
CONCLUSIONS,556,O
DCC,556,O
is,556,O
a,556,O
prognostic,556,O
marker,556,O
in,556,O
patients,556,O
with,556,O
stage,556,B-CompositeMention
II,556,I-CompositeMention
or,556,I-CompositeMention
stage,556,I-CompositeMention
III,556,I-CompositeMention
colorectal,556,I-CompositeMention
cancer,556,I-CompositeMention
.,556,O
In,557,O
stage,557,B-SpecificDisease
II,557,I-SpecificDisease
colorectal,557,I-SpecificDisease
carcinomas,557,I-SpecificDisease
",",557,O
the,557,O
absence,557,O
of,557,O
DCC,557,O
identifies,557,O
a,557,O
subgroup,557,O
of,557,O
patients,557,O
with,557,O
lesions,557,O
that,557,O
behave,557,O
like,557,O
stage,557,B-DiseaseClass
III,557,I-DiseaseClass
cancers,557,I-DiseaseClass
.,557,O
These,558,O
findings,558,O
may,558,O
thus,558,O
have,558,O
therapeutic,558,O
implications,558,O
in,558,O
this,558,O
group,558,O
of,558,O
patients,558,O
Association,559,O
of,559,O
anxiety-related,559,B-DiseaseClass
traits,559,I-DiseaseClass
with,559,O
a,559,O
polymorphism,559,O
in,559,O
the,559,O
serotonin,559,O
transporter,559,O
gene,559,O
regulatory,559,O
region,559,O
.,559,O
Transporter-facilitated,560,O
uptake,560,O
of,560,O
serotonin,560,O
(,560,O
5-hydroxytryptamine,560,O
or,560,O
5-HT,560,O
),560,O
has,560,O
been,560,O
implicated,560,O
in,560,O
anxiety,560,B-DiseaseClass
in,560,O
humans,560,O
and,560,O
animal,560,O
models,560,O
and,560,O
is,560,O
the,560,O
site,560,O
of,560,O
action,560,O
of,560,O
widely,560,O
used,560,O
uptake-inhibiting,560,O
antidepressant,560,O
and,560,O
antianxiety,560,O
drugs,560,O
.,560,O
Human,561,O
5-HT,561,O
transporter,561,O
(,561,O
5-HTT,561,O
),561,O
gene,561,O
transcription,561,O
is,561,O
modulated,561,O
by,561,O
a,561,O
common,561,O
polymorphism,561,O
in,561,O
its,561,O
upstream,561,O
regulatory,561,O
region,561,O
.,561,O
The,562,O
short,562,O
variant,562,O
of,562,O
the,562,O
polymorphism,562,O
reduces,562,O
the,562,O
transcriptional,562,O
efficiency,562,O
of,562,O
the,562,O
5-HTT,562,O
gene,562,O
promoter,562,O
",",562,O
resulting,562,O
in,562,O
decreased,562,O
5-HTT,562,O
expression,562,O
and,562,O
5-HT,562,O
uptake,562,O
in,562,O
lymphoblasts,562,O
.,562,O
Association,563,O
studies,563,O
in,563,O
two,563,O
independent,563,O
samples,563,O
totaling,563,O
505,563,O
individuals,563,O
revealed,563,O
that,563,O
the,563,O
5-HTT,563,O
polymorphism,563,O
accounts,563,O
for,563,O
3,563,O
to,563,O
4,563,O
percent,563,O
of,563,O
total,563,O
variation,563,O
and,563,O
7,563,O
to,563,O
9,563,O
percent,563,O
of,563,O
inherited,563,O
variance,563,O
in,563,O
anxiety-related,563,B-DiseaseClass
personality,563,I-DiseaseClass
traits,563,I-DiseaseClass
in,563,O
individuals,563,O
as,563,O
well,563,O
as,563,O
sibships,563,O
..,563,O
Phenotypic,564,O
and,564,O
genotypic,564,O
overlap,564,O
between,564,O
atelosteogenesis,564,B-SpecificDisease
type,564,I-SpecificDisease
2,564,I-SpecificDisease
and,564,O
diastrophic,564,B-SpecificDisease
dysplasia,564,I-SpecificDisease
.,564,O
Mutations,565,O
in,565,O
the,565,O
diastrophic,565,B-Modifier
dysplasia,565,I-Modifier
sulfate,565,O
transporter,565,O
gene,565,O
DTDST,565,O
have,565,O
been,565,O
associated,565,O
with,565,O
a,565,O
family,565,O
of,565,O
chondrodysplasias,565,B-DiseaseClass
that,565,O
comprises,565,O
",",565,O
in,565,O
order,565,O
of,565,O
increasing,565,O
severity,565,O
",",565,O
diastrophic,565,B-SpecificDisease
dysplasia,565,I-SpecificDisease
(,565,O
DTD,565,B-SpecificDisease
),565,O
",",565,O
atelosteogenesis,565,B-SpecificDisease
type,565,I-SpecificDisease
2,565,I-SpecificDisease
(,565,O
AO2,565,B-SpecificDisease
),565,O
",",565,O
and,565,O
achondrogenesis,565,B-SpecificDisease
type,565,I-SpecificDisease
1B,565,I-SpecificDisease
(,565,O
ACG1B,565,B-SpecificDisease
),565,O
.,565,O
To,566,O
learn,566,O
more,566,O
about,566,O
the,566,O
molecular,566,O
basis,566,O
of,566,O
DTDST,566,B-SpecificDisease
chondrodysplasias,566,I-SpecificDisease
and,566,O
about,566,O
genotype-phenotype,566,O
correlations,566,O
",",566,O
we,566,O
studied,566,O
fibroblast,566,O
cultures,566,O
of,566,O
three,566,O
new,566,O
patients,566,O
one,566,O
with,566,O
AO-2,566,B-SpecificDisease
",",566,O
one,566,O
with,566,O
DTD,566,B-SpecificDisease
",",566,O
and,566,O
one,566,O
with,566,O
an,566,O
intermediate,566,O
phenotype,566,O
(,566,O
AO2/DTD,566,B-SpecificDisease
),566,O
.,566,O
Reduced,567,O
incorporation,567,O
of,567,O
inorganic,567,O
sulfate,567,O
into,567,O
macromolecules,567,O
was,567,O
found,567,O
in,567,O
all,567,O
three,567,O
.,567,O
Each,568,O
of,568,O
the,568,O
three,568,O
patients,568,O
was,568,O
found,568,O
to,568,O
be,568,O
heterozygous,568,O
for,568,O
a,568,O
c862t,568,O
transition,568,O
predicting,568,O
a,568,O
R279W,568,O
substitution,568,O
in,568,O
the,568,O
third,568,O
extracellular,568,O
loop,568,O
of,568,O
DTDST,568,O
.,568,O
In,569,O
two,569,O
patients,569,O
(,569,O
DTD,569,B-SpecificDisease
and,569,O
AO2/DTD,569,B-SpecificDisease
),569,O
",",569,O
no,569,O
other,569,O
structural,569,O
mutation,569,O
was,569,O
found,569,O
",",569,O
but,569,O
polymerase,569,O
chain,569,O
reaction,569,O
amplification,569,O
and,569,O
single-strand,569,O
conformation,569,O
polymorphism,569,O
analysis,569,O
of,569,O
fibroblast,569,O
cDNA,569,O
showed,569,O
reduced,569,O
mRNA,569,O
levels,569,O
of,569,O
the,569,O
wild-type,569,O
DTDST,569,O
allele,569,O
these,569,O
two,569,O
patients,569,O
may,569,O
be,569,O
compound,569,O
heterozygotes,569,O
for,569,O
the,569,O
``,569,O
Finnish,569,O
``,569,O
mutation,569,O
(,569,O
as,569,O
yet,569,O
uncharacterized,569,O
at,569,O
the,569,O
DNA,569,O
level,569,O
),569,O
",",569,O
which,569,O
causes,569,O
reduced,569,O
expression,569,O
of,569,O
DTDST,569,O
.,569,O
The,570,O
third,570,O
patient,570,O
(,570,O
with,570,O
AO2,570,B-SpecificDisease
),570,O
had,570,O
the,570,O
R279W,570,O
mutation,570,O
compounded,570,O
with,570,O
a,570,O
novel,570,O
mutation,570,O
",",570,O
the,570,O
deletion,570,O
of,570,O
cytosine,570,O
418,570,O
(,570,O
delta,570,O
c418,570,O
),570,O
",",570,O
predicting,570,O
a,570,O
frameshift,570,O
with,570,O
premature,570,O
termination,570,O
.,570,O
Also,571,O
the,571,O
delta,571,O
c418,571,O
allele,571,O
was,571,O
underrepresented,571,O
in,571,O
the,571,O
cDNA,571,O
",",571,O
in,571,O
accordance,571,O
with,571,O
previous,571,O
observations,571,O
that,571,O
premature,571,O
stop,571,O
codons,571,O
reduce,571,O
mRNA,571,O
levels,571,O
.,571,O
The,572,O
presence,572,O
of,572,O
the,572,O
DTDST,572,O
R279W,572,O
mutation,572,O
in,572,O
a,572,O
total,572,O
of,572,O
11,572,O
patients,572,O
with,572,O
AO2,572,B-SpecificDisease
or,572,O
DTD,572,B-SpecificDisease
emphasizes,572,O
the,572,O
overlap,572,O
between,572,O
these,572,O
conditions,572,O
.,572,O
This,573,O
mutation,573,O
has,573,O
not,573,O
been,573,O
found,573,O
so,573,O
far,573,O
in,573,O
8,573,O
analyzed,573,O
ACG1B,573,B-Modifier
patients,573,O
",",573,O
suggesting,573,O
that,573,O
it,573,O
allows,573,O
some,573,O
residual,573,O
activity,573,O
of,573,O
the,573,O
sulfate,573,O
transporter,573,O
..,573,O
Identification,574,O
of,574,O
WASP,574,O
mutations,574,O
",",574,O
mutation,574,O
hotspots,574,O
and,574,O
genotype-phenotype,574,O
disparities,574,O
in,574,O
24,574,O
patients,574,O
with,574,O
the,574,O
Wiskott-Aldrich,574,B-SpecificDisease
syndrome,574,I-SpecificDisease
.,574,O
The,575,O
Wiskott-Aldrich,575,B-SpecificDisease
syndrome,575,I-SpecificDisease
(,575,O
WAS,575,B-SpecificDisease
),575,O
",",575,O
an,575,O
X-linked,575,B-DiseaseClass
immunodeficiency,575,I-DiseaseClass
disease,575,I-DiseaseClass
caused,575,O
by,575,O
mutation,575,O
in,575,O
the,575,O
recently,575,O
isolated,575,O
gene,575,O
encoding,575,O
WAS,575,B-Modifier
protein,575,O
(,575,O
WASP,575,O
),575,O
",",575,O
is,575,O
known,575,O
to,575,O
be,575,O
associated,575,O
with,575,O
extensive,575,O
clinical,575,O
heterogeneity,575,O
.,575,O
Cumulative,576,O
mutation,576,O
data,576,O
have,576,O
revealed,576,O
that,576,O
WASP,576,O
genotypes,576,O
are,576,O
also,576,O
highly,576,O
variable,576,O
among,576,O
WAS,576,B-Modifier
patients,576,O
",",576,O
but,576,O
the,576,O
relationship,576,O
of,576,O
phenotype,576,O
with,576,O
genotype,576,O
in,576,O
this,576,O
disease,576,O
remains,576,O
unclear,576,O
.,576,O
To,577,O
address,577,O
this,577,O
issue,577,O
we,577,O
characterized,577,O
WASP,577,O
mutations,577,O
in,577,O
24,577,O
unrelated,577,O
WAS,577,B-Modifier
patients,577,O
",",577,O
including,577,O
18,577,O
boys,577,O
with,577,O
severe,577,O
classical,577,O
WAS,577,B-SpecificDisease
and,577,O
6,577,O
boys,577,O
expressing,577,O
mild,577,O
forms,577,O
of,577,O
the,577,O
disease,577,O
",",577,O
and,577,O
then,577,O
examined,577,O
the,577,O
degree,577,O
of,577,O
correlation,577,O
of,577,O
these,577,O
as,577,O
well,577,O
as,577,O
all,577,O
previously,577,O
published,577,O
WASP,577,O
mutations,577,O
with,577,O
disease,577,O
severity,577,O
.,577,O
By,578,O
analysis,578,O
of,578,O
these,578,O
compiled,578,O
mutation,578,O
data,578,O
",",578,O
we,578,O
demonstrated,578,O
clustering,578,O
of,578,O
WASP,578,O
mutations,578,O
within,578,O
the,578,O
four,578,O
most,578,O
N-terminal,578,O
exons,578,O
of,578,O
the,578,O
gene,578,O
and,578,O
also,578,O
identified,578,O
several,578,O
sites,578,O
within,578,O
this,578,O
region,578,O
as,578,O
hotspots,578,O
for,578,O
WASP,578,O
mutation,578,O
.,578,O
These,579,O
characteristics,579,O
were,579,O
observed,579,O
",",579,O
however,579,O
",",579,O
in,579,O
both,579,O
severe,579,O
and,579,O
mild,579,O
cases,579,O
of,579,O
the,579,O
disease,579,O
.,579,O
Similarly,580,O
",",580,O
while,580,O
the,580,O
cumulative,580,O
data,580,O
revealed,580,O
a,580,O
predominance,580,O
of,580,O
missense,580,O
mutations,580,O
among,580,O
the,580,O
WASP,580,O
gene,580,O
lesions,580,O
observed,580,O
in,580,O
boys,580,O
with,580,O
isolated,580,B-SpecificDisease
thrombocytopenia,580,I-SpecificDisease
",",580,O
missense,580,O
mutations,580,O
were,580,O
not,580,O
exclusively,580,O
associated,580,O
with,580,O
milder,580,O
WAS,580,B-Modifier
phenotypes,580,O
",",580,O
but,580,O
also,580,O
comprised,580,O
a,580,O
substantial,580,O
portion,580,O
(,580,O
38,580,O
%,580,O
),580,O
of,580,O
the,580,O
WASP,580,O
gene,580,O
defects,580,O
found,580,O
in,580,O
patients,580,O
with,580,O
severe,580,O
disease,580,O
.,580,O
These,581,O
findings,581,O
",",581,O
as,581,O
well,581,O
as,581,O
the,581,O
detection,581,O
of,581,O
identical,581,O
WASP,581,O
mutations,581,O
in,581,O
patients,581,O
with,581,O
disparate,581,O
phenotypes,581,O
",",581,O
reveal,581,O
a,581,O
lack,581,O
of,581,O
phenotype,581,O
concordance,581,O
with,581,O
genotype,581,O
in,581,O
WAS,581,B-SpecificDisease
and,581,O
thus,581,O
imply,581,O
that,581,O
phenotypic,581,O
outcome,581,O
in,581,O
this,581,O
disease,581,O
can,581,O
not,581,O
be,581,O
reliably,581,O
predicted,581,O
solely,581,O
on,581,O
the,581,O
basis,581,O
of,581,O
WASP,581,O
genotypes,581,O
..,581,O
Germline,582,O
mutations,582,O
in,582,O
the,582,O
3,582,O
',582,O
part,582,O
of,582,O
APC,582,B-Modifier
exon,582,O
15,582,O
do,582,O
not,582,O
result,582,O
in,582,O
truncated,582,O
proteins,582,O
and,582,O
are,582,O
associated,582,O
with,582,O
attenuated,582,O
adenomatous,582,B-SpecificDisease
polyposis,582,I-SpecificDisease
coli,582,I-SpecificDisease
.,582,O
Familial,583,B-SpecificDisease
adenomatous,583,I-SpecificDisease
polyposis,583,I-SpecificDisease
(,583,O
FAP,583,B-SpecificDisease
),583,O
is,583,O
an,583,O
inherited,583,O
predisposition,583,O
to,583,O
colorectal,583,B-SpecificDisease
cancer,583,I-SpecificDisease
characterized,583,O
by,583,O
the,583,O
development,583,O
of,583,O
numerous,583,O
adenomatous,583,B-DiseaseClass
polyps,583,I-DiseaseClass
predominantly,583,O
in,583,O
the,583,O
colorectal,583,O
region,583,O
.,583,O
Germline,584,O
mutations,584,O
in,584,O
the,584,O
adenomatous,584,B-Modifier
polyposis,584,I-Modifier
coli,584,I-Modifier
(,584,O
APC,584,B-Modifier
),584,O
gene,584,O
are,584,O
responsible,584,O
for,584,O
most,584,O
cases,584,O
of,584,O
FAP,584,B-SpecificDisease
.,584,O
Mutations,585,O
at,585,O
the,585,O
5,585,O
end,585,O
of,585,O
APC,585,B-SpecificDisease
are,585,O
known,585,O
to,585,O
be,585,O
associated,585,O
with,585,O
a,585,O
relatively,585,O
mild,585,O
form,585,O
of,585,O
the,585,O
disease,585,O
",",585,O
called,585,O
attenuated,585,B-SpecificDisease
adenomatous,585,I-SpecificDisease
polyposis,585,I-SpecificDisease
coli,585,I-SpecificDisease
(,585,O
AAPC,585,B-SpecificDisease
),585,O
.,585,O
We,586,O
identified,586,O
a,586,O
frameshift,586,O
mutation,586,O
in,586,O
the,586,O
3,586,O
part,586,O
of,586,O
exon,586,O
15,586,O
",",586,O
resulting,586,O
in,586,O
a,586,O
stop,586,O
codon,586,O
at,586,O
1862,586,O
",",586,O
in,586,O
a,586,O
large,586,O
Dutch,586,O
kindred,586,O
with,586,O
AAPC,586,B-SpecificDisease
.,586,O
Western,587,O
blot,587,O
analysis,587,O
of,587,O
lymphoblastoid,587,O
cell,587,O
lines,587,O
derived,587,O
from,587,O
affected,587,O
family,587,O
members,587,O
from,587,O
this,587,O
kindred,587,O
",",587,O
as,587,O
well,587,O
as,587,O
from,587,O
a,587,O
previously,587,O
reported,587,O
Swiss,587,O
family,587,O
carrying,587,O
a,587,O
frameshift,587,O
mutation,587,O
at,587,O
codon,587,O
1987,587,O
and,587,O
displaying,587,O
a,587,O
similar,587,O
attenuated,587,O
phenotype,587,O
",",587,O
showed,587,O
only,587,O
the,587,O
wild-type,587,O
APC,587,B-Modifier
protein,587,O
.,587,O
Our,588,O
study,588,O
indicates,588,O
that,588,O
chain-terminating,588,O
mutations,588,O
located,588,O
in,588,O
the,588,O
3,588,O
part,588,O
of,588,O
APC,588,B-SpecificDisease
do,588,O
not,588,O
result,588,O
in,588,O
detectable,588,O
truncated,588,O
polypeptides,588,O
and,588,O
we,588,O
hypothesize,588,O
that,588,O
this,588,O
is,588,O
likely,588,O
to,588,O
be,588,O
the,588,O
basis,588,O
for,588,O
the,588,O
observed,588,O
AAPC,588,B-Modifier
phenotype,588,O
..,588,O
Complete,589,O
genomic,589,O
sequence,589,O
and,589,O
analysis,589,O
of,589,O
117,589,O
kb,589,O
of,589,O
human,589,O
DNA,589,O
containing,589,O
the,589,O
gene,589,O
BRCA1,589,O
.,589,O
Over,590,O
100,590,O
distinct,590,O
disease-associated,590,O
mutations,590,O
have,590,O
been,590,O
identified,590,O
in,590,O
the,590,O
breast-ovarian,590,B-Modifier
cancer,590,I-Modifier
susceptibility,590,O
gene,590,O
BRCA1,590,O
.,590,O
Loss,591,O
of,591,O
the,591,O
wild-type,591,O
allele,591,O
in,591,O
>,591,O
90,591,O
%,591,O
of,591,O
tumors,591,B-DiseaseClass
from,591,O
patients,591,O
with,591,O
inherited,591,O
BRCA1,591,O
mutations,591,O
indicates,591,O
tumor,591,B-Modifier
suppressive,591,O
function,591,O
.,591,O
The,592,O
low,592,O
incidence,592,O
of,592,O
somatic,592,O
mutations,592,O
suggests,592,O
that,592,O
BRCA1,592,O
inactivation,592,O
in,592,O
sporadic,592,O
tumors,592,B-DiseaseClass
occurs,592,O
by,592,O
alternative,592,O
mechanisms,592,O
",",592,O
such,592,O
as,592,O
interstitial,592,O
chromosomal,592,O
deletion,592,O
or,592,O
reduced,592,O
transcription,592,O
.,592,O
To,593,O
identify,593,O
possible,593,O
features,593,O
of,593,O
the,593,O
BRCA1,593,O
genomic,593,O
region,593,O
that,593,O
may,593,O
contribute,593,O
to,593,O
chromosomal,593,O
instability,593,O
as,593,O
well,593,O
as,593,O
potential,593,O
transcriptional,593,O
regulatory,593,O
elements,593,O
",",593,O
a,593,O
117,593,O
",",593,O
143-bp,593,O
DNA,593,O
sequence,593,O
encompassing,593,O
BRCA1,593,O
was,593,O
obtained,593,O
by,593,O
random,593,O
sequencing,593,O
of,593,O
four,593,O
cosmids,593,O
identified,593,O
from,593,O
a,593,O
human,593,O
chromosome,593,O
17,593,O
specific,593,O
library,593,O
.,593,O
The,594,O
24,594,O
exons,594,O
of,594,O
BRCA1,594,O
span,594,O
an,594,O
81-kb,594,O
region,594,O
that,594,O
has,594,O
an,594,O
unusually,594,O
high,594,O
density,594,O
of,594,O
Alu,594,O
repetitive,594,O
DNA,594,O
(,594,O
41,594,O
.,594,O
5,595,O
%,595,O
),595,O
",",595,O
but,595,O
relatively,595,O
low,595,O
density,595,O
(,595,O
4,595,O
.,595,O
8,596,O
%,596,O
),596,O
of,596,O
other,596,O
repetitive,596,O
sequences,596,O
.,596,O
BRCA1,597,O
intron,597,O
lengths,597,O
range,597,O
in,597,O
size,597,O
from,597,O
403,597,O
bp,597,O
to,597,O
9,597,O
.,597,O
2,598,O
kb,598,O
and,598,O
contain,598,O
the,598,O
intragenic,598,O
microsatellite,598,O
markers,598,O
D17S1323,598,O
",",598,O
D17S1322,598,O
",",598,O
and,598,O
D17S855,598,O
",",598,O
which,598,O
localize,598,O
to,598,O
introns,598,O
12,598,O
",",598,O
19,598,O
",",598,O
and,598,O
20,598,O
",",598,O
respectively,598,O
.,598,O
In,599,O
addition,599,O
to,599,O
BRCA1,599,O
",",599,O
the,599,O
contig,599,O
contains,599,O
two,599,O
complete,599,O
genes,599,O
Rho7,599,O
",",599,O
a,599,O
member,599,O
of,599,O
the,599,O
rho,599,O
family,599,O
of,599,O
GTP,599,O
binding,599,O
proteins,599,O
",",599,O
and,599,O
VAT1,599,O
",",599,O
an,599,O
abundant,599,O
membrane,599,O
protein,599,O
of,599,O
cholinergic,599,O
synaptic,599,O
vesicles,599,O
.,599,O
Partial,600,O
sequences,600,O
of,600,O
the,600,O
1A1-3B,600,O
B-box,600,O
protein,600,O
pseudogene,600,O
and,600,O
IFP,600,O
35,600,O
",",600,O
an,600,O
interferon,600,O
induced,600,O
leucine,600,O
zipper,600,O
protein,600,O
",",600,O
reside,600,O
within,600,O
the,600,O
contig,600,O
.,600,O
An,601,O
L21,601,O
ribosomal,601,O
protein,601,O
pseudogene,601,O
is,601,O
embedded,601,O
in,601,O
BRCA1,601,O
intron,601,O
13,601,O
.,601,O
The,602,O
order,602,O
of,602,O
genes,602,O
on,602,O
the,602,O
chromosome,602,O
is,602,O
centromere-1FP,602,O
35-VAT1-Rho7-BRCA1-1A1-3B-telomere,602,O
Identification,603,O
of,603,O
a,603,O
RING,603,O
protein,603,O
that,603,O
can,603,O
interact,603,O
in,603,O
vivo,603,O
with,603,O
the,603,O
BRCA1,603,O
gene,603,O
product,603,O
.,603,O
The,604,O
hereditary,604,B-Modifier
breast,604,I-Modifier
and,604,I-Modifier
ovarian,604,I-Modifier
cancer,604,I-Modifier
gene,604,O
",",604,O
BRCA1,604,O
",",604,O
encodes,604,O
a,604,O
large,604,O
polypeptide,604,O
that,604,O
contains,604,O
the,604,O
cysteine-rich,604,O
RING,604,O
motif,604,O
",",604,O
a,604,O
zinc-binding,604,O
domain,604,O
found,604,O
in,604,O
a,604,O
variety,604,O
of,604,O
regulatory,604,O
proteins,604,O
.,604,O
Here,605,O
we,605,O
describe,605,O
a,605,O
novel,605,O
protein,605,O
that,605,O
interacts,605,O
in,605,O
vivo,605,O
with,605,O
the,605,O
N-terminal,605,O
region,605,O
of,605,O
BRCA1,605,O
.,605,O
This,606,O
BRCA1-associated,606,O
RING,606,O
domain,606,O
(,606,O
BARD1,606,O
),606,O
protein,606,O
contains,606,O
an,606,O
N-terminal,606,O
RING,606,O
motif,606,O
",",606,O
three,606,O
tandem,606,O
ankyrin,606,O
repeats,606,O
",",606,O
and,606,O
a,606,O
C-terminal,606,O
sequence,606,O
with,606,O
significant,606,O
homology,606,O
to,606,O
the,606,O
phylogenetically,606,O
conserved,606,O
BRCT,606,O
domains,606,O
that,606,O
lie,606,O
near,606,O
the,606,O
C,606,O
terminus,606,O
of,606,O
BRCA1,606,O
.,606,O
The,607,O
BARD1/BRCA1,607,O
interaction,607,O
is,607,O
disrupted,607,O
by,607,O
BRCA1,607,O
missense,607,O
mutations,607,O
that,607,O
segregate,607,O
with,607,O
breast,607,B-Modifier
cancer,607,I-Modifier
susceptibility,607,O
",",607,O
indicating,607,O
that,607,O
BARD1,607,O
may,607,O
be,607,O
involved,607,O
in,607,O
mediating,607,O
tumour,607,B-Modifier
suppression,607,O
by,607,O
BRCA1,607,O
..,607,O
Detection,608,O
of,608,O
heterozygous,608,O
mutations,608,O
in,608,O
BRCA1,608,O
using,608,O
high,608,O
density,608,O
oligonucleotide,608,O
arrays,608,O
and,608,O
two-colour,608,O
fluorescence,608,O
analysis,608,O
.,608,O
The,609,O
ability,609,O
to,609,O
scan,609,O
a,609,O
large,609,O
gene,609,O
rapidly,609,O
and,609,O
accurately,609,O
for,609,O
all,609,O
possible,609,O
heterozygous,609,O
mutations,609,O
in,609,O
large,609,O
numbers,609,O
of,609,O
patient,609,O
samples,609,O
will,609,O
be,609,O
critical,609,O
for,609,O
the,609,O
future,609,O
of,609,O
medicine,609,O
.,609,O
We,610,O
have,610,O
designed,610,O
high-density,610,O
arrays,610,O
consisting,610,O
of,610,O
over,610,O
96,610,O
",",610,O
600,610,O
oligonucleotides,610,O
20-nucleotides,610,O
(,610,O
nt,610,O
),610,O
in,610,O
length,610,O
to,610,O
screen,610,O
for,610,O
a,610,O
wide,610,O
range,610,O
of,610,O
heterozygous,610,O
mutations,610,O
in,610,O
the,610,O
3,610,O
.,610,O
45-kilobases,611,O
(,611,O
kb,611,O
),611,O
exon,611,O
11,611,O
of,611,O
the,611,O
hereditary,611,B-Modifier
breast,611,I-Modifier
and,611,I-Modifier
ovarian,611,I-Modifier
cancer,611,I-Modifier
gene,611,O
BRCA1,611,O
.,611,O
Reference,612,O
and,612,O
test,612,O
samples,612,O
were,612,O
co-hybridized,612,O
to,612,O
these,612,O
arrays,612,O
and,612,O
differences,612,O
in,612,O
hybridization,612,O
patterns,612,O
quantitated,612,O
by,612,O
two-colour,612,O
analysis,612,O
.,612,O
Fourteen,613,O
of,613,O
fifteen,613,O
patient,613,O
samples,613,O
with,613,O
known,613,O
mutations,613,O
were,613,O
accurately,613,O
diagnosed,613,O
",",613,O
and,613,O
no,613,O
false,613,O
positive,613,O
mutations,613,O
were,613,O
identified,613,O
in,613,O
20,613,O
control,613,O
samples,613,O
.,613,O
Eight,614,O
single,614,O
nucleotide,614,O
polymorphisms,614,O
were,614,O
also,614,O
readily,614,O
detected,614,O
.,614,O
DNA,615,O
chip-based,615,O
assays,615,O
may,615,O
provide,615,O
a,615,O
valuable,615,O
new,615,O
technology,615,O
for,615,O
high-throughput,615,O
cost-efficient,615,O
detection,615,O
of,615,O
genetic,615,O
alterations,615,O
.,615,O
Autosomal,616,O
dominant,616,O
primary,616,O
hyperparathyroidism,616,B-SpecificDisease
and,616,I-SpecificDisease
jaw,616,I-SpecificDisease
tumor,616,I-SpecificDisease
syndrome,616,I-SpecificDisease
associated,616,O
with,616,O
renal,616,B-SpecificDisease
hamartomas,616,I-SpecificDisease
and,616,O
cystic,616,B-DiseaseClass
kidney,616,I-DiseaseClass
disease,616,I-DiseaseClass
:,616,O
linkage,616,O
to,616,O
1q21-q32,616,O
and,616,O
loss,616,O
of,616,O
the,616,O
wild,616,O
type,616,O
allele,616,O
in,616,O
renal,616,B-SpecificDisease
hamartomas,616,I-SpecificDisease
.,616,O
Hereditary,617,B-SpecificDisease
hyperparathyroidism-jaw,617,I-SpecificDisease
tumor,617,I-SpecificDisease
syndrome,617,I-SpecificDisease
(,617,O
HPT-JT,617,B-SpecificDisease
),617,O
is,617,O
an,617,O
autosomal,617,B-DiseaseClass
dominant,617,I-DiseaseClass
disease,617,I-DiseaseClass
(,617,O
OMIM,617,O
145001,617,O
),617,O
that,617,O
has,617,O
recently,617,O
been,617,O
mapped,617,O
to,617,O
chromosomal,617,O
region,617,O
1q21-q32,617,O
(,617,O
HRPT2,617,O
),617,O
.,617,O
Here,618,O
we,618,O
report,618,O
two,618,O
families,618,O
with,618,O
HPT-JT,618,B-SpecificDisease
syndrome,618,I-SpecificDisease
in,618,O
which,618,O
adult,618,B-SpecificDisease
renal,618,I-SpecificDisease
hamartomas,618,I-SpecificDisease
or,618,O
cystic,618,B-DiseaseClass
kidney,618,I-DiseaseClass
disease,618,I-DiseaseClass
were,618,O
prominent,618,O
associated,618,O
features,618,O
",",618,O
possibly,618,O
representing,618,O
a,618,O
new,618,O
phenotypic,618,O
variant,618,O
of,618,O
the,618,O
HPT-JT,618,B-SpecificDisease
syndrome,618,I-SpecificDisease
.,618,O
In,619,O
the,619,O
first,619,O
family,619,O
",",619,O
renal,619,B-DiseaseClass
lesions,619,I-DiseaseClass
were,619,O
present,619,O
in,619,O
five,619,O
out,619,O
of,619,O
six,619,O
affected,619,O
individuals,619,O
",",619,O
whereas,619,O
HPT,619,B-SpecificDisease
and,619,O
JT,619,B-SpecificDisease
were,619,O
seen,619,O
in,619,O
four,619,O
and,619,O
two,619,O
cases,619,O
",",619,O
respectively,619,O
.,619,O
In,620,O
the,620,O
second,620,O
family,620,O
",",620,O
JT,620,B-SpecificDisease
was,620,O
found,620,O
in,620,O
three,620,O
of,620,O
the,620,O
five,620,O
affected,620,O
individuals,620,O
and,620,O
two,620,O
affected,620,O
members,620,O
also,620,O
exhibited,620,O
polycystic,620,B-SpecificDisease
kidney,620,I-SpecificDisease
disease,620,I-SpecificDisease
.,620,O
The,621,O
possibility,621,O
of,621,O
the,621,O
latter,621,O
cosegregating,621,O
as,621,O
a,621,O
separate,621,O
autosomal,621,O
dominant,621,O
gene,621,O
can,621,O
not,621,O
be,621,O
ruled,621,O
out,621,O
.,621,O
A,622,O
sex-dependent,622,O
penetrance,622,O
of,622,O
primary,622,B-SpecificDisease
HPT,622,I-SpecificDisease
",",622,O
resulting,622,O
in,622,O
predominantly,622,O
male-affected,622,O
cases,622,O
was,622,O
evident,622,O
in,622,O
the,622,O
two,622,O
families,622,O
.,622,O
Twenty,623,O
microsatellite,623,O
markers,623,O
in,623,O
the,623,O
HRPT2,623,O
region,623,O
were,623,O
typed,623,O
",",623,O
in,623,O
addition,623,O
to,623,O
markers,623,O
in,623,O
the,623,O
multiple,623,B-Modifier
endocrine,623,I-Modifier
neoplasia,623,I-Modifier
(,623,I-Modifier
MEN,623,I-Modifier
),623,I-Modifier
types,623,I-Modifier
1,623,I-Modifier
and,623,I-Modifier
2,623,I-Modifier
regions,623,O
at,623,O
11q13,623,O
and,623,O
10q11,623,O
.,623,O
The,624,O
disease,624,O
in,624,O
these,624,O
two,624,O
kindreds,624,O
was,624,O
linked,624,O
to,624,O
five,624,O
markers,624,O
in,624,O
the,624,O
1q21-q32,624,O
region,624,O
(,624,O
logarithm-of-odds,624,O
scores,624,O
3,624,O
.,624,O
2-4,625,O
2-4,625,O
.,625,O
2,626,O
),626,O
",",626,O
whereas,626,O
linkage,626,O
to,626,O
the,626,O
MEN1,626,B-Modifier
and,626,O
MEN2,626,B-Modifier
regions,626,O
was,626,O
excluded,626,O
.,626,O
Meiotic,627,O
recombinations,627,O
detected,627,O
in,627,O
affected,627,O
individuals,627,O
placed,627,O
the,627,O
locus,627,O
telomeric,627,O
of,627,O
D1S215,627,O
",",627,O
thus,627,O
narrowing,627,O
the,627,O
HRPT2,627,O
region,627,O
from,627,O
>,627,O
60,627,O
to,627,O
approximately,627,O
34,627,O
centimorgans,627,O
.,627,O
Loss,628,O
of,628,O
heterozygosity,628,O
was,628,O
studied,628,O
in,628,O
seven,628,O
renal,628,B-SpecificDisease
hamartomas,628,I-SpecificDisease
from,628,O
two,628,O
affected,628,O
individuals,628,O
in,628,O
the,628,O
first,628,O
family,628,O
",",628,O
as,628,O
well,628,O
as,628,O
in,628,O
a,628,O
jaw,628,B-SpecificDisease
tumor,628,I-SpecificDisease
and,628,O
a,628,O
parathyroid,628,B-SpecificDisease
tumor,628,I-SpecificDisease
from,628,O
the,628,O
second,628,O
family,628,O
.,628,O
All,629,O
renal,629,B-SpecificDisease
hamartomas,629,I-SpecificDisease
showed,629,O
loss,629,O
of,629,O
heterozygosity,629,O
at,629,O
the,629,O
1q21-q32,629,O
region,629,O
.,629,O
The,630,O
losses,630,O
invariably,630,O
involved,630,O
the,630,O
wild,630,O
type,630,O
allele,630,O
derived,630,O
from,630,O
the,630,O
unaffected,630,O
parent,630,O
",",630,O
suggesting,630,O
the,630,O
inactivation,630,O
of,630,O
a,630,O
tumor,630,B-Modifier
suppressor,630,O
gene,630,O
in,630,O
this,630,O
region,630,O
Independent,631,O
origin,631,O
of,631,O
single,631,O
and,631,O
double,631,O
mutations,631,O
in,631,O
the,631,O
human,631,O
glucose,631,O
6-phosphate,631,O
dehydrogenase,631,O
gene,631,O
.,631,O
The,632,O
vast,632,O
majority,632,O
of,632,O
both,632,O
polymorphic,632,O
and,632,O
sporadic,632,O
G6PD,632,O
variants,632,O
are,632,O
due,632,O
to,632,O
single,632,O
missense,632,O
mutations,632,O
.,632,O
In,633,O
the,633,O
four,633,O
polymorphic,633,O
variants,633,O
that,633,O
have,633,O
two,633,O
point,633,O
mutations,633,O
",",633,O
one,633,O
of,633,O
the,633,O
mutations,633,O
is,633,O
always,633,O
376,633,O
A,633,O
--,633,O
>,633,O
G,633,O
(,633,O
126,633,O
Asn,633,O
--,633,O
>,633,O
Asp,633,O
),633,O
",",633,O
which,633,O
on,633,O
its,633,O
own,633,O
gives,633,O
rise,633,O
to,633,O
the,633,O
nondeficient,633,O
polymorphic,633,O
variant,633,O
",",633,O
G6PD,633,O
A,633,O
.,633,O
In,634,O
a,634,O
study,634,O
of,634,O
G6PD,634,B-Modifier
deficient,634,I-Modifier
patients,634,O
who,634,O
presented,634,O
with,634,O
clinical,634,O
favism,634,B-SpecificDisease
in,634,O
Spain,634,O
",",634,O
we,634,O
have,634,O
found,634,O
a,634,O
new,634,O
polymorphic,634,O
variant,634,O
that,634,O
we,634,O
have,634,O
called,634,O
G6PD,634,O
Malaga,634,O
",",634,O
whose,634,O
only,634,O
abnormality,634,O
is,634,O
a,634,O
542,634,O
A,634,O
--,634,O
>,634,O
T,634,O
(,634,O
181,634,O
Asp,634,O
--,634,O
>,634,O
Val,634,O
),634,O
mutation,634,O
.,634,O
This,635,O
is,635,O
the,635,O
same,635,O
mutation,635,O
as,635,O
previously,635,O
found,635,O
in,635,O
association,635,O
with,635,O
the,635,O
mutation,635,O
of,635,O
G6PD,635,O
A,635,O
in,635,O
the,635,O
double,635,O
mutant,635,O
",",635,O
G6PD,635,O
Santamaria,635,O
.,635,O
G6PD,636,O
Malaga,636,O
is,636,O
associated,636,O
with,636,O
enzyme,636,B-DiseaseClass
deficiency,636,I-DiseaseClass
(,636,O
class,636,O
III,636,O
),636,O
",",636,O
and,636,O
the,636,O
enzymic,636,O
properties,636,O
of,636,O
G6PD,636,O
Malaga,636,O
and,636,O
G6PD,636,O
Santamaria,636,O
are,636,O
quite,636,O
similar,636,O
",",636,O
indicating,636,O
that,636,O
in,636,O
this,636,O
case,636,O
the,636,O
effects,636,O
of,636,O
the,636,O
two,636,O
mutations,636,O
are,636,O
additive,636,O
rather,636,O
than,636,O
synergistic,636,O
.,636,O
G6PD,637,O
Santamaria,637,O
might,637,O
have,637,O
been,637,O
produced,637,O
by,637,O
recombination,637,O
between,637,O
G6PD,637,O
A,637,O
and,637,O
G6PD,637,O
Malaga,637,O
;,637,O
however,637,O
haplotype,637,O
analysis,637,O
",",637,O
including,637,O
the,637,O
use,637,O
of,637,O
a,637,O
new,637,O
silent,637,O
polymorphism,637,O
",",637,O
suggests,637,O
that,637,O
the,637,O
same,637,O
542,637,O
A,637,O
--,637,O
>,637,O
T,637,O
mutation,637,O
has,637,O
taken,637,O
place,637,O
independently,637,O
in,637,O
a,637,O
G6PD,637,O
B,637,O
gene,637,O
to,637,O
give,637,O
G6PD,637,O
Malaga,637,O
and,637,O
in,637,O
a,637,O
G6PD,637,O
A,637,O
gene,637,O
to,637,O
give,637,O
G6PD,637,O
Santamaria,637,O
.,637,O
These,638,O
findings,638,O
help,638,O
to,638,O
outline,638,O
the,638,O
relationship,638,O
and,638,O
evolution,638,O
of,638,O
mutations,638,O
in,638,O
the,638,O
human,638,O
G6PD,638,O
locus,638,O
..,638,O
BRCA1,639,O
R841W,639,O
:,639,O
a,639,O
strong,639,O
candidate,639,O
for,639,O
a,639,O
common,639,O
mutation,639,O
with,639,O
moderate,639,O
phenotype,639,O
.,639,O
BRCA1,640,O
mutations,640,O
cause,640,O
increased,640,O
risk,640,O
for,640,O
breast,640,O
and,640,O
ovarian,640,O
cancer,640,O
",",640,O
frequently,640,O
of,640,O
early,640,O
onset,640,O
.,640,O
Many,641,O
different,641,O
mutations,641,O
occur,641,O
in,641,O
BRCA1,641,O
",",641,O
including,641,O
several,641,O
examples,641,O
of,641,O
recurrent,641,O
mutations,641,O
",",641,O
each,641,O
of,641,O
which,641,O
accounts,641,O
for,641,O
a,641,O
significant,641,O
number,641,O
of,641,O
families,641,O
with,641,O
heritable,641,O
cancer,641,B-Modifier
predisposition,641,O
.,641,O
These,642,O
common,642,O
mutations,642,O
have,642,O
an,642,O
etiological,642,O
role,642,O
in,642,O
many,642,O
breast,642,O
and,642,O
ovarian,642,O
cancer,642,O
cases,642,O
and,642,O
provide,642,O
the,642,O
opportunity,642,O
to,642,O
examine,642,O
genotype-phenotype,642,O
correlations,642,O
and,642,O
genotype-environment,642,O
interactions,642,O
in,642,O
individuals,642,O
with,642,O
the,642,O
identical,642,O
BRCA1,642,O
lesion,642,O
.,642,O
We,643,O
report,643,O
a,643,O
novel,643,O
missense,643,O
change,643,O
in,643,O
BRCA1,643,O
",",643,O
2640,643,O
C,643,O
--,643,O
>,643,O
T,643,O
(,643,O
R841W,643,O
),643,O
",",643,O
found,643,O
in,643,O
3,643,O
cases,643,O
from,643,O
a,643,O
subject,643,O
group,643,O
of,643,O
305,643,O
breast,643,O
and,643,O
79,643,O
ovarian,643,O
cancer,643,O
cases,643,O
from,643,O
Orange,643,O
County,643,O
",",643,O
CA,643,O
.,643,O
These,644,O
are,644,O
consecutive,644,O
",",644,O
population-based,644,O
cases,644,O
not,644,O
selected,644,O
for,644,O
age,644,O
or,644,O
family,644,O
history,644,O
.,644,O
In,645,O
all,645,O
three,645,O
cases,645,O
",",645,O
there,645,O
is,645,O
a,645,O
strong,645,O
family,645,O
history,645,O
of,645,O
breast,645,O
",",645,O
ovarian,645,O
",",645,O
or,645,O
other,645,O
cancers,645,O
possibly,645,O
related,645,O
to,645,O
a,645,O
BRCA1,645,O
defect,645,O
and,645,O
family,645,O
members,645,O
showed,645,O
a,645,O
high,645,O
concordance,645,O
of,645,O
cancer,645,B-Modifier
incidence,645,O
with,645,O
the,645,O
presence,645,O
of,645,O
R841W,645,O
.,645,O
The,646,O
age,646,O
of,646,O
cancer,646,B-Modifier
onset,646,O
was,646,O
not,646,O
always,646,O
distinct,646,O
from,646,O
typical,646,O
sporadic,646,O
cases,646,O
.,646,O
Testing,647,O
of,647,O
a,647,O
sample,647,O
of,647,O
413,647,O
unrelated,647,O
individuals,647,O
to,647,O
examine,647,O
the,647,O
hypothesis,647,O
that,647,O
R841W,647,O
might,647,O
be,647,O
a,647,O
rare,647,O
polymorphism,647,O
detected,647,O
one,647,O
additional,647,O
instance,647,O
in,647,O
a,647,O
woman,647,O
with,647,O
breast,647,B-SpecificDisease
cancer,647,I-SpecificDisease
diagnosed,647,O
at,647,O
age,647,O
77,647,O
years,647,O
",",647,O
and,647,O
cancer,647,B-DiseaseClass
in,647,O
one,647,O
parent,647,O
.,647,O
R841W,648,O
is,648,O
likely,648,O
to,648,O
be,648,O
an,648,O
etiologically,648,O
significant,648,O
lesion,648,O
with,648,O
involvement,648,O
in,648,O
close,648,O
to,648,O
1,648,O
%,648,O
(,648,O
95,648,O
%,648,O
confidence,648,O
interval,648,O
of,648,O
0-1,648,O
.,648,O
7,649,O
%,649,O
),649,O
of,649,O
all,649,O
breast,649,O
and,649,O
ovarian,649,O
cancers,649,O
in,649,O
this,649,O
population,649,O
.,649,O
Ataxia-telangiectasia,650,B-SpecificDisease
:,650,O
founder,650,O
effect,650,O
among,650,O
north,650,O
African,650,O
Jews,650,O
.,650,O
The,651,O
ATM,651,O
gene,651,O
is,651,O
responsible,651,O
for,651,O
the,651,O
autosomal,651,B-DiseaseClass
recessive,651,I-DiseaseClass
disorder,651,I-DiseaseClass
ataxia-telangiectasia,651,B-SpecificDisease
(,651,O
A-T,651,B-SpecificDisease
),651,O
",",651,O
characterized,651,O
by,651,O
cerebellar,651,B-DiseaseClass
degeneration,651,I-DiseaseClass
",",651,O
immunodeficiency,651,B-DiseaseClass
and,651,O
cancer,651,B-DiseaseClass
predisposition,651,I-DiseaseClass
.,651,O
A-T,652,B-Modifier
carriers,652,O
were,652,O
reported,652,O
to,652,O
be,652,O
moderately,652,O
cancer-prone,652,B-DiseaseClass
.,652,O
A,653,O
wide,653,O
variety,653,O
of,653,O
A-T,653,B-Modifier
mutations,653,O
",",653,O
most,653,O
of,653,O
which,653,O
are,653,O
unique,653,O
to,653,O
single,653,O
families,653,O
",",653,O
were,653,O
identified,653,O
in,653,O
various,653,O
ethnic,653,O
groups,653,O
",",653,O
precluding,653,O
carrier,653,O
screening,653,O
with,653,O
mutation-specific,653,O
assays,653,O
.,653,O
However,654,O
",",654,O
a,654,O
single,654,O
mutation,654,O
was,654,O
observed,654,O
in,654,O
32/33,654,O
defective,654,O
ATM,654,O
alleles,654,O
in,654,O
Jewish,654,O
A-T,654,B-Modifier
families,654,O
of,654,O
North,654,O
African,654,O
origin,654,O
",",654,O
coming,654,O
from,654,O
various,654,O
regions,654,O
of,654,O
Morocco,654,O
and,654,O
Tunisia,654,O
.,654,O
This,655,O
mutation,655,O
",",655,O
103C,655,O
--,655,O
>,655,O
T,655,O
",",655,O
results,655,O
in,655,O
a,655,O
stop,655,O
codon,655,O
at,655,O
position,655,O
35,655,O
of,655,O
the,655,O
ATM,655,O
protein,655,O
.,655,O
In,656,O
keeping,656,O
with,656,O
the,656,O
nature,656,O
of,656,O
this,656,O
mutation,656,O
",",656,O
various,656,O
antibodies,656,O
directed,656,O
against,656,O
the,656,O
ATM,656,O
protein,656,O
failed,656,O
to,656,O
defect,656,O
this,656,O
protein,656,O
in,656,O
patient,656,O
cells,656,O
.,656,O
A,657,O
rapid,657,O
carrier,657,O
detection,657,O
assay,657,O
detected,657,O
this,657,O
mutation,657,O
in,657,O
three,657,O
out,657,O
of,657,O
488,657,O
ATM,657,O
alleles,657,O
of,657,O
Jewish,657,O
Moroccan,657,O
or,657,O
Tunisian,657,O
origin,657,O
.,657,O
This,658,O
founder,658,O
effect,658,O
provides,658,O
a,658,O
unique,658,O
opportunity,658,O
for,658,O
population-based,658,O
screening,658,O
for,658,O
A-T,658,B-Modifier
carriers,658,O
in,658,O
a,658,O
large,658,O
Jewish,658,O
community,658,O
..,658,O
Mutation,659,O
analysis,659,O
of,659,O
BRCA1,659,O
and,659,O
BRCA2,659,O
in,659,O
a,659,O
male,659,B-Modifier
breast,659,I-Modifier
cancer,659,I-Modifier
population,659,O
.,659,O
A,660,O
population-based,660,O
series,660,O
of,660,O
54,660,O
male,660,B-Modifier
breast,660,I-Modifier
cancer,660,I-Modifier
cases,660,O
from,660,O
Southern,660,O
California,660,O
were,660,O
analyzed,660,O
for,660,O
germ-line,660,O
mutations,660,O
in,660,O
the,660,O
inherited,660,B-Modifier
breast/ovarian,660,I-Modifier
cancer,660,I-Modifier
genes,660,O
",",660,O
BRCA1,660,O
and,660,O
BRCA2,660,O
.,660,O
Nine,661,O
(,661,O
17,661,O
%,661,O
),661,O
of,661,O
the,661,O
patients,661,O
had,661,O
a,661,O
family,661,O
history,661,O
of,661,O
breast,661,B-CompositeMention
and/or,661,I-CompositeMention
ovarian,661,I-CompositeMention
cancer,661,I-CompositeMention
in,661,O
at,661,O
least,661,O
one,661,O
first-degree,661,O
relative,661,O
.,661,O
A,662,O
further,662,O
seven,662,O
(,662,O
13,662,O
%,662,O
),662,O
of,662,O
the,662,O
patients,662,O
reported,662,O
breast/ovarian,662,B-CompositeMention
cancer,662,I-CompositeMention
in,662,O
at,662,O
least,662,O
one,662,O
second-degree,662,O
relative,662,O
and,662,O
in,662,O
no,662,O
first-degree,662,O
relatives,662,O
.,662,O
No,663,O
germ-line,663,O
BRCA1,663,O
mutations,663,O
were,663,O
found,663,O
.,663,O
Two,664,O
male,664,B-Modifier
breast,664,I-Modifier
cancer,664,I-Modifier
patients,664,O
(,664,O
4,664,O
%,664,O
of,664,O
the,664,O
total,664,O
),664,O
were,664,O
found,664,O
to,664,O
carry,664,O
novel,664,O
truncating,664,O
mutations,664,O
in,664,O
the,664,O
BRCA2,664,O
gene,664,O
.,664,O
Only,665,O
one,665,O
of,665,O
the,665,O
two,665,O
male,665,B-Modifier
breast,665,I-Modifier
cancer,665,I-Modifier
patients,665,O
carrying,665,O
a,665,O
BRCA2,665,O
mutation,665,O
had,665,O
a,665,O
family,665,O
history,665,O
of,665,O
cancer,665,B-DiseaseClass
",",665,O
with,665,O
one,665,O
case,665,O
of,665,O
ovarian,665,B-SpecificDisease
cancer,665,I-SpecificDisease
in,665,O
a,665,O
first-degree,665,O
relative,665,O
.,665,O
The,666,O
remaining,666,O
eight,666,O
cases,666,O
(,666,O
89,666,O
%,666,O
),666,O
of,666,O
male,666,B-SpecificDisease
breast,666,I-SpecificDisease
cancer,666,I-SpecificDisease
with,666,O
a,666,O
family,666,O
history,666,O
of,666,O
breast/ovarian,666,B-CompositeMention
cancer,666,I-CompositeMention
in,666,O
first-degree,666,O
relatives,666,O
remain,666,O
unaccounted,666,O
for,666,O
by,666,O
mutations,666,O
in,666,O
either,666,O
the,666,O
BRCA1,666,O
gene,666,O
or,666,O
the,666,O
BRCA2,666,O
gene,666,O
..,666,O
Molecular,667,O
basis,667,O
for,667,O
Duarte,667,B-CompositeMention
and,667,I-CompositeMention
Los,667,I-CompositeMention
Angeles,667,I-CompositeMention
variant,667,I-CompositeMention
galactosemia,667,I-CompositeMention
.,667,O
Human,668,O
orythrocytes,668,O
that,668,O
are,668,O
homozygous,668,O
for,668,O
the,668,O
Duarte,668,B-SpecificDisease
enzyme,668,I-SpecificDisease
variant,668,I-SpecificDisease
of,668,I-SpecificDisease
galactosemia,668,I-SpecificDisease
(,668,O
D/D,668,O
),668,O
have,668,O
a,668,O
characteristic,668,O
isoform,668,O
on,668,O
isoelectric,668,O
focusing,668,O
and,668,O
50,668,O
%,668,O
reduction,668,O
in,668,O
galactose-1-phosphate,668,O
uridyltransferase,668,O
(,668,O
GALT,668,O
),668,O
enzyme,668,O
activity,668,O
.,668,O
The,669,O
Duarte,669,O
biochemical,669,O
phenotype,669,O
has,669,O
a,669,O
molecular,669,O
genotype,669,O
of,669,O
N314D/N314D,669,O
.,669,O
The,670,O
characteristic,670,O
Duarte,670,O
isoform,670,O
is,670,O
also,670,O
associated,670,O
with,670,O
a,670,O
variant,670,O
called,670,O
the,670,O
``,670,O
Los,670,O
Angeles,670,O
(,670,O
LA,670,O
),670,O
phenotype,670,O
",",670,O
``,670,O
which,670,O
has,670,O
increased,670,O
GALT,670,O
enzyme,670,O
activity,670,O
.,670,O
We,671,O
evaluated,671,O
GALT,671,O
enzyme,671,O
activity,671,O
and,671,O
screened,671,O
the,671,O
GALT,671,O
genes,671,O
of,671,O
145,671,O
patients,671,O
with,671,O
one,671,O
or,671,O
more,671,O
N314D-containing,671,O
alleles,671,O
.,671,O
We,672,O
found,672,O
seven,672,O
with,672,O
the,672,O
LA,672,O
biochemical,672,O
phenotype,672,O
",",672,O
and,672,O
all,672,O
had,672,O
a,672,O
1721C,672,O
--,672,O
>,672,O
T,672,O
transition,672,O
in,672,O
exon,672,O
7,672,O
in,672,O
cis,672,O
with,672,O
the,672,O
N314D,672,O
missense,672,O
mutation,672,O
.,672,O
The,673,O
1721C,673,O
--,673,O
>,673,O
T,673,O
transition,673,O
is,673,O
a,673,O
neutral,673,O
polymorphism,673,O
for,673,O
leucine,673,O
at,673,O
amino,673,O
acid,673,O
218,673,O
(,673,O
L218L,673,O
),673,O
.,673,O
In,674,O
pedigree,674,O
analyses,674,O
",",674,O
this,674,O
1721C,674,O
--,674,O
>,674,O
T,674,O
transition,674,O
segregated,674,O
with,674,O
the,674,O
LA,674,O
phenotype,674,O
of,674,O
increased,674,O
GALT,674,O
activity,674,O
in,674,O
three,674,O
different,674,O
biochemical,674,O
phenotypes,674,O
(,674,O
LA/N,674,O
",",674,O
LA/G,674,O
",",674,O
and,674,O
LA/D,674,O
),674,O
.,674,O
To,675,O
determine,675,O
the,675,O
mechanism,675,O
for,675,O
increased,675,O
activity,675,O
of,675,O
the,675,O
LA,675,O
variant,675,O
",",675,O
we,675,O
compared,675,O
GALT,675,O
mRNA,675,O
",",675,O
protein,675,O
abundance,675,O
",",675,O
and,675,O
enzyme,675,O
thermal,675,O
stability,675,O
in,675,O
lymphoblast,675,O
cell,675,O
lines,675,O
of,675,O
D,675,O
and,675,O
LA,675,O
phenotypes,675,O
with,675,O
comparable,675,O
genotypes,675,O
.,675,O
GALT,676,O
protein,676,O
abundance,676,O
was,676,O
increased,676,O
in,676,O
LA,676,O
compared,676,O
to,676,O
D,676,O
alleles,676,O
",",676,O
but,676,O
mRNA,676,O
was,676,O
similar,676,O
among,676,O
all,676,O
genotypes,676,O
.,676,O
When,677,O
LA/D,677,O
and,677,O
D/D,677,O
GALT,677,O
biochemical,677,O
phenotypes,677,O
were,677,O
compared,677,O
to,677,O
N/N,677,O
GALT,677,O
phenotypes,677,O
",",677,O
both,677,O
had,677,O
50,677,O
%,677,O
",",677,O
as,677,O
compared,677,O
to,677,O
21,677,O
%,677,O
",",677,O
reduction,677,O
in,677,O
GALT,677,O
activity,677,O
in,677,O
the,677,O
wild,677,O
type,677,O
(,677,O
N/N,677,O
),677,O
after,677,O
exposure,677,O
at,677,O
identical,677,O
initial,677,O
enzyme,677,O
activity,677,O
to,677,O
50,677,O
degrees,677,O
C,677,O
for,677,O
15,677,O
min,677,O
.,677,O
We,678,O
conclude,678,O
that,678,O
the,678,O
codon,678,O
change,678,O
N314D,678,O
in,678,O
cis,678,O
with,678,O
the,678,O
base-pair,678,O
transition,678,O
1721C,678,O
--,678,O
>,678,O
T,678,O
produces,678,O
the,678,O
LA,678,B-SpecificDisease
variant,678,I-SpecificDisease
of,678,I-SpecificDisease
galactosemia,678,I-SpecificDisease
and,678,O
that,678,O
this,678,O
nucleotide,678,O
change,678,O
increases,678,O
GALT,678,O
activity,678,O
by,678,O
increasing,678,O
GALT,678,O
protein,678,O
abundance,678,O
without,678,O
increasing,678,O
transcription,678,O
or,678,O
decreasing,678,O
thermal,678,O
lability,678,O
.,678,O
A,679,O
favorable,679,O
codon,679,O
bias,679,O
for,679,O
the,679,O
mutated,679,O
codon,679,O
with,679,O
consequently,679,O
increased,679,O
translation,679,O
rates,679,O
is,679,O
postulated,679,O
as,679,O
the,679,O
mechanism,679,O
..,679,O
The,680,O
TSG101,680,O
tumor,680,B-Modifier
susceptibility,680,O
gene,680,O
is,680,O
located,680,O
in,680,O
chromosome,680,O
11,680,O
band,680,O
p15,680,O
and,680,O
is,680,O
mutated,680,O
in,680,O
human,680,O
breast,680,B-SpecificDisease
cancer,680,I-SpecificDisease
.,680,O
Recent,681,O
work,681,O
has,681,O
identified,681,O
a,681,O
mouse,681,O
gene,681,O
(,681,O
tsg101,681,O
),681,O
whose,681,O
inactivation,681,O
in,681,O
fibroblasts,681,O
results,681,O
in,681,O
cellular,681,O
transformation,681,O
and,681,O
the,681,O
ability,681,O
to,681,O
produce,681,O
metastatic,681,B-DiseaseClass
tumors,681,I-DiseaseClass
in,681,O
nude,681,O
mice,681,O
.,681,O
Here,682,O
",",682,O
we,682,O
report,682,O
that,682,O
the,682,O
human,682,O
homolog,682,O
",",682,O
TSG101,682,O
",",682,O
which,682,O
we,682,O
isolated,682,O
and,682,O
mapped,682,O
to,682,O
chromosome,682,O
11,682,O
",",682,O
bands,682,O
15,682,O
.,682,O
1-15,683,O
1-15,683,O
.,683,O
2,684,O
",",684,O
a,684,O
region,684,O
proposed,684,O
to,684,O
contain,684,O
tumor,684,B-Modifier
suppressor,684,O
gene,684,O
(,684,O
s,684,O
),684,O
",",684,O
is,684,O
mutated,684,O
at,684,O
high,684,O
frequency,684,O
in,684,O
human,684,O
breast,684,B-SpecificDisease
cancer,684,I-SpecificDisease
.,684,O
In,685,O
7,685,O
of,685,O
15,685,O
uncultured,685,O
primary,685,O
human,685,O
breast,685,B-SpecificDisease
carcinomas,685,I-SpecificDisease
",",685,O
intragenic,685,O
deletions,685,O
were,685,O
shown,685,O
in,685,O
TSG101,685,O
genomic,685,O
DNA,685,O
and,685,O
transcripts,685,O
by,685,O
gel,685,O
and,685,O
sequence,685,O
analysis,685,O
",",685,O
and,685,O
mutations,685,O
affecting,685,O
two,685,O
TSG101,685,O
alleles,685,O
were,685,O
identified,685,O
in,685,O
four,685,O
of,685,O
these,685,O
cancers,685,B-DiseaseClass
.,685,O
No,686,O
TSG101,686,O
defects,686,O
were,686,O
found,686,O
in,686,O
matched,686,O
normal,686,O
breast,686,O
tissue,686,O
from,686,O
the,686,O
breast,686,B-Modifier
cancer,686,I-Modifier
patients,686,O
.,686,O
These,687,O
findings,687,O
strongly,687,O
implicate,687,O
TSG101,687,O
mutations,687,O
in,687,O
human,687,O
breast,687,B-SpecificDisease
cancer,687,I-SpecificDisease
Moderate,688,O
intergenerational,688,O
and,688,O
somatic,688,O
instability,688,O
of,688,O
a,688,O
55-CTG,688,O
repeat,688,O
in,688,O
transgenic,688,O
mice,688,O
.,688,O
Myotonic,689,B-SpecificDisease
dystrophy,689,I-SpecificDisease
(,689,O
DM,689,B-SpecificDisease
),689,O
is,689,O
associated,689,O
with,689,O
the,689,O
expansion,689,O
of,689,O
a,689,O
(,689,O
CTG,689,O
),689,O
n,689,O
trinucleotide,689,O
repeat,689,O
in,689,O
the,689,O
3,689,O
untranslated,689,O
region,689,O
(,689,O
UTR,689,O
),689,O
of,689,O
the,689,O
DM,689,B-Modifier
protein,689,O
kinase,689,O
gene,689,O
(,689,O
DMPK,689,O
),689,O
.,689,O
The,690,O
(,690,O
CTG,690,O
),690,O
n,690,O
repeat,690,O
is,690,O
polymorphic,690,O
and,690,O
varies,690,O
in,690,O
size,690,O
between,690,O
5,690,O
and,690,O
37,690,O
repeats,690,O
in,690,O
unaffected,690,O
individuals,690,O
whereas,690,O
in,690,O
affected,690,O
patients,690,O
there,690,O
are,690,O
between,690,O
50,690,O
and,690,O
4,690,O
",",690,O
000,690,O
CTGs,690,O
.,690,O
The,691,O
size,691,O
of,691,O
the,691,O
(,691,O
CTG,691,O
),691,O
n,691,O
repeat,691,O
",",691,O
which,691,O
increases,691,O
through,691,O
generations,691,O
",",691,O
generally,691,O
correlates,691,O
with,691,O
clinical,691,O
severity,691,O
and,691,O
age,691,O
of,691,O
onset,691,O
.,691,O
The,692,O
instability,692,O
of,692,O
the,692,O
CTG,692,O
repeat,692,O
appears,692,O
to,692,O
depend,692,O
on,692,O
its,692,O
size,692,O
as,692,O
well,692,O
as,692,O
on,692,O
the,692,O
sex,692,O
of,692,O
the,692,O
transmitting,692,O
parent,692,O
.,692,O
Moreover,693,O
",",693,O
mitotic,693,O
instability,693,O
analysis,693,O
of,693,O
different,693,O
human,693,O
DM,693,B-Modifier
tissues,693,O
shows,693,O
length,693,O
mosaicism,693,O
between,693,O
different,693,O
cell,693,O
lineages,693,O
.,693,O
The,694,O
molecular,694,O
mechanisms,694,O
of,694,O
triplet,694,O
instability,694,O
remain,694,O
elusive,694,O
.,694,O
To,695,O
investigate,695,O
the,695,O
role,695,O
of,695,O
genomic,695,O
sequences,695,O
in,695,O
instability,695,O
",",695,O
we,695,O
produced,695,O
transgenic,695,O
mice,695,O
containing,695,O
a,695,O
45-kb,695,O
genomic,695,O
segment,695,O
with,695,O
a,695,O
55-CTG,695,O
repeat,695,O
cloned,695,O
from,695,O
a,695,O
mildly,695,O
affected,695,O
patient,695,O
.,695,O
In,696,O
contrast,696,O
to,696,O
other,696,O
mouse,696,O
models,696,O
containing,696,O
CAG,696,O
repeats,696,O
within,696,O
cDNAs,696,O
",",696,O
these,696,O
mice,696,O
showed,696,O
both,696,O
intergenerational,696,O
and,696,O
somatic,696,O
repeat,696,O
instability,696,O
..,696,O
Missense,697,O
mutations,697,O
in,697,O
the,697,O
Fas,697,O
gene,697,O
resulting,697,O
in,697,O
autoimmune,697,B-SpecificDisease
lymphoproliferative,697,I-SpecificDisease
syndrome,697,I-SpecificDisease
:,697,O
a,697,O
molecular,697,O
and,697,O
immunological,697,O
analysis,697,O
.,697,O
Programmed,698,O
cell,698,O
death,698,O
(,698,O
or,698,O
apoptosis,698,O
),698,O
is,698,O
a,698,O
physiological,698,O
process,698,O
essential,698,O
to,698,O
the,698,O
normal,698,O
development,698,O
and,698,O
homeostatic,698,O
maintenance,698,O
of,698,O
the,698,O
immune,698,O
system,698,O
.,698,O
The,699,O
Fas/Apo-1,699,O
receptor,699,O
plays,699,O
a,699,O
crucial,699,O
role,699,O
in,699,O
the,699,O
regulation,699,O
of,699,O
apoptosis,699,O
",",699,O
as,699,O
demonstrated,699,O
by,699,O
lymphoproliferation,699,O
in,699,O
MRL-lpr/lpr,699,O
mice,699,O
and,699,O
by,699,O
the,699,O
recently,699,O
described,699,O
autoimmune,699,B-SpecificDisease
lymphoproliferative,699,I-SpecificDisease
syndrome,699,I-SpecificDisease
(,699,O
ALPS,699,B-SpecificDisease
),699,O
in,699,O
humans,699,O
",",699,O
both,699,O
of,699,O
which,699,O
are,699,O
due,699,O
to,699,O
mutations,699,O
in,699,O
the,699,O
Fas,699,O
gene,699,O
.,699,O
We,700,O
describe,700,O
a,700,O
novel,700,O
family,700,O
with,700,O
ALPS,700,B-SpecificDisease
in,700,O
which,700,O
three,700,O
affected,700,O
siblings,700,O
carry,700,O
two,700,O
distinct,700,O
missense,700,O
mutations,700,O
on,700,O
both,700,O
the,700,O
Fas,700,O
gene,700,O
alleles,700,O
and,700,O
show,700,O
lack,700,O
of,700,O
Fas-induced,700,O
apoptosis,700,O
.,700,O
The,701,O
children,701,O
share,701,O
common,701,O
clinical,701,O
features,701,O
including,701,O
splenomegaly,701,B-DiseaseClass
and,701,O
lymphadenopathy,701,B-DiseaseClass
",",701,O
but,701,O
only,701,O
one,701,O
developed,701,O
severe,701,O
autoimmune,701,B-DiseaseClass
manifestations,701,I-DiseaseClass
.,701,O
In,702,O
all,702,O
three,702,O
siblings,702,O
",",702,O
we,702,O
demonstrated,702,O
the,702,O
presence,702,O
of,702,O
anergic,702,O
CD3,702,O
+,702,O
CD4-CD8-,702,O
(,702,O
double,702,O
negative,702,O
",",702,O
[,702,O
DN,702,O
],702,O
),702,O
T,702,O
cells,702,O
;,702,O
moreover,702,O
",",702,O
a,702,O
chronic,702,O
lymphocyte,702,O
activation,702,O
was,702,O
found,702,O
",",702,O
as,702,O
demonstrated,702,O
by,702,O
the,702,O
presence,702,O
of,702,O
high,702,O
levels,702,O
of,702,O
HLA-DR,702,O
expression,702,O
on,702,O
peripheral,702,O
CD3,702,O
+,702,O
cells,702,O
and,702,O
by,702,O
the,702,O
presence,702,O
of,702,O
high,702,O
levels,702,O
of,702,O
serum,702,O
activation,702,O
markers,702,O
such,702,O
as,702,O
soluble,702,O
interleukin-2,702,O
receptor,702,O
(,702,O
slL-2R,702,O
),702,O
and,702,O
soluble,702,O
CD30,702,O
(,702,O
sCD30,702,O
),702,O
..,702,O
The,703,O
ataxia-telangiectasia,703,B-Modifier
gene,703,O
product,703,O
",",703,O
a,703,O
constitutively,703,O
expressed,703,O
nuclear,703,O
protein,703,O
that,703,O
is,703,O
not,703,O
up-regulated,703,O
following,703,O
genome,703,O
damage,703,O
.,703,O
The,704,O
product,704,O
of,704,O
the,704,O
ataxia-telangiectasia,704,B-Modifier
gene,704,O
(,704,O
ATM,704,O
),704,O
was,704,O
identified,704,O
by,704,O
using,704,O
an,704,O
antiserum,704,O
developed,704,O
to,704,O
a,704,O
peptide,704,O
corresponding,704,O
to,704,O
the,704,O
deduced,704,O
amino,704,O
acid,704,O
sequence,704,O
.,704,O
The,705,O
ATM,705,O
protein,705,O
is,705,O
a,705,O
single,705,O
",",705,O
high-molecular,705,O
weight,705,O
protein,705,O
predominantly,705,O
confined,705,O
to,705,O
the,705,O
nucleus,705,O
of,705,O
human,705,O
fibroblasts,705,O
",",705,O
but,705,O
is,705,O
present,705,O
in,705,O
both,705,O
nuclear,705,O
and,705,O
microsomal,705,O
fractions,705,O
from,705,O
human,705,O
lymphoblast,705,O
cells,705,O
and,705,O
peripheral,705,O
blood,705,O
lymphocytes,705,O
.,705,O
ATM,706,O
protein,706,O
levels,706,O
and,706,O
localization,706,O
remain,706,O
constant,706,O
throughout,706,O
all,706,O
stages,706,O
of,706,O
the,706,O
cell,706,O
cycle,706,O
.,706,O
Truncated,707,O
ATM,707,O
protein,707,O
was,707,O
not,707,O
detected,707,O
in,707,O
lymphoblasts,707,O
from,707,O
ataxia-telangiectasia,707,B-Modifier
patients,707,O
homozygous,707,O
for,707,O
mutations,707,O
leading,707,O
to,707,O
premature,707,O
protein,707,O
termination,707,O
.,707,O
Exposure,708,O
of,708,O
normal,708,O
human,708,O
cells,708,O
to,708,O
gamma-irradiation,708,O
and,708,O
the,708,O
radiomimetic,708,O
drug,708,O
neocarzinostatin,708,O
had,708,O
no,708,O
effect,708,O
on,708,O
ATM,708,O
protein,708,O
levels,708,O
",",708,O
in,708,O
contrast,708,O
to,708,O
a,708,O
noted,708,O
rise,708,O
in,708,O
p53,708,O
levels,708,O
over,708,O
the,708,O
same,708,O
time,708,O
interval,708,O
.,708,O
These,709,O
findings,709,O
are,709,O
consistent,709,O
with,709,O
a,709,O
role,709,O
for,709,O
the,709,O
ATM,709,O
protein,709,O
in,709,O
ensuring,709,O
the,709,O
fidelity,709,O
of,709,O
DNA,709,O
repair,709,O
and,709,O
cell,709,O
cycle,709,O
regulation,709,O
following,709,O
genome,709,O
damage,709,O
..,709,O
Type,710,O
III,710,O
collagen,710,O
is,710,O
crucial,710,O
for,710,O
collagen,710,O
I,710,O
fibrillogenesis,710,O
and,710,O
for,710,O
normal,710,O
cardiovascular,710,O
development,710,O
.,710,O
Type,711,O
III,711,O
collagen,711,O
is,711,O
a,711,O
fibrillar,711,O
forming,711,O
collagen,711,O
comprising,711,O
three,711,O
alpha1,711,O
(,711,O
III,711,O
),711,O
chains,711,O
and,711,O
is,711,O
expressed,711,O
in,711,O
early,711,O
embryos,711,O
and,711,O
throughout,711,O
embryogenesis,711,O
.,711,O
In,712,O
the,712,O
adult,712,O
",",712,O
type,712,O
III,712,O
collagen,712,O
is,712,O
a,712,O
major,712,O
component,712,O
of,712,O
the,712,O
extracellular,712,O
matrix,712,O
in,712,O
a,712,O
variety,712,O
of,712,O
internal,712,O
organs,712,O
and,712,O
skin,712,O
.,712,O
Mutations,713,O
in,713,O
the,713,O
COL3A1,713,O
gene,713,O
have,713,O
been,713,O
implicated,713,O
as,713,O
a,713,O
cause,713,O
of,713,O
type,713,B-SpecificDisease
IV,713,I-SpecificDisease
Ehlers-Danlos,713,I-SpecificDisease
syndrome,713,I-SpecificDisease
",",713,O
a,713,O
disease,713,O
leading,713,O
to,713,O
aortic,713,B-SpecificDisease
rupture,713,I-SpecificDisease
in,713,O
early,713,O
adult,713,O
life,713,O
.,713,O
To,714,O
directly,714,O
study,714,O
the,714,O
role,714,O
of,714,O
Col3a1,714,O
in,714,O
development,714,O
and,714,O
disease,714,O
",",714,O
we,714,O
have,714,O
inactivated,714,O
the,714,O
Col3a1,714,O
gene,714,O
in,714,O
embryonic,714,O
stem,714,O
cells,714,O
by,714,O
homologous,714,O
recombination,714,O
.,714,O
The,715,O
mutated,715,O
allele,715,O
was,715,O
transmitted,715,O
through,715,O
the,715,O
mouse,715,O
germ,715,O
line,715,O
and,715,O
homozygous,715,O
mutant,715,O
animals,715,O
were,715,O
derived,715,O
from,715,O
heterozygous,715,O
intercrosses,715,O
.,715,O
About,716,O
10,716,O
%,716,O
of,716,O
the,716,O
homozygous,716,O
mutant,716,O
animals,716,O
survived,716,O
to,716,O
adulthood,716,O
but,716,O
have,716,O
a,716,O
much,716,O
shorter,716,O
life,716,O
span,716,O
compared,716,O
with,716,O
wild-type,716,O
mice,716,O
.,716,O
The,717,O
major,717,O
cause,717,O
of,717,O
death,717,O
of,717,O
mutant,717,O
mice,717,O
was,717,O
rupture,717,O
of,717,O
the,717,O
major,717,O
blood,717,O
vessels,717,O
",",717,O
similar,717,O
to,717,O
patients,717,O
with,717,O
type,717,B-SpecificDisease
IV,717,I-SpecificDisease
Ehlers-Danlos,717,I-SpecificDisease
syndrome,717,I-SpecificDisease
.,717,O
Ultrastructural,718,O
analysis,718,O
of,718,O
tissues,718,O
from,718,O
mutant,718,O
mice,718,O
revealed,718,O
that,718,O
type,718,O
III,718,O
collagen,718,O
is,718,O
essential,718,O
for,718,O
normal,718,O
collagen,718,O
I,718,O
fibrillogenesis,718,O
in,718,O
the,718,O
cardiovascular,718,O
system,718,O
and,718,O
other,718,O
organs,718,O
..,718,O
Nonsense,719,O
mutation,719,O
in,719,O
exon,719,O
3,719,O
of,719,O
the,719,O
proteolipid,719,O
protein,719,O
gene,719,O
(,719,O
PLP,719,O
),719,O
in,719,O
a,719,O
family,719,O
with,719,O
an,719,O
unusual,719,O
form,719,O
of,719,O
Pelizaeus-Merzbacher,719,B-SpecificDisease
disease,719,I-SpecificDisease
.,719,O
We,720,O
report,720,O
a,720,O
G,720,O
--,720,O
>,720,O
A,720,O
transition,720,O
at,720,O
nucleotide,720,O
431,720,O
of,720,O
the,720,O
proteolipid,720,O
protein,720,O
gene,720,O
(,720,O
PLP,720,O
),720,O
results,720,O
in,720,O
a,720,O
nonsense,720,O
codon,720,O
in,720,O
a,720,O
family,720,O
with,720,O
an,720,O
unusual,720,O
form,720,O
of,720,O
Pelizaeus-Merzbacher,720,B-SpecificDisease
disease,720,I-SpecificDisease
(,720,O
PMD,720,B-SpecificDisease
),720,O
.,720,O
The,721,O
mutation,721,O
",",721,O
which,721,O
creates,721,O
a,721,O
second,721,O
AluI,721,O
restriction,721,O
site,721,O
",",721,O
results,721,O
in,721,O
a,721,O
nonsense,721,O
mutation,721,O
in,721,O
PLP,721,O
.,721,O
The,722,O
clinical,722,O
picture,722,O
resembles,722,O
somewhat,722,O
that,722,O
of,722,O
X-linked,722,B-SpecificDisease
spastic,722,I-SpecificDisease
paraplegia,722,I-SpecificDisease
(,722,O
SPG,722,B-SpecificDisease
),722,O
.,722,O
It,723,O
differs,723,O
from,723,O
this,723,O
and,723,O
both,723,O
the,723,O
classical,723,O
and,723,O
connatal,723,O
forms,723,O
of,723,O
PMD,723,B-SpecificDisease
in,723,O
that,723,O
it,723,O
is,723,O
relatively,723,O
mild,723,O
in,723,O
form,723,O
",",723,O
onset,723,O
is,723,O
delayed,723,O
beyond,723,O
age,723,O
2,723,O
years,723,O
",",723,O
nystagmus,723,B-DiseaseClass
is,723,O
absent,723,O
",",723,O
tremors,723,B-DiseaseClass
are,723,O
prominent,723,O
",",723,O
mental,723,B-DiseaseClass
retardation,723,I-DiseaseClass
is,723,O
not,723,O
severe,723,O
",",723,O
some,723,O
patients,723,O
show,723,O
dementia,723,B-DiseaseClass
or,723,O
personality,723,B-DiseaseClass
disorders,723,I-DiseaseClass
",",723,O
the,723,O
disease,723,O
is,723,O
progressive,723,O
rather,723,O
than,723,O
static,723,O
in,723,O
some,723,O
",",723,O
and,723,O
several,723,O
females,723,O
show,723,O
signs,723,O
of,723,O
disease,723,O
.,723,O
The,724,O
nonsense,724,O
mutation,724,O
",",724,O
which,724,O
is,724,O
in,724,O
exon,724,O
3B,724,O
",",724,O
should,724,O
block,724,O
the,724,O
synthesis,724,O
of,724,O
normal,724,O
PLP,724,O
but,724,O
spare,724,O
DM20,724,O
",",724,O
the,724,O
isoform,724,O
whose,724,O
persistence,724,O
has,724,O
been,724,O
associated,724,O
with,724,O
mild,724,O
forms,724,O
of,724,O
PLP-associated,724,B-DiseaseClass
disease,724,I-DiseaseClass
in,724,O
both,724,O
humans,724,O
and,724,O
mice,724,O
..,724,O
Common,725,O
BRCA1,725,O
variants,725,O
and,725,O
susceptibility,725,O
to,725,O
breast,725,O
and,725,O
ovarian,725,O
cancer,725,O
in,725,O
the,725,O
general,725,O
population,725,O
.,725,O
Most,726,O
multiple,726,O
case,726,O
families,726,O
of,726,O
young,726,O
onset,726,O
breast,726,B-SpecificDisease
cancer,726,I-SpecificDisease
and,726,O
ovarian,726,B-SpecificDisease
cancer,726,I-SpecificDisease
are,726,O
thought,726,O
to,726,O
be,726,O
due,726,O
to,726,O
highly,726,O
penetrant,726,O
mutations,726,O
in,726,O
the,726,O
predisposing,726,O
genes,726,O
BRCA1,726,O
and,726,O
BRCA2,726,O
.,726,O
However,727,O
",",727,O
these,727,O
mutations,727,O
are,727,O
uncommon,727,O
in,727,O
the,727,O
population,727,O
and,727,O
they,727,O
probably,727,O
account,727,O
for,727,O
only,727,O
a,727,O
few,727,O
percent,727,O
of,727,O
all,727,O
breast,727,B-Modifier
cancer,727,I-Modifier
incidence,727,O
.,727,O
A,728,O
much,728,O
larger,728,O
fraction,728,O
of,728,O
breast,728,B-SpecificDisease
cancer,728,I-SpecificDisease
might,728,O
",",728,O
in,728,O
principle,728,O
",",728,O
be,728,O
due,728,O
to,728,O
common,728,O
variants,728,O
which,728,O
confer,728,O
more,728,O
modest,728,O
individual,728,O
risks,728,O
.,728,O
There,729,O
are,729,O
several,729,O
common,729,O
polymorphisms,729,O
in,729,O
the,729,O
BRCA1,729,O
gene,729,O
which,729,O
generate,729,O
amino,729,O
acid,729,O
substitutions,729,O
.,729,O
We,730,O
have,730,O
examined,730,O
the,730,O
frequency,730,O
of,730,O
four,730,O
of,730,O
these,730,O
polymorphisms,730,O
Gln356Arg,730,O
",",730,O
Pro871Leu,730,O
",",730,O
Glu1038Gly,730,O
and,730,O
Ser1613Gly,730,O
in,730,O
large,730,O
series,730,O
of,730,O
breast,730,O
and,730,O
ovarian,730,O
cancer,730,O
cases,730,O
and,730,O
matched,730,O
controls,730,O
.,730,O
Due,731,O
to,731,O
strong,731,O
linkage,731,O
disequilibrium,731,O
",",731,O
these,731,O
four,731,O
sites,731,O
generate,731,O
only,731,O
three,731,O
haplotypes,731,O
with,731,O
a,731,O
frequency,731,O
>,731,O
1,731,O
.,731,O
3,732,O
%,732,O
.,732,O
The,733,O
most,733,O
common,733,O
haplotypes,733,O
",",733,O
defined,733,O
by,733,O
the,733,O
alleles,733,O
Gln356Pro871Glu1038Ser1613,733,O
and,733,O
Gln356Leu871Gly1038Gly1613,733,O
",",733,O
have,733,O
frequencies,733,O
of,733,O
0,733,O
.,733,O
57,734,O
and,734,O
0,734,O
.,734,O
32,735,O
respectively,735,O
",",735,O
and,735,O
these,735,O
frequencies,735,O
do,735,O
not,735,O
differ,735,O
significantly,735,O
between,735,O
patient,735,O
and,735,O
control,735,O
groups,735,O
.,735,O
Thus,736,O
the,736,O
most,736,O
common,736,O
polymorphisms,736,O
of,736,O
the,736,O
BRCA1,736,O
gene,736,O
do,736,O
not,736,O
make,736,O
a,736,O
significant,736,O
contribution,736,O
to,736,O
breast,736,O
or,736,O
ovarian,736,O
cancer,736,O
risk,736,O
.,736,O
However,737,O
",",737,O
our,737,O
data,737,O
suggest,737,O
that,737,O
the,737,O
Arg356,737,O
allele,737,O
may,737,O
have,737,O
a,737,O
different,737,O
genotype,737,O
distribution,737,O
in,737,O
breast,737,B-Modifier
cancer,737,I-Modifier
patients,737,O
from,737,O
that,737,O
in,737,O
controls,737,O
(,737,O
Arg356,737,O
homozygotes,737,O
are,737,O
more,737,O
frequent,737,O
in,737,O
the,737,O
control,737,O
groups,737,O
",",737,O
P,737,O
=,737,O
0,737,O
.,737,O
01,738,O
),738,O
",",738,O
indicating,738,O
that,738,O
it,738,O
may,738,O
be,738,O
protective,738,O
against,738,O
breast,738,B-SpecificDisease
cancer,738,I-SpecificDisease
.,738,O
If,739,O
this,739,O
finding,739,O
can,739,O
be,739,O
confirmed,739,O
",",739,O
it,739,O
may,739,O
provide,739,O
an,739,O
insight,739,O
into,739,O
the,739,O
structural,739,O
features,739,O
of,739,O
the,739,O
BRCA1,739,O
protein,739,O
that,739,O
are,739,O
important,739,O
for,739,O
its,739,O
function,739,O
.,739,O
Kniest,740,B-SpecificDisease
dysplasia,740,I-SpecificDisease
:,740,O
Dr.,740,O
W.,740,O
Kniest,740,O
",",740,O
his,740,O
patient,740,O
",",740,O
the,740,O
molecular,740,O
defect,740,O
.,740,O
Kniest,741,B-SpecificDisease
dysplasia,741,I-SpecificDisease
is,741,O
a,741,O
severe,741,O
chondrodysplasia,741,B-DiseaseClass
caused,741,O
by,741,O
the,741,O
defective,741,B-DiseaseClass
formation,741,I-DiseaseClass
of,741,I-DiseaseClass
type,741,I-DiseaseClass
II,741,I-DiseaseClass
collagen,741,I-DiseaseClass
.,741,O
We,742,O
report,742,O
about,742,O
Dr.,742,O
Kniest,742,O
",",742,O
who,742,O
first,742,O
described,742,O
the,742,O
condition,742,O
in,742,O
1952,742,O
",",742,O
and,742,O
his,742,O
patient,742,O
",",742,O
who,742,O
",",742,O
at,742,O
the,742,O
age,742,O
of,742,O
50,742,O
years,742,O
is,742,O
severely,742,B-DiseaseClass
handicapped,742,I-DiseaseClass
with,742,O
short,742,B-DiseaseClass
stature,742,I-DiseaseClass
",",742,O
restricted,742,B-DiseaseClass
joint,742,I-DiseaseClass
mobility,742,I-DiseaseClass
",",742,O
and,742,O
blindness,742,B-DiseaseClass
but,742,O
is,742,O
mentally,742,O
alert,742,O
and,742,O
leads,742,O
an,742,O
active,742,O
life,742,O
.,742,O
Molecular,743,O
analysis,743,O
of,743,O
the,743,O
patients,743,O
DNA,743,O
showed,743,O
a,743,O
single,743,O
base,743,O
(,743,O
G,743,O
),743,O
deletion,743,O
involving,743,O
the,743,O
GT,743,O
dinucleotide,743,O
at,743,O
the,743,O
start,743,O
of,743,O
intron,743,O
18,743,O
destroying,743,O
a,743,O
splice,743,O
site,743,O
of,743,O
the,743,O
COL2A1,743,O
gene,743,O
.,743,O
This,744,O
is,744,O
in,744,O
accordance,744,O
with,744,O
molecular,744,O
findings,744,O
in,744,O
other,744,O
patients,744,O
with,744,O
Kniest,744,B-SpecificDisease
dysplasia,744,I-SpecificDisease
and,744,O
confirms,744,O
",",744,O
in,744,O
the,744,O
original,744,O
patient,744,O
",",744,O
that,744,O
the,744,O
disorder,744,O
is,744,O
caused,744,O
by,744,O
small,744,O
inframe,744,O
deletions,744,O
often,744,O
due,744,O
to,744,O
exon,744,O
skipping,744,O
as,744,O
a,744,O
result,744,O
of,744,O
COL2A1,744,O
splice,744,O
site,744,O
mutations,744,O
..,744,O
Cloning,745,O
of,745,O
the,745,O
homogentisate,745,O
"1,2-dioxygenase",745,O
gene,745,O
",",745,O
the,745,O
key,745,O
enzyme,745,O
of,745,O
alkaptonuria,745,B-SpecificDisease
in,745,O
mouse,745,O
.,745,O
We,746,O
determined,746,O
48,746,O
amino,746,O
acid,746,O
residues,746,O
from,746,O
five,746,O
peptides,746,O
from,746,O
the,746,O
homogeneous,746,O
monomer,746,O
of,746,O
homogentisate,746,O
1,746,O
",",746,O
2-dioxygenase,746,O
(,746,O
HGO,746,O
;,746,O
E.,746,O
C.,746,O
1,746,O
.,746,O
13,747,O
.,747,O
11,748,O
.,748,O
15,749,O
),749,O
of,749,O
mouse,749,O
liver,749,O
.,749,O
After,750,O
digestion,750,O
with,750,O
trypsin,750,O
",",750,O
peptides,750,O
were,750,O
separated,750,O
by,750,O
reversed,750,O
phase,750,O
chromatography,750,O
and,750,O
amino,750,O
acid,750,O
sequenced,750,O
.,750,O
The,751,O
deduced,751,O
codon,751,O
sequence,751,O
of,751,O
three,751,O
peptides,751,O
was,751,O
used,751,O
to,751,O
derive,751,O
degenerated,751,O
oligomeres,751,O
.,751,O
By,752,O
combining,752,O
these,752,O
oligos,752,O
",",752,O
we,752,O
were,752,O
able,752,O
to,752,O
amplify,752,O
fragments,752,O
from,752,O
100,752,O
to,752,O
300,752,O
bases,752,O
(,752,O
b,752,O
),752,O
from,752,O
mouse,752,O
liver,752,O
cDNA,752,O
by,752,O
polymerase,752,O
chain,752,O
reaction,752,O
after,752,O
reverse,752,O
transcription,752,O
(,752,O
RT-PCR,752,O
),752,O
.,752,O
A,753,O
fragment,753,O
of,753,O
200,753,O
b,753,O
was,753,O
cloned,753,O
and,753,O
used,753,O
as,753,O
a,753,O
probe,753,O
to,753,O
screen,753,O
a,753,O
mouse,753,O
liver,753,O
cDNA,753,O
library,753,O
.,753,O
One,754,O
clone,754,O
from,754,O
this,754,O
library,754,O
contained,754,O
the,754,O
complete,754,O
cDNA-insert,754,O
for,754,O
HGO,754,O
as,754,O
determined,754,O
by,754,O
sequencing,754,O
.,754,O
The,755,O
cDNA,755,O
encodes,755,O
for,755,O
a,755,O
protein,755,O
of,755,O
50,755,O
kDa,755,O
",",755,O
as,755,O
predicted,755,O
.,755,O
The,756,O
cDNA,756,O
of,756,O
mouse,756,O
HGO,756,O
has,756,O
an,756,O
overall,756,O
identity,756,O
of,756,O
41,756,O
%,756,O
to,756,O
the,756,O
corresponding,756,O
gene,756,O
hmgA,756,O
from,756,O
Aspergillus,756,O
.,756,O
Sequence,757,O
similarities,757,O
to,757,O
human,757,O
expressed,757,O
sequence,757,O
tags,757,O
(,757,O
EST,757,O
),757,O
clones,757,O
ranged,757,O
from,757,O
70,757,O
%,757,O
to,757,O
20,757,O
%,757,O
.,757,O
The,758,O
positions,758,O
of,758,O
122,758,O
conserved,758,O
amino,758,O
acids,758,O
could,758,O
be,758,O
determined,758,O
by,758,O
multiple,758,O
sequence,758,O
alignment,758,O
.,758,O
We,759,O
identified,759,O
one,759,O
first,759,O
intron,759,O
of,759,O
928,759,O
b,759,O
in,759,O
the,759,O
mouse,759,O
gene,759,O
.,759,O
The,760,O
gene,760,O
for,760,O
HGO,760,O
seems,760,O
to,760,O
be,760,O
expressed,760,O
in,760,O
various,760,O
tissues,760,O
",",760,O
as,760,O
shown,760,O
by,760,O
RT-PCR,760,O
on,760,O
different,760,O
cDNAs,760,O
.,760,O
FISH,761,O
experiments,761,O
with,761,O
the,761,O
whole,761,O
murine,761,O
cDNA,761,O
as,761,O
probe,761,O
clearly,761,O
revealed,761,O
signals,761,O
at,761,O
the,761,O
human,761,O
chromosomal,761,O
band,761,O
3q13,761,O
.,761,O
3-q21,762,O
.,762,O
This,763,O
corresponds,763,O
well,763,O
to,763,O
the,763,O
previous,763,O
assignment,763,O
of,763,O
the,763,O
locus,763,O
for,763,O
the,763,O
human,763,O
alkaptonuria,763,B-Modifier
gene,763,O
(,763,O
AKU,763,O
),763,O
to,763,O
the,763,O
same,763,O
chromosomal,763,O
region,763,O
by,763,O
multipoint,763,O
linkage,763,O
analysis,763,O
.,763,O
We,764,O
therefore,764,O
conclude,764,O
that,764,O
the,764,O
HGO,764,O
cDNA,764,O
encodes,764,O
the,764,O
gene,764,O
responsible,764,O
for,764,O
alkaptonuria,764,B-SpecificDisease
.,764,O
PTEN,765,O
",",765,O
a,765,O
putative,765,O
protein,765,O
tyrosine,765,O
phosphatase,765,O
gene,765,O
mutated,765,O
in,765,O
human,765,O
brain,765,O
",",765,O
breast,765,O
",",765,O
and,765,O
prostate,765,O
cancer,765,O
.,765,O
Mapping,766,O
of,766,O
homozygous,766,O
deletions,766,O
on,766,O
human,766,O
chromosome,766,O
10q23,766,O
has,766,O
led,766,O
to,766,O
the,766,O
isolation,766,O
of,766,O
a,766,O
candidate,766,O
tumor,766,B-Modifier
suppressor,766,O
gene,766,O
",",766,O
PTEN,766,O
",",766,O
that,766,O
appears,766,O
to,766,O
be,766,O
mutated,766,O
at,766,O
considerable,766,O
frequency,766,O
in,766,O
human,766,O
cancers,766,B-DiseaseClass
.,766,O
In,767,O
preliminary,767,O
screens,767,O
",",767,O
mutations,767,O
of,767,O
PTEN,767,O
were,767,O
detected,767,O
in,767,O
31,767,O
%,767,O
(,767,O
13/42,767,O
),767,O
of,767,O
glioblastoma,767,B-Modifier
cell,767,O
lines,767,O
and,767,O
xenografts,767,O
",",767,O
100,767,O
%,767,O
(,767,O
4/4,767,O
),767,O
of,767,O
prostate,767,B-Modifier
cancer,767,I-Modifier
cell,767,O
lines,767,O
",",767,O
6,767,O
%,767,O
(,767,O
4/65,767,O
),767,O
of,767,O
breast,767,B-Modifier
cancer,767,I-Modifier
cell,767,O
lines,767,O
and,767,O
xenografts,767,O
",",767,O
and,767,O
17,767,O
%,767,O
(,767,O
3/18,767,O
),767,O
of,767,O
primary,767,B-SpecificDisease
glioblastomas,767,I-SpecificDisease
.,767,O
The,768,O
predicted,768,O
PTEN,768,O
product,768,O
has,768,O
a,768,O
protein,768,O
tyrosine,768,O
phosphatase,768,O
domain,768,O
and,768,O
extensive,768,O
homology,768,O
to,768,O
tensin,768,O
",",768,O
a,768,O
protein,768,O
that,768,O
interacts,768,O
with,768,O
actin,768,O
filaments,768,O
at,768,O
focal,768,O
adhesions,768,O
.,768,O
These,769,O
homologies,769,O
suggest,769,O
that,769,O
PTEN,769,O
may,769,O
suppress,769,O
tumor,769,B-Modifier
cell,769,O
growth,769,O
by,769,O
antagonizing,769,O
protein,769,O
tyrosine,769,O
kinases,769,O
and,769,O
may,769,O
regulate,769,O
tumor,769,B-Modifier
cell,769,O
invasion,769,O
and,769,O
metastasis,769,B-DiseaseClass
through,769,O
interactions,769,O
at,769,O
focal,769,O
adhesions,769,O
..,769,O
Heterogeneity,770,O
in,770,O
Schwartz-Jampel,770,B-SpecificDisease
chondrodystrophic,770,I-SpecificDisease
myotonia,770,I-SpecificDisease
.,770,O
The,771,O
Schwartz-Jampel,771,B-SpecificDisease
syndrome,771,I-SpecificDisease
(,771,O
SJS,771,B-SpecificDisease
;,771,O
chondrodystrophic,771,B-SpecificDisease
myotonia,771,I-SpecificDisease
;,771,O
McK,771,O
255,771,O
",",771,O
800,771,O
),771,O
is,771,O
a,771,O
recessively,771,B-DiseaseClass
inherited,771,I-DiseaseClass
condition,771,I-DiseaseClass
defined,771,O
by,771,O
myotonia,771,B-DiseaseClass
",",771,O
short,771,B-DiseaseClass
stature,771,I-DiseaseClass
",",771,O
and,771,O
bone,771,B-DiseaseClass
dysplasia,771,I-DiseaseClass
.,771,O
Genetic,772,O
linkage,772,O
between,772,O
SJS,772,B-SpecificDisease
and,772,O
chromosomal,772,O
region,772,O
1q36-34,772,O
has,772,O
been,772,O
observed,772,O
in,772,O
several,772,O
families,772,O
",",772,O
but,772,O
the,772,O
gene,772,O
has,772,O
not,772,O
yet,772,O
been,772,O
identified,772,O
.,772,O
We,773,O
studied,773,O
the,773,O
clinical,773,O
and,773,O
radiological,773,O
features,773,O
in,773,O
81,773,O
patients,773,O
from,773,O
the,773,O
literature,773,O
and,773,O
5,773,O
own,773,O
patients,773,O
trying,773,O
to,773,O
identify,773,O
distinct,773,O
subgroups,773,O
.,773,O
In,774,O
addition,774,O
",",774,O
we,774,O
tested,774,O
genetic,774,O
linkage,774,O
to,774,O
the,774,O
SJS,774,B-Modifier
locus,774,O
on,774,O
chromosome,774,O
1,774,O
in,774,O
one,774,O
family,774,O
with,774,O
two,774,O
affected,774,O
sibs,774,O
.,774,O
We,775,O
found,775,O
that,775,O
a,775,O
group,775,O
of,775,O
patients,775,O
have,775,O
mild,775,O
skeletal,775,O
changes,775,O
which,775,O
may,775,O
be,775,O
secondary,775,O
consequences,775,O
of,775,O
myotonia,775,B-DiseaseClass
",",775,O
while,775,O
another,775,O
group,775,O
of,775,O
patients,775,O
appear,775,O
to,775,O
have,775,O
primary,775,O
bone,775,B-DiseaseClass
dysplasia,775,I-DiseaseClass
with,775,O
myotonia,775,B-DiseaseClass
.,775,O
Within,776,O
this,776,O
latter,776,O
group,776,O
",",776,O
there,776,O
are,776,O
differences,776,O
in,776,O
age,776,O
of,776,O
manifestation,776,O
",",776,O
clinical,776,O
course,776,O
and,776,O
pattern,776,O
of,776,O
bone,776,O
changes,776,O
.,776,O
We,777,O
tentatively,777,O
isolate,777,O
three,777,O
different,777,O
types,777,O
of,777,O
SJS,777,B-SpecificDisease
type,777,I-SpecificDisease
1A,777,I-SpecificDisease
",",777,O
usually,777,O
recognized,777,O
in,777,O
childhood,777,O
",",777,O
with,777,O
moderate,777,O
bone,777,B-DiseaseClass
dysplasia,777,I-DiseaseClass
",",777,O
corresponding,777,O
to,777,O
the,777,O
original,777,O
descriptions,777,O
of,777,O
Schwartz,777,O
",",777,O
Jampel,777,O
and,777,O
Aberfeld,777,O
;,777,O
type,777,O
1B,777,O
",",777,O
similar,777,O
to,777,O
type,777,O
1A,777,O
but,777,O
recognizable,777,O
at,777,O
birth,777,O
",",777,O
with,777,O
more,777,O
pronounced,777,O
bone,777,B-DiseaseClass
dysplasia,777,I-DiseaseClass
resembling,777,O
Kniest,777,B-SpecificDisease
dysplasia,777,I-SpecificDisease
;,777,O
and,777,O
type,777,O
2,777,O
",",777,O
manifest,777,O
at,777,O
birth,777,O
",",777,O
with,777,O
increased,777,O
mortality,777,O
and,777,O
bone,777,B-DiseaseClass
dysplasia,777,I-DiseaseClass
resembling,777,O
Pyle,777,B-SpecificDisease
disease,777,I-SpecificDisease
.,777,O
Genetic,778,O
analysis,778,O
of,778,O
the,778,O
family,778,O
with,778,O
two,778,O
sibs,778,O
affected,778,O
by,778,O
SJS,778,B-SpecificDisease
type,778,I-SpecificDisease
2,778,I-SpecificDisease
showed,778,O
evidence,778,O
against,778,O
linkage,778,O
to,778,O
chromosome,778,O
1p36-34,778,O
.,778,O
CONCLUSIONS,779,O
SJS,779,B-SpecificDisease
is,779,O
clinically,779,O
and,779,O
radiologically,779,O
heterogeneous,779,O
.,779,O
The,780,O
causes,780,O
of,780,O
heterogeneity,780,O
are,780,O
not,780,O
known,780,O
yet,780,O
but,780,O
are,780,O
likely,780,O
to,780,O
include,780,O
both,780,O
different,780,O
mutations,780,O
at,780,O
the,780,O
SJS,780,B-Modifier
locus,780,O
on,780,O
chromosome,780,O
1,780,O
and,780,O
the,780,O
presence,780,O
of,780,O
a,780,O
second,780,O
SJS,780,B-Modifier
locus,780,O
.,780,O
A,781,O
tentative,781,O
clinico-radiological,781,O
classification,781,O
can,781,O
be,781,O
useful,781,O
for,781,O
the,781,O
characterization,781,O
of,781,O
patients,781,O
and,781,O
the,781,O
development,781,O
of,781,O
genotype-phenotype,781,O
correlations,781,O
..,781,O
A,782,O
clinical,782,O
overview,782,O
of,782,O
WT1,782,O
gene,782,O
mutations,782,O
.,782,O
Mutations,783,O
in,783,O
the,783,O
WT1,783,O
gene,783,O
were,783,O
anticipated,783,O
to,783,O
explain,783,O
the,783,O
genetic,783,O
basis,783,O
of,783,O
the,783,O
childhood,783,O
kidney,783,B-SpecificDisease
cancer,783,I-SpecificDisease
",",783,O
Wilms,783,B-SpecificDisease
tumour,783,I-SpecificDisease
(,783,O
WT,783,B-SpecificDisease
),783,O
.,783,O
Six,784,O
years,784,O
on,784,O
",",784,O
we,784,O
review,784,O
100,784,O
reports,784,O
of,784,O
intragenic,784,O
WT1,784,O
mutations,784,O
and,784,O
examine,784,O
the,784,O
accompanying,784,O
clinical,784,O
phenotypes,784,O
.,784,O
While,785,O
only,785,O
5,785,O
%,785,O
of,785,O
sporadic,785,B-SpecificDisease
Wilms,785,I-SpecificDisease
tumours,785,I-SpecificDisease
have,785,O
intragenic,785,O
WT1,785,O
mutations,785,O
",",785,O
>,785,O
90,785,O
%,785,O
of,785,O
patients,785,O
with,785,O
the,785,O
Denys-Drash,785,B-SpecificDisease
syndrome,785,I-SpecificDisease
(,785,O
renal,785,B-DiseaseClass
nephropathy,785,I-DiseaseClass
",",785,O
gonadal,785,B-DiseaseClass
anomaly,785,I-DiseaseClass
",",785,O
predisposition,785,B-DiseaseClass
to,785,I-DiseaseClass
WT,785,I-DiseaseClass
),785,O
carry,785,O
constitutional,785,O
intragenic,785,O
WT1,785,O
mutations,785,O
.,785,O
WT1,786,O
mutations,786,O
have,786,O
also,786,O
been,786,O
reported,786,O
in,786,O
juvenile,786,B-SpecificDisease
granulosa,786,I-SpecificDisease
cell,786,I-SpecificDisease
tumour,786,I-SpecificDisease
",",786,O
non-asbestos,786,B-SpecificDisease
related,786,I-SpecificDisease
mesothelioma,786,I-SpecificDisease
",",786,O
desmoplastic,786,B-SpecificDisease
small,786,I-SpecificDisease
round,786,I-SpecificDisease
cell,786,I-SpecificDisease
tumour,786,I-SpecificDisease
and,786,O
",",786,O
most,786,O
recently,786,O
",",786,O
acute,786,B-SpecificDisease
myeloid,786,I-SpecificDisease
leukemia,786,I-SpecificDisease
..,786,O
A,787,O
mutation,787,O
in,787,O
autosomal,787,B-SpecificDisease
dominant,787,I-SpecificDisease
myotonia,787,I-SpecificDisease
congenita,787,I-SpecificDisease
affects,787,O
pore,787,O
properties,787,O
of,787,O
the,787,O
muscle,787,O
chloride,787,O
channel,787,O
.,787,O
Autosomal,788,B-SpecificDisease
dominant,788,I-SpecificDisease
myotonia,788,I-SpecificDisease
congenita,788,I-SpecificDisease
is,788,O
an,788,O
inherited,788,B-DiseaseClass
disorder,788,I-DiseaseClass
of,788,I-DiseaseClass
skeletal,788,I-DiseaseClass
muscle,788,I-DiseaseClass
caused,788,O
by,788,O
mutations,788,O
in,788,O
a,788,O
voltage-gated,788,O
Cl-,788,O
channel,788,O
gene,788,O
(,788,O
CLCN1,788,O
",",788,O
7q35,788,O
),788,O
.,788,O
Here,789,O
",",789,O
we,789,O
report,789,O
that,789,O
a,789,O
mutation,789,O
predicting,789,O
the,789,O
substitution,789,O
of,789,O
Gly,789,O
230,789,O
by,789,O
glutamic,789,O
acid,789,O
(,789,O
G230E,789,O
),789,O
between,789,O
segments,789,O
D3,789,O
and,789,O
D4,789,O
dramatically,789,O
alters,789,O
the,789,O
pore,789,O
properties,789,O
of,789,O
a,789,O
recombinant,789,O
human,789,O
muscle,789,O
Cl-,789,O
channel,789,O
(,789,O
hCIC-1,789,O
),789,O
expressed,789,O
in,789,O
a,789,O
mammalian,789,O
cell,789,O
line,789,O
(,789,O
tsA201,789,O
),789,O
.,789,O
The,790,O
G230E,790,O
mutation,790,O
causes,790,O
substantial,790,O
changes,790,O
in,790,O
anion,790,O
and,790,O
cation,790,O
selectivity,790,O
as,790,O
well,790,O
as,790,O
a,790,O
fundamental,790,O
change,790,O
in,790,O
rectification,790,O
of,790,O
the,790,O
current-voltage,790,O
relationship,790,O
.,790,O
Whereas,791,O
wild-type,791,O
channels,791,O
are,791,O
characterized,791,O
by,791,O
pronounced,791,O
inward,791,O
rectification,791,O
and,791,O
a,791,O
Cl,791,O
>,791,O
thiocyanate,791,O
>,791,O
Br,791,O
>,791,O
NO,791,O
(,791,O
3,791,O
),791,O
>,791,O
I,791,O
>,791,O
CH,791,O
(,791,O
3,791,O
),791,O
SO,791,O
(,791,O
3,791,O
),791,O
selectivity,791,O
",",791,O
G230E,791,O
exhibits,791,O
outward,791,O
rectification,791,O
at,791,O
positive,791,O
potentials,791,O
and,791,O
a,791,O
thiocyanate,791,O
>,791,O
NO,791,O
(,791,O
3,791,O
),791,O
>,791,O
I,791,O
>,791,O
Br,791,O
>,791,O
Cl,791,O
>,791,O
CH,791,O
(,791,O
3,791,O
),791,O
SO,791,O
(,791,O
3,791,O
),791,O
selectivity,791,O
.,791,O
Furthermore,792,O
",",792,O
the,792,O
cation-to-anion,792,O
permeability,792,O
ratio,792,O
of,792,O
the,792,O
mutant,792,O
is,792,O
much,792,O
greater,792,O
than,792,O
that,792,O
of,792,O
the,792,O
wild-type,792,O
channel,792,O
.,792,O
Voltage-dependent,793,O
blocks,793,O
by,793,O
intracellular,793,O
and,793,O
extracellular,793,O
iodide,793,O
help,793,O
to,793,O
distinguish,793,O
two,793,O
distinct,793,O
ion,793,O
binding,793,O
sites,793,O
within,793,O
the,793,O
hClC-1,793,O
conduction,793,O
pathway,793,O
.,793,O
Both,794,O
binding,794,O
sites,794,O
are,794,O
preserved,794,O
in,794,O
the,794,O
mutant,794,O
but,794,O
have,794,O
decreased,794,O
affinities,794,O
for,794,O
iodide,794,O
.,794,O
These,795,O
findings,795,O
suggest,795,O
that,795,O
Gly,795,O
230,795,O
is,795,O
critical,795,O
for,795,O
normal,795,O
ion,795,O
conductance,795,O
in,795,O
hClC-1,795,O
and,795,O
that,795,O
this,795,O
residue,795,O
resides,795,O
within,795,O
the,795,O
channel,795,O
pore,795,O
..,795,O
The,796,O
incidence,796,O
of,796,O
PAX6,796,O
mutation,796,O
in,796,O
patients,796,O
with,796,O
simple,796,O
aniridia,796,B-SpecificDisease
:,796,O
an,796,O
evaluation,796,O
of,796,O
mutation,796,O
detection,796,O
in,796,O
12,796,O
cases,796,O
.,796,O
Twelve,797,O
aniridia,797,B-Modifier
patients,797,O
",",797,O
five,797,O
with,797,O
a,797,O
family,797,O
history,797,O
and,797,O
seven,797,O
presumed,797,O
to,797,O
be,797,O
sporadic,797,O
",",797,O
were,797,O
exhaustively,797,O
screened,797,O
in,797,O
order,797,O
to,797,O
test,797,O
what,797,O
proportion,797,O
of,797,O
people,797,O
with,797,O
aniridia,797,B-SpecificDisease
",",797,O
uncomplicated,797,O
by,797,O
associated,797,O
anomalies,797,O
",",797,O
carry,797,O
mutations,797,O
in,797,O
the,797,O
human,797,O
PAX6,797,O
gene,797,O
.,797,O
Mutations,798,O
were,798,O
detected,798,O
in,798,O
90,798,O
%,798,O
of,798,O
the,798,O
cases,798,O
.,798,O
Three,799,O
mutation,799,O
detection,799,O
techniques,799,O
were,799,O
used,799,O
to,799,O
determine,799,O
if,799,O
one,799,O
method,799,O
was,799,O
superior,799,O
for,799,O
this,799,O
gene,799,O
.,799,O
The,800,O
protein,800,O
truncation,800,O
test,800,O
(,800,O
PTT,800,O
),800,O
was,800,O
used,800,O
on,800,O
RT-PCR,800,O
products,800,O
",",800,O
SSCP,800,O
on,800,O
genomic,800,O
PCR,800,O
amplifications,800,O
",",800,O
and,800,O
chemical,800,O
cleavage,800,O
of,800,O
mismatch,800,O
on,800,O
both,800,O
RT-PCR,800,O
and,800,O
genomic,800,O
amplifications,800,O
.,800,O
For,801,O
RT-PCR,801,O
products,801,O
",",801,O
only,801,O
the,801,O
translated,801,O
portion,801,O
of,801,O
the,801,O
gene,801,O
was,801,O
screened,801,O
.,801,O
On,802,O
genomic,802,O
products,802,O
exons,802,O
1,802,O
to,802,O
13,802,O
(,802,O
including,802,O
740,802,O
bp,802,O
of,802,O
the,802,O
3,802,O
untranslated,802,O
sequence,802,O
and,802,O
all,802,O
intron/exon,802,O
boundaries,802,O
),802,O
were,802,O
screened,802,O
",",802,O
as,802,O
was,802,O
a,802,O
neuroretina,802,O
specific,802,O
enhancer,802,O
in,802,O
intron,802,O
4,802,O
.,802,O
Ten,803,O
of,803,O
the,803,O
possible,803,O
12,803,O
mutations,803,O
in,803,O
the,803,O
five,803,O
familial,803,O
cases,803,O
and,803,O
five,803,O
of,803,O
the,803,O
sporadic,803,O
patients,803,O
were,803,O
found,803,O
",",803,O
all,803,O
of,803,O
which,803,O
conformed,803,O
to,803,O
a,803,O
functional,803,O
outcome,803,O
of,803,O
haploinsufficiency,803,O
.,803,O
Five,804,O
were,804,O
splice,804,O
site,804,O
mutations,804,O
(,804,O
one,804,O
in,804,O
the,804,O
donor,804,O
site,804,O
of,804,O
intron,804,O
4,804,O
",",804,O
two,804,O
in,804,O
the,804,O
donor,804,O
site,804,O
of,804,O
intron,804,O
6,804,O
",",804,O
one,804,O
in,804,O
each,804,O
of,804,O
the,804,O
acceptor,804,O
sites,804,O
of,804,O
introns,804,O
8,804,O
and,804,O
9,804,O
),804,O
and,804,O
five,804,O
were,804,O
nonsense,804,O
mutations,804,O
in,804,O
exons,804,O
8,804,O
",",804,O
9,804,O
",",804,O
10,804,O
",",804,O
11,804,O
",",804,O
and,804,O
12,804,O
.,804,O
SSCP,805,O
analysis,805,O
of,805,O
individually,805,O
amplified,805,O
exons,805,O
",",805,O
with,805,O
which,805,O
nine,805,O
of,805,O
the,805,O
10,805,O
mutations,805,O
were,805,O
seen,805,O
",",805,O
was,805,O
the,805,O
most,805,O
useful,805,O
detection,805,O
method,805,O
for,805,O
PAX6,805,O
..,805,O
Insulin,806,O
gene,806,O
region,806,O
contributes,806,O
to,806,O
genetic,806,O
susceptibility,806,O
to,806,O
",",806,O
but,806,O
may,806,O
not,806,O
to,806,O
low,806,O
incidence,806,O
of,806,O
",",806,O
insulin-dependent,806,B-SpecificDisease
diabetes,806,I-SpecificDisease
mellitus,806,I-SpecificDisease
in,806,O
Japanese,806,O
.,806,O
In,807,O
the,807,O
Caucasian,807,O
population,807,O
",",807,O
it,807,O
has,807,O
been,807,O
demonstrated,807,O
that,807,O
the,807,O
insulin,807,O
gene,807,O
(,807,O
INS,807,O
),807,O
region,807,O
contains,807,O
the,807,O
insulin-dependent,807,B-Modifier
diabetes,807,I-Modifier
mellitus,807,I-Modifier
locus,807,O
(,807,O
IDDM2,807,O
),807,O
.,807,O
In,808,O
the,808,O
Japanese,808,O
population,808,O
",",808,O
however,808,O
",",808,O
there,808,O
has,808,O
been,808,O
no,808,O
report,808,O
demonstrating,808,O
the,808,O
contribution,808,O
of,808,O
IDDM2,808,O
to,808,O
the,808,O
pathogenesis,808,O
of,808,O
IDDM,808,B-SpecificDisease
.,808,O
We,809,O
conducted,809,O
an,809,O
association,809,O
study,809,O
of,809,O
IDDM,809,B-SpecificDisease
in,809,O
a,809,O
large,809,O
number,809,O
of,809,O
Japanese,809,O
subjects,809,O
with,809,O
multiple,809,O
polymorphisms,809,O
in,809,O
INS,809,O
region,809,O
.,809,O
We,810,O
found,810,O
a,810,O
significant,810,O
association,810,O
of,810,O
the,810,O
INS,810,O
region,810,O
with,810,O
IDDM,810,B-SpecificDisease
.,810,O
Alleles,811,O
positively,811,O
associated,811,O
with,811,O
IDDM,811,B-SpecificDisease
in,811,O
INS,811,O
region,811,O
were,811,O
the,811,O
same,811,O
as,811,O
those,811,O
positively-associated,811,O
with,811,O
IDDM,811,B-SpecificDisease
in,811,O
Caucasian,811,O
population,811,O
",",811,O
although,811,O
positively-associated,811,O
alleles,811,O
are,811,O
very,811,O
common,811,O
(,811,O
allele,811,O
frequencies,811,O
>,811,O
0,811,O
.,811,O
9,812,O
),812,O
in,812,O
the,812,O
Japanese,812,O
general,812,O
population,812,O
.,812,O
These,813,O
data,813,O
suggest,813,O
that,813,O
IDDM2,813,O
is,813,O
involved,813,O
in,813,O
the,813,O
genetic,813,O
susceptibility,813,O
to,813,O
IDDM,813,B-SpecificDisease
in,813,O
Japanese,813,O
.,813,O
The,814,O
high,814,O
frequencies,814,O
of,814,O
disease-associated,814,O
alleles,814,O
in,814,O
the,814,O
general,814,O
population,814,O
suggest,814,O
that,814,O
IDDM2,814,O
locus,814,O
is,814,O
not,814,O
responsible,814,O
for,814,O
the,814,O
low,814,O
incidence,814,O
of,814,O
IDDM,814,B-SpecificDisease
in,814,O
Japanese,814,O
.,814,O
The,815,O
human,815,O
complement,815,O
C9,815,O
gene,815,O
:,815,O
identification,815,O
of,815,O
two,815,O
mutations,815,O
causing,815,O
deficiency,815,O
and,815,O
revision,815,O
of,815,O
the,815,O
gene,815,O
structure,815,O
.,815,O
The,816,O
ninth,816,O
component,816,O
of,816,O
human,816,O
complement,816,O
(,816,O
C9,816,O
),816,O
is,816,O
the,816,O
last,816,O
of,816,O
the,816,O
terminal,816,O
complement,816,O
components,816,O
creating,816,O
the,816,O
membrane,816,O
attack,816,O
complex,816,O
.,816,O
C9,817,O
is,817,O
a,817,O
single-chain,817,O
serum,817,O
protein,817,O
that,817,O
is,817,O
encoded,817,O
by,817,O
a,817,O
gene,817,O
located,817,O
on,817,O
chromosome,817,O
5p,817,O
.,817,O
Deficiency,818,B-SpecificDisease
of,818,I-SpecificDisease
terminal,818,I-SpecificDisease
complement,818,I-SpecificDisease
components,818,I-SpecificDisease
is,818,O
generally,818,O
associated,818,O
with,818,O
recurrent,818,O
neisseria,818,B-SpecificDisease
infections,818,I-SpecificDisease
.,818,O
We,819,O
studied,819,O
a,819,O
previously,819,O
described,819,O
Swiss,819,O
family,819,O
with,819,O
inherited,819,B-SpecificDisease
C9,819,I-SpecificDisease
deficiency,819,I-SpecificDisease
.,819,O
To,820,O
identify,820,O
the,820,O
genetic,820,O
basis,820,O
of,820,O
C9,820,B-SpecificDisease
deficiency,820,I-SpecificDisease
",",820,O
we,820,O
developed,820,O
an,820,O
approach,820,O
using,820,O
exon-specific,820,O
PCR,820,O
and,820,O
direct,820,O
DNA,820,O
sequencing,820,O
.,820,O
As,821,O
a,821,O
cause,821,O
of,821,O
C9,821,B-SpecificDisease
deficiency,821,I-SpecificDisease
",",821,O
we,821,O
found,821,O
two,821,O
different,821,O
point,821,O
mutations,821,O
",",821,O
both,821,O
generating,821,O
TGA,821,O
stop,821,O
codons,821,O
in,821,O
the,821,O
coding,821,O
sequence,821,O
.,821,O
One,822,O
mutation,822,O
",",822,O
a,822,O
C,822,O
to,822,O
A,822,O
exchange,822,O
",",822,O
was,822,O
detected,822,O
in,822,O
exon,822,O
2,822,O
at,822,O
cDNA,822,O
position,822,O
166,822,O
",",822,O
the,822,O
other,822,O
",",822,O
a,822,O
C,822,O
to,822,O
T,822,O
exchange,822,O
",",822,O
was,822,O
located,822,O
in,822,O
exon,822,O
4,822,O
(,822,O
cDNA,822,O
position,822,O
464,822,O
),822,O
.,822,O
In,823,O
family,823,O
studies,823,O
of,823,O
three,823,O
first-degree,823,O
relatives,823,O
with,823,O
heterozygous,823,O
C9,823,B-SpecificDisease
deficiency,823,I-SpecificDisease
",",823,O
we,823,O
demonstrated,823,O
that,823,O
the,823,O
two,823,O
mutations,823,O
are,823,O
segregating,823,O
independently,823,O
.,823,O
Therefore,824,O
",",824,O
these,824,O
mutations,824,O
are,824,O
sufficient,824,O
to,824,O
explain,824,O
the,824,O
complete,824,O
deficiency,824,O
of,824,O
both,824,O
the,824,O
probands,824,O
studied,824,O
.,824,O
DNA,825,O
sequencing,825,O
of,825,O
the,825,O
exon-intron,825,O
junctions,825,O
revealed,825,O
a,825,O
number,825,O
of,825,O
revisions,825,O
regarding,825,O
the,825,O
boundaries,825,O
between,825,O
exons,825,O
4,825,O
",",825,O
5,825,O
",",825,O
and,825,O
6,825,O
as,825,O
well,825,O
as,825,O
between,825,O
exons,825,O
10,825,O
and,825,O
11,825,O
.,825,O
No,826,O
additional,826,O
introns,826,O
were,826,O
detected,826,O
in,826,O
exons,826,O
6,826,O
and,826,O
10,826,O
.,826,O
Furthermore,827,O
",",827,O
DNA,827,O
marker,827,O
studies,827,O
were,827,O
conducted,827,O
using,827,O
known,827,O
polymorphisms,827,O
of,827,O
the,827,O
C6,827,O
",",827,O
C7,827,O
",",827,O
and,827,O
C9,827,O
genes,827,O
",",827,O
confirming,827,O
the,827,O
linkage,827,O
of,827,O
the,827,O
observed,827,O
C9,827,O
mutations,827,O
with,827,O
defined,827,O
haplotypes,827,O
..,827,O
BRCA1,828,O
mutations,828,O
in,828,O
women,828,O
attending,828,O
clinics,828,O
that,828,O
evaluate,828,O
the,828,O
risk,828,O
of,828,O
breast,828,B-SpecificDisease
cancer,828,I-SpecificDisease
.,828,O
BACKGROUND,829,O
To,829,O
define,829,O
the,829,O
incidence,829,O
of,829,O
BRCA1,829,O
mutations,829,O
among,829,O
patients,829,O
seen,829,O
in,829,O
clinics,829,O
that,829,O
evaluate,829,O
the,829,O
risk,829,O
of,829,O
breast,829,B-SpecificDisease
cancer,829,I-SpecificDisease
",",829,O
we,829,O
analyzed,829,O
DNA,829,O
samples,829,O
from,829,O
women,829,O
seen,829,O
in,829,O
this,829,O
setting,829,O
and,829,O
constructed,829,O
probability,829,O
tables,829,O
to,829,O
provide,829,O
estimates,829,O
of,829,O
the,829,O
likelihood,829,O
of,829,O
finding,829,O
a,829,O
BRCA1,829,O
mutation,829,O
in,829,O
individual,829,O
families,829,O
.,829,O
METHODS,830,O
Clinical,830,O
information,830,O
",",830,O
family,830,O
histories,830,O
",",830,O
and,830,O
blood,830,O
for,830,O
DNA,830,O
analysis,830,O
were,830,O
obtained,830,O
from,830,O
263,830,O
women,830,O
with,830,O
breast,830,B-SpecificDisease
cancer,830,I-SpecificDisease
.,830,O
Conformation-sensitive,831,O
gel,831,O
electrophoresis,831,O
and,831,O
DNA,831,O
sequencing,831,O
were,831,O
used,831,O
to,831,O
identify,831,O
BRCA1,831,O
mutations,831,O
.,831,O
RESULTS,832,O
BRCA1,832,O
mutations,832,O
were,832,O
identified,832,O
in,832,O
16,832,O
percent,832,O
of,832,O
women,832,O
with,832,O
a,832,O
family,832,O
history,832,O
of,832,O
breast,832,B-SpecificDisease
cancer,832,I-SpecificDisease
.,832,O
Only,833,O
7,833,O
percent,833,O
of,833,O
women,833,O
from,833,O
families,833,O
with,833,O
a,833,O
history,833,O
of,833,O
breast,833,B-SpecificDisease
cancer,833,I-SpecificDisease
but,833,O
not,833,O
ovarian,833,B-SpecificDisease
cancer,833,I-SpecificDisease
had,833,O
BRCA1,833,O
mutations,833,O
.,833,O
The,834,O
rates,834,O
were,834,O
higher,834,O
among,834,O
women,834,O
from,834,O
families,834,O
with,834,O
a,834,O
history,834,O
of,834,O
both,834,O
breast,834,O
and,834,O
ovarian,834,O
cancer,834,O
.,834,O
Among,835,O
family,835,O
members,835,O
",",835,O
an,835,O
average,835,O
age,835,O
of,835,O
less,835,O
than,835,O
55,835,O
years,835,O
at,835,O
the,835,O
diagnosis,835,O
of,835,O
breast,835,B-SpecificDisease
cancer,835,I-SpecificDisease
",",835,O
the,835,O
presence,835,O
of,835,O
ovarian,835,B-SpecificDisease
cancer,835,I-SpecificDisease
",",835,O
the,835,O
presence,835,O
of,835,O
breast,835,O
and,835,O
ovarian,835,O
cancer,835,O
in,835,O
the,835,O
same,835,O
woman,835,O
",",835,O
and,835,O
Ashkenazi,835,O
Jewish,835,O
ancestry,835,O
were,835,O
all,835,O
associated,835,O
with,835,O
an,835,O
increased,835,O
risk,835,O
of,835,O
detecting,835,O
a,835,O
BRCA1,835,O
mutation,835,O
.,835,O
No,836,O
association,836,O
was,836,O
found,836,O
between,836,O
the,836,O
presence,836,O
of,836,O
bilateral,836,O
breast,836,B-SpecificDisease
cancer,836,I-SpecificDisease
or,836,O
the,836,O
number,836,O
of,836,O
breast,836,B-SpecificDisease
cancers,836,I-SpecificDisease
in,836,O
a,836,O
family,836,O
and,836,O
the,836,O
detection,836,O
of,836,O
a,836,O
BRCA1,836,O
mutation,836,O
",",836,O
or,836,O
between,836,O
the,836,O
position,836,O
of,836,O
the,836,O
mutation,836,O
in,836,O
the,836,O
BRCA1,836,O
gene,836,O
and,836,O
the,836,O
presence,836,O
of,836,O
ovarian,836,B-SpecificDisease
cancer,836,I-SpecificDisease
in,836,O
a,836,O
family,836,O
.,836,O
CONCLUSIONS,837,O
Among,837,O
women,837,O
with,837,O
breast,837,B-SpecificDisease
cancer,837,I-SpecificDisease
and,837,O
a,837,O
family,837,O
history,837,O
of,837,O
the,837,O
disease,837,O
",",837,O
the,837,O
percentage,837,O
with,837,O
BRCA1,837,O
coding-region,837,O
mutations,837,O
is,837,O
less,837,O
than,837,O
the,837,O
45,837,O
percent,837,O
predicted,837,O
by,837,O
genetic-linkage,837,O
analysis,837,O
.,837,O
These,838,O
results,838,O
suggest,838,O
that,838,O
even,838,O
in,838,O
a,838,O
referral,838,O
clinic,838,O
specializing,838,O
in,838,O
screening,838,O
women,838,O
from,838,O
high-risk,838,O
families,838,O
",",838,O
the,838,O
majority,838,O
of,838,O
tests,838,O
for,838,O
BRCA1,838,O
mutations,838,O
will,838,O
be,838,O
negative,838,O
and,838,O
therefore,838,O
uninformative,838,O
..,838,O
Mutations,839,O
in,839,O
the,839,O
arginine-rich,839,O
protein,839,O
gene,839,O
(,839,O
ARP,839,O
),839,O
in,839,O
pancreatic,839,B-SpecificDisease
cancer,839,I-SpecificDisease
.,839,O
The,840,O
ARP,840,O
gene,840,O
encodes,840,O
a,840,O
highly,840,O
conserved,840,O
arginine-rich,840,O
protein,840,O
from,840,O
chromosomal,840,O
band,840,O
3p21,840,O
.,840,O
1,841,O
1,841,O
.,841,O
At,842,O
the,842,O
cytogenetic,842,O
level,842,O
this,842,O
region,842,O
is,842,O
frequently,842,O
deleted,842,O
in,842,O
a,842,O
variety,842,O
of,842,O
different,842,O
solid,842,B-DiseaseClass
tumors,842,I-DiseaseClass
",",842,O
although,842,O
not,842,O
in,842,O
pancreatic,842,B-SpecificDisease
cancer,842,I-SpecificDisease
.,842,O
We,843,O
have,843,O
reported,843,O
the,843,O
presence,843,O
of,843,O
a,843,O
specific,843,O
mutation,843,O
(,843,O
ATG50,843,O
--,843,O
>,843,O
AGG,843,O
),843,O
or,843,O
deletion,843,O
of,843,O
codon,843,O
50,843,O
of,843,O
the,843,O
ARP,843,O
gene,843,O
in,843,O
different,843,O
tumor,843,B-DiseaseClass
types,843,I-DiseaseClass
(,843,O
Shridhar,843,O
et,843,O
al.,843,O
",",843,O
1996,843,O
",",843,O
1996a,843,O
),843,O
.,843,O
In,844,O
the,844,O
present,844,O
study,844,O
",",844,O
we,844,O
have,844,O
observed,844,O
mutations,844,O
involving,844,O
codon,844,O
50,844,O
in,844,O
11,844,O
of,844,O
37,844,O
pancreatic,844,B-SpecificDisease
tumors,844,I-SpecificDisease
.,844,O
The,845,O
frequency,845,O
of,845,O
codon,845,O
50,845,O
mutation,845,O
is,845,O
roughly,845,O
the,845,O
same,845,O
in,845,O
pancreatic,845,B-SpecificDisease
tumors,845,I-SpecificDisease
as,845,O
in,845,O
the,845,O
other,845,O
types,845,O
of,845,O
tumors,845,B-DiseaseClass
previously,845,O
examined,845,O
.,845,O
In,846,O
addition,846,O
",",846,O
we,846,O
have,846,O
detected,846,O
mutations,846,O
at,846,O
codon,846,O
51,846,O
in,846,O
multiple,846,O
PCR,846,O
subclones,846,O
in,846,O
two,846,O
other,846,O
pancreatic,846,B-SpecificDisease
tumors,846,I-SpecificDisease
.,846,O
Mutations,847,O
in,847,O
the,847,O
ARP,847,O
gene,847,O
are,847,O
thus,847,O
commonly,847,O
observed,847,O
in,847,O
pancreatic,847,B-SpecificDisease
cancer,847,I-SpecificDisease
",",847,O
as,847,O
well,847,O
as,847,O
many,847,O
other,847,O
cancers,847,B-DiseaseClass
.,847,O
Difficulties,848,O
in,848,O
the,848,O
ascertainment,848,O
of,848,O
C9,848,B-SpecificDisease
deficiency,848,I-SpecificDisease
:,848,O
lessons,848,O
to,848,O
be,848,O
drawn,848,O
from,848,O
a,848,O
compound,848,O
heterozygote,848,O
C9-deficient,848,B-Modifier
subject,848,O
.,848,O
A,849,O
group,849,O
of,849,O
patients,849,O
with,849,O
long-surviving,849,O
mismatched,849,O
kidney,849,O
allografts,849,O
were,849,O
investigated,849,O
for,849,O
complement,849,O
function,849,O
using,849,O
haemolytic,849,O
assays,849,O
in,849,O
agarose,849,O
gels,849,O
.,849,O
One,850,O
patient,850,O
was,850,O
found,850,O
to,850,O
have,850,O
no,850,O
alternative,850,O
pathway,850,O
activity,850,O
but,850,O
a,850,O
low,850,O
normal,850,O
classical,850,O
pathway,850,O
.,850,O
Surprisingly,851,O
",",851,O
investigation,851,O
revealed,851,O
that,851,O
the,851,O
patients,851,O
complement,851,O
was,851,O
normal,851,O
for,851,O
all,851,O
components,851,O
except,851,O
C9,851,O
",",851,O
which,851,O
was,851,O
functionally,851,O
absent,851,O
.,851,O
The,852,O
patient,852,O
was,852,O
shown,852,O
to,852,O
be,852,O
heterozygous,852,O
for,852,O
DNA,852,O
markers,852,O
in,852,O
the,852,O
C6,852,O
",",852,O
C7,852,O
and,852,O
C9,852,O
region,852,O
of,852,O
chromosome,852,O
5,852,O
and,852,O
therefore,852,O
appears,852,O
to,852,O
be,852,O
a,852,O
compound,852,O
heterozygote,852,O
for,852,O
two,852,O
uncharacterized,852,O
C9,852,B-Modifier
deficiency,852,I-Modifier
genes,852,O
.,852,O
Serological,853,O
analysis,853,O
by,853,O
ELISA,853,O
revealed,853,O
that,853,O
he,853,O
has,853,O
trace,853,O
concentrations,853,O
of,853,O
a,853,O
non-functional,853,O
C9,853,O
molecule,853,O
.,853,O
Western,854,O
blot,854,O
analysis,854,O
was,854,O
not,854,O
sufficiently,854,O
sensitive,854,O
to,854,O
permit,854,O
detection,854,O
of,854,O
this,854,O
molecule,854,O
.,854,O
We,855,O
hypothesize,855,O
that,855,O
the,855,O
patient,855,O
is,855,O
heterozygous,855,O
for,855,O
a,855,O
complete,855,B-SpecificDisease
deficiency,855,I-SpecificDisease
of,855,I-SpecificDisease
C9,855,I-SpecificDisease
and,855,O
for,855,O
a,855,O
gene,855,O
directing,855,O
hyposynthesis,855,O
of,855,O
a,855,O
defective,855,O
C9,855,O
.,855,O
We,856,O
also,856,O
suggest,856,O
that,856,O
C9,856,B-SpecificDisease
deficiency,856,I-SpecificDisease
may,856,O
be,856,O
more,856,O
common,856,O
among,856,O
Caucasians,856,O
than,856,O
has,856,O
been,856,O
reported,856,O
..,856,O
Screening,857,O
for,857,O
ESR,857,O
mutations,857,O
in,857,O
breast,857,B-Modifier
and,857,I-Modifier
ovarian,857,I-Modifier
cancer,857,I-Modifier
patients,857,O
.,857,O
In,858,O
the,858,O
present,858,O
study,858,O
",",858,O
leukocyte,858,O
DNA,858,O
from,858,O
143,858,O
patients,858,O
with,858,O
familial,858,O
clustering,858,O
of,858,O
breast,858,B-CompositeMention
and/or,858,I-CompositeMention
ovarian,858,I-CompositeMention
cancer,858,I-CompositeMention
and,858,O
tumour,858,B-Modifier
DNA,858,O
from,858,O
96,858,O
breast,858,B-SpecificDisease
carcinomas,858,I-SpecificDisease
were,858,O
screened,858,O
for,858,O
base,858,O
mutations,858,O
in,858,O
the,858,O
estrogen,858,O
receptor,858,O
gene,858,O
(,858,O
ESR,858,O
),858,O
.,858,O
Three,859,O
patients,859,O
with,859,O
a,859,O
family,859,O
history,859,O
of,859,O
cancer,859,B-DiseaseClass
were,859,O
carrying,859,O
a,859,O
Gly160Cys,859,O
germline,859,O
substitution,859,O
.,859,O
This,860,O
alteration,860,O
was,860,O
also,860,O
detected,860,O
in,860,O
eight,860,O
(,860,O
four,860,O
females,860,O
and,860,O
four,860,O
males,860,O
),860,O
of,860,O
729,860,O
controls,860,O
(,860,O
366,860,O
female,860,O
",",860,O
363,860,O
males,860,O
),860,O
",",860,O
indicating,860,O
that,860,O
the,860,O
substitution,860,O
probably,860,O
represents,860,O
a,860,O
polymorphism,860,O
.,860,O
However,861,O
",",861,O
in,861,O
the,861,O
229,861,O
female,861,O
controls,861,O
in,861,O
whom,861,O
family,861,O
history,861,O
of,861,O
cancer,861,B-DiseaseClass
was,861,O
known,861,O
",",861,O
one,861,O
of,861,O
two,861,O
who,861,O
had,861,O
a,861,O
sister,861,O
with,861,O
breast,861,B-SpecificDisease
cancer,861,I-SpecificDisease
was,861,O
carrying,861,O
the,861,O
variant,861,O
allele,861,O
.,861,O
Hence,862,O
",",862,O
a,862,O
possible,862,O
clinical,862,O
significance,862,O
of,862,O
the,862,O
glycine,862,O
into,862,O
cysteine,862,O
can,862,O
not,862,O
be,862,O
completely,862,O
ruled,862,O
out,862,O
and,862,O
should,862,O
be,862,O
further,862,O
investigated,862,O
.,862,O
Somatic,863,O
mutations,863,O
were,863,O
not,863,O
detected,863,O
in,863,O
any,863,O
of,863,O
the,863,O
tumours,863,B-DiseaseClass
studied,863,O
",",863,O
and,863,O
the,863,O
present,863,O
data,863,O
do,863,O
not,863,O
provide,863,O
support,863,O
for,863,O
somatic,863,O
ESR,863,O
base,863,O
mutations,863,O
as,863,O
an,863,O
important,863,O
mechanism,863,O
for,863,O
hormonal,863,O
therapy,863,O
resistance,863,O
in,863,O
estrogen,863,B-SpecificDisease
receptor-positive,863,I-SpecificDisease
breast,863,I-SpecificDisease
carcinomas,863,I-SpecificDisease
..,863,O
Molecular,864,O
bases,864,O
of,864,O
C7,864,B-SpecificDisease
deficiency,864,I-SpecificDisease
:,864,O
three,864,O
different,864,O
defects,864,O
.,864,O
The,865,O
molecular,865,O
basis,865,O
of,865,O
C7,865,B-SpecificDisease
deficiency,865,I-SpecificDisease
has,865,O
been,865,O
investigated,865,O
in,865,O
two,865,O
Irish,865,O
families,865,O
and,865,O
a,865,O
number,865,O
of,865,O
Israeli,865,O
families,865,O
of,865,O
Moroccan,865,O
Sephardic,865,O
Jewish,865,O
origin,865,O
.,865,O
Exon,866,O
PCR,866,O
and,866,O
sequencing,866,O
revealed,866,O
a,866,O
heterozygous,866,O
point,866,O
mutation,866,O
at,866,O
the,866,O
3,866,O
splice,866,O
acceptor,866,O
site,866,O
of,866,O
intron,866,O
1,866,O
in,866,O
one,866,O
Irish,866,O
family,866,O
.,866,O
In,867,O
the,867,O
other,867,O
Irish,867,O
family,867,O
",",867,O
exons,867,O
7,867,O
and,867,O
8,867,O
failed,867,O
to,867,O
amplify,867,O
and,867,O
they,867,O
were,867,O
shown,867,O
to,867,O
be,867,O
deleted,867,O
.,867,O
Marker,868,O
haplotype,868,O
studies,868,O
of,868,O
the,868,O
C6,868,O
and,868,O
C7,868,O
gene,868,O
region,868,O
and,868,O
Southern,868,O
blots,868,O
show,868,O
that,868,O
the,868,O
Irish,868,O
family,868,O
with,868,O
the,868,O
splice,868,O
defect,868,O
also,868,O
segregate,868,O
for,868,O
the,868,O
deletion,868,O
",",868,O
which,868,O
is,868,O
not,868,O
easily,868,O
detected,868,O
in,868,O
heterozygotes,868,O
.,868,O
The,869,O
Israeli,869,O
C7-deficient,869,B-Modifier
cases,869,O
all,869,O
share,869,O
a,869,O
C7,869,O
haplotype,869,O
and,869,O
are,869,O
homozygous,869,O
for,869,O
a,869,O
mis-sense,869,O
mutation,869,O
in,869,O
exon,869,O
9,869,O
.,869,O
However,870,O
",",870,O
one,870,O
individual,870,O
is,870,O
heterozygous,870,O
for,870,O
markers,870,O
at,870,O
adjacent,870,O
C6,870,O
loci,870,O
",",870,O
showing,870,O
that,870,O
there,870,O
has,870,O
been,870,O
an,870,O
intergenic,870,O
recombination,870,O
and,870,O
suggesting,870,O
that,870,O
the,870,O
deficiency,870,O
mutation,870,O
is,870,O
of,870,O
appreciable,870,O
antiquity,870,O
..,870,O
Molecular,871,O
heterogeneity,871,O
of,871,O
classical,871,B-CompositeMention
and,871,I-CompositeMention
Duarte,871,I-CompositeMention
galactosemia,871,I-CompositeMention
:,871,O
mutation,871,O
analysis,871,O
by,871,O
denaturing,871,O
gradient,871,O
gel,871,O
electrophoresis,871,O
.,871,O
Classical,872,B-SpecificDisease
galactosemia,872,I-SpecificDisease
is,872,O
caused,872,O
by,872,O
one,872,O
common,872,O
missense,872,O
mutation,872,O
(,872,O
Q188R,872,O
),872,O
and,872,O
by,872,O
several,872,O
rare,872,O
mutations,872,O
in,872,O
the,872,O
galactose-1-phosphate,872,O
uridyltransferase,872,O
(,872,O
GALT,872,O
),872,O
gene,872,O
.,872,O
The,873,O
most,873,O
common,873,O
variant,873,O
of,873,O
GALT,873,O
",",873,O
the,873,O
Duarte,873,O
variant,873,O
",",873,O
occurs,873,O
as,873,O
two,873,O
types,873,O
",",873,O
Duarte-1,873,O
(,873,O
D-1,873,O
),873,O
and,873,O
Duarte-2,873,O
(,873,O
D-2,873,O
),873,O
",",873,O
both,873,O
of,873,O
which,873,O
carry,873,O
the,873,O
sequence,873,O
change,873,O
N314D,873,O
.,873,O
D-1,874,O
increases,874,O
",",874,O
whereas,874,O
D-2,874,O
decreases,874,O
GALT,874,O
activity,874,O
.,874,O
To,875,O
study,875,O
the,875,O
molecular,875,O
genetics,875,O
of,875,O
classical,875,B-CompositeMention
and,875,I-CompositeMention
Duarte,875,I-CompositeMention
galactosemia,875,I-CompositeMention
",",875,O
we,875,O
analyzed,875,O
the,875,O
GALT,875,O
mutations,875,O
in,875,O
30,875,O
families,875,O
with,875,O
classical,875,B-SpecificDisease
galactosemia,875,I-SpecificDisease
",",875,O
in,875,O
10,875,O
families,875,O
with,875,O
the,875,O
D-2,875,O
variant,875,O
and,875,O
in,875,O
3,875,O
individuals,875,O
carrying,875,O
the,875,O
D-1,875,O
allele,875,O
by,875,O
denaturing,875,O
gradient,875,O
gel,875,O
electrophoresis,875,O
(,875,O
DGGE,875,O
),875,O
.,875,O
DGGE,876,O
detected,876,O
59,876,O
of,876,O
the,876,O
60,876,O
classical,876,O
galactosemia,876,B-Modifier
alleles,876,O
.,876,O
Q188R,877,O
accounted,877,O
for,877,O
60,877,O
%,877,O
",",877,O
K285N,877,O
accounted,877,O
for,877,O
28,877,O
%,877,O
of,877,O
these,877,O
alleles,877,O
.,877,O
Eight,878,O
novel,878,O
candidate,878,O
galactosemia,878,B-Modifier
mutations,878,O
were,878,O
found,878,O
.,878,O
On,879,O
all,879,O
D-2,879,O
alleles,879,O
N314D,879,O
occurred,879,O
in,879,O
cis,879,O
with,879,O
two,879,O
intronic,879,O
sequence,879,O
changes,879,O
",",879,O
on,879,O
the,879,O
D-1,879,O
alleles,879,O
in,879,O
cis,879,O
with,879,O
a,879,O
neutral,879,O
mutation,879,O
in,879,O
exon,879,O
7,879,O
.,879,O
We,880,O
conclude,880,O
that,880,O
the,880,O
mutations,880,O
causing,880,O
galactosemia,880,B-SpecificDisease
are,880,O
highly,880,O
heterogeneous,880,O
and,880,O
that,880,O
K285N,880,O
is,880,O
a,880,O
second,880,O
common,880,O
galactosemia,880,B-Modifier
mutation,880,O
in,880,O
our,880,O
population,880,O
..,880,O
Isolation,881,O
of,881,O
full-length,881,O
ATM,881,O
cDNA,881,O
and,881,O
correction,881,O
of,881,O
the,881,O
ataxia-telangiectasia,881,B-Modifier
cellular,881,O
phenotype,881,O
.,881,O
A,882,O
gene,882,O
mutated,882,O
in,882,O
the,882,O
human,882,O
genetic,882,B-DiseaseClass
disorder,882,I-DiseaseClass
ataxia-telangiectasia,882,B-SpecificDisease
(,882,O
A-T,882,B-SpecificDisease
),882,O
",",882,O
ATM,882,O
",",882,O
was,882,O
recently,882,O
identified,882,O
by,882,O
positional,882,O
cloning,882,O
.,882,O
ATM,883,O
is,883,O
a,883,O
member,883,O
of,883,O
the,883,O
phosphatidylinositol-3-kinase,883,O
superfamily,883,O
",",883,O
some,883,O
of,883,O
which,883,O
are,883,O
protein,883,O
kinases,883,O
and,883,O
appear,883,O
to,883,O
have,883,O
important,883,O
roles,883,O
in,883,O
cell,883,O
cycle,883,O
control,883,O
and,883,O
radiation,883,O
signal,883,O
transduction,883,O
.,883,O
We,884,O
describe,884,O
herein,884,O
",",884,O
to,884,O
our,884,O
knowledge,884,O
",",884,O
for,884,O
the,884,O
first,884,O
time,884,O
",",884,O
the,884,O
cloning,884,O
of,884,O
a,884,O
full-length,884,O
cDNA,884,O
for,884,O
ATM,884,O
and,884,O
correction,884,O
of,884,O
multiple,884,O
aspects,884,O
of,884,O
the,884,O
radio-sensitive,884,O
phenotype,884,O
of,884,O
A-T,884,B-Modifier
cells,884,O
by,884,O
transfection,884,O
with,884,O
this,884,O
cDNA,884,O
.,884,O
Overexpression,885,O
of,885,O
ATM,885,O
cDNA,885,O
in,885,O
A-T,885,B-Modifier
cells,885,O
enhanced,885,O
the,885,O
survival,885,O
of,885,O
these,885,O
cells,885,O
in,885,O
response,885,O
to,885,O
radiation,885,O
exposure,885,O
",",885,O
decreased,885,O
radiation-induced,885,O
chromosome,885,O
aberrations,885,O
",",885,O
reduced,885,O
radio-resistant,885,O
DNA,885,O
synthesis,885,O
",",885,O
and,885,O
partially,885,O
corrected,885,O
defective,885,O
cell,885,O
cycle,885,O
checkpoints,885,O
and,885,O
induction,885,O
of,885,O
stress-activated,885,O
protein,885,O
kinase,885,O
.,885,O
This,886,O
correction,886,O
of,886,O
the,886,O
defects,886,O
in,886,O
A-T,886,B-Modifier
cells,886,O
provides,886,O
further,886,O
evidence,886,O
of,886,O
the,886,O
multiplicity,886,O
of,886,O
effector,886,O
functions,886,O
of,886,O
the,886,O
ATM,886,O
protein,886,O
and,886,O
suggests,886,O
possible,886,O
approaches,886,O
to,886,O
gene,886,O
therapy,886,O
..,886,O
Fusion,887,O
genes,887,O
resulting,887,O
from,887,O
alternative,887,O
chromosomal,887,O
translocations,887,O
are,887,O
overexpressed,887,O
by,887,O
gene-specific,887,O
mechanisms,887,O
in,887,O
alveolar,887,B-SpecificDisease
rhabdomyosarcoma,887,I-SpecificDisease
.,887,O
Chromosomal,888,O
translocations,888,O
identified,888,O
in,888,O
hematopoietic,888,B-CompositeMention
and,888,I-CompositeMention
solid,888,I-CompositeMention
tumors,888,I-CompositeMention
result,888,O
in,888,O
deregulated,888,O
expression,888,O
of,888,O
protooncogenes,888,O
or,888,O
creation,888,O
of,888,O
chimeric,888,O
proteins,888,O
with,888,O
tumorigenic,888,O
potential,888,O
.,888,O
In,889,O
the,889,O
pediatric,889,O
solid,889,B-DiseaseClass
tumor,889,I-DiseaseClass
alveolar,889,B-SpecificDisease
rhabdomyosarcoma,889,I-SpecificDisease
",",889,O
a,889,O
consistent,889,O
t,889,O
(,889,O
2,889,O
;,889,O
13,889,O
),889,O
(,889,O
q35,889,O
;,889,O
q14,889,O
),889,O
or,889,O
variant,889,O
t,889,O
(,889,O
1,889,O
;,889,O
13,889,O
),889,O
(,889,O
p36,889,O
;,889,O
q14,889,O
),889,O
translocation,889,O
generates,889,O
PAX3-FKHR,889,O
or,889,O
PAX7-FKHR,889,O
fusion,889,O
proteins,889,O
",",889,O
respectively,889,O
.,889,O
In,890,O
this,890,O
report,890,O
",",890,O
we,890,O
demonstrate,890,O
that,890,O
in,890,O
addition,890,O
to,890,O
functional,890,O
alterations,890,O
these,890,O
translocations,890,O
are,890,O
associated,890,O
with,890,O
fusion,890,O
product,890,O
overexpression,890,O
.,890,O
Furthermore,891,O
",",891,O
PAX3-FKHR,891,O
and,891,O
PAX7-FKHR,891,O
overexpression,891,O
occurs,891,O
by,891,O
distinct,891,O
mechanisms,891,O
.,891,O
Transcription,892,O
of,892,O
PAX3-FKHR,892,O
is,892,O
increased,892,O
relative,892,O
to,892,O
wild-type,892,O
PAX3,892,O
by,892,O
a,892,O
copy,892,O
number-independent,892,O
process,892,O
.,892,O
In,893,O
contrast,893,O
",",893,O
PAX7-FKHR,893,O
overexpression,893,O
results,893,O
from,893,O
fusion,893,O
gene,893,O
amplification,893,O
.,893,O
Thus,894,O
",",894,O
gene-specific,894,O
mechanisms,894,O
were,894,O
selected,894,O
to,894,O
overexpress,894,O
PAX3-FKHR,894,O
and,894,O
PAX7-FKHR,894,O
in,894,O
alveolar,894,B-SpecificDisease
rhabdomyosarcoma,894,I-SpecificDisease
",",894,O
presumably,894,O
due,894,O
to,894,O
differences,894,O
in,894,O
regulation,894,O
between,894,O
the,894,O
wild-type,894,O
loci,894,O
.,894,O
We,895,O
postulate,895,O
that,895,O
these,895,O
overexpression,895,O
mechanisms,895,O
ensure,895,O
a,895,O
critical,895,O
level,895,O
of,895,O
gene,895,O
product,895,O
for,895,O
the,895,O
oncogenic,895,O
effects,895,O
of,895,O
these,895,O
fusions,895,O
..,895,O
atm,896,O
and,896,O
p53,896,O
cooperate,896,O
in,896,O
apoptosis,896,O
and,896,O
suppression,896,O
of,896,O
tumorigenesis,896,O
",",896,O
but,896,O
not,896,O
in,896,O
resistance,896,O
to,896,O
acute,896,B-SpecificDisease
radiation,896,I-SpecificDisease
toxicity,896,I-SpecificDisease
.,896,O
Mutations,897,O
in,897,O
atm,897,O
and,897,O
p53,897,O
cause,897,O
the,897,O
human,897,O
cancer-associated,897,B-DiseaseClass
diseases,897,I-DiseaseClass
ataxia-telangiectasia,897,B-SpecificDisease
and,897,O
Li-Fraumeni,897,B-SpecificDisease
syndrome,897,I-SpecificDisease
",",897,O
respectively,897,O
.,897,O
The,898,O
two,898,O
genes,898,O
are,898,O
believed,898,O
to,898,O
interact,898,O
in,898,O
a,898,O
number,898,O
of,898,O
pathways,898,O
",",898,O
including,898,O
regulation,898,O
of,898,O
DNA,898,O
damage-induced,898,O
cell-cycle,898,O
checkpoints,898,O
",",898,O
apoptosis,898,O
and,898,O
radiation,898,O
sensitivity,898,O
",",898,O
and,898,O
cellular,898,O
proliferation,898,O
.,898,O
Atm-null,899,O
mice,899,O
",",899,O
as,899,O
well,899,O
as,899,O
those,899,O
null,899,O
for,899,O
p53,899,O
",",899,O
develop,899,O
mainly,899,O
T-cell,899,B-SpecificDisease
lymphomas,899,I-SpecificDisease
",",899,O
supporting,899,O
the,899,O
view,899,O
that,899,O
these,899,O
genes,899,O
have,899,O
similar,899,O
roles,899,O
in,899,O
thymocyte,899,O
development,899,O
.,899,O
To,900,O
study,900,O
the,900,O
interactions,900,O
of,900,O
these,900,O
two,900,O
genes,900,O
on,900,O
an,900,O
organismal,900,O
level,900,O
",",900,O
we,900,O
bred,900,O
mice,900,O
heterozygous,900,O
for,900,O
null,900,O
alleles,900,O
of,900,O
both,900,O
atm,900,O
and,900,O
p53,900,O
to,900,O
produce,900,O
all,900,O
genotypic,900,O
combinations,900,O
.,900,O
Mice,901,O
doubly,901,O
null,901,O
for,901,O
atm,901,O
and,901,O
p53,901,O
exhibited,901,O
a,901,O
dramatic,901,O
acceleration,901,O
of,901,O
tumour,901,B-Modifier
formation,901,O
relative,901,O
to,901,O
singly,901,O
null,901,O
mice,901,O
",",901,O
indicating,901,O
that,901,O
both,901,O
genes,901,O
collaborate,901,O
in,901,O
a,901,O
significant,901,O
manner,901,O
to,901,O
prevent,901,O
tumorigenesis,901,O
.,901,O
With,902,O
respect,902,O
to,902,O
their,902,O
roles,902,O
in,902,O
apoptosis,902,O
",",902,O
loss,902,O
of,902,O
atm,902,O
rendered,902,O
thymocytes,902,O
only,902,O
partly,902,O
resistant,902,O
to,902,O
irradiation-induced,902,O
apoptosis,902,O
",",902,O
whereas,902,O
additional,902,O
loss,902,O
of,902,O
p53,902,O
engendered,902,O
complete,902,O
resistance,902,O
.,902,O
This,903,O
implies,903,O
that,903,O
the,903,O
irradiation-induced,903,O
atm,903,O
and,903,O
p53,903,O
apoptotic,903,O
pathways,903,O
are,903,O
not,903,O
completely,903,O
congruent,903,O
.,903,O
Finally-and,904,O
in,904,O
contrast,904,O
to,904,O
prior,904,O
predictions-atm,904,O
and,904,O
p53,904,O
do,904,O
not,904,O
appear,904,O
to,904,O
interact,904,O
in,904,O
acute,904,B-SpecificDisease
radiation,904,I-SpecificDisease
toxicity,904,I-SpecificDisease
",",904,O
suggesting,904,O
a,904,O
separate,904,O
atm,904,O
effector,904,O
pathway,904,O
for,904,O
this,904,O
DNA,904,O
damage,904,O
response,904,O
and,904,O
having,904,O
implications,904,O
for,904,O
the,904,O
prognosis,904,O
and,904,O
treatment,904,O
of,904,O
human,904,O
tumours,904,B-DiseaseClass
..,904,O
Trinucleotide,905,O
repeat,905,O
expansion,905,O
at,905,O
the,905,O
myotonic,905,B-Modifier
dystrophy,905,I-Modifier
locus,905,O
reduces,905,O
expression,905,O
of,905,O
DMAHP,905,O
.,905,O
Myotonic,906,B-SpecificDisease
dystrophy,906,I-SpecificDisease
",",906,O
or,906,O
dystrophia,906,B-SpecificDisease
myotonica,906,I-SpecificDisease
(,906,O
DM,906,B-SpecificDisease
),906,O
",",906,O
is,906,O
an,906,O
autosomal,906,B-DiseaseClass
dominant,906,I-DiseaseClass
multisystem,906,I-DiseaseClass
disorder,906,I-DiseaseClass
caused,906,O
by,906,O
the,906,O
expansion,906,O
of,906,O
a,906,O
CTG,906,O
trinucleotide,906,O
repeat,906,O
in,906,O
the,906,O
3,906,O
untranslated,906,O
region,906,O
of,906,O
the,906,O
DMPK,906,O
protein,906,O
kinase,906,O
gene,906,O
on,906,O
chromosome,906,O
19q13,906,O
.,906,O
3,907,O
(,907,O
refs,907,O
1-3,907,O
),907,O
.,907,O
Although,908,O
the,908,O
DM,908,B-Modifier
mutation,908,O
was,908,O
identified,908,O
more,908,O
than,908,O
five,908,O
years,908,O
ago,908,O
",",908,O
the,908,O
pathogenic,908,O
mechanisms,908,O
underlying,908,O
this,908,O
most,908,O
prevalent,908,O
form,908,O
of,908,O
hereditary,908,O
adult,908,O
neuromuscular,908,B-DiseaseClass
disease,908,I-DiseaseClass
remain,908,O
elusive,908,O
.,908,O
Previous,909,O
work,909,O
from,909,O
our,909,O
laboratory,909,O
demonstrated,909,O
that,909,O
a,909,O
DNase,909,O
l-hypersensitive,909,O
site,909,O
located,909,O
adjacent,909,O
to,909,O
the,909,O
repeats,909,O
on,909,O
the,909,O
wild-type,909,O
allele,909,O
is,909,O
eliminated,909,O
by,909,O
repeat,909,O
expansion,909,O
",",909,O
indicating,909,O
that,909,O
large,909,O
CTG-repeat,909,O
arrays,909,O
may,909,O
be,909,O
associated,909,O
with,909,O
a,909,O
local,909,O
chromatin,909,O
environment,909,O
that,909,O
represses,909,O
gene,909,O
expression,909,O
.,909,O
Here,910,O
we,910,O
report,910,O
that,910,O
the,910,O
hypersensitive,910,O
site,910,O
contains,910,O
an,910,O
enhancer,910,O
element,910,O
that,910,O
regulates,910,O
transcription,910,O
of,910,O
the,910,O
adjacent,910,O
DMAHP,910,O
homeobox,910,O
gene,910,O
.,910,O
Analysis,911,O
of,911,O
DMAHP,911,O
expression,911,O
in,911,O
the,911,O
cells,911,O
of,911,O
DM,911,B-Modifier
patients,911,O
with,911,O
loss,911,O
of,911,O
the,911,O
hypersensitive,911,O
site,911,O
revealed,911,O
a,911,O
two-,911,O
to,911,O
fourfold,911,O
reduction,911,O
in,911,O
steady-state,911,O
DMAHP,911,O
transcript,911,O
levels,911,O
relative,911,O
to,911,O
wild-type,911,O
controls,911,O
.,911,O
Allele-specific,912,O
analysis,912,O
of,912,O
DMAHP,912,O
expression,912,O
showed,912,O
that,912,O
steady-state,912,O
transcript,912,O
levels,912,O
from,912,O
the,912,O
expanded,912,O
allele,912,O
were,912,O
greatly,912,O
reduced,912,O
in,912,O
comparison,912,O
to,912,O
those,912,O
from,912,O
the,912,O
wild-type,912,O
allele,912,O
.,912,O
Together,913,O
",",913,O
these,913,O
results,913,O
demonstrate,913,O
that,913,O
CTG-repeat,913,O
expansions,913,O
can,913,O
suppress,913,O
local,913,O
gene,913,O
expression,913,O
and,913,O
implicate,913,O
DMAHP,913,O
in,913,O
DM,913,B-Modifier
pathogenesis,913,O
.,913,O
Constitutively,914,O
methylated,914,O
CpG,914,O
dinucleotides,914,O
as,914,O
mutation,914,O
hot,914,O
spots,914,O
in,914,O
the,914,O
retinoblastoma,914,B-Modifier
gene,914,O
(,914,O
RB1,914,O
),914,O
.,914,O
A,915,O
wide,915,O
spectrum,915,O
of,915,O
mutations,915,O
",",915,O
ranging,915,O
from,915,O
point,915,O
mutations,915,O
to,915,O
large,915,O
deletions,915,O
",",915,O
have,915,O
been,915,O
described,915,O
in,915,O
the,915,O
retinoblastoma,915,B-Modifier
gene,915,O
(,915,O
RB1,915,O
),915,O
.,915,O
Mutations,916,O
have,916,O
been,916,O
found,916,O
throughout,916,O
the,916,O
gene,916,O
;,916,O
however,916,O
",",916,O
these,916,O
genetic,916,O
alterations,916,O
do,916,O
not,916,O
appear,916,O
to,916,O
be,916,O
homogeneously,916,O
distributed,916,O
.,916,O
In,917,O
particular,917,O
",",917,O
a,917,O
significant,917,O
proportion,917,O
of,917,O
disease-causing,917,O
mutations,917,O
results,917,O
in,917,O
the,917,O
premature,917,O
termination,917,O
of,917,O
protein,917,O
synthesis,917,O
",",917,O
and,917,O
the,917,O
majority,917,O
of,917,O
these,917,O
mutations,917,O
occur,917,O
as,917,O
C,917,O
--,917,O
>,917,O
T,917,O
transitions,917,O
at,917,O
CpG,917,O
dinucleotides,917,O
(,917,O
CpGs,917,O
),917,O
.,917,O
Such,918,O
recurrent,918,O
CpG,918,O
mutations,918,O
",",918,O
including,918,O
those,918,O
found,918,O
in,918,O
RB1,918,O
",",918,O
are,918,O
likely,918,O
the,918,O
result,918,O
of,918,O
the,918,O
deamination,918,O
of,918,O
5-methylcytosine,918,O
within,918,O
these,918,O
CpGs,918,O
.,918,O
In,919,O
the,919,O
present,919,O
study,919,O
",",919,O
we,919,O
used,919,O
the,919,O
sodiumbisulfite,919,O
conversion,919,O
method,919,O
to,919,O
detect,919,O
cytosine,919,O
methylation,919,O
in,919,O
representative,919,O
exons,919,O
of,919,O
RB1,919,O
.,919,O
We,920,O
analyzed,920,O
DNA,920,O
from,920,O
a,920,O
variety,920,O
of,920,O
tissues,920,O
and,920,O
specifically,920,O
targeted,920,O
CGA,920,O
codons,920,O
in,920,O
RB1,920,O
",",920,O
where,920,O
recurrent,920,O
premature,920,O
termination,920,O
mutations,920,O
have,920,O
been,920,O
reported,920,O
.,920,O
We,921,O
found,921,O
that,921,O
DNA,921,O
methylation,921,O
within,921,O
RB1,921,O
exons,921,O
8,921,O
",",921,O
14,921,O
",",921,O
25,921,O
",",921,O
and,921,O
27,921,O
appeared,921,O
to,921,O
be,921,O
restricted,921,O
to,921,O
CpGs,921,O
",",921,O
including,921,O
six,921,O
CGA,921,O
codons,921,O
.,921,O
Other,922,O
codons,922,O
containing,922,O
methylated,922,O
cytosines,922,O
have,922,O
not,922,O
been,922,O
reported,922,O
to,922,O
be,922,O
mutated,922,O
.,922,O
Therefore,923,O
",",923,O
disease-causing,923,O
mutations,923,O
at,923,O
CpGs,923,O
in,923,O
RB1,923,O
appear,923,O
to,923,O
be,923,O
determined,923,O
by,923,O
several,923,O
factors,923,O
",",923,O
including,923,O
the,923,O
constitutive,923,O
presence,923,O
of,923,O
DNA,923,O
methylation,923,O
at,923,O
cytosines,923,O
within,923,O
CpGs,923,O
",",923,O
the,923,O
specific,923,O
codon,923,O
within,923,O
which,923,O
the,923,O
methylated,923,O
cytosine,923,O
is,923,O
located,923,O
",",923,O
and,923,O
the,923,O
particular,923,O
region,923,O
of,923,O
the,923,O
gene,923,O
within,923,O
which,923,O
that,923,O
codon,923,O
resides,923,O
..,923,O
The,924,O
von,924,B-Modifier
Hippel-Lindau,924,I-Modifier
tumor,924,I-Modifier
suppressor,924,O
gene,924,O
product,924,O
interacts,924,O
with,924,O
Sp1,924,O
to,924,O
repress,924,O
vascular,924,O
endothelial,924,O
growth,924,O
factor,924,O
promoter,924,O
activity,924,O
.,924,O
The,925,O
von,925,B-Modifier
Hippel-Lindau,925,I-Modifier
tumor,925,I-Modifier
suppressor,925,O
gene,925,O
(,925,O
VHL,925,O
),925,O
has,925,O
a,925,O
critical,925,O
role,925,O
in,925,O
the,925,O
pathogenesis,925,O
of,925,O
clear-cell,925,B-SpecificDisease
renal,925,I-SpecificDisease
cell,925,I-SpecificDisease
carcinoma,925,I-SpecificDisease
(,925,O
RCC,925,B-SpecificDisease
),925,O
",",925,O
as,925,O
VHL,925,O
mutations,925,O
have,925,O
been,925,O
found,925,O
in,925,O
both,925,O
von,925,B-CompositeMention
Hippel-Lindau,925,I-CompositeMention
disease-associated,925,I-CompositeMention
and,925,I-CompositeMention
sporadic,925,I-CompositeMention
RCCs,925,I-CompositeMention
.,925,O
Recent,926,O
studies,926,O
suggest,926,O
that,926,O
vascular,926,O
endothelial,926,O
growth,926,O
factor,926,O
(,926,O
VEGF,926,O
),926,O
mRNA,926,O
is,926,O
upregulated,926,O
in,926,O
RCC-,926,B-CompositeMention
and,926,I-CompositeMention
von,926,I-CompositeMention
Hippel-Lindau,926,I-CompositeMention
disease-associated,926,I-CompositeMention
tumors,926,I-CompositeMention
.,926,O
We,927,O
have,927,O
therefore,927,O
assessed,927,O
the,927,O
effect,927,O
of,927,O
the,927,O
VHL,927,O
gene,927,O
product,927,O
on,927,O
VEGF,927,O
expression,927,O
.,927,O
VEGF,928,O
promoter-luciferase,928,O
constructs,928,O
were,928,O
transiently,928,O
cotransfected,928,O
with,928,O
a,928,O
wild-type,928,O
VHL,928,O
(,928,O
wt-VHL,928,O
),928,O
vector,928,O
in,928,O
several,928,O
cell,928,O
lines,928,O
",",928,O
including,928,O
293,928,O
embryonic,928,O
kidney,928,O
and,928,O
RCC,928,B-Modifier
cell,928,O
lines,928,O
.,928,O
wt-VHL,929,O
protein,929,O
inhibited,929,O
VEGF,929,O
promoter,929,O
activity,929,O
in,929,O
a,929,O
dose-dependent,929,O
manner,929,O
up,929,O
to,929,O
5-,929,O
to,929,O
10-fold,929,O
.,929,O
Deletion,930,O
analysis,930,O
defined,930,O
a,930,O
144-bp,930,O
region,930,O
of,930,O
the,930,O
VEGF,930,O
promoter,930,O
necessary,930,O
for,930,O
VHL,930,O
repression,930,O
.,930,O
This,931,O
VHL-responsive,931,O
element,931,O
is,931,O
GC,931,O
rich,931,O
and,931,O
specifically,931,O
binds,931,O
the,931,O
transcription,931,O
factor,931,O
Sp1,931,O
in,931,O
crude,931,O
nuclear,931,O
extracts,931,O
.,931,O
In,932,O
Drosophila,932,O
cells,932,O
",",932,O
cotransfected,932,O
VHL,932,O
represses,932,O
Sp1-mediated,932,O
activation,932,O
but,932,O
not,932,O
basal,932,O
activity,932,O
of,932,O
the,932,O
VEGF,932,O
promoter,932,O
.,932,O
We,933,O
next,933,O
demonstrated,933,O
in,933,O
coimmunoprecipitates,933,O
that,933,O
VHL,933,O
and,933,O
Sp1,933,O
were,933,O
part,933,O
of,933,O
the,933,O
same,933,O
complex,933,O
and,933,O
",",933,O
by,933,O
using,933,O
a,933,O
glutathione-S-transferase-VHL,933,O
fusion,933,O
protein,933,O
and,933,O
purified,933,O
Sp1,933,O
",",933,O
that,933,O
VHL,933,O
and,933,O
Sp1,933,O
directly,933,O
interact,933,O
.,933,O
Furthermore,934,O
",",934,O
endogenous,934,O
VEGF,934,O
mRNA,934,O
levels,934,O
were,934,O
suppressed,934,O
in,934,O
permanent,934,O
RCC,934,B-Modifier
cell,934,O
lines,934,O
expressing,934,O
wt-VHL,934,O
",",934,O
and,934,O
nuclear,934,O
run-on,934,O
studies,934,O
indicated,934,O
that,934,O
VHL,934,O
regulation,934,O
of,934,O
VEGF,934,O
occurs,934,O
at,934,O
least,934,O
partly,934,O
at,934,O
the,934,O
transcriptional,934,O
level,934,O
.,934,O
These,935,O
observations,935,O
support,935,O
a,935,O
new,935,O
mechanism,935,O
for,935,O
VHL-mediated,935,O
transcriptional,935,O
repression,935,O
via,935,O
a,935,O
direct,935,O
inhibitory,935,O
action,935,O
on,935,O
Sp1,935,O
and,935,O
suggest,935,O
that,935,O
loss,935,O
of,935,O
Sp1,935,O
inhibition,935,O
may,935,O
be,935,O
important,935,O
in,935,O
the,935,O
pathogenesis,935,O
of,935,O
von,935,B-SpecificDisease
Hippel-Lindau,935,I-SpecificDisease
disease,935,I-SpecificDisease
and,935,O
RCC,935,B-SpecificDisease
..,935,O
Adult,936,B-SpecificDisease
onset,936,I-SpecificDisease
globoid,936,I-SpecificDisease
cell,936,I-SpecificDisease
leukodystrophy,936,I-SpecificDisease
(,936,O
Krabbe,936,B-SpecificDisease
disease,936,I-SpecificDisease
),936,O
:,936,O
analysis,936,O
of,936,O
galactosylceramidase,936,O
cDNA,936,O
from,936,O
four,936,O
Japanese,936,O
patients,936,O
.,936,O
We,937,O
examined,937,O
galactosylceramidase,937,O
(,937,O
GALC,937,O
),937,O
cDNA,937,O
in,937,O
four,937,O
Japanese,937,O
patients,937,O
with,937,O
adult,937,B-SpecificDisease
onset,937,I-SpecificDisease
globoid,937,I-SpecificDisease
cell,937,I-SpecificDisease
leukodystrophy,937,I-SpecificDisease
(,937,O
Krabbe,937,B-SpecificDisease
disease,937,I-SpecificDisease
;,937,O
AO-GLD,937,B-SpecificDisease
),937,O
by,937,O
polymerase,937,O
chain,937,O
reaction/single-strand,937,O
conformation,937,O
polymorphism,937,O
(,937,O
PCR-SSCP,937,O
),937,O
analysis,937,O
",",937,O
subsequent,937,O
sequence,937,O
determination,937,O
",",937,O
and,937,O
restriction,937,O
enzyme,937,O
digestion,937,O
of,937,O
PCR,937,O
products,937,O
",",937,O
initial,937,O
symptoms,937,O
were,937,O
the,937,O
onset,937,O
of,937,O
slowly,937,O
progressive,937,O
spastic,937,B-DiseaseClass
paraplegia,937,I-DiseaseClass
from,937,O
the,937,O
middle,937,O
of,937,O
the,937,O
second,937,O
decade,937,O
",",937,O
and,937,O
all,937,O
patients,937,O
had,937,O
diminished,937,B-DiseaseClass
GALC,937,I-DiseaseClass
activity,937,I-DiseaseClass
in,937,O
their,937,O
leukocytes,937,O
.,937,O
We,938,O
identified,938,O
three,938,O
missense,938,O
mutations,938,O
(,938,O
I66M,938,O
",",938,O
G270D,938,O
",",938,O
L618S,938,O
),938,O
and,938,O
one,938,O
exon-6,938,O
skipping,938,O
(,938,O
535-573del,938,O
),938,O
.,938,O
Two,939,O
of,939,O
the,939,O
patients,939,O
had,939,O
only,939,O
the,939,O
I66M,939,O
mutant,939,O
mRNA,939,O
",",939,O
and,939,O
one,939,O
only,939,O
the,939,O
G27OD,939,O
mutant,939,O
mRNA,939,O
.,939,O
The,940,O
fourth,940,O
patient,940,O
carried,940,O
a,940,O
compound,940,O
heterozygous,940,O
mutation,940,O
of,940,O
535-573del,940,O
and,940,O
L618S,940,O
.,940,O
To,941,O
determine,941,O
the,941,O
enzymatic,941,O
activities,941,O
produced,941,O
by,941,O
these,941,O
mutations,941,O
",",941,O
we,941,O
constructed,941,O
mutated,941,O
GALC,941,O
cDNAs,941,O
and,941,O
expressed,941,O
them,941,O
in,941,O
COS-1,941,O
cells,941,O
.,941,O
Three,942,O
mutations,942,O
",",942,O
viz.,942,O
",",942,O
G270D,942,O
",",942,O
L618S,942,O
",",942,O
and,942,O
exon-6,942,O
skipping,942,O
(,942,O
535-573del,942,O
),942,O
",",942,O
produced,942,O
diminished,942,B-DiseaseClass
GALC,942,I-DiseaseClass
activity,942,I-DiseaseClass
as,942,O
expected,942,O
.,942,O
The,943,O
I66M,943,O
mutation,943,O
in,943,O
the,943,O
wild-type,943,O
GALC,943,O
cDNA,943,O
(,943,O
I289,943,O
),943,O
had,943,O
normal,943,O
activity,943,O
",",943,O
but,943,O
when,943,O
this,943,O
mutation,943,O
and,943,O
the,943,O
V289,943,O
polymorphism,943,O
were,943,O
introduced,943,O
into,943,O
the,943,O
same,943,O
allele,943,O
",",943,O
it,943,O
had,943,O
decreased,943,O
activity,943,O
.,943,O
Thus,944,O
",",944,O
the,944,O
combination,944,O
of,944,O
a,944,O
unique,944,O
mutation,944,O
and,944,O
polymorphism,944,O
causes,944,O
conformational,944,O
change,944,O
in,944,O
the,944,O
GALC,944,O
enzyme,944,O
",",944,O
resulting,944,O
in,944,O
low,944,O
enzymatic,944,O
activity,944,O
.,944,O
AO-GLD,945,B-Modifier
mutations,945,O
",",945,O
including,945,O
those,945,O
found,945,O
here,945,O
",",945,O
are,945,O
located,945,O
in,945,O
the,945,O
N-terminus,945,O
(,945,O
I66M,945,O
",",945,O
G270D,945,O
",",945,O
535-573del,945,O
),945,O
or,945,O
C-terminus,945,O
(,945,O
L618S,945,O
),945,O
of,945,O
the,945,O
GALC,945,O
enzyme,945,O
",",945,O
whereas,945,O
the,945,O
reported,945,O
mutations,945,O
in,945,O
the,945,O
infantile,945,O
form,945,O
(,945,O
IF-GLD,945,B-SpecificDisease
),945,O
are,945,O
in,945,O
the,945,O
central,945,O
domain,945,O
.,945,O
This,946,O
difference,946,O
in,946,O
mutation,946,O
sites,946,O
may,946,O
affect,946,O
the,946,O
clinical,946,O
features,946,O
of,946,O
GLD,946,B-SpecificDisease
.,946,O
